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Breast cancer is responsible for the most new cancer cases and is the second highest cause of 
cancer related deaths among women. Localized breast cancer is effectively treated surgically. In 
contrast, metastatic cancers often remain undetected as dormant micrometastases for years to 
decades after primary surgery. Emergence of micrometastases to form clinically evident 
metastases complicates therapeutic intervention, making survival rates poor. The often long lag 
time between primary tumor diagnosis and emergence of metastatic disease motivates the 
development or repurposing of agents to act as safe, long term adjuvants to prevent disease 
progression. 
The statin drugs have been FDA approved for the treatment of hypercholesterolemia for 
three decades. Despite their well-studied effects on lipid homeostasis, statins feature beneficial 
pleiotropic effects on other organ systems and pathologies. Several epidemiological studies have 
demonstrated statins do not affect cancer incidence but do reduce breast cancer mortality. Previous 
in vitro work has demonstrated growth-suppressive and apoptosis-inducing effects of statins in 
tumor cell lines. However, the mechanisms and markers that contribute to statin’s suppressive 
effects on tumor cells remain unclear. We hypothesize that statins benefit cancer mortality by 
directly suppressing the outgrowth of dormant metastatic disease. 
The data presented herein demonstrate that statins reduce tumor cell growth and survival, 
in part due to suppression of Ras and Akt signaling. Importantly, these effects are limited to the 
membrane-permeant lipophilic statins. In ex vivo and in vivo models of metastatic breast cancer, 
BREAST CANCER METASTATIC DORMANCY AND EMERGENCE, A ROLE FOR 
ADJUVANT STATIN THERAPY 
Colin Henry Beckwitt 
University of Pittsburgh, 2018 
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statins reduce the proliferation at the site of metastasis but not the primary tumor. Tumor cells 
expressing membrane E-cadherin are relatively more resistant to statin therapy, which implies that 
the clinical cancer mortality benefit observed is due to decreased outgrowth of dormant epithelial 
micrometastases into clinically evident mesenchymal macrometastases. These data motivate the 
further study of statins as safe, long term adjuvants to prevent emergent breast cancer. Moreover, 
these data recommend a therapeutic switch to lipophilic statins in breast cancer patients taking 
statins for other diseases. That statins selectively suppress metastatic but not primary tumor growth 
is promising for their use as safe, long term adjuvants to reduce recurrence and mortality from 
metastatic breast cancer.  
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1.0  BREAST CANCER PATHOPHYSIOLOGY AND THERAPY 
1.1 INTRODUCTION 
Breast cancer is a significant cause of morbidity and mortality in the United States, with over 
250,000 new diagnoses and 40,000 deaths per year from the disease. The work herein demonstrates 
the feasibility of repurposing members of the statin drug class to combat metastatic breast cancer 
recurrence, the primary cause of breast cancer mortality, using the liver as a model organ system 
for metastasis. The first three chapters of this dissertation provide background material to frame 
these investigations. First, important aspects of breast cancer, including clinical and 
molecular designations and therapy, are discussed. Second, a historical and mechanistic 
perspective on the statins, including their use in cancer, is presented. Finally, liver physiology 
and relevance as a model for metastatic disease are introduced. 
1.2 CLINICAL EPIDEMIOLOGY 
Breast cancer is the most prevalent cancer and the second highest cause of cancer-related 
mortality in women and will be responsible for an estimated 266,120 new cases and 40,920 
deaths in 20185. Importantly, only about 1% of new breast cancer cases and deaths occur in 
men, making this disease one almost entirely of the female gender6. In addition to these new 
cases, approximately 1 
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63,410 cases of breast carcinoma in situ will be diagnosed, some of which will progress to invasive 
disease6. One in eight women can be expected to be diagnosed with invasive breast cancer in her 
lifetime6. Breast cancer carries the highest financial cancer-associated healthcare burden with an 
estimated cost of $16.5 billion in 20107. This cost is projected to increase to $20.5 billion by 2020, 
the highest percentage increase in cancer spending (32%) aside from prostate cancer (42%)7.  
 
 
 
Figure 1. Female cancer incidence 
Female cancer incidence between 1975 and 2013. The increase in incidence in breast cancer from 1980-1987 is due 
to increased mammography screening. Breast cancer remains the most commonly diagnosed non-skin cancer in 
women. Data are open access and modified from Cancer Statistics 20176. 
 
 
The incidence of breast cancer has been steadily increasing by 0.4% per year in the general 
population. This rate of increase in breast cancer incidence has been stable except during the period 
of 1980-1987 (Figure 1), due in large part to the significant rise in screening mammography that 
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resulted from the 20-30% decrease in mortality due to screening mammograms observed in 
Swedish randomized trials in the 1970s and 1980s8–10. The rate of death from breast cancer has 
decreased by approximately 1.5% per year since 1989, with the mortality rate in 2014 being 21.2 
per 100,0006 (Figure 2). 
 
 
 
Figure 2. Female cancer death 
Female cancer deaths between 1930 and 2014. The female specific death rates for breast, colorectal, and lung 
cancers have decreased by 1.5%, 1.3%, and 1.4% per year since their inflection point of descent, respectively. Data 
are open access and modified from Cancer Statistics 20176. 
 
 
Only 6% of primary diagnoses involve metastatic (distant) disease (Figure 3), and therefore 
the decrease in breast cancer mortality must be primarily due to better treatment of localized and, 
especially, regional disease6,11. The five year survival rate for localized disease increased from 
97% to 99% in two decades, while the corresponding survival rate for regional disease showed a 
larger increase from 76% to 85% (Figure 3). While survival rates for metastatic disease improved 
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from 20% to 26% over the same two decades (Figure 3), the continuing significantly lower survival 
rates demonstrate the need for therapeutic strategies that benefit patients with metastatic disease.  
 
 
 
Figure 3. Breast cancer stage distribution at diagnosis and associated mortality rates 
(A,B) Breast cancer stage at patient diagnosis and (C,D) five year survival rate for various stages of breast cancer 
from data published in (A,C) Cancer Statistics 1996 and (B,D) Cancer Statistics 2017. Figures were constructed 
using data provided in these references6,11 
 
  5 
Many factors influence a woman’s susceptibility to developing breast cancer. Women have 
a higher risk of developing breast cancer with increasing age, with an incidence plateau occurring 
in a woman’s 7th decade6,12. Women whom have earlier onset of menarche and later onset of 
menopause are at a higher risk for breast cancer, which is likely due to higher cumulative estrogen 
exposure12,13. Indeed, other studies have linked postmenopausal obesity (increased estrone 
production from adipocytes) and long term estrogen replacement therapy to an increased breast 
cancer risk, primarily associated with hormone positive breast cancers14,15. Conversely, earlier age 
of first full term pregnancy is associated with a decreased risk of breast cancer, likely due to 
differentiation of mammary cells to a more quiescent phenotype following parturition16,17. While 
the use of oral contraceptives increases the risk of breast cancer, their use also decreases the 
proportion of tumors found upon diagnosis that have spread to sites outside the breast18.  
Several genetic factors influence the risk for developing breast cancer. The main breast 
cancer syndromes involve loss of a tumor suppressor gene. The most common genes involved in 
hereditary breast cancer are BRCA1 and BRCA2. These genes increase risk for breast cancer in 
an autosomal dominant fashion and account for roughly 5-15% of all breast cancer diagnoses, with 
a higher prevalence observed in women with asynchronous contralateral breast cancer12,19,20. The 
cumulative risk for developing contralateral breast cancer with a BRCA1 or BRCA2 mutation is 
almost 50% by 25 years after diagnosis of the first breast cancer21. Other common genetic diseases 
that dramatically increase the lifetime risk of breast cancer, in addition to other cancers, are Li-
Fraumeni syndrome (p53 mutation) and Cowden syndrome (PTEN mutation), which will not be 
further discussed. For a more comprehensive discussion of genetic conditions and genes that 
predispose women to an increased risk of breast cancer, the reader is directed to other references22–
24. 
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In addition to estrogen exposure and genetic factors, lifestyle decisions can also impact 
breast cancer risk in women. As mentioned above, obesity increases risk for breast cancer both in 
disease incidence, tumor burden, and higher grade of tumors25. Higher estrogen levels have been 
found in women with higher BMI, suggesting estrogen plays a role in increasing breast cancer risk 
in obese women. Adipokines, such as leptin and adiponectin, have also been implicated in breast 
cancer development26,27. Alcohol consumption also increases breast cancer risk in women even at 
exposure as low as three drinks per week28,29. As with obesity, it has been proposed that alcohol 
consumption raises breast cancer risk by increasing endogenous estrogens secondary to decreasing 
liver catabolism of sex steroids30. Finally, low physical activity also increases the risk for breast 
cancer and is more significant for women with BMI less than twenty five31,32. Physical activity is 
thought to reduce breast cancer risk through decreasing body fat, insulin levels, adipokines, and as 
a result, hormone levels32,33. 
In conclusion, breast cancer is the most common and second most mortal cancer in women 
(after lung cancer). Several lifestyle and genetic factors can predispose women to the development 
of breast cancer, including BRCA1/2 mutations, obesity, estrogen exposure, alcohol use, and 
physical activity. While mortality from breast cancer has decreased by 38% over the past 25 years, 
the survival rate in distant breast cancer remains low. These epidemiological data motivate the 
development of therapeutic strategies that can extend the survival of patients with metastatic breast 
cancer.   
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1.3 DEVELOPMENT, ANATOMY, AND PHYSIOLOGY 
The development, anatomy, and physiology of the breast are all important for the development of 
primary cancer and its eventual metastatic spread. The human female breast begins developing as 
early as 4 to 6 weeks of gestation and continues developing into adulthood34,35. Breast tissue 
consists of both epithelial and mesenchymal (stromal) elements, which are organized into a 
branching ductular system ending in the terminal ductal lobular unit (TDLU) (Figure 4). The 
branching of breast ductules is modest until their rapid expansion via side branching in women 
under the influence of sex hormones that accompanies thelarche34–36. The breast ductular structure 
further develops during and after pregnancy and is responsible for decreasing breast cancer risk in 
women after parturition. 
 
 
 
Figure 4. The terminal ductal lobular unit of the breast 
The breast is organized into a branched network of ducts ending in a terminal ductal lobular unit (TDLU). This 
image is copyrighted by Dr. Amini as indicated, has not been changed, and its free use has been allowed by the 
terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 license. 
  8 
The female breast lies on the anterior thoracic wall, deep to the dermis and superficial to 
the pectoralis major fascia37. Approximately 10-15% of the breast is composed of epithelial tissue, 
whereas the remainder comprises stromal elements. The breast is anchored to the skin by the 
suspensory ligaments of Cooper, whose contraction (by malignant cancers or tissue fibrosis) can 
cause dimpling of the skin37. The blood supply entering the breast consists of branches of the 
internal mammary artery, axillary artery, and posterior intercostal arteries. The venous drainage 
follows the arteries to the axilla, with branches of the internal thoracic vein serving as the highest 
contributors to flow37. The lymphatic drainage to the breast is more than 75% to the axillary lymph 
nodes, with the medial aspect of the breast instead draining to the parasternal lymph nodes or deep 
cervical nodes37. Importantly, lymph nodes are both a common route for the metastatic spread of 
breast cancer and are one of the most significant prognostic marker for patient survival37,38. 
Normal breast physiology, especially in the context of puberty, pregnancy, lactation, and 
menopause is quite complex and will not be discussed in its entirety. To summarize, after pubertal 
breast development, a cyclical microscopic proliferation and regression of breast tissue occurs 
during the menstrual cycle. During pregnancy, the breast develops in preparation for lactation after 
parturition and is fully developed after only 16 weeks gestation35. This development consists of 
three main phases: lactogenesis (the start of milk secretion), lactation (sustained milk secretion), 
and involution (epithelial apoptosis and reversion to a pre-pregnant morphology)35. Importantly, 
the differentiation that accompanies lactation results in a decreased risk for pre-menopausal breast 
cancer39,40. For a comprehensive review of breast physiology, the reader is directed to more 
complete references35,41. 
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1.4 DISEASE PROGRESSION 
Breast cancer is a complex entity, with stages encompassing the range from the benign breast 
carcinoma in situ to highly invasive metastatic breast cancer. The loss of tumor suppressor genes 
and/or presence of oncogenes catalyzes the progression between phases. This process is commonly 
referred to as the metastatic cascade and involves the spread of aggressive tumor cells from the 
primary organ (breast in this case) to distant sites through the circulatory system. The rest of this 
section provides a brief review of the metastatic cascade and its implications for survival, as is 
relevant for the work contained herein.  
The metastatic cascade begins with tumor growth at the primary tumor site and ends with 
metastatic growth at a distant site. The steps are illustrated in Figure 5 and summarized in Table 1 
below. The metastatic cascade begins with the growth of tumor cells in the breast to form a breast 
carcinoma in situ that is initially constrained by the basolateral basement membrane of the 
TDLU42. Tumor progression through the basement membrane and into the surrounding 
environment allows for dissemination by two distinct modes. First, local invasion commences 
when a tumor cell achieves at least partial separation from the primary mass. The process continues 
when this cell reorganizes and migrates through surrounding tissue to arrive at an adjacent site as 
a cohesive expansion of the primary mass43,44. Second, tumor cells can disseminate to distant 
organs through complete separation from the primary tumor, invasion through the surrounding 
tissue, and intravasation into a conduit (lymphatic or vascular)43. Importantly, this stage often 
involves a transition from an epithelial phenotype, in which E-cadherin expression facilitates 
cohesion between neighboring cells, to a mesenchymal phenotype, in which E-cadherin loss 
facilitates cellular elongation and dissociation from neighboring cells44,45. This transition is called 
an epithelial to mesenchymal transition (EMT). 
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Figure 5. A simplified schematic of breast cancer metastasis to the liver 
(1) Primary breast tumors grow and undergo (2) epithelial-to-mesenchymal transition (EMT), in which they lose E-
cadherin and subsequently invade through the basement membrane. (3) Invading tumor cells intravasate into nearby 
vessels, (4) travel through the vasculature to the liver, and (5) extravasate into the surrounding parenchyma. (6) 
Tumor cells seed in the liver parenchyma as micrometastases by undergoing a mesenchymal-to-epithelial reverting 
transition (MErT) involving the re-expression of E-cadherin. (7) Seeded tumor cells next enter a period of 
dormancy. After years to decades, (8) dormant tumor cells undergo a secondary EMT and outgrow to form 
macrometastases. This diagram was created using images from Servier Medical Art46. 
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Table 1. The stages of the metastatic cascade 
Step Description 
Growth Proliferation at the primary tumor site, confined by the basement membrane 
Invasion Extension through the basement membrane, often accompanied by EMT (loss of E-cadherin) 
Intravasation Invasion into a lymphatic or vascular conduit 
Vascular Transit Survival in the vasculature from shear stress, immune attack, and survival factor depletion 
Extravasation Recognition of endothelial cells at a distant site and invasion through the vascular basement membrane into the tissue parenchyma 
Metastatic 
Seeding 
Integration into the local tissue parenchyma, facilitated by MErT (re-expression of E-
cadherin) 
Dormancy A period of quiescence lasting years to decades 
Outgrowth Microenvironmental signals stimulate a second EMT (loss of E-cadherin) and proliferation to form a clinically detectable metastasis 
Tumor cells need to accomplish all steps in order to form an overt, clinically detectable metastasis.  
EMT = epithelial to mesenchymal transition; MErT = mesenchymal to epithelial reverting transition44,45,47,48. 
 
 
Following cell intravasation into the vasculature, the tumor cells must survive transit to the 
distant organ site and recognize resident endothelial cells44. Of note, lymphatogenous metastases 
eventually drain into the vasculature through the left subclavian vein. This phase of the metastatic 
cascade is the most difficult for tumor cells due to the lack of supportive survival signals from the 
tumor microenvironment, immune surveillance, and presence of high shear stresses44,48. Upon 
recognition of endothelial cells at the distant site, tumor cells must extravasate and integrate into 
the surrounding parenchyma. This is facilitated by tumor cell plasticity, as breast carcinoma cells 
often re-express E-cadherin upon metastatic seeding, facilitating their integration into the 
surrounding parenchyma and providing survival signals44,45,49. This transition is called a 
mesenchymal to epithelial reverting transition (MErT). Tumor cells often remain in a quiescent 
state after metastatic seeding, termed “dormancy,” which can last years to decades after metastatic 
seeding44,48. The last stage of the metastatic cascade is outgrowth of tumor cells at the distant site, 
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likely due to stimulatory factors from the microenvironment44,47,48. This phase is accompanied by 
a second EMT, as E-cadherin loss is characteristic of large metastases49.  
Metastasis is the largest predictor for breast cancer morbidity and mortality, with only 10% 
of patients surviving ten years beyond discovery of their metastasis50. Moreover, metastases are 
often undetected at initial presentation, in particular when not involving the bone, as these often 
result in more presentable symptoms like as hypercalcemia or pathologic fractures (Table 2)51. 
Whereas rates of bone metastases in breast cancer patients are comparable between initial 
presentation and autopsy, rates of lung and liver metastases are 4 to 15 fold higher at autopsy 
(Table 2)50, indicating that the issue is more of detection than presence, and that the bone, liver, 
and lung are most likely all involved as end sites for the metastatic cascade during initial 
dissemination. 
 
 
Table 2. Prevalence of breast cancer metastases 
Metastasis Site At Presentation (%) At Autopsy (%) 
Bone 40-75 44-71 
Lung 5-15 59-75 
Pleura 5-15 23-51 
Liver 3-10 56-65 
Brain <5 9-20 
Prevalence of breast cancer metastases at initial presentation and upon autopsy. Data were taken from Jolly et al50. 
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Table 3. Primary causes of death from metastatic breast cancer 
Cause of Death % Total Commonly (% Subclass) % Due to Mets 
Pulmonary Insufficiency 26 Metastases (65%) Restrictive Disease (31%) 65 
Infection 24 Pneumonia (58%) N/A 
Cardiac Failure 15 
Heart Failure (29%) 
Pericardium (29%) 
MI (21%) 
38 
Hepatic Failure 14 Metastases (100%) 100 
CNS failure 9 Meninges (40%) Brain (40%) 80 
Hemorrhage 9 
Organic (47%) 
DIC (20%) 
Local Tumor Invasion (13%) 
13% 
Primary causes of death from metastatic breast cancer as a clinicopathologic investigation. Data were taken from 
Hagemeister et al52. Mets = metastases, CNS = central nervous system, Organic = unrelated to disease or treatment, 
DIC = disseminated intravascular coagulation. 
 
 
Patients with metastatic disease have poor survival. The metastases themselves are 
responsible for approximately half of all metastatic breast cancer deaths52. Other significant 
primary causes for death from metastatic breast cancer are infection, hemorrhage, and hepatic and 
central nervous system failure52. These data are summarized in Table 3. That liver failure results 
in 1 in 7 deaths from breast cancer is surprising, as the liver has a larger reserve capacity than most 
other organs. This highlights the involvement of the liver in breast cancer metastasis. 
In summary, breast cancer progression to metastatic disease is accomplished through the 
metastatic cascade, which begins with primary tumor growth and ends with emergence of dormant 
metastases to form clinically evident metastases. Once a patient has metastatic disease, her 
prognosis is poor. The extent of metastatic disease is often underestimated until autopsy, in 
particular in the liver and lung. The most common causes of death from breast cancer are 
pulmonary insufficiency, infection, and failure of the heart, liver, and central nervous system. 
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Inhibition or delay of the steps of the metastatic process is desirable to reduce the mortality from 
breast cancer. 
1.5 CLINICAL AND MOLECULAR PATHOLOGY 
Breast cancer can be classified pathologically by three main systems: histological, clinical, and 
molecular. The histological classification of breast cancer refers to the morphology observed on 
classical hematoxylin and eosin stained slides of tumor samples. The clinical classification of 
breast cancer refers to a combination of tumor stage and grade. Finally, the molecular 
characterization of breast cancers refers to a combined assessment of histological appearance and 
expression of markers such as estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (HER2). The next several sections expand on each of these 
three classification systems in turn. 
1.5.1 Histologic Classification of Breast Cancer 
There are currently 17 discrete histological classifications for breast cancer53. The majority of 
cancers are classified as invasive ductal carcinoma (IDC), which accounts for approximately 75% 
of tumors53,54. Invasive lobular carcinoma (ILC) comprises 15% of all breast cancers, and the 
remaining 10% of tumors can be classified into multiple subtypes including apocrine carcinoma, 
adenoid cystic sarcoma, metaplastic carcinoma, micropapillary carcinoma, and tubular 
carcinoma53–55. The two most common types of breast cancer, IDC and ILC, which together 
account for 90% of all breast cancers, are discussed briefly below. 
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Invasive ductal carcinoma is the most common malignant neoplasm of the breast. First 
reported almost fifty years ago, the initial stage of ductal carcinoma of the breast is marked by 
regions of hyperplasia and carcinoma in situ developing from the terminal ductal lobular unit 
(TDLU)56,57. It is important to note that the word “stage” in this context refers to the histological 
organization of the tumor cells and not to the clinical stage, to be discussed below. This initial 
stage is followed by ductular unfolding, distension, and subsequent union of multiple smaller 
ductules to form larger oviform lesions57. The modern terminology for these various stages, in 
order, is: 1) hyperplastic enlarged lobular units (HELU), 2) atypical ductal hyperplasia (ADH), 
and 3) ductal carcinoma in situ (DCIS)58. All of these stages are classified as premalignant without 
any obligation for progression. However, once cancerous cells invade across the basement 
membrane into the surrounding tissue, the pathology is then classified as invasive ductal 
carcinoma42. Morphologically, ductal carcinoma cells resemble the ductal epithelium in that they 
are moderate to large in size, columnar in appearance and organization, and are frequently 
polarized59.  
Lobular carcinoma follows an identical progression scheme to that of ductal carcinoma 
with similar terminology. For example, atypical lobular hyperplasia (ALH) and lobular carcinoma 
in situ (LCIS) are equivalent stages of ADH and DCIS respectively. As lobular carcinomas emerge 
from the lobular cells in the TDLU, they appear morphologically similar to their physiological 
counterpart. Namely, lobular carcinoma cells are relatively smaller in size than ductal carcinoma 
cells, are non-polarized, and are cuboidal in appearance and organization59. Due to the lack of 
cohesion between cells, lobular carcinoma cells typically invade the stroma in a ‘single-file’ 
manner60. This lack of cohesion is most commonly due to lack of E-cadherin expression, which is 
absent in 90% of invasive lobular carcinomas (ILC), but present in almost 100% of IDC61,62. The 
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incidence of ILC has increased more rapidly than that of IDC, which is concerning, as the former 
is more difficult to detect by both mammography and physical exam63. The more variable 
incidence of ILC has been attributed to its stronger dependence on female hormone exposure64. 
While IDC and ILC both arise from the TDLU, their pathology differs in several ways. 
First, ILC tends to have better short and long-term survival than IDC, which is likely due to the 
former commonly being low-to-middle grade, exhibiting low proliferative markers (Ki-67) but 
high expression of hormone receptors, and lacking HER2 overexpression or amplification60,65,66. 
However, this may be primarily due to a bias on tumor stage at diagnosis, as a large stage- matched 
study comparing IDC and ILC demonstrated worse long-term prognosis for the latter67. Moreover, 
due to their lower grade and higher expression of hormone receptors than IDC, ILC tends to be 
more chemoresistant, though some patients can achieve pathologic complete response60,68. Finally, 
while the rates of metastasis are similar between IDC and ILC, the sites of metastasis vary. For 
example, ILC tends to metastasize more to the gastrointestinal system, peritoneum, and 
gynecologic organs, while IDC metastases are found more commonly in the lung, pleura, and 
bone69. In summary, invasive ductal carcinoma and invasive lobular carcinoma are complex 
diseases with differing prognoses and therapies. For the sake of this dissertation, invasive ductal 
carcinoma will be the focus, as it is the most common breast cancer in women and also the tumor 
type of all commonly used human breast cancer cell lines, such as MCF-7, MDA-MB-231, T-47D, 
and BT-474. 
1.5.2 Clinical Classification of Breast Cancer 
In addition to classifying tumors based on histological appearance (Section 1.5.1), breast cancers 
are clinically ranked by tumor stage and grade. Tumor stage refers to the clinical status of the 
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patient and is determined by the TNM system, initially established by the American Joint 
Committee on Cancer (AJCC)70. TNM is an acronym for the three components that determine the 
cancer stage: Tumor (T), Nodal status (N), and Metastasis status (M). A specific TNM 
classification system exists for each type of cancer, so only the specific AJCC criteria for breast 
cancer are listed in Table 471.  
 
 
Table 4. Breast cancer stages 
Stage Primary Tumor Nodes Metastasis 
IA ≤ 20mm None None 
IB None ≤ 20mm Nodal micrometastasis (0.2-2mm or >200 cells) None 
IIA ≤ 20mm 20-50mm 
N1 
None None 
IIB 20-50mm > 50mm 
N1 
None None 
IIIA ≤ 50mm > 50mm 
N2 
N1 or N2 None 
IIIB T4 None, N1, or N2 None 
IIIC Any size N3 None 
IV Any size Any status Yes 
Breast cancer stages as according to the TNM staging system developed by the AJCC in their 8th edition manual71. 
AxN = Axillary lymph node; IMN = internal mammary lymph node; ScLN: supraclavicular lymph node; IcLN: 
infraclavicular lymph node; SLNB = sentinel lymph node biopsy; Tumor abbreviations: T4 = any size tumor with 
extension into the chest wall and or skin (ulceration/nodules); Nodal Abbreviations: N1 = 1-3 AxN/IMN on SLNB; 
N2 = 4-9 AxN on SLNB or clinically detected IMN; N3 = ≥10 AxN, ≥1 IcLN, clinically detected IMN + ≥1 AxN or 
IMN + >3 AxN on SLNB, or ≥1 ipsilateral ScLN. 
 
 
The full breast cancer staging criteria are described in Table 471. The most tangible 
definitions are as follows. Breast cancer can be classified as Stage 0, I, II, III, or IV. Stage 0 breast 
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cancer is ductal carcinoma in situ (DCIS), which has not progressed to invasive breast cancer. 
Stage I breast cancer applies to primary tumors less than 2cm in size and is further separated into 
IA and IB, with the latter exhibiting nodal micrometastases. Stage II breast cancer is similarly 
separated into IIA and IIB, with IIB exhibiting either a larger primary tumor or higher nodal status. 
Stage III breast cancer is subclassified into IIIA, IIIB, and IIIC, with increasing levels of invasion. 
For example, Stage IIIA cancers have lower nodal involvement than Stage IIIC, while Stage IIIB 
tumors involve extension to the chest wall or skin. Finally, Stage IV cancer refers to breast cancer 
with detectable metastases and is not dependent on tumor size or nodal status. 
While tumor stage is a clinical diagnosis based on a combination of the tumor size, nodal 
status, and metastasis status, tumor grade is dependent on cellular morphology and histology 
determined by cytological analyses. The most common grading system used in the US is the 
Nottingham Histologic Score72,73, whose parameters are listed in Table 5. 
 
 
Table 5. The Nottingham histologic score 
Histologic Parameters  Score  
 1 2 3 
Tubule Formation > 75%  10-75% < 10% 
Nuclear Pleomorphism Small, regular, and uniform 
Moderate increase in size 
and variability High variability 
Mitotic Counts / 10 HPF 0-5 6-10 > 10 
Total Score 3-5 6-7 8-9 
Grade 1 (Low) 2 (Moderate) 3 (High) 
Tubule formation, nuclear pleomorphism, and mitotic counts are determined for breast cancer tumor sections72,73. 
Mitotic count cutoffs listed are for a microscope with a field area of 0.152 mm2 as reported72. HPF = high powered 
field. 
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Tubule formation refers to the appeared differentiation of the histological sample, namely 
how glandular (with patent lumens) the tumor cell organization is. Tubules are a sign of well-
differentiated tumors, as they resemble the physiological glandular breast. Nuclear pleomorphism 
refers to the morphology of the nuclei of the tumor cells. A higher degree of variability and larger 
size of cancer cell nuclei are found in higher grade tumors. Finally, the mitotic count assesses the 
proliferative capacity of the tumor, with a higher mitotic score corresponding to a higher grade 
tumor. The Nottingham Histologic Score has been proven to be as effective as nodal status and 
more effective than primary tumor size at predicting patient prognosis72,74. 
1.5.3 Molecular Classification of Breast Cancer 
The molecular classification of breast cancer has become more complex, largely due to genomic 
advances in the past decade. For the purpose of this dissertation, only the four most common 
subtypes of breast cancer will be discussed: Luminal A, Luminal B, HER2 positive, and basal-like 
/ triple negative75,76. Claudin-low and normal-like breast cancers are newer subclasses of basal-
like / triple negative breast cancer, marked by lack of expression of basal markers like cytokeratins 
5 and 1477,78. For contextual reasons, these two subtypes will be grouped with other triple negative 
breast cancers. It should be noted that although these four subtypes are deemed to express or lack 
specific molecular markers, some tumors deviate from these criteria and some individual tumors 
can contain multiple subtypes78. 
Luminal breast cancer was initially described as a single type of breast cancer based on ER 
positivity (ER) and gene expression data79. Now, it is recognized that two forms of luminal breast 
cancer exist – luminal A and luminal B – which have different prognoses and tumor traits. Luminal 
breast cancer accounts for 60-70% of all breast cancer, with approximately 1/3rd of luminal cases 
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corresponding to the luminal B subtype76,80,81. Since all luminal breast cancers are ER positive, the 
A and B subtypes are distinguished by tumor expression of HER2, Ki-67, and progesterone 
receptor (PR). Whereas luminal A cancers are mostly HER2 negative, Ki-67 low, and PR high, 
luminal B can present with either positive or negative HER2 expression. HER2 positive luminal 
B tumors are ER positive and have no criteria for Ki-67 or PR expression, whereas HER2 negative 
luminal B tumors are ER positive and either Ki-67 high or PR low82. Since luminal B tumors either 
express HER2 or have high Ki-67, they are more aggressive, and their prognosis is worse than that 
of luminal A breast cancers80,82,83. 
HER2 type tumors were initially identified for their positivity for the human epidermal 
growth factor receptor 2 (HER2) and make up approximately 10-15% of breast cancers75,80,81. It 
should be noted that this classification is determined by gene expression clusters and not 
necessarily protein expression by immunohistochemistry, as 30% of HER2 type tumors do not 
respond to HER2-targetted therapy and are clinically negative for HER2 enrichment84. 
Approximately 50% of HER2 type tumors also express hormone receptors85, and HER2 type 
tumors are clinically more aggressive than luminal type tumors80,83,86.   
Finally, basal-like / triple negative breast cancers account for 15-20% of all breast cancers 
and are aggressive like HER2 positive disease80,81,87. This subtype commonly groups basal-like 
tumors with triple-negative tumors; however, these are not inclusive entities. Breast cancers that 
are negative for ER, PR, and HER2 are defined as triple negative78,88. Similar to these tumors, 
those that express one or more high molecular weight cytokeratins present in the normal basal 
epithelium of the breast (CKs 5, 6, 14, and 17), and commonly also lack ER, PR, and HER2 
expression, are referred to as basal-like78. As stated briefly above, normal-like and claudin-low are 
two forms of triple negative breast cancer that are not basal-like due to lack of expression of basal 
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markers78. Half of basal-like tumors express EGFR, which negatively impacts 
survival,independent of tumor size or nodal status87,89.  
In summary, the four main molecular classifications of breast cancer can be defined by 
expression of markers and dictates disease prognosis. Patients with luminal A disease have a fairly 
good prognosis, patients with luminal B have an intermediate prognosis, and patients with HER2-
type or basal-like / triple negative breast cancers have poor prognosis75. The molecular 
characteristics of each of these subtypes are shown below in Table 6. Careful classification of 
breast cancers is critical to identifying the signatures of tumors that will respond best to a particular 
therapeutic approach. 
 
 
Table 6. Molecular markers for cancer subtypes 
Subtype ER PR HER2 Ki-67 Basal CK 
Luminal A + + - - - 
 
Luminal B 
 
+ 
+ 
+ 
- / + 
+ 
- 
+ 
- 
- 
- / + 
+ 
- 
- 
- 
- 
HER2-Type - / + - / + +   
TNBC - - - - / + - / + 
Basal-like - - - - / + + 
Luminal A, Luminal B, HER2-type, triple negative, and basal-like breast cancer gene expression patterns. TNBC = 
Triple Negative Breast Cancer; ER = estrogen receptor, PR = progesterone receptor; CK = cytokeratin. 
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1.6 CELLULAR AND MOLECULAR PATHOLOGY 
The progression of a particular instance of breast cancer depends not only on its classification 
according to the three systems discussed above, but also the behavior of the relevant signaling 
pathways and genes that are often implicated in breast carcinogenesis and progression. In 
particular, the hormone receptors (estrogen receptor and progesterone receptor), the ErbB family 
proteins, the mitogen activated protein kinase (MAPK) cascade, and the phosphoinositide 3-kinase 
– Akt signaling axis are the most relevant to breast cancer pathogenesis. It is important to
acknowledge that the signaling networks presented below are simplified for clarity. In the past 
decade, breast cancers have been grouped more sophisticatedly by analyzing RNA expression and 
micro-RNA type and abundance. For a more extensive review of these items and other relevant 
markers in breast cancer, the reader is directed to more comprehensive references90–99. 
1.6.1 The Estrogen Receptor 
1.6.1.1 History 
The estrogen receptor has been implicated in the pathogenesis of breast cancer since Dr. George 
Beatson induced regression of metastatic breast cancer by surgical removal of both ovaries 
(bilateral oophorectomy) in 1896100. The estrogen receptor was first described by Jensen in 1958 
when he noticed the accumulation of radiolabeled estrogen in estrogen-target tissues, such as the 
uterus101. Other scientists noticed similar findings in both the female reproductive organs and 
breast cancers102,103. Starting in the 1970s, the biology of the estrogen receptor in the context of 
cancer had been determined, and its overexpression was hypothesized as a predictive factor for 
responsiveness to hormone therapy (Section 1.10)104–107. In 1974, comprehensive data were 
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presented in the support of using estrogen receptor expression as a predictive marker for response 
to endocrine therapy in breast cancer and to suggest tumors without its expression will not respond 
to endocrine therapy108,109. Moreover, lack of estrogen receptor expression was found to be an 
independent prognostic factor for early cancer recurrence110.  
Detection methods for estrogen receptor expression on tumor tissue evolved over the 
following several decades. Initial tests to determine the expression of estrogen receptor consisted 
of homogenization and purification of tumor lysate from fresh frozen tissue and assessment of 
ligand (estradiol) binding106,109. Separation of bound and free estradiol was most commonly 
achieved by centrifugation with dextran-coated charcoal106,111, although this technique may be 
inaccurate for dilute tumor lysate samples112. Advancements in the detection of estrogen receptor 
expression were made with the discovery of specific monoclonal antibodies in 1984 that suggested 
primarily nuclear localization of the estrogen receptor113. These antibodies were first used for an 
estrogen receptor monoclonal enzyme immunoassay (ER-EIA) that demonstrated higher 
sensitivity and specificity for proper classification of tumor specimens114. Moreover, tumor 
samples did not need to be processed immediately, as ER-EIA could be performed on 6-month old 
cryopreserved samples114. In the 1990s, immunohistochemical (IHC) determination of estrogen 
receptor in frozen and paraffin embedded sections was developed, with higher accuracy initially 
obtained using the former115. By the early-to-mid 1990s, IHC determination of estrogen receptor 
status became the standard due to convenience, low-cost, and high sensitivity116,117. Clinical 
studies have classified the relative abundance of ER required for disease free survival and overall 
survival benefits with hormone therapy118. 
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1.6.1.2 Molecular Biology 
The estrogen receptor is a nuclear hormone receptor with two isoforms: ERα and ERβ. The 
estrogen receptor (later determined to be ERα) was first discovered by Jensen in 1958. The full 
ERα, encoded by the ESR1 gene, was first successfully cloned from MCF-7 breast cancer cells in 
1985 by Walter and colleagues119. A decade later, a second isoform of the estrogen receptor, ERβ, 
encoded by the ESR2 gene, was described and cloned in 1996 first by Kuiper and subsequently by 
Mosselman120,121. The specific role of ERβ remains unclear. Some studies suggest ERβ expression 
correlates with improved overall survival, possibly through suppression of cell proliferation.122,123 
However, currently used ERβ antibodies are non-specific, which precludes any concrete 
conclusions from being drawn124. As such, for the remainder of this section, ERα will be discussed 
exclusively. 
The estrogen receptor can influence gene transcription through many different 
mechanisms. First, the estrogen receptor can act in the nucleus to influence gene transcription by 
either direct binding to the DNA at estrogen response elements (EREs) or by association with other 
transcription factors such as Sp-1, AP-1, and NF-κB95,96,125. Second, the estrogen receptor can act 
in the mitochondria to inhibit the early stages of apoptosis through transcription and augmentation 
of signaling through factors such as NRF-196,126,127. Finally, and especially pertinent for breast 
cancer, estradiol binding allows the estrogen receptor to interact with signaling pathways such as 
MAPK and PI3K-Akt128–130. In summary, the estrogen receptor has multiple downstream pathways 
through which it can signal, both through direct interactions with transcriptional machinery and 
through interacting with other signaling networks. For a more thorough review of the mechanisms 
of action of the estrogen receptor, the reader is directed to the literature95,96,131,132. 
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The estrogen receptor plays both physiological and pathological roles in the human breast. 
In normal physiology, ERα is essential for mammary gland morphogenesis and ductal elongation. 
Importantly, ERα expression is critical both in the mammary epithelial cells and in the stroma. For 
example, transplantation of a receptor negative fat pad into wild type mice is sufficient to inhibit 
ductal ingrowth due to a requirement for growth factor secretion by ERα positive stromal cells133. 
In breast cancer, estrogen receptor overexpression is the most common mechanism for pathology, 
almost half of which can be attributed to gene amplification134. Constitutively active mutations in 
ERα have been described135; however, only 1% of primary breast cancers demonstrate mutations 
in the coding region of ERα136, so these mutations are not relevant to most breast cancer cases. 
Additionally, it should be noted that ERα overexpression can also induce ligand-independent 
signaling137. Other mechanisms for ERα upregulation in breast cancer include altered promoter 
activity and decreased protein degradation138,139.    
In summary, the estrogen receptor has played the largest role in understanding breast 
cancer pathogenesis and responsiveness to therapy. The estrogen receptor isoform alpha (ERα) 
acts through transcription (direct or indirect through other transcription factors) and through 
interactions with other signaling factors (PI3K and tyrosine kinases involved in the MAPK 
cascade) to induce proliferation of breast epithelial cells during physiological development and 
malignancy. In breast cancers, half of estrogen receptor positive cancers are due to gene 
amplification of ESR1, whereas the other half are due to altered promoter activity or decreased 
protein degradation. Estrogen receptor positivity is an important prognostic factor and predictive 
factor for response to hormone therapies (Section 1.10). The interactions between the estrogen 
receptor and other oncogenes implicated in breast cancer, such as EGFR and HER2, are important 
for optimization of therapy for patients with estrogen receptor positive breast cancer140,141. 
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1.6.2 The Progesterone Receptor 
The progesterone receptors A and B (PR-A and PR-B) have been significantly less studied in breast 
cancer than the estrogen receptor, yet they play significant roles in both mammary development 
and cancer pathogenesis. Currently, there are no FDA approved anti-progesterone therapies for 
breast cancer, as agents tried in clinical trials present with severe side effects or cross-react with 
the glucocorticoid receptor142. Longitudinal clinical studies have in fact demonstrated an increased 
incidence of breast cancer in women receiving combined (estrogen + progestin) hormone therapy 
as compared to estrogen alone143. Therefore, information on the progesterone receptor presented 
below is focused on its role in physiology, its molecular signaling networks, and its use as a 
prognostic marker in breast cancer, rather than any future therapeutic modality.  
The progesterone receptor plays several important roles in normal breast physiology. 
Progesterone receptor stimulation is responsible for alveologenesis and alveolar organization into 
lobules during puberty and also in lobular-alveolar expansion during pregnancy in preparation for 
lactation144,145. Moreover, the high levels of progesterone during the luteal phase of the menstrual 
cycle correlate with a high proliferative index of the breast epithelium144. Of the two progesterone 
receptor isoforms, PR-B plays the most significant role in breast epithelial cell proliferation, as 
knock out of PR-A in mice results in a breast glandular structure similar to that of wild type 
mice146. Finally, progesterone action suppresses milk protein synthesis, which is particularly 
important in the late stages of pregnancy144. For a complete review of the role of progesterone 
receptor in normal physiology, the reader is referred to the following comprehensive reference144. 
Progesterone receptor (PR) is commonly implicated in breast cancer, with two-thirds 
(66%) of breast cancer patients classifying as PR positive81. Importantly, the progesterone receptor 
is directly regulated by ERα, and as such is often clinically used as an indicator for estrogen 
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receptor activity147. While the progesterone receptor isoforms (PR-A and PR-B) are expressed 1:1 
in normal tissue, this ratio is often altered in breast cancer, predominantly with a decrease in PR-
B93,148,149. While the relative loss of PR-B could be explained by an overexpression of PR-A, the 
majority of the data is in support of increased phosphorylation-turnover of PR-B, reflective of a 
high degree of crosstalk between PR and other signaling axes such as MAPK149–151 and the 
estrogen receptor152. As proliferative signaling in the breast is primarily due to PR-B activity and 
a higher relative expression of PR-A is correlated with higher tumor grade153, it is likely that 
increased signaling from PR-B causing increased turnover results in an apparent loss of PR-B 
despite its heightened activity145,149. Clinical detection of PR by IHC is not isoform specific. As 
such, altered ratios between PR-A and PR-B may explain some of the variability in responsiveness 
of PR positive tumors to endocrine therapy152.  
Expression of the progesterone receptor is a useful prognostic marker for breast cancer, 
and is predictive of increased responsiveness to endocrine therapy and decreased recurrence147,154–
156. Since progesterone receptor is directly regulated by estrogen receptor, tumor cells addicted to 
estrogen receptor signaling, and thus responsive to hormone therapy, are likely to express higher 
levels of progesterone receptor147. More recent studies have suggested that lack of progesterone 
receptor expression, independent of estrogen receptor status, is a negative prognostic marker for 
overall survival, breast cancer-specific survival, and disease-free survival157. 
In summary, while traditionally used as an indicator of estrogen receptor activity, the 
progesterone receptor serves multiple roles in the physiological and pathological human breast. 
Progesterone signaling is important for breast development during puberty and pregnancy and also 
plays critical roles in timing lactogenesis. In breast cancer, progesterone receptor isoform 
expression is altered, with the observed loss of progesterone receptor and corresponding poor 
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clinical prognosis likely due to increased signaling and degradation of PR-B. While estrogen 
receptor directly regulates progesterone receptor levels, PR is an independent beneficial prognostic 
marker for breast cancer, as patients harnessing tumors with absent PR expression have worse 
overall survival. These findings dictate the importance of progesterone receptor in the pathogenesis 
and prognosis of breast cancer. 
1.6.3 The ErbB Receptor Family 
The ErbB family of proteins contains four tyrosine kinase receptors all structurally related to the 
epidermal growth factor receptor (EGFR). The four receptors are ErbB1 (EGFR), ErbB2 
(HER2/Neu), ErbB3 (HER3), and ErbB4 (HER4). As EGFR and HER2 are the most commonly 
implicated and targeted for therapy in breast cancer, these two isoforms will be the primary focus 
of this section, whereas HER3 and HER4 will be discussed in less detail.  
1.6.3.1 The Epidermal Growth Factor Receptor (EGFR) 
The epidermal growth factor receptor (EGFR), also known as HER (Human EGF Receptor), is 
present on all epithelial and stromal cells, and its expression is polarized to the basolateral surface 
to prevent autocrine signaling from luminal EGF158. Approximately 18-24% of breast cancers 
overexpress EGFR, and roughly half of these are due to an increase in gene copy number159–161. 
EGFR expression is even more common in triple negative breast cancer, and its expression is 
inversely correlated with hormone receptor expression162,163. EGFR serves as an upstream 
regulator of several signaling cascades. The Ras – mitogen activated protein kinase pathway (Ras 
– MAPK) and the phosphatidyl inositol 3-kinase and Akt pathway (PI3K – Akt) are the most
significant to breast cancer164 and are discussed further in the Sections 1.6.4 and 1.6.5. 
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EGFR signaling is complex and only the essential features will be described here. For more 
details, the reader is referred to the literature158,165.  In short, non-ligand bound EGFR exists in a 
preferentially closed conformation, preventing association with like receptors. Once EGFR binds 
to a ligand, its open conformation is stabilized which allows for homo- and hetero-dimerization 
with EGFR or other members of the ErbB family respectively166. EGFR has seven known ligands: 
epidermal growth factor (EGF), betacellulin, heparin-binding EGF (HB-EGF), transforming 
growth factor alpha (TGFα), amphiregulin, epigen, and epiregulin, with the last three exhibiting 
approximately 10-100 fold lower affinity for EGFR than the first four167. EGFR dimerization 
facilitates activation of the cytoplasmic kinase domain and subsequent cross-phosphorylation of 
the c-terminal receptor tails. Phosphorylation allows for the recruitment of proteins harboring Src 
homology 2 (SH2) and phosphotyrosine-binding (PTB) domains, which subsequently instigate 
downstream intracellular signaling167. After activation of EGFR, the receptor complex is 
internalized and either recycled back to the plasma membrane or degraded in the lysosome. The 
fate of internalized EGFR is dependent on the ligand to which it is bound, with higher affinity and 
non-dissociable ligands (such as EGF) preferentially driving degradation158.  
EGFR plays dynamic roles in the progression of breast cancer. Clinically, EGFR over-
expression is a poor prognostic indicator in breast cancer89,159 because it has contrasting effects on 
tumor biology at the site of the primary tumor and at distant metastatic lesions. At the site of the 
primary tumor, EGFR plays a significant role in breast cancer EMT, often through autocrine EGFR 
activity that drives E-cadherin internalization45. Moreover, autocrine EGFR signaling stimulates 
tumor cell proliferation and invasion45. In contrast, progressing macrometastases exhibit decreased 
expression and nuclear localization of EGFR, which induces resistance to EGFR-targeted 
therapies. Moreover, EGF-stimulation can result in growth arrest and apoptosis of tumor cells at 
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the metastatic site165. That EGFR plays significant roles across the entire breast cancer metastatic 
cascade demonstrates its importance in human breast cancer. 
1.6.3.2 The Human Epidermal Growth Factor Receptor 2 (HER2) 
HER2 gene amplification, leading to its overexpression at the protein level, was first demonstrated 
in breast cancer by Slamon and colleagues in 1987168. This study linked overexpression of HER2 
to decreased overall survival and decreased relapse-free survival. The human epidermal growth 
factor receptor 2 (HER2) is overexpressed in 15-30% of human breast cancers and remains a 
marker of more aggressive disease despite significant advances in HER2 targeted therapies169–171. 
In contrast to the other three members of the ErbB receptor family (EGFR, HER3, and HER4), 
HER2 has no known ligands. It homo- or hetero-dimerizes with other members of the HER family 
to influence downstream signaling in a manner similar to that discussed in the “EGFR” section 
previously170, with the involvement of signaling pathways such as Ras – MAPK and PI3K – Akt.  
While HER2 can form both homo- and hetero-dimers with other members of the HER 
family, the latter more strongly stimulates mitogenic signaling169. Homodimers in human tumors 
are thought to be due to a high receptor density at the cell membrane, allowing spontaneous 
dimerization172. Indeed, expression of a high membrane density of HER2 in human cells is 
sufficient for oncogenic transformation173. Analysis of the HER2 analog in rodents, neu, has also 
demonstrated that point mutagenesis at key residues can enhance homodimerization, although 
human tumors do not demonstrate the same mutation172. HER2 is the preferential partner for 
EGFR, HER3, and HER4 for heterodimerization174, with HER2-HER3 heterodimers being most 
preferable. This finding is also illustrated by the relative mitogenic potentials of different homo- 
and hetero-dimers, shown in Table 7169.  
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Table 7. HER family dimer mitogenic potential 
Ligand bound: EGFR HER2 HER3 
EGFR 3.2 N/A 6.5 
HER2 5.0 3.1 10.5 
HER3 3.1 N/A 0 
The relative mitogenic potential of different homo- and hetero-dimers of the HER family. The top row illustrates the 
member of the HER family that is ligand bound (in the case of hetero-dimers). HER2 homodimer mitogenic 
potential was demonstrated by dimerization with a non-blocking antibody. HER4 data are not included as this 
receptor antagonizes cell proliferation. Data are modified from Yarden et al, 2001169. 
Hetero-dimers signal more potently than their homodimer counterparts, primarily due to 
lower rates of ligand dissociation, which is further enhanced when HER2 is the binding 
partner175,176. Prolonged binding allows for preferential mitogenic (sustained) signaling through 
mediators such as the MAPK pathway169. In addition to reducing ligand dissociation rates, HER2 
can prolong mitogenic signals by enhancing receptor recycling upon ligand-stimulated 
internalization of dimers. For example, while EGFR homodimers that bind high affinity ligands 
are targeted for degradation by adapter proteins (such as the ubiquitin ligase c-Cbl), EGFR-HER2 
hetero-dimers bind these adapter proteins with less affinity, facilitating recycling of EGFR to the 
membrane and prolonged signaling. Interestingly, one of the proposed mechanisms of Herceptin 
(anti-HER2 monoclonal antibody discussed in more detail in Section 1.10) is recruitment of c-Cbl 
to HER2 molecules, facilitating receptor degradation169,177. 
In summary, HER2 acts as an oncogenic driver in breast cancer through gene amplification 
and protein over-expression. Most commonly, HER2 associates with EGFR, HER3, and HER4 in 
hetero-dimers to potentiate and prolong mitogenic signaling and decrease ligand-facilitated 
internalization and degradation of signaling complexes. HER2 can also spontaneously 
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homodimerize at high membrane receptor densities and directly signal to downstream pathways 
such as Ras – MAPK and PI3K – Akt. HER2 is an important therapeutic target in breast cancer 
and its overexpression is predictive of response to anti-HER2 based therapies. Targeted therapies 
against HER2 will be discussed in detail in Section 1.10.  
1.6.3.3 The Human Epidermal Growth Factor Receptor 3 (HER3) 
HER3 is uniquely different from the other three HER family members in that the alteration of 
several critical residues in the kinase domain inactivates its catalytic function178. Thus, while 
heterodimers containing HER3 are capable of downstream signaling, HER3 homodimers cannot 
signal because they lack the ability to phosphorylate the C-terminal residues that serve as signaling 
protein docking sites178. Moreover, heterodimers containing ligand-bound HER3 are capable of 
more prolonged mitogenic signaling than other receptor pairs169, in particular in HER2 amplified 
breast cancer179. HER3 has two known ligands, Neuregulin-1 and -2 (NRG1, NRG2), which 
mediate homo- and hetero-dimerization.  
HER3 contains multiple docking sites for p85 PI3K, which can mediate resistance to anti-
HER2 therapy in amplified tumors179 and contribute to metastatic colonization180. While 
suppression of EGFR or HER2 signaling using tyrosine kinase inhibitors transiently suppresses 
HER3 phosphorylation, an upregulation of HER3 protein at the membrane and reduced 
phosphatase activity eventually causes restoration of oncogenic signaling181. This resistance 
signaling is mediated by a suppression of PI3K/Akt signaling that induces transcription factors, 
such as FoxO1, that drive upregulation and phosphorylation of multiple receptor tyrosine kinases 
including HER3182. Thus, HER3 acts as a significant mediator of anti-HER therapy resistance and 
oncogenic signaling in breast cancer. While these data suggest that HER3 would be a poor 
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prognostic marker in breast cancer, clinical studies remain inconclusive on its influence on breast 
cancer survival183. 
1.6.3.4 The Human Epidermal Growth Factor Receptor 4 (HER4) 
In contrast to the other three HER family members, HER4 signaling is associated with anti-
proliferative and pro-apoptotic effects in breast cancer183. HER4 can bind to many ligands, 
including all of the Neuregulin growth factors (NRG-1, -2, -3, and -4), betacellulin, epiregulin, 
and HB-EGF183,184. Nuclear localization of HER4 results in anti-proliferative effects in breast 
cancer cells, while mitochondrial localization of HER4 and subsequent interaction with BAK 
promotes apoptosis184. As expected, HER4 expression in breast cancer is associated with lower 
grade, hormone receptor positive disease185. Moreover, HER4 expression is an independent 
prognostic marker for improved overall survival in breast cancer185–187. Finally, HER4 has been 
shown to antagonize HER2 signaling both in vitro and in clinical studies187. 
1.6.3.5 ErbB Family Summary 
In summary, the ErbB / HER family plays significant pathologic and prognostic roles in breast 
cancer. EGFR is associated with tumor invasion and metastasis due to its role in promoting EMT. 
HER2 is associated with oncogenic transformation and proliferation of breast cancer cells and is 
the most common target of antibody-based therapy in breast cancer. HER3, while kinase inactive, 
contributes to mitogenic signaling and anti-HER therapy resistance in breast cancer. Finally, HER4 
signals for growth inhibition and apoptosis of breast cancer cells, and its expression bears good 
clinical prognosis. The effects of these four receptors are summarized in Table 8.  
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Table 8. HER family effects in breast cancer 
Effects in Breast Cancer EGFR HER2 HER3 HER4 
Oncogenesis and Growth +/- + + - 
Invasion and Metastasis + + + - 
Clinical Prognosis - - +/- + 
The influences of the HER family members on oncogenesis and growth, invasion and metastasis, and clinical 
prognosis of breast cancer. (+) positive effector, (-) negative effector, (+/-) context-dependent effector. 
 
 
1.6.4 Ras – MAPK Signaling 
The Ras – MAPK signaling cascade plays important roles in the progression of breast cancer. This 
is not meant to be a comprehensive review, rather to provide background sufficient to understand 
data presented herein. There are four major mitogen-associated protein kinase (MAPK) signaling 
cascades in humans, all of which end with transcriptional activity performed by the association of 
the MAP kinase in the pathway with nuclear transcriptional factors. These four effector MAP 
kinases are Erk1/2, Erk5, Jnk, and p38188. Generally, Erk1/2 and Erk5 are responses to extracellular 
growth factor stimulation, whereas Jnk and p38 are associated with cellular stress signals188–190. 
As the present work only involves Erk1/2, it is only necessary to discuss this MAPK effector and 
its upstream factors, focusing on the signaling cascade followed by the in vitro and in vivo 
influences of this signaling cascade on breast cancer progression. Finally, the clinical relevance of 
this pathway is described. 
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Figure 6. The Ras - MAPK and PI3K - Akt signaling pathways 
A simplified representation of the Ras – MAPK and PI3K – Akt signaling networks, illustrating the crosstalk 
between the pathways using a receptor tyrosine kinase (RTK) common input. Phosphorylation of the intracellular 
domain of RTK (for example, EGFR) attracts the SH2 domain of Grb2, which subsequently attracts Sos-1 through 
its SH3 domain. Sos-1 acts as a guanine exchange factor (GEF) for Ras, converting it into the “on” state. Ras signals 
downstream through Raf and PI3K as its major effectors. PI3K signals through Akt whereas Raf signals through 
Mek1/2, then Erk1/2, to activate transcriptional programs that lead to growth migration and survival. RTKs can also 
directly signal through PI3K. Phosphorylated Akt can suppress Raf activity as one of the mechanisms of crosstalk 
between these two signaling networks. Inhibitors of PI3K (LY294002) and Mek1/2 (PD98059) signaling are 
illustrated. This diagram was created using images from Servier Medical Art46.  
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Since Erk1/2 signaling commonly begins with growth factors binding to the extracellular 
domain of receptor tyrosine kinases (RTKs), EGFR activation will be used to illustrate this 
signaling pathway (Figure 6). EGFR binds ligand, which induces receptor homo- or hetero-
dimerization and phosphorylation of the cytoplasmic receptor tails158. Phosphorylation of the 
EGFR intracellular domain recruits proteins harboring SH2 and PTB binding domains, such as 
Grb2191,192. In turn, Grb2 associates through its SH3 domain with the guanine exchange factor 
(GEF) Sos-1193,194. Sos-1 catalyzes the exchange of GDP for GTP on several small signaling G-
proteins, such as Ras, which acts as an activation signal. Importantly, in order to associate with 
Sos-1, Ras must be tethered to either the plasma membrane or lipid rafts through prenyl groups195.  
After activation, Ras recruits Raf to the membrane through the latter’s Ras binding domain 
(RBD), which removes Raf auto-inhibition and allows for partial activation of Raf kinase activity 
by its phosphorylation by other membrane kinases, such as CK2 and Shc196,197. Dimerization of 
Raf induces its catalytic activity and results in the recruitment of Mek1/2 and its phosphorylation 
and activation197. Activated Mek1/2 subsequently phosphorylates and activates Erk1/2, which 
translocates to the nucleus and interacts with transcription factors such as Elk1 and Elf1 to induce 
transcription of target genes197,198. Importantly for breast cancer, nuclear Erk1/2 can interact with 
and activate the estrogen receptor198. Finally, feedback inhibition of this MAPK cascade acts as an 
important regulatory mechanism whereby, for example, active Erk1/2 phosphorylates upstream 
proteins at inhibitory sites to reduce downstream activation of the pathway199. 
Erk1/2 signaling in breast cancer can be described as either independent of or dependent 
on estrogen signaling. Estrogen independent Erk1/2 activity is traditionally due to upstream signals 
from growth factors, such as EGF, TGFα, and IGF-1, which transmit mitogenic and migratory 
signals down the MAPK cascade200. In contrast, estrogen dependent Erk1/2 activity can occur from 
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both immediate (signal-based) and late (genomic) effects. Estrogen can activate Erk1/2 within five 
minutes of stimulation in ER positive MCF-7 breast cancer cells, which is due in part to activation 
of c-Src201. Similarly, the estrogen receptor mediates transcription of growth factors such as TGFα 
and IGF-1, which can subsequently act in an autocrine or paracrine manner to enhance Erk1/2 
activity202. Importantly, enhanced Erk1/2 activity is commonly found in breast cancers subjected 
to anti-estrogen therapies, suggesting this pathway serves as an adaptation mechanism. For 
example, breast cancer xenografts formed from long-term estrogen deprived cells were more 
sensitive to the mitogenic effects of estrogen than their wild type counterparts, which was due to 
increased MAPK activity in the former203. Moreover, breast cancer cells resistant to anti-estrogen 
therapies rely in part on Erk1/2 activation for cell growth204. 
Hyper-activation of Erk1/2 is common in breast cancer pathologic specimens. For example, 
there is a 5-fold upregulation in both phosphorylation and protein expression of Erk1/2 in breast 
carcinoma as compared to benign pathologies, such as fibroadenoma205, and similar upregulation 
compared to matched control tissue206,207. Likewise, Erk1/2 activity is further increased in lymph 
node metastases as compared to primary breast tumors, suggesting it plays an important role in the 
metastatic cascade207. Moreover, highly activated MAPK signatures are associated with loss of 
estrogen receptor expression in clinical breast cancer specimens, decreased responsiveness to anti-
estrogen therapy, and poor prognosis208–210. 
In summary, the Ras – MAPK signaling pathway, focusing specifically on Erk1/2 as the 
downstream effector, is commonly dysregulated in breast cancer. Mitogenic and migratory signals 
from Erk1/2 originate from growth factor stimulation, through EGFR and other RTKs, and from 
estrogen stimulation, through the estrogen receptor and c-Src. Enhanced Erk1/2 activity in breast 
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cancer is a resistance mechanism to anti-estrogen therapy, is implicated in tumor metastasis, and 
bears poor clinical prognosis. 
1.6.5 PI3K – Akt Signaling 
Another important factor in breast cancer is the PI3K – Akt signaling cascade, particularly PI3K 
activation, recruitment of Akt, and downstream signals. The in vitro and in vivo influences of this 
signaling cascade on breast cancer progression will be discussed and then the clinical relevance of 
this pathway will be examined. 
The phosphatidylinositol 3-kinase (PI3K) family of enzymes comprises many different 
classes and subclasses based on enzyme structure and activity. Generally, PI3K is composed of 
p110 (catalytic, PI3KCA gene) and p85 (regulatory) subunits211. Activation of PI3K can occur 
through at least three independent pathways, all of which involve binding of ligand and activation 
of RTKs212. First, the SH2 domain of p85 can directly bind phospho-tyrosine consensus sequences 
on the cytoplasmic tails of activated RTKs, which in turn activates the p110 catalytic subunit213. 
Second, Grb2 association with the RTK can recruit Gab, which in turn can bind p85 and activate 
p110214. Finally, Ras can directly activate p110, independent of p85 involvement212 (Figure 6). 
Downstream signaling is initiated by the kinase activity of activated p110, which generates 
the second messenger phosphatidylinositol 3,4,5-triphosphate (PIP3) by phosphorylation of its 
precursor, phosphatidylinositol 4,5-bisphosphate (PIP2)215. Subsequently, PIP3 can initiate 
intracellular signaling by binding to Pleckstrin Homology (PH) domains of downstream kinases, 
such as phosphoinositide-dependent kinase 1 (PDK1) and Akt212,216. The ensuing recruitment of 
both PDK1 and Akt to the membrane by PIP3 binding brings these two proteins into close 
proximity and allows the former to activate the latter by phosphorylation at threonine 308217. A 
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second phosphorylation at serine 473 is required for the complete activation of Akt, which is 
predominantly achieved by mTORC2 activity218,219.  
Akt acts through different downstream mediators to promote cell growth and survival. For 
example, inactivating phosphorylation of pro-apoptotic factors Bad and procaspase-9 and negative 
regulation of NF-κB promote cellular survival212,220. Moreover, inhibition of GSK3 by Akt 
prevents the phosphorylation of cytoplasmic β-catenin and its subsequent degradation, which 
allows β-catenin to translocate to the nucleus and induce the expression of growth promoting genes 
such as Cyclin D1220. Finally, mTORC1 activation by Akt enhances protein synthesis and regulates 
ribosomal biogenesis221. PI3K – Akt signaling is negatively regulated by the phosphatases PTEN 
and PP2A, which dephosphorylate PIP3 and Akt respectively220,222.  
In breast cancer specifically, hyper-activation of the PI3K – Akt pathway plays a role in 
tumor development, progression, and resistance to therapy223. While homozygous germline 
knockouts of PTEN are lethal, heterozygous or mammary gland specific knockouts of PTEN  were 
sufficient to induce spontaneous tumors in mice224. Similarly, homozygous and heterozygous 
knockout of Akt1 prevented or delayed tumor formation in mice that over-expressed mammary 
gland specific HER2225. Additionally, conditional over-expression of PI3KCA or Akt1 in mice 
was sufficient to induce mammary tumor formation and progression226,227. Importantly, Akt 
isoforms play differential roles in breast cancer development and progression. While Akt1 over-
expression strongly induces primary tumor growth, down-regulation of Akt1 with up-regulation 
of Akt2 induces invasion and metastasis228. Finally, activation of the PI3K – Akt pathway is 
sufficient to induce resistance to endocrine and HER2 directed therapy in breast cancer cell lines 
in vitro, and inhibition of this pathway re-sensitizes cells to therapy229–231. 
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Dysregulation of the PI3K – Akt pathway is common in breast cancer. Mutations in 
PI3KCA are the most common genetic alteration in this pathway, present in approximately 36% 
of breast cancers,232 with 80% of these mutations occurring in either the helical or kinase 
domains233. In contrast, only 2% and 3% of breast cancers harbor mutations in Akt and PTEN, 
respectively232. Similar to increased activation of Erk1/2, PI3K-Akt signaling contributes to 
resistance to endocrine233,234 and HER2235 directed therapies. While therapies targeting 
downstream elements of this pathway (Everolimus to inhibit mTORC1) are clinically approved 
for breast cancer, PI3K and Akt inhibitors have shown limited success in clinical trials due to off-
target toxicities236–238. Akt activation in breast cancer bears poor clinical prognosis228,239. 
In summary, PI3K – Akt signaling plays multiple roles in the development, progression, 
and treatment of breast cancer. PI3K activity is regulated by both membrane (e.g. RTKs) and 
intracellular (e.g. Ras) kinases. Activation of the PI3K – Akt signaling axis promotes cell cycle 
progression, enhances protein synthesis, and induces resistance to apoptotic stimuli. In breast 
cancer, more than one third of tumors harbor an activating mutation in PI3K, which promotes 
initial tumor growth, invasion and metastasis, and resistance to endocrine and HER2 targeted 
therapies. Finally, high activity of the PI3K - Akt signaling pathway is a negative prognostic factor 
in breast cancer. 
1.6.6 Ras – MAPK and PI3K – Akt Crosstalk 
Crosstalk between the Ras – MAPK and PI3K – Akt cascades has already been introduced in the 
previous sections. The mechanisms by which the two pathways communicate will be briefly 
summarized here. First, active (GTP-bound) Ras can directly bind and activate the p110 subunit 
PI3K212. Second, Akt can negatively regulate the MAPK pathway at the level of Raf by inhibitory 
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phosphorylation240. In contrast, Raf – MAPK activity can potently induce Ras and PI3K by 
autocrine production of growth factors that signal through cell surface RTKs241. Third, active 
Erk1/2 phosphorylation of Gab1 inhibits Gab1-mediated recruitment of PI3K to the membrane, 
preventing its subsequent activation214. In contrast, Erk1/2 phosphorylation of TSC2, a negative 
regulator of mTORC1 which is also regulated by Akt, promotes activation of mTORC1 in a PI3K-
independent manner242. Finally, PI3K association with Gab1 in a positive feedback loop can 
prolong Ras signaling by increasing the number of Grb2 – Sos-1 complexes recruited to the plasma 
membrane243. In summary, the Ras – MAPK and PI3K – Akt pathways are intimately involved 
with each other, and each can provide both inhibitory and stimulatory regulation of the other 
(Figure 6). 
1.6.7 Tumor Heterogeneity 
For four decades, it has been shown that some breast cancers exhibit tumors and metastases with 
molecular and cellular heterogeneity244. While still not completely understood, tumor 
heterogeneity was initially thought to arise from the clonal evolution of cancer245. In this model, 
tumor cell evolution is stochastic according to Darwinian Evolution, whereby tumor clones with a 
greater survival or growth advantage emerge246. These advantages can be driven by epigenetic 
changes and mutations, which alter the activity of oncogenes and tumor suppressor genes247. More 
recently, the theory of tumors being driven by cancer stem cells has provided an alternative and 
complementary explanation for heterogeneity248. In contrast to the clonal evolution model, the 
cancer stem cell model states that heterogeneity is driven by the composition of a small fraction of 
tumor cells (the stem cells), which creates a hierarchical organization of different, “terminally 
differentiated” tumor clones249. In this way, proliferation and terminal differentiation of a small 
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subpopulation of stem cells, each of which may exhibit different gene expression profiles, sustains 
the tumor.  
To illustrate the difference between these two theories, let us consider a breast cancer tumor 
with five major clones being challenged by treatment with a chemotherapy. In the case of the 
clonal evolution model, the breast cancer subpopulation most resistant to the chemotherapy will 
selectively outgrow, which may eliminate some of the initial clones and allow for subsequent 
evolution to occur. In contrast, the cancer stem cell theory suggests that all of the terminally 
differentiated cancer cells will be eliminated by the chemotherapy while the slowly dividing cancer 
stem cells will remain, resulting in an eventual repopulation of the initial heterogeneity after 
removal of the chemotherapy. 
Tumor heterogeneity is a major cause of therapy failure and tumor progression. In breast 
cancer, heterogeneity may present as differential expression of biomarkers (e.g. The Estrogen 
Receptor) in a single tumor, differences in biomarker expression between primary and metastatic 
lesions, and differences in tumor cell phenotype or gene expression250. In particular, heterogeneity 
is emphasized in tumors that exhibit high genomic instability251. As such, heterogeneity motivates 
a combination-based approach to treating breast cancer, since a single agent may not be effective 
against all tumor cells. 
1.7 SURGERY 
The first recorded mention of breast cancer dates back to the Edwin Smith Surgical Papyrus in 
3000-2500 B.C., in which this incurable disease was described as “cool to touch, bulging and 
spread all over the breast”252. Until the late 19th century, treatment of breast cancer consisted of 
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barbaric surgeries and faith-based healing252. The modernization of breast cancer surgery began 
with Dr. William S. Halstead who performed the first radical mastectomy at Johns Hopkins in June 
1889, with particular attention paid to removal of surrounding involved muscle tissue (pectoralis 
major)252,253. 
Surgical management at the start of the 20th century incorporated the radical mastectomies 
of Dr. Halstead and the aggressive bilateral oophorectomies and adrenalectomies pioneered by Dr. 
George Beatson at the end of the 19th century252,254. The first major step towards breast-conserving 
surgery began with a report from Drs. Patey and Dyson in 1948 that demonstrated no difference 
in survival when the pectoralis major was preserved during mastectomy255,256. Further 
modifications to the radical mastectomy were made by Drs. Auchincloss and Madden, who 
additionally preserved the pectoralis minor muscle and argued against the paradigm of complete 
axillary lymph node dissection256,257. 
The first reports of successful breast-conserving therapy (lumpectomy) for early stage 
breast cancer were published by Veronesi and colleagues in 1981 and demonstrated no difference 
in recurrence or survival with their quandrantectomy procedure as compared to radical 
mastectomy258. Furthermore, no difference in either overall or breast cancer-specific survival were 
noticed after twenty years of follow up259. Fisher and colleagues demonstrated similar data with a 
larger cohort of patients, in which survival was equivalent between lumpectomy and total 
mastectomy260,261. The cosmetic outcome of lumpectomy was improved through pioneering less 
invasive procedures, such as skin- and nipple-sparing mastectomies262,263. Further cosmesis can be 
achieved using breast reconstructive procedures, in which the removed breast tissue is replaced by 
implants or autologous tissue, in the form of a free flap, perforator flap, or fat graft264. 
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Current recommendations for breast cancer surgical management can be classified into 
three broad categories depending on the stage of the tumor: early stage primary breast cancer, 
locally advanced primary breast cancer, and metastatic breast cancer. Early stage breast cancers 
(Stage 0, I, or II) are preferentially treated with breast-conserving surgery. A total mastectomy is 
used if negative tumor margins cannot be adequately achieved with lumpectomy or if the patient 
desires a different cosmetic outcome265,266. Locally advanced primary breast cancers, defined as 
Stage III, are often treated with neoadjuvant chemotherapy (discussed more in Sect 1.9) in order 
to shrink the primary tumor prior to surgery. Surgical management after neoadjuvant 
chemotherapy is similar to early stage breast cancer; however, axillary lymph node management 
is generally more aggressive266,267. Surgical management of metastatic disease (Stage IV cancer) 
is primarily palliative. Some studies show a survival benefit in women with metastatic breast 
cancer upon removal of their primary tumor, but it is difficult to generalize these data due to 
publication bias and the retrospective nature of the studies268. Surgery of metastatic lesions in the 
lung may be beneficial in metastatic breast cancer patients, but their main benefit is in 
distinguishing pulmonary metastasis from primary lung cancer in patients with a solitary lung 
nodule and no extra-thoracic disease268,269. Surgical management of hepatic nodules may be 
beneficial in patients with completely resectable metastatic nodules and no extrahepatic disease 
(except for bone metastases which are managed well with radiotherapy). However, removal of 
hepatic breast cancer metastases is rare, whereas hepatic colorectal carcinoma metastases are more 
commonly treated with surgery268,270. 
Axillary lymph node evaluation accompanies breast cancer surgery. Currently, axillary 
lymph node dissection is performed in all patients with clinically positive nodes, whereas patients 
with clinically node-negative disease undergo sentinel lymph node biopsy to evaluate the need for 
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axillary dissection265. For example, patients with stage IIIA disease may only need a sentinel 
lymph node biopsy, whereas patients with stage IIIB or IIIC disease often undergo initial axillary 
lymph node dissection, the extent of which depends on the presence of gross nodal metastases in 
proximal nodes265,266. There is no benefit to nodal dissection in patients with proven metastatic 
disease266. 
In summary, breast cancer surgery has evolved dramatically over the past century. Initial 
radical mastectomies have been replaced largely with breast-conserving surgery and subsequent 
breast reconstruction to achieve a cosmetic outcome. For patients with early stage breast cancer, 
surgery in the form of lumpectomy or mastectomy with reconstruction is recommended as the 
initial therapy. For patients with locally-advanced breast cancer, neoadjuvant chemotherapy is 
commonly used to shrink the primary tumor prior to surgery. Axillary lymph node evaluation is 
critical in patients with non-metastatic breast cancer and is performed at the time of surgery. For 
patients with clinically node-negative disease, a sentinel lymph node biopsy is used to rule out the 
need for axillary lymph node dissection. For patients with clinically node-positive disease, primary 
axillary lymph node dissection is performed to guide future treatment. Finally, surgical 
management of primary and metastatic tumors in metastatic breast cancer patients may provide 
some palliation or survival benefit in a select group of patients with favorable prognostic factors, 
but these patients are most commonly managed with systemic therapies. 
1.8 RADIATION THERAPY 
The use of radiation therapy (radiotherapy) to treat disease was implemented soon after Dr. 
Wilhelm Röntgen was the first to characterize X-rays in 1895271. Dr. Emil Grubbe is credited with 
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the first use of X-rays to treat recurrent breast cancer in 1896272. Radiation therapy has evolved 
dramatically over the past century and is now a critical component of breast cancer treatment.  
Radiation therapy uses either particles or photons (x-rays and gamma radiation) to deliver 
energy to tumors in order to cause cell damage and death. Radiation can be delivered using an 
external beam or with an internal (brachytherapy) device. The energy transferred by particle 
radiation per unit distance increases with the mass of the particle used and is quantified by the 
linear energy transfer (LET)273. The higher the LET of a radiotherapy modality, the more 
effectively it deposits energy in the target tissue. Radiation dosages are described by total dosage 
amount and number of fractions. The dosage amount is described in grays (Gys), which is the 
number of joules per kilogram of tissue. The number of fractions describes the quantity of sessions 
over which the total dose of radiation is given. Recently, hypo-fractionated radiotherapy, meaning 
fewer fractions with more energy per fraction, has grown in favor due to fewer off-target effects 
on the surrounding non-tumor tissue274. 
The most common types of radiotherapy employed in modern cancer treatment are photon 
and charged particle beams. Photon based therapies either use X-rays (lower energy) or gamma 
rays (higher energy) to create secondary electrons that cause ionization and tissue damage as they 
travel away from the primary beam. X-ray sources include cathode ray tubes and linear 
accelerators, while gamma rays are generated by the decay of radioactive substances, most 
commonly cobalt-60, radium, and cesium275. Importantly, lower energy photon beams are thought 
to be more biologically effective against cancer due to their production of lower energy secondary 
electrons, which exhibit a relatively higher LET276. In contrast, charged particle beams use higher 
energy, heavier particles rather than massless photons. Examples of charged particle beams are 
electron, proton, neutron, and alpha-particle beams275. As charged particle beams are more 
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commonly used in radio-resistant cancers, such as prostate carcinoma and sarcomas, they will not 
be more extensively discussed here273. 
The main mechanism of action of radiotherapy is the ionization of molecules, which can 
cause tumor cell damage and death. The primary target of radiation in tumor cells are DNA 
molecules, which can be influenced directly or indirectly by the ionization of the DNA itself or of 
water molecules, which subsequently generate free radicals that induce DNA damage277. For X-
rays and gamma rays, approximately 60% of the damage of radiation is indirect, resulting from 
the ionization of water and generation of free radicals278. DNA damage induced by radiation 
triggers a multitude of responses inside the irradiated cells, mediated by cytokines, growth factors, 
and chemokines278. The main therapeutic effect accomplished by these triggered responses is cell 
death, which can be achieved through apoptosis, mitotic catastrophe, necrosis, senescence, or 
autophagic cell death275. Moreover, induction of DNA damage in irradiated cells can release 
signals (cytokines, reactive oxygen species, secreted extracellular matrix proteins, etc.) that affect 
and kill neighboring tumor cells in a paracrine or juxtacrine manner278. Interestingly, while rare, 
primary tumor irradiation can even result in the regression of metastatic lesions, termed the 
abscopal effect. This effect is thought to be due to activation of anti-tumor immunity through the 
release of damage-associated molecular patterns (DAMPs), cytokines (such as TNF and IL-1), and 
chemokines (such as CXCL10) that can enhance the generation of cytotoxic T-lymphocytes279–282.  
Radiation therapy plays an extensive role in the management of both early and metastatic 
breast cancer and typically occurs after primary surgery and adjuvant chemotherapy. The primary 
use of radiotherapy is to reduce locoregional recurrence. For Stage 0, I, and II breast cancer after 
lumpectomy, node-negative patients receive whole breast radiotherapy (WBRT) therapy with or 
without a boost to the tumor bed265. The dosage for WBRT is 50 Gy in 23-25 fractions or 40-42.5 
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Gy in 15-16 fractions, for standard and hypofractionated radiotherapy respectively. Common 
tumor boost dosages are 10-16 Gy in 4-8 fractions266. For node-positive patients undergoing 
lumpectomy, regional radiotherapy is recommended. For patients receiving mastectomy, chest 
wall radiotherapy (CWRT) and irradiation of the axillary and clavicular regions are recommended 
in all patients, except those with a small (<5cm) primary tumor, node negative disease, and 
negative margin (>1mm) resections266. Almost all patients with stage III breast cancer will receive 
adjuvant WBRT (for lumpectomy) or CWRT (for mastectomy), with or without a boost to the 
surgical site, and supplemented by irradiation of the axillary, infraclavicular, supraclavicular, and 
internal mammary node regions265,266. Finally, radiotherapy for metastatic breast cancer is 
primarily palliative and is most commonly used to treat bone metastases to decrease pain and 
reduce the incidence of skeletal-related events283,284. 
In summary, radiation therapy has dramatically evolved over the past century and has 
become a staple in the treatment of breast cancer. Photon-based radiotherapy is primarily used in 
breast cancer, which can take the form of X-rays or gamma rays. The radiation applied by external 
or internal sources causes the ionization of intracellular water or DNA molecules that induce cell 
damage and death pathways. These effects can be both direct and indirect, the latter of which 
denotes the ability of irradiated cells to generate signals that cause local or distant tumor cell death. 
Radiotherapy is primarily used to reduce locoregional recurrence in early stage or locally advanced 
breast cancer, but it is also used to palliate metastatic breast lesions, most commonly those in bone. 
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1.9 CHEMOTHERAPY 
Chemotherapy is the centerpiece in the treatment of localized and metastatic breast cancer. This 
chapter discusses the classes of chemotherapy relevant to breast cancer treatment, with particular 
emphasis placed on the mechanism of action and pharmacokinetics of each drug class. The drug 
classes discussed are anthracyclines (e.g. doxorubicin), alkylating agents (e.g. platins and 
cyclophosphamide), mitosis inhibitors (e.g. taxanes, eribulin, and vinorelbine), and antimetabolite 
compounds (e.g. capecitabine). Section 1.10, “Biological Agents,” discusses anti-estrogen, anti-
HER2, and other targeted therapies used in the treatment of breast cancer. At the end of both 
sections, a brief description of common systemic regimens is presented that encompasses both 
chemotherapies and targeted agents.  A summary of chemotherapeutic agents, including their 
mechanisms of action and pharmacokinetic properties, is given in Table 9. 
1.9.1 Anthracyclines 
The first two anthracyclines were isolated from the bacterium Streptomyces peucetius in the early 
1960s and were named doxorubicin (Dox) and daunorubicin (Dnr)285. Due to clinical trials in the 
1980s and 1990s that demonstrated anthracycline-based chemotherapy regimens were associated 
with lower rates of breast cancer recurrence and increased survival, their clinical usage escalated 
at the end of the 20th century286. By 2000, approximately 70-80% of women with breast cancer 
under the age of 70 were receiving anthracycline-based chemotherapy regimens286. In order to 
improve efficacy and reduce toxicity, other anthracyclines were synthesized, with epirubicin (Epi) 
and idarubicin (Ida) garnering FDA approval. Other anthracyclines, such as pirarubicin and 
mitoxantrone, have been studied in clinical trials but have demonstrated more severe cardiac 
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toxicity than desirable285. Currently, Dox and Epi are FDA-approved and clinically used for the 
treatment of early and metastatic breast cancer, whereas Dnr and Ida are both used in the treatment 
of leukemias287, so will not be further discussed.  
 
 
Table 9. A summary of chemotherapeutic agents used in the treatment of breast cancer 
Compound Mechanism(s) of Action 
Mechanisms of 
Resistance 
T1/2 
(h) Toxicities 
Doxorubicin 
Epirubicin 
TopII inhibition 
DNA damage 
↓ Erk, Cyclin D 
↑ Cols 1, 12, 21, 
TGFβ1 
34 
30 
Cardiac 
Muco-cutaneous 
Myelosupp 
Cyclophosphamide DNA crosslinks ↑ALDH 
↑GST 2-8 
Hemorrhagic myositis and 
cystitis 
BLC and Leukemias 
Cisplatin 
Carboplatin DNA crosslinks 
↑ NER 
↑E-cad, ZEB1, Akt 
0.5 
2 
Neurotoxicity 
Myelosupp 
sb-Paclitaxel 
nab-Paclitaxel 
Docetaxel 
Microtubule 
stabilization 
↑ MDR1, MRP2,7  
↑ β3-tubulin 
20.5 
21.6 
13.5 
Neutropenia 
Neurotoxicity 
Febrile neutropenia 
Ixabepilone Microtubule stabilization 
β1-tubulin 
polymorphisms 52 
Neutropenia 
Neurotoxicity 
Eribulin Microtubule destabilization ↑ MDR1, MRP8 40 
Neutropenia 
Neurotoxicity 
Vinorelbine Microtubule destabilization ↑ MDR1, MRP7 35 Neutropenia 
5-FU 
Capecitabine 
TS inhibition 
DNA/RNA Inc. ↑ TS, DPD 
0.25 
0.75 
Myelosupp, GI, HFS 
Like 5-FU, but milder 
Gemcitabine DNA Inc. RNR inhibition ↑ PI3K/Akt, NF-κB 0.25 
Neutropenia 
Thrombocytopenia 
T1/2 = elimination half-life; Myelosupp = Myelosuppression; ALDH = aldehyde dehydrogenase; Col = Collagen; 
TopII = Topoisomerase II; GST = glutathione S-transferase; BLC = bladder carcinoma; NER = nucleotide excision 
repair; E-cad = E-cadherin; sb = solvent bound; nab = nanoparticle albumin bound; 5-FU = 5-Fluorouracil; Inc. = 
incorporation; TS = thymidylate synthase; DPD = dihydropyrimidine dehydrogenase; GI = gastrointestinal; HFS = 
hand-foot syndrome; RNR = ribonucleotide reductase. 
 
 
Anthracyclines work by several mechanisms of action. Since Dox and Epi demonstrate 
equivalent efficacy against breast cancer, Dox will be used to illustrate the mechanisms by which 
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anthracyclines exert anti-tumor effects. Importantly, Dox efficacy is dependent on nuclear 
localization, which is guided by the 26S proteasome. Dox binds to the 20S subunit of the 
proteasome with high affinity, which is then translocated into the nucleus through the nuclear 
pores288. Once in the nucleus, Dox avidly binds to the DNA due to its higher affinity for DNA than 
the 20S subunit of the proteasome288. This mechanism can explain the preferential accumulation 
of doxorubicin in proliferating cells, as these cells often demonstrated enhanced nuclear 
localization of the proteasome288. Moreover, Dox binding to the 20S subunit of the proteasome 
reduces its protease activity and promotes the accumulation of ubiquitinated proteins, which can 
induce apoptosis in tumor cells to a similar degree as proteasome inhibitors289. Resistance to Dox 
in breast cancer is mediated by the alteration of proliferative gene expression (e.g. Cyclin D and 
Erk) and extracellular matrix molecules, such as collagens 1, 12, 21, and TGFβ1290–292. 
Once in the nucleus, the main mechanism of action of Dox is inhibition of the nuclear 
enzyme topoisomerase II (TopII)285 . Physiologically, TopII acts to untangle DNA helices by 
binding to the DNA, inducing controlled double stranded breaks, and subsequently ligating these 
breaks after the unknotting is completed293. Dox stabilizes the TopII – DNA complex to inhibit the 
ligation of formed DNA breaks, which subsequently results in enhanced DNA cleavage by the 
enzyme294. The DNA damage that accumulates results in growth arrest in either G1 or G2, with 
subsequent activation of intracellular apoptosis pathways295–297. Moreover, Dox resistance has 
been observed in cells with altered expression of TopII, and the genetic status of the TopIIα gene 
is predictive of the clinical response to anthracycline based therapy285,298,299. 
The second mechanism by which anthracyclines act involves DNA damage through TopII-
independent mechanisms. The central ring of Dox and other anthracyclines is a quinone moiety 
that can generate free radicals upon reduction to a semiquinone300. These free radicals can induce 
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DNA damage either directly, through lipid peroxidation and subsequent formation of DNA 
adducts, or through the formation of oxidative base lesions285. Moreover, free radical reactions can 
modify Dox and allow it to directly intercalate into DNA301. Finally, Dox treatment has been 
shown to induce p53 and reduce telomerase activity, which can induce cell death or senescence302. 
The pharmacokinetics of Dox and Epi are similar. Both medications are dosed 
intravenously (IV), meaning the bioavailability is 100%. The tissue distribution of Dox and Epi is 
rapid, with a plasma elimination half-life under 5 minutes303. This initial tissue uptake is succeeded 
by two longer tissue elimination phases, with a terminal half-life of approximately 34 and 30 hours 
for Dox and Epi respectively303,304. Clearance of Dox, Epi, and their metabolites is primarily 
through biliary excretion, with some urinary excretion that is observed more prominently with Epi. 
Hepatic metabolism of Dox and Epi is predominantly through CYP3A4 and CYP2D6305. The main 
toxicities of Dox and Epi are myelosuppression, mucosal and cutaneous toxicities, and 
cardiotoxicity. Cardiotoxicity typically presents as dilated cardiomyopathy in adults and is less 
common with Epi than Dox306. Liposomal-encapsulation of Dox has been shown clinically to 
increase the half-life and decrease the toxicity of the parent drug307,308. 
1.9.2 Alkylating Agents 
The two classes of alkylating agents used in the treatment of breast cancer are nitrogen mustards 
and platinum-based chemotherapeutics (“platins”). Cyclophosphamide is the only clinically 
approved nitrogen mustard for breast cancer, whereas two platins, cisplatin and carboplatin, are 
approved. Cyclophosphamide and platins will be discussed in more detail below, specifically 
focusing on their mechanism of action and pharmacokinetics.  
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1.9.2.1 Cyclophosphamide 
The first use of chemotherapeutic agents was in 1942 when a Polish immigrant was treated with 
nitrogen mustard for lymphosarcoma309. The only clinically used alkylating agent in breast cancer 
is cyclophosphamide (Cpa). Cpa was first clinically implemented in 1958 and FDA approved one 
year later310,311. All alkylating agents act by the addition of an alkyl group to DNA bases, most 
preferentially guanine. These added groups form intra- and inter-strand linkages that inhibit the 
ability of DNA polymerase to replicate the DNA, resulting in growth arrest and apoptosis312. 
Moreover, these alkylation events can also form DNA-DNA and DNA-protein crosslinks, with the 
former being shown to be the mechanism of cellular toxicity310. These adducts lead to induction 
of apoptotic pathways, ending with caspase and PARP cleavage and cell death313,314.  
Resistance to Cpa is multifactorial. First, aldehyde dehydrogenase (ALDH) plays a 
significant role in resistance to Cpa315,316. Increased ALDH activity is associated with Cpa 
resistance and can be reversed with the ALDH inhibitor disulfiram315. Second, altered expression 
of genes involved with apoptosis, such as p53 and caspase-3, can induce resistance to Cpa316,317. 
Third, increased synthesis of glutathione, by alterations in glutathione S-transferases, can reduce 
the efficacy of Cpa by quenching its reactivity towards DNA317–319.  
The pharmacokinetics of Cpa begins with oral or IV administration, followed by a 
necessary activation step in the liver, predominantly accomplished by CYP2B6 and 
CYP3A4312,319. Oral and IV administration achieve near equivalent serum concentrations, as Cpa 
has 85-100% oral bioavailability310. Cpa is distributed into total body water with minimal fat 
distribution320, which results in an elimination half-life of 2-8 hours depending on dosage310. Cpa 
is primarily excreted in the urine as metabolites of the activated drug321. Inactivation of Cpa is 
primarily accomplished by cellular ALDH, most predominantly by the isoform ALDH1A1311. The 
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dose-limiting toxicity for Cpa is hemorrhagic myocarditis, with some transient minor cardiac 
toxicity observable in up to half of patients311. Other significant side effects are hemorrhagic 
cystitis, development of secondary malignancies such as bladder cell carcinoma and leukemias, 
and gonadal failure311.  
1.9.2.2 Platinum-containing drugs 
Platinum-based chemotherapeutics (“platins”) act as alkylating-like compounds. Platins 
covalently bond to DNA and generate intra- and inter-strand crosslinks, which interfere with DNA 
repair, causing growth arrest and apoptosis322. There are two platins used in the treatment of breast 
cancer: cisplatin (Cis) and carboplatin (Crb). Cis and Crb behave very similarly, forming identical 
DNA adducts, but with the latter exhibiting lower potency and toxicities323,324. The most common 
cause of cytotoxicity with platins is the formation of intra-strand G-G adducts, constituting about 
90% of all adducts. Importantly, cells with dysfunctional DNA repair are more susceptible to platin 
therapy325. Cisplatin has multiple other mechanisms of action, such as the formation of reactive 
oxygen species and lipid peroxidation. These factors and genomic instability cause the activation 
of the intrinsic apoptotic pathway, in part mediated by DNA damage response proteins such as 
p53, and result in cell death322. 
Resistance to Cis occurs through a multitude of mechanisms, with altered expression of 
genes that mediate apoptosis, DNA damage-repair, the cell cycle, cytoskeletal proteins, small 
GTPases, and transcription factors326–328. In particular, the nucleotide excision repair (NER) 
pathway is primarily responsible for repairing adducts caused by Cis329. Additionally, alterations 
in membrane transporters, such as copper transporter 1 (CTR1) and efflux ATPases ATP7A and 
ATP7B, play a significant role in Cis resistance326,329. Moreover, E-cadherin expression and related 
survival pathways, such as Akt, have been shown to increase resistance to Cis330,331. Finally, 
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increased expression of zinc finger E-box binding homeobox 1 (ZEB1) has been shown to increase 
Cis resistance by activating ATM-initiated homologous recombination-mediated DNA damage 
repair332. 
Both Cis and Crb are administered intravenously. After administration, Cis and Crb are 
activated by hydrolysis of chloride or cyclobutane groups respectively323. Cis and Crb have similar 
volumes of distribution and excretion profiles, with both compounds demonstrating predominantly 
renal clearance, with elimination half-lives of 0.5 and 2 hours respectively333–335. In contrast to 
Crb, Cis can be metabolized in the proximal tubule of the kidney into a renal toxic metabolite336. 
Generally, Crb has lower toxicity than Cis due to its lower reactivity. Common toxicities with 
platins include nephrotoxicity, neurotoxicity, myelosuppression, hepatotoxicity, and 
cardiotoxicity322,323. In particular, the most severe dose-limiting toxicities for Cis and Crb are 
neurotoxicity and myelosuppression respectively. Cis causes permanent hearing loss in 40-80% of 
treated patients and has been detected in the cochlea years after treatment337. Approximately 85% 
of patients with a cumulative Cis dose of greater than 300 mg/m2 have some degree of peripheral 
sensory neuropathy323. Crb causes severe thrombocytopenia and neutropenia in 25% and 18% of 
patients respectively, which are fortunately reversible upon cessation of treatment323. 
1.9.3 Mitotic Inhibitors 
The dynamic assembly and disassembly of microtubules is essential for mitosis. All mitotic 
inhibitors used in the treatment of breast cancer act to inhibit the role microtubules play in cell 
division. These drugs include the taxanes, eribulin, ixabepilone, and vinorelbine. Inhibition of 
microtubule action can occur either by stabilizing their polymerization or by promoting their 
turnover338. Taxanes and ixabepilone bind to the Taxol-domain of β-tubulin and function as 
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microtubule-stabilizing agents, whereas eribulin and vinorelbine bind to the vinca-domain of β-
tubulin and function as microtubule-destabilizing agents339. While the taxane drug class is used for 
management of both primary and recurrent/metastatic breast cancer, eribulin, ixabepilone, and 
vinorelbine are solely used for the latter339. For this reason, the taxane drug class will be discussed 
more extensively, as it is used in the treatment of all stages of breast cancer. Subsequently, eribulin, 
ixabepilone, and vinorelbine will be covered together in Section 1.9.3.2, “Other Microtubule 
Inhibitors.” 
1.9.3.1 Taxanes 
The incorporation of taxanes in the management of breast cancer in the mid-1990’s dramatically 
improved the outcomes of patients with both early and late stage breast cancer340,341. The two 
clinically used taxanes in the management of breast cancer are paclitaxel (Ptx) and docetaxel (Dtx), 
with higher efficacy and toxicity seen in the latter due to higher affinity for β-tubulin and a longer 
intracellular retention time338,341. Both Ptx and Dtx act to induce cell cycle arrest and apoptosis by 
binding to β-tubulin, which results in microtubule polymerization, existing tubule stabilization, 
and a G2/M phase arrest338,339,342,343. Since Dtx exhibits a higher affinity for β-tubulin, it can also 
inhibit centrosome organization and exhibit cytotoxic effects on S-phase cells338. Finally, Ptx and 
Dtx can directly induce apoptosis through phosphorylation of Bcl-2, which is achieved at a 100-
fold lower concentration with Dtx than Ptx344.  
There are four main mechanisms of resistance to taxanes that have been uncovered in vitro, 
though the clinical significance of these mechanisms as biomarkers to guide therapy is still 
unclear345. The primary mechanism of resistance involves the expression of membrane efflux 
pumps, such as MDR1 (P-glycoprotein), MRP2, and MRP7339,346. A secondary mechanism of 
resistance to taxanes is an alteration of the expression of or mutations in the β-tubulin isotype 
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genes. Most predominantly, increased expression of β3-, βV-, and βII-tubulin are associated with 
taxane resistance347. Furthermore, mutations in tubulin genes have been detected in cell lines 
resistant to taxanes, but the low clinical prevalence of these mutations precludes their use as 
biomarkers348. Third, some studies suggest taxane resistance is associated with mutations in or 
altered expression of apoptotic signaling proteins, such as P53, Bcl-2, Bcl-xL, and NF-κB339, yet 
there also exist conflicting reports345. Finally, both in vitro and clinical taxane resistance is 
associated with a deficiency in spindle assembly checkpoint proteins, such as Mad2 and BubR1, 
which suggests checkpoint functionality is required for taxane sensitivity349,350.  
Ptx and Dtx have substantial differences in pharmacokinetics. Both compounds are 
administered by IV infusion. There are two formulations of Ptx: solvent-based (most commonly 
Cremophor EL) and nanoparticle albumin bound (nab). Both formulations exhibit non-linear 
pharmacokinetics, meaning dosage changes result in a disproportionate change in the total drug 
exposure338,351. Solvent-based Ptx (sb-Ptx) is infused over 3 hours, whereas nab-Ptx is 
administered over 30 minutes352. The main pharmacokinetic difference between sb-Ptx and nab-
Ptx is that unbound Ptx concentration and cellular transport is higher in the latter, which results in 
a higher tumor response rate and overall survival351,353. Additionally, nab-Ptx is void of Cremophor 
EL – mediated toxicities, such as hypersensitivity and neurotoxicity354. In contrast, Dtx is 
administered over one hour and exhibits linear (proportional) pharmacokinetics338. Both Ptx and 
Dtx are extensively metabolized by CYP450 enzymes, most predominantly by CYP3A4, and 
biliary excretion is responsible for >95% of drug clearance338,355,356. The elimination half-life is 
slightly lower for Dtx, with values of 20.5, 21.6, and 13.5 hours for sb-Ptx, nab-Ptx, and Dtx 
respectively357,358. The dose-limiting toxicities for sb-Ptx and nab-Ptx are neuropathy and 
neutropenia, with sb-Ptx demonstrating a higher incidence of neutropenia but a lower incidence of 
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neuropathy compared to nab-Ptx359. In contrast, the main dose-limiting toxicities for Dtx is febrile 
neutropenia360. Other side effects seen with Dtx are fluid retention, nail toxicity, pneumonitis, and 
neuropathy, with the incidence of the last much lower than observed with Ptx360. 
1.9.3.2 Other Microtubule Inhibitors 
While anthracyclines and taxanes have greatly improved the overall survival of women with breast 
cancer, recurrent metastatic breast cancer remains difficult to treat. In particular, due to the 
increasing use of anthracyclines and taxanes in the adjuvant setting, ixabepilone, eribulin, and 
vinorelbine are playing more significant roles in the management of metastatic breast cancer. The 
mechanism of action, pharmacokinetics, and toxicity of these drugs will be described in the next 
few paragraphs. 
Ixabepilone acts similarly to paclitaxel by stabilizing microtubules through binding β-
tubulin at the Taxol domain. Currently, ixabepilone is approved as mono- and combination therapy 
with capecitabine for the treatment of taxane and anthracycline resistant, recurrent breast cancer361. 
In contrast to paclitaxel, ixabepilone can bind to multiple isomers of β-tubulin, including the 
isomer β3 to which paclitaxel binds316. Due to the multiple sites at which ixabepilone can bind, it 
has been shown to be effective in taxane-resistant metastatic breast cancer. Additionally, 
ixabepilone exhibits low activity as a substrate for drug transporters often overexpressed in taxane 
resistance, such as MDR1362. Mechanisms of resistance to ixabepilone are still poorly 
characterized, but one proposed mechanism involves polymorphisms in β1-tubulin363. Ixabepilone 
is excreted primarily through the bile (65%), both unchanged and as metabolites formed through 
CYP3A4364, and urine (21%) with an elimination half-life of 52 hours365. The most common dose-
limiting toxicities observed are neutropenia and neuropathy, with a lower incidence of neuropathy 
as compared to taxanes366. 
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Eribulin acts as a microtubule destabilizing agent through binding β-tubulin at the Vinca 
domain, limiting microtubule growth, and causing mitotic catastrophe, resulting in cell death367. 
Eribulin is currently approved as monotherapy for extensively pretreated metastatic breast 
cancer368,369. In contrast to paclitaxel, eribulin efficacy is inversely proportional to β3-tubulin 
abundance370. In addition to destabilizing microtubules, studies have shown that eribulin can 
induce tumor vascular remodeling and reversal of EMT, which may play roles in its overall 
survival benefit observed in metastatic breast cancer367. Resistance to eribulin is often associated 
with upregulation of MDR1 or MRP8371,372. While eribulin is a substrate of CYP3A4 in vitro, the 
majority of the drug is excreted unchanged in the bile (61%), a minority unchanged in the urine 
(8%), and <1% of drug in the plasma is in the form of metabolites373. The elimination half-life is 
40 hours373. The most common dose-limiting toxicities observed are neutropenia and neuropathy. 
While high grade neutropenia is observed in almost half of patients, febrile neutropenia is only 
seen in 3% of patients, much lower than that observed with docetaxel treatment (up to 40%)367,374. 
Vinorelbine acts as a microtubule destabilizing agent through binding β-tubulin at the 
Vinca domain, inhibiting the formation of the mitotic spindle, which results in mitotic catastrophe 
and cell death375. Vinorelbine shows high specificity for mitotic microtubules, which precludes the 
neurotoxicity commonly seen with microtubule agents376. The use of vinorelbine in metastatic 
breast cancer is becoming more common as a second line therapy after anthracycline and taxane 
treatment366,377. Beneficially, vinorelbine has both IV and oral formulations, the latter of which is 
useful for patients desiring fewer hospital visits377. Mechanisms of resistance to vinorelbine 
include upregulation of MDR1 and MRP7378,379. Vinorelbine extensively binds to platelets in the 
plasma and is metabolized by CYP3A4380,381. The majority of vinorelbine is excreted in the bile 
(30-60%), a minority in the urine (20%), and metabolites are present in very low concentrations in 
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the plasma381. The elimination half-life is approximately 35 hours381. The most common dose-
limiting toxicity observed is neutropenia, observed in 40% of patients, with <5% associated with 
a febrile event377. 
1.9.4 Antimetabolite Drugs 
The three antimetabolite drugs used in the treatment of breast cancer are 5-fluorouracil (5-FU), 
capecitabine (Cap), and gemcitabine (Gem). Whereas 5-FU is solely used in combination chemo 
regimens for both early and late stage breast cancer, Cap and Gem are both approved as single 
agents or in combination with targeted agents for metastatic breast cancer265. 
1.9.4.1 5-Fluorouracil and Capecitabine 
The drugs 5-FU and Cap both belong to the fluoropyrimidine drug class. The use of 5-FU and Cap 
differ, in that the former is FDA-approved for both early and metastatic breast cancer, whereas the 
latter is only approved for anthracycline and/or docetaxel resistant metastatic breast cancer265,382. 
Cap is an oral prodrug of the IV administered 5-FU. The enzymatic conversion of Cap to 5-FU 
involves the following three steps: 1) cleavage by carboxylesterase in the liver, 2) deamination by 
cytidine deaminase, and 3) processing by thymidine phosphorylase to generate 5-FU383. 
Importantly, the enzymes important for steps 2 and 3 of this conversion have the highest activity 
in the liver and tumor tissue, which makes Cap most selectively activated in these tissues384. Once 
5-FU is generated, it undergoes either anabolic (activating) or catabolic (deactivating) metabolism, 
which dictate its mechanism of action. 
Both 5-FU and Cap have several mechanisms of action. First, three phosphorylation steps 
of 5-FU generate 5-FUTP (5-fluorouracil triphosphate), which is recognized as UTP (uracil 
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triphosphate) and is capable of incorporating into all classes of RNA and exerting damaging effects 
on RNA processing, cellular metabolism, and cell viability385. Second, 5-FU can be converted into 
5-FdUMP (5-fluorodeoxyuridine monophosphate), which is a potent competitive inhibitor of 
thymidylate synthase (TS), critical to the intracellular synthesis of thymidine383. Thus, abundance 
of 5-FdUMP reduces the formation of dTMP (deoxythymidine monophosphate) and reduces the 
availability of this critical nucleotide for DNA replication and repair, which can facilitate 
activation of apoptotic pathways383. Finally, phosphorylation of 5-FdUMP into 5-FdUTP allows 
for direct incorporation of 5-FU into DNA, which induces DNA damage, cell cycle arrest, and 
attempted repair through the base excision repair pathway386.  
Inactivation of 5-FU is accomplished by a three step catabolic pathway, the first and rate 
limiting step catalyzed by the enzyme dihydropyrimidine dehydrogenase (DPD). Further 
enzymatic steps generate further metabolites, which eventually produce FBAL (α-fluoro-β-
alanine). Mechanisms of resistance to 5-FU and Cap include increased expression of DPD and 
TS383,387–389.  
While 5-FU is given as either an IV bolus or continuous infusion over a 24 hour period, 
Cap is an oral drug with extensive absorption in the GI tract, followed by subsequent modification 
in the liver383,390. As discussed above, metabolism of Cap into 5-FU and subsequent anabolic steps 
result in its activation. Both 5-FU and its metabolites undergo almost entirely urinary excretion, 
with an elimination half-lives of 15 minutes and 45 minutes for 5-FU and Cap respectively390,391. 
The main toxicities of 5-FU depend on the method of administration. For bolus IV injection of 5-
FU, the most common toxicities are myelosuppression, oral mucositis, and gastrointestinal (GI) 
toxicity (diarrhea), the latter mostly due to the phosphorylation of 5-FU in the gut epithelium383,392. 
In contrast, for continuous infusion of 5-FU, toxicities include hand-foot syndrome and a lower 
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incidence of myelo- and GI-toxicity383. Infrequent, reversible cardiotoxicity and neurotoxicity can 
also be observed with 5-FU treatment. The preferential accumulation and activation of Cap in 
tumor tissue results in a more mild toxicity profile than is observed with 5-FU390,392. Importantly, 
Cap is an inhibitor of CYP2C9, so drug interactions with warfarin and phenytoin have been 
reported393.  
1.9.4.2 Gemcitabine 
Gemcitabine (Gem) exerts its cytotoxic effects through insertion into the DNA as an analog of 
cytosine. Similarly to 5-FU, Gem requires intracellular phosphorylation by deoxycytidine kinase 
for activity394. There are two main cytotoxic mechanisms of action of Gem that interact with each 
other. First, gemcitabine triphosphate competes with deoxycytidine triphosphate (dCTP) for 
incorporation into DNA, which inhibits DNA synthesis and initiates DNA repair and apoptosis 
pathways395. Second, gemcitabine diphosphate is a potent inhibitor of ribonucleotide reductase, 
which prevents the synthesis of dCTP, thus potentiating the ability of gemcitabine triphosphate to 
be incorporated into DNA395,396. Breast cancer resistance to Gem is seen with upregulation of 
survival signaling pathways, such as PI3K/Akt and NF-κB, though typically is less common than 
other chemotherapeutic agents, such as anthracyclines and taxanes397,398. 
Gemcitabine is given as a short (30 minute) infusion for the treatment of metastatic breast 
cancer. Due to rapid deamination, Gem has a short elimination half-life of only 15 minutes. Its 
deaminated byproduct, difluoro-deoxyuridine (dFdU), has a much longer half-life of 50 hours399. 
Gem and its metabolites primarily undergo renal excretion399. Gem typically has a lower toxicity 
profile than other agents used in the management of metastatic breast cancer, with the most 
common dose-limiting toxicities being neutropenia and thrombocytopenia396.  
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1.10 BIOLOGICAL AGENTS 
Targeted therapies play a large role in the treatment of breast cancer. Approximately 70-80% of 
breast cancers are estrogen receptor positive, and 15-20% of breast cancers are HER2 type 76,80,81. 
As such, anti-estrogen and anti-HER2 based therapies are commonly used in conjunction with the 
chemotherapeutic agents discussed in the previous sections. Similarly, a select group of cancers 
are responsive to therapies that target EGFR, cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), 
poly-ADP-ribose polymerase (PARP), and the checkpoint proteins programmed death-1 and -
ligand 1 (PD-1/PD-L1). The mechanism of action and pharmacokinetics of each of these drug 
classes are discussed below in Table 10. 
 
 
Table 10. A summary of biological agents used in the treatment of breast cancer 
Compound Drug Class Mechanisms of Resistance T1/2 (h) Toxicities 
Tamoxifen 
Raloxifene SERM 
↑ EGFR/HER2, SCR3, ERβ 
↓ CYP2D6/3A4, ERα (or mut) 
168 
27.7 
EC, TED, cataracts 
TED  
Fulvestrant SERD ↑ PI3K/MAPK, FOXA1, NF-κB 
↓ ERα (or mut) 1176 Nausea, asthenia, pain 
Letrozole 
Anastrazole 
Exemestane 
Aromatase Inh 
↑ EGFR/HER2, ERα Sens. 
p53 mut 
↓ ERα (or mut) 
42 
41 
27 
Osteoporosis, fracture, 
ischemic CVEs 
Trastuzumab 
 
T-DM1 
Pertuzumab 
 
Lapatinib 
HER2 Inh 
 
HER2 Inh, MTI 
HER2 Inh 
 
HER2/EGFR Inh 
HER2 mut, ↑ PI3K/Akt, 
EGFR/HER3, FcγR mut 
↓ HER2, HER2 shedding 
HER2 shedding, ↑ PI3K/Akt, 
EGFR/HER3 
HER2 mut, ↑ HER3, Akt 
672 
 
96 
456 
 
24 
↓ LVEF, pneumonitis 
Thrombocytopenia 
↓ LVEF 
 
Diarrhea, rash 
Palbociclib 
Ribociclib 
Abemaciclib 
CDK4/6 Inhibitor ↑ Cyclin E, p16
Ink4a 
↓ Rb 
26 
36 
17-38 
Neutropenia 
Neutropenia 
Fatigue 
T1/2 = elimination half-life; SERM = selective estrogen receptor modulator; EC = endometrial carcinoma; TED = 
thromboembolic disease; mut = mutation; SERD = selective estrogen receptor degrader; Sens. = sensitivity LVEF = 
left ventricular ejection fraction; Inh = Inhibitor; MTI = microtubule inhibitor; FcγR = Fc-gamma receptor; CHF = 
congestive heart failure; CDK4/6 = cyclin dependent kinase 4 and 6. 
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1.10.1 Anti-Estrogen Therapies 
Most breast cancers are ER positive, so anti-estrogen therapies play a significant role in medical 
management. There are four main classes of anti-estrogen therapies used in the management of 
estrogen receptor positive breast cancer: selective estrogen receptor modulators (SERMs), 
selective estrogen receptor degraders (SERDs), aromatase inhibitors (AIs), and luteinizing 
hormone releasing hormone (LHRH) analogues.  
1.10.1.1 Selective Estrogen Receptor Modulators (SERMs) 
Selective estrogen receptor modulators (SERMs) have been clinically approved for the treatment 
of breast cancer for four decades. Initially discovered as a non-steroidal anti-estrogen compound 
and used unsuccessfully as a contraceptive, tamoxifen was first clinically tested in metastatic 
breast cancer in 1971 and subsequently approved in 1977400. The success with tamoxifen 
motivated the synthesis of similar drugs, with the discovery of raloxifene in 1982401. Subsequently, 
studies in the 1980s, after advances in cloning of the ERα gene, suggested tamoxifen and raloxifene 
worked by selectively modifying ER signaling400. Investigation of tamoxifen for the 
chemoprevention of breast cancer began in 1985, with eventual approval of tamoxifen for breast 
cancer risk reduction in 1998400,402. Raloxifene was approved for the treatment and prevention of 
osteoporosis in postmenopausal women in 1998403. Subsequently, clinical trials demonstrated 
equivalence between raloxifene and tamoxifen in breast cancer risk reduction, granting raloxifene 
a second approval for the chemoprevention of breast cancer in 2007404–406. Importantly, raloxifene 
is not approved for the treatment of breast cancer, only for risk reduction in postmenopausal 
women406,407. 
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The three most pertinent sites of action for SERMs are those in which estrogen signaling 
plays a significant role in organ pathophysiology, namely in the breast, the bone, and the uterus. 
Importantly, tamoxifen and raloxifene exhibit different tissue sites of action. While tamoxifen and 
raloxifene act as anti-estrogens in breast carcinoma and as pro-estrogens in the bone, only 
tamoxifen acts as a pro-estrogen in the uterus408,409. Thus, while both tamoxifen and raloxifene 
share similar effects on breast cancer and osteoporosis prevention, only tamoxifen increases the 
clinical risk for endometrial carcinoma407–409.  
The tissue dependence of SERM activity is intimately involved with their ability to 
influence estrogen receptor conformation and binding to coregulatory molecules. While the 
SERMs bind in the same pocket as estradiol, the binding of tamoxifen, raloxifene, and estradiol 
induce different conformations of the estrogen receptor409–411. Additionally, the interaction of 
coactivators and corepressors with ligand-bound estrogen receptor is dependent on the ligand. 
Coregulator interactions with the estrogen receptor are mediated through the AF1 and AF2 
domains, which are regulated by MAPK activity and estradiol binding, respectively412. 
Importantly, SERMs primarily alter signaling through the AF2 domain and exhibit variable effects 
on the AF1 domain responsible for estrogen agonistic activity413. For example, SRC-1 is a 
coactivator that mediates estrogen agonistic effects of both estradiol and tamoxifen but is required 
for agonist activity of the latter414. Similarly, the corepressor SMRT can reduce the agonist activity 
of tamoxifen but not estradiol414. Moreover, the relative abundance of the estrogen receptor 
isoforms ERα and ERβ can guide the activity of the SERMs in affecting gene transcription415. 
Finally, the agonist/antagonist effects of SERMs can be influenced by intracellular signaling 
networks, such as protein kinase A416. In summary, the mechanism of action of SERMs depends 
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on the relative abundance of the target receptor isoforms, presence of coregulators, and activation 
of intracellular signaling networks.  
Mechanisms of resistance to SERMs can be classified as either intrinsic or acquired. 
Intrinsic resistance to SERMs is most often due to crosstalk from other signaling pathways or 
differences in drug metabolism. For example, HER2 overexpression results in increased estrogen-
independent ER signaling, making tumors resistant to de novo SERM treatment417–419. Intrinsic 
resistance to tamoxifen can also be observed in patients with polymorphisms in CYP2D6 and 
CYP3A4, the two CYP450 isozymes responsible for metabolic activation of tamoxifen418,419. 
Acquired resistance to tamoxifen often involves alterations in the expression of estrogen receptor 
isoforms, coregulators, and activity of other intracellular signaling networks. Increased expression 
of ERβ and loss of ERα have been observed in tamoxifen-resistant breast cancer420,421. Similarly, 
mutations in ERα are common drivers of resistance420,422. Moreover, expression of SRC3, an ERα 
co-activator expressed in over 50% of breast tumors, can increase the estrogen agonist effects of 
tamoxifen, which leads to resistance412. Finally, overexpression of HER2 or EGFR act as a 
mechanisms of acquired resistance to tamoxifen by enhancing Erk1/2 and Akt activity420,423.  
Tamoxifen is administered orally and produces peak serum levels after 3-6 hours and 
steady state levels after 4 weeks424. Tamoxifen is extensively bound to albumin (~98%), which 
results in a long elimination half-life of 7 days425. Tamoxifen is extensively metabolized by the 
CYP450 system, which is required for its activation. The two primary active metabolites of 
tamoxifen are endoxifen and 4-hydroxytamoxifen, with the former found at more than 10-fold 
higher concentrations in patient serum426. The two main CYP450 isoforms that are responsible for 
tamoxifen metabolism are CYP2D6 and CYP3A4424. Tamoxifen is eliminated primarily by biliary 
excretion, with polar conjugates of tamoxifen and its metabolites formed through glucuronidation, 
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accounting for 75% of the excreted drug426. The most common toxicities with tamoxifen are a 2-5 
fold increase in uterine cancer, a 2-3 fold increase in thromboembolic disease (only seen in 
postmenopausal women), hot flashes, and vaginal discharge407,427. Additionally, patients receiving 
tamoxifen are at a slightly greater risk for the formation of cataracts407,427. 
Raloxifene undergoes significant first pass metabolism by glucuronidation, resulting in 
only 2% of the drug dose reaching the plasma428. Similar to tamoxifen, raloxifene is extensively 
plasma protein bound (95%), yet has a much lower elimination half-life at 27.7 hours428. The 
metabolism of raloxifene is primarily accomplished by glucuronidation without involvement of 
the CYP450 ensemble428. Similar to tamoxifen, raloxifene primarily undergoes biliary excretion. 
Raloxifene has fewer adverse effects than tamoxifen, yet still results in a 3 fold increase in risk for 
thromboembolic disease409. 
1.10.1.2 Selective Estrogen Receptor Degraders (SERDs) 
Selective estrogen receptor degraders (SERDs) were pioneered to overcome endocrine-resistant 
breast cancer through targeting ERα, which commonly plays a role in tamoxifen-resistant 
disease429. Currently, fulvestrant is the only SERD approved for the treatment of locally advanced 
and metastatic ER+ breast cancer, either as monotherapy for endocrine therapy naive disease or as 
monotherapy or combination therapy for endocrine-resistant breast cancer430. The success of 
fulvestrant and its inconvenient delivery method (intramuscular injection) have motivated the 
development of other orally bioavailable SERDs, which have shown promising preclinical efficacy 
and are currently being investigated in clinical trials429,431. 
Fulvestrant is an estradiol analogue that interferes with estrogen receptor signaling through 
multiple mechanisms of action. Fulvestrant is a competitive antagonist of the estrogen receptor, 
with a binding affinity similar to that of estradiol432. Additionally, fulvestrant-bound estrogen 
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receptor shows impaired dimerization and nuclear localization433. Moreover, fulvestrant binding 
induces conformational changes in the estrogen receptor that disable both AF1 and AF2, in contrast 
to tamoxifen, which primarily disables AF2 binding432. This means that fulvestrant demonstrates 
no estrogen agonist activity434,435. Finally, fulvestrant increases turnover of the estrogen receptor 
by targeting it to the proteasome for degradation436–438. Mechanisms of resistance to fulvestrant 
include estrogen receptor downregulation or mutation, activation of PI3K and MAPK, and 
activation of NF-κB and FOXA1438–440. 
Fulvestrant is most commonly given as a single intramuscular (IM) injection of 500mg. In 
comparison to IV dosing, IM administration results in a long-acting delivery of fulvestrant, with 
an elimination half-life of approximately 49 days441. Fulvestrant is primarily metabolized by 
sulfate conjugation, and while it is a substrate for CYP3A4 metabolism, this does not play a major 
role in drug clearance442. Fulvestrant is generally well tolerated, with the most common adverse 
events being nausea, asthenia, pain, and headache435. 
1.10.1.3 Aromatase Inhibitors 
Aromatase inhibitors have several uses in the management of postmenopausal women with 
estrogen receptor positive breast cancer. First, in postmenopausal women with a high risk of 
developing breast cancer, aromatase inhibitors are effective at reducing the incidence of, but not 
the mortality of, breast cancer443. Second, neoadjuvant use of aromatase inhibitors has been shown 
to be as effective as tamoxifen and in some groups of patients more effective, in particular in 
patients with triple positive (ER+/PR+/HER2+) disease444. Third, adjuvant use of aromatase 
inhibitors is recommended in place of tamoxifen, due to clinical trials that demonstrated lower 
recurrence with adjuvant aromatase inhibitors versus tamoxifen445. Finally, aromatase inhibitors 
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are used in the context of metastatic breast cancer, often as combination therapy with other 
estrogen targeted therapies, such as fulvestrant446. 
Aromatase inhibitors reduce circulating estrogens by preventing the peripheral conversion 
of androgens to estrone. In premenopausal women, granulosa cells in the ovaries synthesize 
estradiol from cholesterol, which circulates as the predominant form of natural estrogens447. In 
postmenopausal women, the ovaries have lost the ability to synthesize estradiol, necessitating the 
peripheral conversion of androgens into estrone, which serves as the primary source of natural 
estrogens. This peripheral conversion is facilitated by the enzyme aromatase, a member of the 
CYP450 family and the product of the CYP19 gene found in adipose, skin, bone, breast, and brain 
tissue447,448. Since postmenopausal women cannot synthesize estradiol, newer selective aromatase 
inhibitors are able to reduce circulating estrogens by over 95%448–450. There are three clinically 
used aromatase inhibitors - letrozole, anastrazole, and exemestane – which all act by blocking 
aromatase, although they vary slightly in chemical structure.  
Exemestane is a steroidal aromatase inhibitor whose structure is derived from 
androstenedione, the natural substrate of aromatase, which binds irreversibly to the enzyme451. In 
contrast, letrozole and anastrazole are non-steroidal aromatase inhibitors, which are derived from 
phenobarbitone and bind reversibly to the enzyme451. While all three aromatase inhibitors achieve 
similar decreases in plasma estrogen levels and increases in bone resorption, exemestane also 
induces bone formation due to its androgen likeness452. Some data suggests that anastrazole may 
be more selective for aromatase than letrozole453.  
Resistance to aromatase inhibitors can occur by multiple pathways. First, the estrogen 
receptor can develop hypersensitivity to estrogen, allowing even the miniscule quantities of 
circulating estrogens after aromatase inhibitor therapy to activate downstream pathways447,454. 
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Moreover, mutations and translocations in the estrogen receptor gene, such as those that allow 
ligand-independent signaling, can induce aromatase inhibitor resistance455. Second, mutations in 
p53 can cause both de novo and acquired resistance to aromatase inhibitor therapy and is often 
associated with more aggressive ER+ disease455. Finally, activity of other signaling pathways, such 
as those mediated by EGFR and HER2, can induce resistance to aromatase inhibitors454,455. 
Importantly, cross-resistance between steroidal and non-steroidal aromatase inhibitors does not 
always occur. This allows for a trial of the alternative aromatase inhibitor class, should resistance 
to the initial class emerge456.  
The pharmacokinetics of the three aromatase inhibitors are similar. All three drugs are 
administered orally once per day and achieve maximal efficacy after 2-4 days for anastrazole and 
letrozole and 7 days for exemestane457. The elimination half-lives of letrozole, anastrazole, and 
exemestane are 42 hours, 41 hours, and 27 hours respectively458–460. All three aromatase inhibitors 
are metabolized by different CYP450 enzymes and undergo different excretion patterns. Letrozole 
is metabolized by CYP3A4 and CYP2A6 into an inactive metabolite, glucuronidated, and renally 
excreted461. In contrast, anastrazole undergoes hepatic metabolism through CYP1A2, CYP2C8/9, 
and CYP3A4, with primarily biliary excretion and minimal renal involvement457,462. Finally, 
exemestane is extensively metabolized by CYP3A4 and excreted equally in the bile and urine463. 
The primary toxicities of aromatase inhibitors are musculoskeletal, most commonly seen as 
osteoporosis and bone fracture451,454. Some studies have also suggested that aromatase inhibitors 
carry a significantly higher risk of ischemic cardiovascular events when compared to tamoxifen, 
but these differences are quite small numerically454. Beneficially, since aromatase inhibitors 
possess no estrogen agonist activity, they do not exhibit the increased risk of endometrial cancer 
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and thromboembolic disease that is seen with tamoxifen (see “Selective Estrogen Receptor 
Modulators” above)443,448. 
1.10.1.4 Luteinizing Hormone Releasing Hormone (LHRH) Analogues 
Initial treatment for estrogen receptor positive breast cancer, prior to the era of tamoxifen and 
aromatase inhibitors, involved ovarian suppression, either by surgical castration or medical 
castration using luteinizing hormone releasing hormone (LHRH) analogues. The most commonly 
used LHRH analogue is goserelin, but leuprolide and triptorelin have also been studied. A large 
meta-analysis demonstrated that while LHRH usage with chemotherapy had no impact on breast 
cancer survival or recurrence in premenopausal breast cancer patients, women receiving LHRH 
analogues had a lower rate of premature ovarian failure464. These data suggest LHRH analogues 
might have use in preserving fertility in young women receiving chemotherapy. However, as these 
drugs are not commonly used in the treatment of breast cancer, their pharmacology will not be 
further discussed. 
1.10.2 HER2 Targeted Therapies 
HER2 is overexpressed in 15-30% of human breast cancers and is a marker for aggressive 
disease169–171. This has motivated the development of several therapies that target HER2, of which 
there are currently three different classes. Trastuzumab and trastuzumab emtansine (T-DM1) bind 
to the extracellular domain 4 of HER2, pertuzumab binds to the extracellular domain 2 of HER2, 
and lapatinib directly inhibits the kinase activity of both HER2 and EGFR465.  
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1.10.2.1 Trastuzumab and T-DM1 
Trastuzumab, also known as Herceptin, was approved in 1998 for the treatment of HER2 
overexpressing breast cancer in both early and advanced disease. For early breast cancer, 
trastuzumab can be used in the adjuvant setting as combination therapy or as a single agent after 
completion of a multi-modality anthracycline-based therapy regimen466. For metastatic breast 
cancer, trastuzumab is used either in combination with paclitaxel or as a single agent in patients 
whom have received at least one prior chemotherapeutic regimen466. Due to its extended clinical 
use for the past twenty years, trastuzumab has become the standard of care for patients with HER2 
positive breast cancer467,468. In 2013, trastuzumab conjugated with emtansine (T-DM1), a 
microtubule inhibitor, was approved for use in metastatic breast cancer patients previously treated 
with trastuzumab and a taxane469. 
Trastuzumab and T-DM1 work by similar mechanisms of action. First, when trastuzumab 
binds to the extracellular domain 4 of HER2, it inhibits formation of ligand-independent HER2-
HER3 heterodimers, which form when HER2 is overexpressed470. Second, trastuzumab binding 
prevents the proteolytic cleavage and shedding of the HER2 extracellular domain, inhibiting 
formation of the kinase active membrane bound fragment p95471. Third, when trastuzumab binds 
to HER2, it induces antibody-dependent cellular cytotoxicity (ADCC) by engaging Fc receptors 
on effector immune cells472. Finally, it has been proposed that trastuzumab may induce HER2 
internalization and degradation through activation of c-Cbl473. In addition to these mechanisms, T-
DM1 possesses cytotoxic mechanisms of action due to the conjugated emtansine. Internalization 
of HER2 – T-DM1 complexes allows lysosomal degradation of MCC, a non-reducible thioether 
that links trastuzumab and emtansine, which releases emtansine into the cell474. Subsequently, 
emtansine binds to microtubules and inhibits their assembly, resulting in mitotic arrest or 
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catastrophe, and eventual cell death474. For additional information on the mechanisms of action of 
other anti-microtubule agents, see Section 1.9.3, “Mitotic Inhibitors”. 
Resistance to trastuzumab arises through multiple mechanisms. First, polymorphisms in 
the Fc receptor on immune cells may decrease trastuzumab-mediated ADCC and result in worse 
prognosis475. Second, overexpression of other HER family members (in particular EGFR and 
HER3) and other tyrosine kinase receptors, such as insulin growth factor 1 receptor (IGF1R), are 
commonly implicated in trastuzumab resistance476. Third, alterations of HER2, including shedding 
of the extracellular domain or expression of splice variants, can decrease response to 
trastuzumab477. Finally, hyper-activation of the PI3K – Akt signaling pathway by multiple 
mechanisms has been shown to cause trastuzumab resistance476. The mechanisms of resistance to 
T-DM1 are not well understood but are likely associated with decreased HER2 expression, 
shedding of the extracellular domain, altered receptor-complex internalization, or drug efflux by 
MDR1474. 
Both trastuzumab and T-DM1 are administered by intravenous infusion. While 
trastuzumab has a relatively long elimination half-life of 28 days, T-DM1 has a shorter half-life of 
4 days due to proteolytic degradation of the emtansine linker466,478,479. The elimination pathways 
of trastuzumab and T-DM1 are unknown but are hypothesized to be similar to homeostatic 
management of immunoglobulin G466. The most clinically significant toxicities associated with 
trastuzumab treatment are cardiotoxicity and pulmonary toxicity, which manifest most 
aggressively as congestive heart failure and pneumonitis respectively466,480. The most clinically 
significant toxicities associated with T-DM1 use are thrombocytopenia and transaminitis (the 
elevation of AST and ALT), without any reports of hepatic injury481. 
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1.10.2.2 Pertuzumab 
While trastuzumab is the standard of care for women with HER2 positive breast cancer, 
approximately 15% of women relapse despite trastuzumab therapy482. Pertuzumab was approved 
in 2012 for women with HER2 positive breast cancer in combination with trastuzumab and 
chemotherapy483,484. Pertuzumab binds to the extracellular domain 2 of HER2 and is effective at 
reducing ligand-dependent formation of HER2 heterodimers, most specifically heregulin-induced 
HER2-HER3 dimers485,486. In contrast, trastuzumab is only effective at blocking ligand-
independent dimerization470. Similar to trastuzumab, the Fc domain of pertuzumab can interact 
with the Fc receptor on immune cells and induce ADCC487. Resistance mechanisms to pertuzumab 
are not as well characterized as those of trastuzumab. Some proposed resistance mechanisms 
include formation of HER3-EGFR heterodimers, HER2 extracellular domain shedding, and 
PIK3CA expression488,489. 
Pertuzumab is administered by intravenous injection and has a terminal elimination half-
life of approximately 19 days490. Similar to trastuzumab, the elimination of pertuzumab is thought 
to be conducted similarly to homeostatic management of immunoglobulin G490. The most 
clinically severe toxicities observed are cardiotoxicity, most commonly a decrease in left 
ventricular ejection fraction (LVEF). Importantly, LVEF dysfunction incidence is not significantly 
increased when pertuzumab is added to trastuzumab therapy491. 
1.10.2.3 Lapatinib 
Lapatinib is a dual specificity EGFR/HER2 small molecule kinase inhibitor. It is currently 
approved for women with HER2 positive breast cancer in combination with capecitabine who have 
received prior therapy with trastuzumab, an anthracycline, and a taxane492. Additionally, lapatinib, 
in combination with letrozole, is approved for use in hormone receptor positive metastatic breast 
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cancer that overexpresses HER2492. The mechanism of action of lapatinib is inhibition of EGFR 
and HER2 kinase activity by acting as an analogue of ATP to prevent ATP-mediated 
transphosphorylation of receptor dimers493. Additionally, lapatinib can also impact HER3 
phosphorylation in the context of EGFR-HER3 or HER2-HER3 heterodimers494. Disruption of 
these receptor tyrosine kinases inhibits downstream signaling through MAPK, PI3K-Akt, and 
PLCγ494. Resistance to lapatinib most commonly occurs with activation of compensatory 
pathways, including other receptor tyrosine kinases and intracellular kinases, or mutation of the 
tyrosine kinase domain of HER2495. 
Lapatinib is an orally administered agent and exhibits an elimination half-life of 24 
hours493. Lapatinib is primarily eliminated by biliary excretion after hepatic metabolism by 
CYP3A4496. Importantly, lapatinib metabolites can act as covalent inhibitors of CYP3A4, which 
can cause drug-drug interactions and hepatotoxicity497,498. Lapatinib is generally well-tolerated, 
with the most common adverse effects being diarrhea, rash, nausea, and fatigue499. 
1.10.3 EGFR Targeted Therapies 
EGFR targeted therapies have been successfully employed in colorectal, lung, and head and neck 
cancer since the initial approval of gefitinib for non-small cell lung carcinoma in 2003500. 
Unfortunately, the response of breast cancers to EGFR inhibitors has been mixed – while some 
patients respond to therapy, clinical trials have shown little benefit, likely due to insufficient 
patient stratification501,502. Clinical trials to determine whether EGFR inhibitors can provide 
survival benefit in breast cancer, in particular triple negative breast cancers which often 
overexpress EGFR, are currently being conducted. As there are no approved EGFR inhibitors for 
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breast cancer (except for lapatinib, discussed above in “HER2 Targeted Therapies”), the 
pharmacology of this drug class will not be further discussed. 
1.10.4 CDK4/6 Targeted Therapies 
Cyclin dependent kinase 4/6 (CDK4/6) inhibitors were developed to help overcome the endocrine 
therapy resistance that is often seen with advanced hormone receptor positive breast cancer503. 
Additionally, CDK4/6 selective inhibitors were developed due to the high incidence of dose-
limiting toxicities with pan-CDK inhibitors503. There are three CDK4/6 inhibitors currently 
approved for the treatment of advanced hormone receptor positive, HER2 negative, advanced 
breast cancer: palbociclib, ribociclib, and abemaciblib503,504. These drugs are currently in clinical 
trials to extend their application to different breast cancer subtypes, in particular triple negative 
breast cancer503,505.    
The mechanism of action of CDK4/6 inhibitors is to block the G1 to S phase transition in 
the cell cycle, resulting in growth arrest506. This checkpoint, also known as the restriction or R 
point, is mediated by a complex formed between cyclin D and either CDK4 or CDK6. This 
complex hypophosphorylates retinoblastoma (Rb), which then allows the complex of Cyclin E and 
CDK2 to hyperphosphorylate Rb upon further passage through the R point. Hyperphosphorylation 
of Rb results in the release of bound E2F, which subsequently activates S phase genes that mediate 
further cell cycle progression506. Importantly, inhibition of CDK4 and CDK6 is both necessary and 
sufficient to induce cell cycle arrest, whereas the role of CDK2 is less essential for progression 
through the R point507. 
There are many mechanisms of CDK4/6 inhibitors, all of which can either result in intrinsic 
or acquired resistance. Since CDK4/6 inhibitors act by preventing the phosphorylation of Rb, only 
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tumors with functional Rb, which account for 65-80% of all and 97% of ER+/HER2- breast 
cancers, are treatment responsive506,508,509. Moreover, tumors that express high levels of p16Ink4a 
(an endogenous CDK4/6 inhibitor) are often resistant to CDK4/6 inhibitors. Additionally, 3-
phosphoinositide-dependent protein kinase 1 (PDK1) expression has been shown to decrease 
sensitivity to CDK4/6 inhibition510. Finally, overexpression of Cyclin E may result in resistance to 
CDK4/6 inhibitors, but no clinical association has been shown between Cyclin E amplification 
and CDK4/6 inhibitor response509,511,512. 
Attractively, all three clinically approved CDK4/6 inhibitors are orally administered 
medications that exhibit slow absorption kinetics503. These inhibitors are extensively tissue bound, 
metabolized, and primarily eliminated through the biliary system with elimination half-lives of 26 
hours, 36 hours, and 17-38 hours for palbociclib, ribociclib, and abemaciclib respectively513–515. 
Drug-related adverse events are relatively common with this drug class due to the ubiquity of the 
cell cycle. While the most common dose-limiting toxicity with palbociclib and ribociclib is 
neutropenia, the most common dose-limiting toxicity with abemaciclib is fatigue503. The lower 
incidence of neutropenia observed with abemaciclib may be related to its relatively higher 
selectively for CDK4 than CDK6514. 
1.10.5 PARP Targeted Therapies 
Poly(ADP-ribose) polymerases (PARPs) are a family of enzymes that play a role in the cellular 
response to DNA damage. The ADP-ribose polymer that is synthesized by PARP enzymes targets 
the assembly of the DNA repair complex at DNA damage sites516. Currently, there is only one 
FDA approved PARP inhibitor for breast cancer therapy. Olaparib is indicated for treating 
metastatic breast cancer in patients who possess a germline BRCA1/2 mutation. While olaparib 
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demonstrated a 3 month increase in progression free survival and improvement in patient quality 
of life, there was no overall survival benefit517. Many clinical trials are underway to extend PARP 
inhibitor usage to breast cancer patients without a germline BRCA1/2 mutation, in particular in 
the context of triple negative breast cancer518. Additionally, other PARP inhibitors, such as 
veliparib, niraparib, and talazoparib, are being investigated for their efficacy516. However, since 
PARP inhibitors are not employed that frequently for the treatment of breast cancer, their 
pharmacology will not be further discussed.  
1.10.6 PD-1 and PD-L1 Targeted Therapies 
Immune checkpoint blockade through targeting PD-1 or its cognate ligand PD-L1 has proven quite 
successful in metastatic melanoma, non-small cell lung cancer, Hodgkin’s lymphoma, and head 
and neck cancer519. Currently, clinical trials are underway to investigate pembrolizumab (PD-1 
inhibitor) and atezolizumab (PD-L1) in the context of breast cancer. The majority of these studies, 
including the two phase 3 clinical trials, test PD-1/PD-L1 inhibition efficacy in advanced triple 
negative breast cancer, which is thought to be more susceptible to checkpoint blockade due to the 
higher level of tumor infiltrating lymphocytes (TILs) found in this breast cancer subtype520. 
However, as there are currently no immune checkpoint blockade agents approved for the treatment 
of breast cancer, their pharmacology will not be further discussed. 
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1.11 COMMON SYSTEMIC THERAPY REGIMENS 
The systemic therapy regimens for breast cancer vary based on cancer molecular subtype and 
stage. This section will briefly describe the preferred regimens based on the national 
comprehensive cancer network (NCCN) guidelines266. For early breast cancer (stage I and II), 
chemotherapy is often given in the adjuvant setting, after surgery and prior to radiotherapy266. 
Common regimens for triple negative breast cancer are 1) dose-dense doxorubicin and 
cyclophosphamide followed by paclitaxel and 2) combination docetaxel and cyclophosphamide. 
Common regimens for HER2 positive disease are 1) doxorubicin and cyclophosphamide followed 
by paclitaxel and trastuzumab and 2) trastuzumab, docetaxel, and carboplatin, with or without 
pertuzumab. Estrogen receptor positive disease is treated in the adjuvant setting with five years of 
tamoxifen or an aromatase inhibitor, for pre- and postmenopausal women respectively521. Some 
early stage estrogen receptor positive breast cancers are treated with chemotherapy, especially for 
large primary tumors or node positive disease522. For locally advanced breast cancer (Stage III), 
chemotherapy is given in the neoadjuvant setting to increase the success rate of the surgical 
intervention523. Additional adjuvant chemotherapy is rarely used in locally advanced breast cancer, 
but adjuvant radiotherapy plays an important role in management523,524. 
For metastatic breast cancer (Stage IV), systemic therapy is the primary form of 
treatment266. Estrogen receptor positive disease is treated with tamoxifen or an aromatase inhibitor, 
for premenopausal and postmenopausal women respectively. Postmenopausal women commonly 
receive a CDK4/6 inhibitor in combination with an aromatase inhibitor to increase progression 
free survival525. HER2 positive metastatic breast cancer is often treated with a taxane (paclitaxel 
or docetaxel) in combination with trastuzumab and pertuzumab266. Resistant disease is commonly 
treated with T-DM1, lapatinib with capecitabine, or trastuzumab combined with vinorelbine or 
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capecitabine266. Triple negative breast cancers can be treated with a multitude of single agent or 
combination therapies, such as gemcitabine, eribulin, gemcitabine with carboplatin, or 
cyclophosphamide with methotrexate and 5-FU266.  
In summary, the management of stage I and II breast cancer commonly involves 
chemotherapy in the adjuvant setting. Estrogen receptor positive disease is often treated with 
tamoxifen or an aromatase inhibitor, with chemotherapy added for locally aggressive disease. 
HER2 positive disease is treated with chemotherapy and trastuzumab. Triple negative breast 
cancer is treated with combination chemotherapy. Stage III breast cancer, in contrast, employs 
neoadjuvant chemotherapy instead of adjuvant chemotherapy in order to improve surgical success 
rates. Finally, the treatment of metastatic breast cancer is complex, multifactorial, and depends on 
the molecular subtype of the breast cancer, previous treatment modalities, and patient and doctor 
preferences526. 
1.12 CLINICAL NEED 
To enhance the current standard of care, there exists a great clinical need for drugs that can delay 
or eliminate the mortality from metastatic breast cancer. This need is best illustrated in the case of 
estrogen receptor positive breast cancer patients, many of whom may demonstrate an apparent 
cure of their disease for decades before dormant micrometastases outgrow into clinically evident 
macrometastases. Once metastatic disease is apparent, treatment is challenging and often palliative 
rather than curative. Thus, one approach to limit the burden of metastatic breast cancer would be 
to maintain dormant metastatic tumor cells in a quiescent state, delaying this mortal phase of 
metastatic outgrowth and recurrence. 
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Clinical development and implementation of new drugs takes years to decades of study and 
is very costly. As such, repurposing already FDA-approved drugs with favorable safety profiles 
may allow for more rapid clinical implementation of effective therapies at low cost527,528. In 
particular, drugs that are employed in the treatment of chronic health conditions with few or mild 
adverse events would be the most suitable for use as a long term adjuvant therapy to prevent 
emergence of dormant micrometastases.  
The statin drugs have been clinically used for the treatment of cardiovascular disease for 
three decades and are well tolerated by the majority of patients529,530. Large retrospective, 
population-based studies have shown that statins reduce breast cancer mortality531–533 without 
influencing incidence of the primary tumor534–536. These clinical data have been supported by cell 
and animal studies that suggest statins suppress growth, induce apoptosis, and/or decrease 
invasiveness of breast cancer cells537–542. However, it remains unclear whether statins can suppress 
outgrowth of metastases in the context of the metastatic microenvironment and what factors guide 
statin efficacy in cancer. The next section will present the current usage and pharmacology of the 
statin drug class as well as discuss basic science and clinical studies that investigate the effects of 
statins on cancer. 
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2.0  STATIN PHARMACOLOGY 
2.1 DISCOVERY 
The discovery and development of the statin drugs was motivated by incontrovertible evidence 
from the Framingham Heart Study that high blood cholesterol levels increased the risk for future 
myocardial infarction543. These epidemiological studies drove investigations into the biochemical 
synthesis of cholesterol and its physiologic regulation544. Subsequent studies demonstrated that 
dietary cholesterol could reduce the synthesis of mevalonate, while the synthesis of its precursor, 
β-Hydroxy β-methylglutaryl-CoA (HMG-CoA), was unaffected545,546. These data suggested that 
the enzyme responsible for this conversion, HMG-CoA reductase (HMGCR), is an important node 
for the regulation of de novo cholesterol synthesis546. In parallel, other cholesterol-lowering agents, 
such as cholesterol excreting agents and fibrates, were found to have limited success due to 
insufficient efficacy or safety concerns547. Moreover, the first clinically used drug that inhibited 
cholesterol biosynthesis, triparanol, was withdrawn from the market for severe ocular and 
cutaneous adverse events548–551. 
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Figure 7. Chemical structures of HMG-CoA, compactin, and FDA-approved statins 
The chemical structures of HMG-CoA, compactin, the first derived statin, and the seven FDA-approved statin drugs. 
Dates in parentheses indicate the initial approval date by the FDA, as according to their website552. Drug structures 
were drawn using ChemDoodle Sketcher553. 
 
 
 
  84 
The first HMGCR competitive inhibitors were isolated by Akira Endo, who hypothesized 
that fungal compounds could inhibit HMGCR activity547. Two compounds with potent HMGCR 
inhibitory activity were isolated in the 1970s, named citrinin and compactin (also known as 
mevastatin)547,554,555. Dr. Endo noted that the pharmacophore of compactin is strikingly similar to 
the structure of HMG-CoA (Figure 10). Unfortunately, citrinin and compactin never reached 
clinical approval due to concerns about renal toxicity and carcinogenicity, respectively547. Several 
years later, in 1979, Dr. Endo and Merck Research Laboratories independently isolated the same 
statin from fungal cultures, which was eventually named lovastatin547. After promising clinical 
studies that demonstrated dramatic reductions in blood cholesterol and no carcinogenicity, 
lovastatin became the first FDA approved statin in 1987547,556.  
Since the approval of lovastatin, seven other statins have garnered FDA approval: 
atorvastatin, cerivastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin 
(Figure 10) 529,547,557. Cerivastatin was subsequently withdrawn from the market in 2001 due to 
significant mortality from rhabdomyolysis-induced kidney failure557. While atorvastatin, 
fluvastatin, pitavastatin, and rosuvastatin are synthetic, pravastatin and simvastatin are 
semisynthetic, being derived with minor modification from compactin and lovastatin 
respectively547. 
2.2 PHARMACODYNAMICS 
 
All statin drugs are competitive inhibitors of the enzyme HMGCR. Statins bind to a portion of the 
HMGCR catalytic domain, which inhibits binding of the natural substrate HMG-CoA530,558. Statins 
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bind the active site of HMGCR with a 100-1000 fold higher affinity than HMG-CoA559. 
Importantly, while all statins share the same pharmacophore (Figure 10), the structural 
characteristics guide their binding affinity to HMGCR560. The mean inhibitory concentration (Ki) 
of the FDA approved statins and the affinity of HMG-CoA for HMGCR are given in Table 
14559,561,562.  
Table 11. Affinity of HMG-CoA and statins for HMGCR 
Molecule HMG-CoA Atorva Fluva Lova Pitava Prava Rosuva Simva 
Kd or Ki (nM) 6600 15.2 17.9 2.7 – 11.1 6.8 55.1 12 18.1 
The affinity (Kd) or mean inhibitory concentration (Ki) of HMG-CoA and statins, respectively, for HMGCR. The 
statin prefixes are used instead of the whole name (e.g. Atorva = Atorvastatin). Affinity and mean inhibitory 
concentration values are reported in nanomolar (nM)559,561,562. 
Statins dramatically reduce flux through the cholesterol biosynthesis pathway by their 
inhibition of the rate limiting enzymatic step, catalyzed by HMGCR563. The most significant steps 
and branch points of the cholesterol biosynthesis pathway are shown in Figure 11. The most 
biologically relevant molecules affected by inhibition of HMGCR are downstream of mevalonate 
– cholesterol, farnesyl pyrophosphate (FPP), and geranylgeranyl pyrophosphate (GGPP). The 
mechanisms of action of statin therapy, both in cardiovascular disease and other diseases, are 
related to reductions in each of these three compounds. Before describing how statins affect cancer 
growth (Section 2.6, “Statin Usage in Cancer”), it is important to first describe the mechanisms 
of action by which statins lower cardiovascular disease risk and mortality.  
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Figure 8. The cholesterol biosynthesis pathway 
Statins block HMG-CoA reductase (HMGCR, shown in blue) to shut down the cholesterol biosynthetic pathway. 
Other inhibitors of this pathway are shown in red. In addition to cholesterol, other downstream mediators are 
affected, such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate. 
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2.2.1 Effects of Statins on Lipid Homeostasis 
One of the main mechanisms of action of statin therapy is the reduction in circulating lipids, most 
specifically cholesterol in the form of low density lipoprotein (LDL) particles564. Statins 
accomplish this by acting selectively in the liver, the primary site of cholesterol biosynthesis565, 
largely due in part to first pass metabolism. Statins enter hepatocytes by diffusion or active 
transport (see “Pharmacokinetics”)530. Statin binding to HMGCR prevents it from converting 
HMG-CoA into mevalonate, which reduces the intracellular cholesterol concentration566. When 
cells are deprived of cholesterol, the transport protein SREBP cleavage-activating protein (SCAP) 
shuttles sterol regulatory element-binding protein 2 (SREBP-2) from the ER to the Golgi, where 
Site-1 Protease (S1P) and Site-2 Protease (S2P) reside567. These two proteases subsequently cleave 
SREBP-2 into its N-terminal active form, which translocates into the nucleus and binds sterol 
response elements (SREs) to enhance transcription of several target genes, including HMGCR, 
Fatty Acid Synthase (FAS), LDL Receptor (LDLR), and Proprotein Convertase Subtiliskin/Kexin 
Type 9 (PCSK9)567–569. Increased expression of LDLR facilitates uptake of LDL particles into 
hepatocytes, which reduces blood cholesterol570. Conversely, PCSK9 acts as a negative regulator 
of LDLR and is negatively regulated by circulating LDL569,571,572. In short, statins both reduce new 
cholesterol synthesis and enhance hepatic uptake of existing, circulating cholesterol. Moreover, 
statin-mediated hepatic uptake of LDL particles also reduces circulating triglyceride levels in 
patients with hypertriglyceridemia573. 
Statin treatment also affects other aspects of lipid homeostasis. Even in patients with 
dysfunctional LDLRs, statins decrease LDL by inhibiting synthesis of apolipoprotein B100, an 
essential protein for the formation of LDL particles574. Additionally, statins enhance circulating 
levels of high density lipoprotein (HDL), which plays an important role in removing cholesterol 
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from peripheral tissues and returning it to the liver575. The increase in HDL is thought to be due to 
inhibition of Cholesterol Ester Transfer Protein (CETP) function, which normally acts to return 
cholesterol esters to LDL particles575,576. Finally, statins can lessen the oxidation of LDL particles 
and decrease their uptake by macrophages through regulation of scavenger receptor expression577. 
2.2.2 Effects on Cardiovascular Pathobiology 
In addition to modifying lipid homeostasis, statins exert pleotropic effects on other aspects of 
cardiovascular pathobiology. Cell-mediated effects stem from reductions in cellular signaling from 
small G-proteins through reducing the availability of FPP and GGPP564. In endothelial cells, 
decreased activation of Rho enhances expression of endothelial nitric oxide synthase (eNOS), 
which protects endothelial function and impedes cardiovascular disease progression578. In smooth 
muscle cells, reduction of Ras and Rho signaling reduces their proliferation and migration, which 
decreases the intimal hyperplasia associated with vascular injury579,580. In inflammatory cells, 
statins act to decrease their proliferation and secretion of proinflammatory cytokines, such as IL-
6, IL-8, and MCP-1581,582. Finally, in myocardial cells, statins can reduce cardiac remodeling 
through suppression of Ras and Rac1583. 
In comparison, additional benefits of statins in cardiovascular disease involve inhibition of 
disease progression. Acute coronary syndromes are the result of rupture of an unstable plaque in 
the vessel wall, which induces thrombosis and subsequent occlusion of blood flow. Statins can 
modify the composition of plaques, reducing the concentration of lipids, increasing collagen 
deposition, and decreasing metalloproteinase activity584. Statins also impede thrombosis by 
inhibiting platelet activation and the coagulation cascade, in part through reductions in Na+/H+ 
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antiporter activity and tissue factor expression respectively585,586. Finally, statins can facilitate 
dissolution of thromboses by upregulation of tissue plasminogen activator (tPA)587. 
2.3 PHARMACOKINETICS 
The seven FDA approved statins have similar, but not identical, pharmacokinetics. 
Pharmacokinetic properties of the seven FDA approved statins are summarized in Table 15, and 
the salient differences between the different drugs are discussed below. Statins are classified as 
lipophilic or hydrophilic depending on their partition coefficients. The value of the partition 
coefficient is dependent on pH, which controls the ionization state of the drug588. The partition 
coefficients reported in Table 15 were obtained at pH 7.4 (defined as log D), which are lower than 
other reported values in the literature that were obtained at acidic pH values (pH = 2.0)588. 
Accordingly, the hydrophilic statins pravastatin and rosuvastatin have Log D values less than zero, 
whereas the other five statins have Log D values greater than zero and are classified as lipophilic 
statins589. 
All statins are administered orally, with relatively little of the administered dose reaching 
the systemic circulation. The highest orally bioavailable statin is pitavastatin (51%), whereas the 
other six statins exhibit an absolute bioavailability less than 25% (Table 15)589. All statin drugs 
reach peak blood concentration levels one to four hours after administration. All statins are 
extensively protein bound in the serum, except pravastatin, and as a result, exhibit minimal extra-
hepatic tissue distribution589,590. After systemic absorption, statins undergo first pass metabolism 
in the liver. Simvastatin and lovastatin are administered as lactone prodrugs, which must be 
hydrolyzed in the gut and liver to generate the active statin acid589.  
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Table 12. Pharmacokinetic properties of the seven FDA approved statins 
Property Atorva Fluva Lova Pitava Prava Rosuva Simva 
Log D 1.11 1.27 1.7 1.49 -0.84 -0.33 1.60 
Bioavailability (%) 14 24 <5 51 17 20 <5 
Tmax (h) 1-2 <1 2-4 1 1-1.5 3-5 4 
Protein Binding (%) > 98 98 >95 99 50 88 95 
CYP450 Isozyme 3A4 2C9 3A4 2C9 2C8 None 2C9 3A4 
Active Metabolites (n) Yes (2) No Yes (4) No No Minimal Yes (3) 
Elimination T1/2 (h) 14 1.2 3 11 1.8 19 2 
Renal Excretion (%) <2 <6 10 15 20 10 13 
Absorption, distribution, metabolism, and excretion parameters for each statin are listed. The statin prefixes are used 
instead of the whole name (e.g. Atorva = Atorvastatin). Times are represented in hours (h). Log D = distribution 
coefficient at pH 7.4 (higher value means more lipophilic); Tmax = time after oral dose to maximum serum 
concentration; CYP450 = cytochrome P450; T1/2 = half-life. Data were acquired from Schachter 2005530, McKenney 
et al 2009589, and Davidson et al 2006591. 
 
 
Statin uptake into cells can occur through passive diffusion (limited to lipophilic statins) 
or carrier-mediated transport, most commonly by OATP1B1 with lesser contributions from 
OATP1B3, 1A2, and 2B1592,593. OATP isoforms 1B1 and 1B3 are exclusively expressed on the 
sinusoidal membrane of hepatocytes, whereas isoforms 1A2 and 2B1 are expressed on other cell 
types, such as enterocytes, neurons, and myocytes. Transporter polymorphisms, particularly in 
OATP1B1, can increase plasma concentrations of statins and increase the risk for toxicity592–595. 
OATP2B1 has been shown to be an uptake receptor for atorvastatin and rosuvastatin in skeletal 
muscle fibers, suggesting it plays a role in statin myotoxicity596. Importantly, except for 
hepatocytes, the majority of cell types do not express these transporters at meaningful levels592. 
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This means lipophilic statins can distribute into extrahepatic tissues by diffusion across the cell 
membrane, whereas hydrophilic statins are inable530. 
Statins undergo differential metabolism by the CYP450 isozymes. Atorvastatin, lovastatin, 
and simvastatin are extensively metabolized by CYP3A4 into pharmacologically active 
metabolites (Table 15)589. In contrast, fluvastatin is extensively metabolized by CYP2C9, while 
pitavastatin and rosuvastatin are minimally (10%) metabolized589. Pravastatin exhibits no 
metabolism by the CYP450 family members. Statins are primarily eliminated by biliary excretion, 
with terminal elimination half-life values between 1.2 and 19 hours (Table 15)530. Efflux of statins 
and their metabolites from cells is primarily accomplished by the transporter ABCB1, also known 
as multi-drug resistance 1 (MDR1), and polymorphisms in the gene that encodes this transporter 
can increase the risk for statin myotoxicity597. 
2.4 TOXICITY 
Statins are typically well tolerated drugs. The most common adverse events associated with statin 
usage involve muscle tissues, which range in severity from myalgia to fatal rhabdomyolysis530. 
Muscle pain (myalgia) is relatively more common among statin users, with an incidence of 
approximately 5%598. Myopathy, or myositis, only occurs in 0.1% of patients taking statins and 
involves pain, weakness, and mobility restrictions that often are accompanied by an elevation in 
serum creatine kinase (CK) to ten times the upper limit of normal (ULN)598. Rarely, myopathy can 
progress to rhabdomyolysis, which involves CK elevations above fifty times the ULN and 
myoglobin accumulation in the blood (myoglobinemia) and urine (myoglobinuria), which can 
induce renal failure598. The incidence of rhabdomyolysis is extremely rare, with an incidence of 
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3.4 per 100,000 person years and mortality rate of approximately 10%599. As stated previously, 
cerivastatin was removed from the market in 2001 because it exhibited a rhabdomyolysis incidence 
of approximately 46 per 100,000 person years557,599. Rhabdomyolysis incidence is higher in 
patients taking atorvastatin, lovastatin, and simvastatin, which is due to their extensive metabolism 
by CYP3A4 and potential for drug-drug interactions600.   
The less common adverse events observed with statin usage involve the liver, pancreas, 
kidney, and peripheral nerves. The most common presentation of hepatotoxicity is an 
asymptomatic, often transient, elevation in serum transaminases, which occurs in 0.5-3% of 
patients589,600,601. Serious liver injury and liver failure, as a result of statin therapy, is extremely 
rare and similar to the rates in the population not taking statins589. Statins have been shown to 
increase the risk of diabetes by approximately 9%, which may be due to the influence of cholesterol 
on pancreatic β-cell function589,602. Statins have also been associated with proteinuria and acute 
renal failure, the latter most often in the context of rhabdomyolysis (see above)589,600. Finally, 
statins have been associated with the development of peripheral neuropathy in some patients, 
which improves or disappears upon cessation of the statin589,603. 
2.5 CLINICAL USAGE 
Statin usage in the United States has increased dramatically over the past several decades. Between 
2003 and 2012, statin usage among adults in the US increased from 18% to 26%604. Any form of 
cholesterol lowering medication is taken by 71% of adults with cardiovascular disease, 63% of 
adults with diabetes, and 54% of adults with hypercholesterolemia604. Of these, statins are taken 
by 93% of patients receiving cholesterol lowering therapy604. The most commonly used statins in 
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2012 were simvastatin (42%), atorvastatin (20.2%), pravastatin (11.2%), rosuvastatin (8.2%), and 
lovastatin (7.4%)604. In parallel with cardiovascular disease risk, statin use in the US increases with 
age, with 17% of adults aged 40-59 and 48% of adults aged 75 and over using cholesterol lowering 
medication604,605.  
The clinical potency of statin drugs and their different dosage amounts is determined by 
the measurement of blood LDL cholesterol (LDL-C) in mg/dL, which has largely replaced total 
cholesterol as a measurement of cardiovascular risk606. Statin regimens that achieve <30%, 30-
50%, or >50% reductions in LDL-C are labeled low-, moderate-, and high-intensity statin therapy 
respectively607. The seven statins and their approved daily dosages are organized by statin therapy 
intensity category below, in Table 16607. 
 
 
Table 13. High- Moderate- and Low-Intensity Statin Therapy 
Low-Intensity Moderate-Intensity High-Intensity 
Daily dose lowers LDL-
C by <30% 
Daily dose lowers LDL-C 
by 30-50% 
Daily dose lowers LDL-C 
by >50% 
Fluvastatin 20-40mg 
Lovastatin 20mg 
Pitavastatin 1mg 
Pravastatin 10-20mg 
Simvastatin 10mg 
Atorvastatin 10 (20) mg  
Fluvastatin 40mg, BID 
Fluvastatin XL 80mg 
Lovastatin 40mg 
Pitavastatin 2-4mg 
Pravastatin 40 (80) mg 
Simvastatin 20-40mg 
Rosuvastatin (5) 10mg 
Atorvastatin 40-80mg 
Rosuvastatin 20 (40) mg  
Statin dosages that achieve plasma reductions in LDL-C of <30% (Low-Intensity), between 30-50% (Moderate-
Intensity), and >50% (High-Intensity), as tested in randomized control trials (RCTs) and reported in the 2013 
American College of Cardiology (ACC) and American Heart Association (AHA) 2013 guidelines607. Statin dosages 
reported in italics are FDA approved but have not been tested in RCTs. BID = twice daily; XL = extended release 
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Statins are the first line treatment for hyperlipidemia and atherosclerotic cardiovascular 
disease (ASCVD) after therapeutic lifestyle changes and are also used as preventative therapy for 
patients at a high risk for developing cardiovascular disease608. The individuals that benefit from 
statin therapy in the context of ASCVD are patients with 1) clinical ASCVD, 2) primary elevations 
of LDL-C greater than 190 mg/dL, 3) diabetes, aged 40-75, with LDL-C between 70-189 mg/dL, 
and without clinical ASCVD, and 4) LDL-C between 70-189 mg/dL and estimated 10-year 
ASCVD risk greater than 7.5%607. Clinical ASCVD is defined as patients with a history of acute 
coronary syndromes, past myocardial infarction, stable or unstable angina, coronary or other 
arterial revascularization, stroke, transient ischemic attack, or peripheral artery disease607. 
Currently, moderate- and high-intensity statin therapy are recommended for the treatment of these 
patient groups, as they do not show an increased risk of statin-related adverse events over low-
intensity therapy and provide additional ASCVD risk reduction607. 
2.6 STATIN USAGE IN CANCER 
Statins have a significant impact on cardiovascular disease mortality without a high incidence of 
severe adverse events. In addition to lowering blood cholesterol, statins derive part of their 
cardiovascular mortality benefit from pleiotropic effects on the endothelium, smooth muscle, 
inflammatory cells, and myocardium, which are related to a reduction in prenylating intermediates 
that normally modify and activate critical signaling proteins involved with intracellular 
signaling583. These pleiotropic effects of statins have been investigated in the context of many 
other diseases. Of relevance to present work are the clinical and basic research studies that have 
investigated the roles of statin drugs in cancer incidence, progression, and mortality. 
  95 
2.6.1 Clinical Research Studies  
While few prospective clinical trials have been conducted to investigate statin therapy in cancer 
patients, multiple retrospective cohort studies and meta-analyses have been published, some with 
large patient numbers. There are several hypotheses that motivate these studies. First, since statins 
lower LDL-C, this many influence carcinogenesis and tumor progression, as rapidly dividing cells 
require increased cholesterol for cell membrane synthesis609. Conversely, low cholesterol has been 
associated with higher incidence of certain cancers610. Moreover, in the context of prostate cancer, 
cholesterol is an essential precursor for steroid hormone synthesis, which is involved with 
carcinogenesis and disease progression609,611. Similarly, statins can compete with 
dehydroepiandosterone sulfate (DHEAS) for OATP2B1-mediated uptake into prostate cancer 
cells, thereby reducing the concentration of testosterone precursors612,613. In addition, the influence 
of statins on reducing prenylation, discussed above in the context of cardiovascular disease, may 
reduce signaling through pathways involved in carcinogenesis and cancer progression, such as Ras 
and Rac1583,614. Finally, statins reduce the secretion of pro-inflammatory cytokines by immune 
cells, which have been shown to drive carcinogenesis and metastasis615,616.  
Since these three factors influence both early (carcinogenesis) and late (metastatic cascade) 
stages of cancer progression, clinical studies have investigated the influence of statins on cancer 
incidence, recurrence, and mortality. These studies will be discussed in the following three sections 
below in the context of these categories, and the data are summarized in Table 17. While data on 
many cancer types will be presented, the primary cancer types discussed will be prostate cancer 
and breast cancer. Prostate cancer will be discussed because it is the most common cancer in men, 
and steroid hormone synthesis is mechanistically affected by statins611. Breast cancer will be the 
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primary focus of these three sections because the objective of this thesis is to investigate the role 
of statins in preventing the emergence of dormant metastatic breast cancer. 
 
 
Table 14. The Influence of Statin Therapy on Cancer Incidence, Recurrence, and Mortality 
Cancer Type 
The Effect of Statin Therapy on Cancer… 
Incidence Recurrence Mortality 
Breast ↔ ↔ (Hydrophilic Statins) 
↓ (All or Lipophilic Statins) 
↔ (Hydrophilic Statins) 
↓ (All or Lipophilic Statins) 
Prostate ↔ ↔ (Radical Prostatectomy) 
↓ (Radiotherapy) 
↓ (All, Lipophilic, or Hydrophilic 
Statins) 
Lung ↔ ↔ (Pravastatin) 
↓ (All Statins) 
↔ (Pravastatin) 
↓ (All Statins) 
Colorectal ↔ ↓ (All Statins) ↓ (All Statins) 
Primary Liver ↓ (All Statins) ↓ (All Statins or Pravastatin) ↓ (All Statins or Pravastatin) 
The influence of statins on cancer incidence, recurrence, and mortality for breast, prostate, lung, colorectal, and 
primary liver cancer. ↔ = no effect, ↓ = reduction. All statins, hydrophilic statins, and lipophilic statins refer to 
studies that were conducted examining patients taking any statin, any hydrophilic statin, or any lipophilic statin 
respectively. 
 
 
2.6.1.1 Statin Influence on Cancer Incidence 
Many studies have investigated the influence of statin therapy on the risk for developing cancer, 
with conflicting results. The CARE trial in 1996 published one of the first associations between 
statins and cancer incidence, in which pravastatin users demonstrated a slight increase in the risk 
of many types of cancer and a statistically significant increase in breast cancer risk617. Similarly, 
the PROSPER trial in 2002 showed a significant increase in new cancer diagnoses in patients 
receiving pravastatin than those on placebo618.  
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In contrast, some studies demonstrate a decreased risk of developing cancer while taking 
statins. For example, Poynter and colleagues found that patients taking simvastatin or pravastatin 
were at a lower risk for developing colorectal cancer619. However, decreased cholesterol is an 
independent risk factor for developing colorectal cancer, and other research has shown that cancer 
risk is unaffected in statin users that continue or discontinue statin therapy620. Shi and colleagues 
demonstrated a reduction in the risk of liver cancer among users of any statin drug621. Other studies 
have corroborated the risk reduction benefit of statins on liver cancer, which could be explained 
by the relatively higher local concentrations of statins in the liver due to drug distribution622,623. 
The largest studies focus on colorectal, lung, prostate, and breast cancer535,624–629. In 
colorectal cancer, three large retrospective cohort studies demonstrated no influence of statins on 
disease incidence630–632. In lung cancer, the largest cohort and meta-analysis studies have shown 
no effect of statins on cancer incidence633,634. Some other large studies show a benefit of statins on 
lung cancer incidence, although smoking habits, which are often not well documented in these 
studies, may confound these results635.   
In prostate cancer, the majority of studies that have investigated the influence of statins on 
prostate cancer incidence find no association, especially when correcting for the rate of prostate-
specific antigen (PSA) screening636–638. Importantly, one confounding factor for these studies is 
the “healthy user bias,” in which chronic medication users are more likely to utilize other 
preventative medical resources, such as cancer screening exams (e.g. colonoscopy, mammogram, 
and prostate-specific antigen) and vaccinations639.  
In breast cancer, no association between statin usage and increased cancer risk has been 
reported in the literature532,640. Meta-analyses conducted by Undela et al534 and Bonovas et al535 
show no significantly different incidence of invasive breast cancer in statin users. Other meta-
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analyses that investigate the incidence of a multitude of cancers among statin users also show no 
difference in breast cancer incidence with statin therapy626,628,641,642. Similarly, in the Nurses’ 
Health Study, no differences in invasive breast cancer incidence were observed between statin 
never users, former users, or current users536. Finally, the Women’s Health Initiative demonstrated 
no difference in incidence of breast cancer between statin users and non-users643; however, a 
decrease in the diagnosis of advanced stage breast cancer was seen in users of lipophilic statins644. 
In summary, statin usage appears to decrease the incidence of certain cancer types but not 
that of others. Several studies suggest statins reduce the risk of primary liver cancer. Some studies 
suggest statins reduce the risk of colorectal carcinoma, yet previous statin users carry a similar risk 
to current users. The majority of evidence suggests statins do not affect the incidence of colorectal, 
lung, or prostate carcinoma. Similarly, in breast cancer, incidence is unaffected by statin usage; 
however, diagnosis of later stage disease may be reduced with statins. In conclusion, statins appear 
to have no effect on the incidence of primary breast cancer. 
2.6.1.2 Statin Influence on Cancer Recurrence 
Fewer studies have investigated the influence of statins on cancer recurrence than incidence and 
mortality. Wu et al demonstrated a decreased recurrence of hepatitis B virus-related primary liver 
cancer after liver resection in patients taking statins645. In colorectal cancer, studies by Lash et al646 
and Ng et al647 suggest no influence of statins on cancer recurrence in patients with stage III or 
stage I - III disease respectively. In lung cancer, statins have been associated with a decreased local 
recurrence in non-small cell lung cancer (NSCLC)648 and an increased progression free survival 
(PFS) in NSCLC patients receiving EGFR tyrosine kinase inhibitor therapy649. A randomized 
phase III clinical trial that investigated adding pravastatin to standard chemotherapy in patients 
with small cell lung cancer (SCLC) showed no influence of the statin on PFS, but this study used 
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a hydrophilic statin and had a relatively small sample size (n = 846)650. The majority of the studies 
that probe the influence of statins on cancer recurrence have been conducted in the context of 
prostate or breast cancer. 
In prostate cancer, the influence of statin usage on disease recurrence is dependent on the 
treatment modality. For patients who receive primary radical prostatectomy, no influence of statin 
usage on cancer recurrence is observed651–653. However, in patients receiving radiotherapy, either 
by external device or internal delivery (brachytherapy), a benefit of statin usage on prostate cancer 
recurrence is seen654. Gutt et al demonstrate statin use in men treated with radiation therapy 
resulted in a significant increase in recurrence free survival (RFS) and biochemical free survival 
(BFS)655. Soto et al show an improvement in 5-year PFS rate in statin users vs non-users in patients 
receiving radiotherapy for localized prostate cancer656. Oh et al show statin users receiving 
permanent iodine-125 brachytherapy results in a significant increase in BFS657. In head to head 
comparisons, both Tan et al651 and Park et al652 demonstrated a benefit of statins on BFS and RFS 
respectively, in prostate cancer patients receiving radiotherapy but not those treated primarily with 
radical prostatectomy. In summary, statin usage reduces prostate cancer recurrence in patients 
treated with radiotherapy but not those treated with radical prostatectomy. Since the incidences of 
radical prostatectomy and curative radiotherapy in locally advanced prostate cancer are 14% and 
52% respectively, the statin recurrence benefit will apply to the majority of prostate cancer 
patients658. 
In breast cancer, the majority of clinical evidence supports a protective effect of statins on 
reducing breast cancer recurrence532. The first strong evidence, presented by Kwan et al, 
demonstrated a significant reduction in breast cancer recurrence in early stage patients using 
lipophilic statins659. A study conducted by Chae et al demonstrated a reduction in recurrence of 
  100 
stage II and III breast cancers in patients taking statins, approximately 90% of which were 
lipophilic statins660. The benefits of statins on reducing breast cancer recurrence appears to be the 
strongest in younger patients, suggesting a longitudinal influence of statin therapy661. Boudreau et 
al showed that statin users have a trending lower risk of recurrence in the contralateral breast, 
although the study was underpowered662. A large meta-analysis conducted by Manthravadi and 
colleagues demonstrated a 36% reduction in the risk of breast cancer recurrence in patients taking 
statins663. Importantly, when the authors separated studies using lipophilic and those using 
hydrophilic statins, they found a significant reduction in breast cancer recurrence in patients taking 
the former but not the latter663. The most convincing evidence in the literature was a population 
study of all Stage I – III breast cancer patients in Denmark conducted by Ahern and colleagues664. 
They demonstrated a 10% reduction in breast cancer recurrence among women who were 
prescribed a lipophilic statin (most commonly simvastatin) but an identical risk in recurrence 
among women who were prescribed a hydrophilic statin664. These data in aggregate suggest 
lipophilic statins, and not hydrophilic statins, reduce the risk of breast cancer recurrence. 
In summary, statins reduce the risk of recurrence of most cancer types. While statins can 
reduce the recurrence of primary liver and lung cancer, they do not appear to affect the recurrence 
of colon cancer. In prostate cancer, statins reduce the risk of recurrence in patients treated with 
radiotherapy but not those treated by primary radical prostatectomy. In breast cancer, lipophilic 
but not hydrophilic statins significantly reduce the risk of recurrence, irrespective of breast cancer 
treatment modalities. Since approximately 20% of statin users take a hydrophilic statin604, they 
would not be expected to benefit from a reduction in cancer recurrence. 
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2.6.1.3 Statin Influence on Cancer Mortality 
Similar to cancer recurrence, the majority of published data suggest that statins have a mortality 
benefit in a multitude of cancer types. In primary liver cancer, pravastatin and any statin usage 
reduces cancer-specific mortality665–667. Similarly, in colorectal cancer, statin usage reduces cancer 
specific mortality, in particular when used either prior to diagnosis or prior to recurrence646,668,669. 
In lung cancer, retrospective studies have shown that statins reduce cancer-specific 
mortality649,670,671. LUNGSTAR, a phase III randomized clinical trial, found no influence of 
pravastatin on the survival of patients with SCLC650. This result is partly expected, as pravastatin 
is hydrophilic, meaning its uptake by tumor cells is limited.  
In prostate cancer, statin usage significantly reduces cancer-specific and all-cause 
mortality. A meta-analysis by Tan et al demonstrated a 32% lower risk of prostate cancer-specific 
mortality (PCSM) in statin users651. A similar meta-analysis by Meng et al demonstrated a 36% 
decrease in PCSM in pre-diagnosis statin users672. Interestingly, a smaller (n=760) matched case-
control study demonstrated a 50% reduction in PCSM by both lipophilic and hydrophilic statins673. 
This equivalence of lipophilic and hydrophilic statins could be due to OATP2B1 expression on 
prostate cancer cells, which has been previously shown to mediate the uptake of both hydrophilic 
statins and testosterone precursors612,613. Finally, in a retrospective study of all men in Denmark 
with prostate cancer, post-diagnosis statin use was found to reduce PCSM by 17%, suggesting 
statins exert longitudinal survival benefits in this patient population674.  
In breast cancer, the majority of studies suggest statin usage significantly reduces breast 
cancer-specific mortality (BCSM). A meta-analysis by Liu et al demonstrated a 43% reduction in 
BCSM in women with breast cancer, which was confined to lipophilic statins675. A nationwide 
cohort study in Finland by Murtola and colleagues demonstrated a 46% and 54% reduction in 
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BCSM for pre- and post-diagnosis statin users respectively676. A nationwide cohort study in the 
UK by Cardwell et al demonstrated a 16% reduction in BCSM, which was higher in patients taking 
simvastatin, a lipophilic statin677. Finally, a nationwide cohort study in Scotland by McMenamin 
et al demonstrated a 15% reduction in BCSM in pre-diagnosis statin users533. 
In summary, statin usage reduces cancer-specific mortality in primary liver, colorectal, 
lung, prostate, and breast cancer. Importantly, this survival benefit is preferentially observed in 
lipophilic statin users, except for prostate cancer in which hydrophilic statins may influence steroid 
hormone synthesis by reducing testosterone precursor uptake612,613. Two additional studies provide 
convincing data for an overall benefit of statins on all site cancer-specific mortality (ASCSM). 
First, a meta-analysis by Zhong et al showed a 31% and 23% reduction in ASCSM in pre- and 
post-diagnosis statin users respectively678. Second, a nationwide cohort study in Denmark 
demonstrated a 13-17% reduction in ASCSM in pre-diagnosis statin users as compared to never-
users. These data suggest both pre- and post-diagnosis statin usage can reduce cancer-specific 
mortality. 
2.6.1.4 Conclusions 
In conclusion, many clinical studies have demonstrated that statins can influence carcinogenesis 
and cancer progression. While statins do not affect the incidence of most cancers, they do appear 
to reduce the risk of developing primary liver cancer, likely due to the inherent selectivity of statins 
for hepatocytes. In contrast, statins exert significant benefits on recurrence and survival in many 
cancer types, including primary liver, lung, colorectal, prostate, and breast. Importantly, statin 
recurrence and mortality benefits are most strongly seen with lipophilic statins. These clinical 
studies motivate further investigation of statins in basic research studies and targeted clinical trials 
to evaluate potential additive or synergistic effects of statins when used with standard therapies. 
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2.6.2 Basic Research Studies 
The clinical studies discussed above have been complemented by basic research studies that focus 
on the mechanisms by which statins exert anti-tumor effects. There are four main categories of 
effects statins exert on tumor cells: 1) growth suppression, 2) apoptosis induction, 3) anti-invasive 
and anti-metastatic, and 4) anti-angiogenic.  
2.6.2.1 Statin Suppression of Cancer Cell Growth 
Previous in vitro studies using leukemia679, hepatocellular680, bladder681, esophageal682, prostate683, 
lung684, cervical685, colorectal686, and breast carcinoma539 cells have demonstrated that statins can 
halt proliferation by inducing a G0/G1 or G2/M arrest in tumor cells. There are many pathways 
that have been described that contribute to this anti-proliferative effect. First, simvastatin  has been 
shown to induce a G1 cell cycle arrest through reduction of CDK4/6 and Cyclin D1, mediated in 
part by increases in PPARγ681 and glycogen synthase kinase 3β (GSK3β)686. Additionally, BRCA1 
overexpression in breast cancer cells has been shown to sensitize cells to lovastatin treatment 
through regulation of CDK4/Cyclin D1687. Second, simvastatin, fluvastatin, and lovastatin have 
been shown to block the CDK2/Cyclin E mediated G1/S transition, either by direct reduction of 
CDK2 or Cyclin E, or by increasing expression of the CDK2 inhibitors p21 and p27540,683,688. 
Statin-mediated increases in p21 and p27 have been linked to inhibition of signal transducer and 
activator of transcription 3 (STAT3) and activation of AMP-activated protein kinase (AMPK) in 
hepatocellular carcinoma cells680. Third, statins block DNA-binding activity of NF-ĸB and 
activator protein-1 (AP-1), which results in decreased transcription of genes that regulate cell 
proliferation537,590. For example, statin-induced suppression of NF-ĸB upregulates PTEN, which 
results in a decrease of Akt-mediated growth signaling538,689. Fourth, statins inhibit activation of 
  104 
activator protein-1. Fifth, statins have been shown to inhibit proliferation of breast cancer cells by 
suppressing FPP and GGPP modification and activation of Ras, Rac, and Rho small GTPases690,691. 
Rho GTPases normally play an important role in p27 degradation, meaning inactivity results in an 
accumulation of p27 and cell cycle arrest692,693. Additionally, Rho GTPases phosphorylate and 
activate YAP and TAZ, transcriptional co-activators in the Hippo pathway, which mediate 
transcription of genes involved with proliferation694. Statin-mediated decreases in Rho GTPase 
activity thus result in decreased YAP/TAZ activity and decreased cell proliferation695. Finally, 
statins have been shown to inhibit DNA methyltransferases, altering gene transcription and 
reducing cancer cell proliferation696,697. 
In summary, statins act to suppress cancer proliferation by inducing cell cycle arrest, 
blocking proliferation signals, and influencing gene transcription. Statins cause G1 cell cycle arrest 
through regulation of CDK4/Cyclin D1 and CDK2/Cyclin E, in part by causing accumulation of 
the CDK2 inhibitors p21 and p27. Statins block proliferation signals from Ras, Rac, and Rho 
GTPases, as well as upregulate PTEN, which results in decreased PI3K pathway activity. Finally, 
statins can modulate gene transcription by limiting NF-ĸB and AP-1 DNA binding and by reducing 
DNA methylation. 
2.6.2.2 Statin Induction of Cancer Cell Apoptosis  
In addition to suppressing growth of tumor cells, there are some reports in the literature that statins 
can induce cancer cell apoptosis. There are several pathways that have been described that 
contribute to induction of apoptosis. First, statins have been shown to decrease the protein levels 
of anti-apoptotic proteins such as Bcl-2 and Bcl-xL698,699. For example, simvastatin can reduce 
Bcl-2 and Bcl-xL expression in PC-3 cells and reduce Bcl-2 expression in MCF-7 cells. Second, 
statins have also been shown to upregulate the activation of pro-apoptotic molecules such as Bax, 
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Bad, and Caspases 3, 8, and 9541,693,698–701. For example, lovastatin and simvastatin can induce 
cleavage and activation of caspases 3, 8, and 9 in prostate cancer cells693, and simvastatin and 
fluvastatin can increase capsase-3 activity in breast cancer cells702,703. Additionally, statins have 
been shown to decrease phosphorylation and degradation of Bim in breast cancer cells704, which 
promotes apoptosis. Third, statins can induce reactive oxygen species (ROS) generation, resulting 
in an increase in p38 MAPK and activation of apoptotic pathways539,705. Similarly, iNOS-mediated 
generation of nitric oxide was shown to contribute to simvastatin and fluvastatin induced apoptosis 
in breast cancer cells.703 Fourth, statins can activate JNK-mediated apoptotic pathways that are 
independent of p53 activation542,706,707. Similarly, simvastatin has been shown to induce pro-
apoptotic Erk activity in colon cancer cells708. Finally, statins can induce calcium-dependent 
apoptosis through increased mitochondrial uptake of calcium through L-type calcium channels, 
resulting in the release of cytochrome c709. It is suggested that these pro-apoptotic effects are 
mainly mediated by a reduction in GGPP rather than FPP modified proteins590. 
However, other studies demonstrate no influence of statins on apoptosis. For example, 
simvastatin was shown to decrease proliferation of bladder cancer cells without inducing 
apoptosis681. Moreover, simvastatin at physiologically relevant concentrations was shown to 
protect osteosarcoma cells from oxidative stress induced apoptosis by upregulation of Bcl-2710. 
While atorvastatin treatment could reduce Bcl-2 expression in MDA-MB-231 breast cancer cells, 
two weeks of neoadjuvant atorvastatin at 80mg/kg in human breast cancer patients was not found 
to alter Bax or Bcl-2 expression706. Moreover, other studies report minimal effects of statins on 
inducing cancer apoptosis711 or a significant influence on apoptosis at concentrations much higher 
than currently used clinically590,712.  
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In summary, statins have been shown to induce apoptosis in many different cancer cell 
lines, including prostate, breast, and colorectal cancer. The proposed mechanisms of apoptosis 
induction involve an upregulation in pro-apoptotic pathway members (e.g. Bax, Bad, Bim), a 
downregulation in anti-apoptotic pathway members (e.g. Bcl-2 and Bcl-xL), increased caspase 
activation, increased ROS generation, and increased calcium-dependent apoptosis. However, these 
effects are typically seen with statin doses much higher than used clinically. Moreover, other 
studies demonstrate no influence of statins on apoptosis in both in vitro and clinical models of 
cancer. Thus, the precise mechanism and magnitude of statin-induced apoptosis of cancer cells 
remains unclear.  
2.6.2.3 Statin Suppression of Angiogenesis 
Statins exert biphasic effects on angiogenesis. While statins exert pro-angiogenic effects at low 
(nanomolar) concentrations, they exert anti-angiogenic effects at higher (micromolar) 
concentrations713. At low concentrations, statins can induce mobilization and differentiation of 
endothelial progenitor cells (EPCs) through stimulation of the PI3K-Akt pathway714. Similarly, 
statin treatment can induce proliferation in EPCs through upregulation of cyclin genes and 
downregulation of the CDK2 inhibitor p27715. Moreover, low statin concentrations can enhance 
endothelial cell migration and tube formation in a PI3K-Akt and endothelial nitric oxide synthase 
(eNOS) dependent manner716. The PI3K-Akt pathways seem to be required for statin-mediated 
angiogenesis, as blocking PI3K eliminates pro-angiogenic effects of statins717. Additionally, 
statin-mediated activation of eNOS is dependent on the ability of heat shock protein 90 (Hsp90) 
to recruit active Akt to eNOS, which results in nitric oxide stimulated angiogenesis718,719. 
In contrast, at higher concentrations, statins negatively impact angiogenesis through 
multiple mechanisms. First, statins have been shown to reduce membrane localization of RhoA by 
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blocking its geranylgeranylation, which reduced the tube forming ability of human endothelial 
cells in vitro and was reversed with GGPP supplementation720. This inhibition of RhoA 
subsequently suppresses signaling through pathways that require RhoA activity, such as VEGFR, 
FAK, and Akt720. Second, statins decrease the abundance of caveolin-1 in endothelial cells, which 
reduces VEGFR2-mediated angiogenic signaling in a cholesterol-independent manner721,722. 
Third, high doses of statins can induce JNK-, Bax/Bcl-2, and caspase-mediated apoptosis of 
endothelial cells713,716,723. Fourth, endothelial cells treated with relatively higher doses of statins 
show a decrease in hypoxia-stimulated secretion of VEGF and expression of VEGFR2713. Finally, 
simvastatin has been shown to upregulate vascular epithelial cadherin (VE-cadherin), which 
limited endothelial cell proliferation, migration, and tube forming ability. 
In the context of cancer, statins can reduce tumor angiogenesis through several different 
mechanisms. First, statins can directly affect the endothelial cells to reduce tumor angiogenesis. 
For example, simvastatin and lovastatin treatment were both shown to decrease tumor 
vascularization in mice at high statin doses713,724. Second, statins can act indirectly on the 
endothelium by reducing pro-angiogenic or increasing anti-angiogenic protein secretion by tumor 
cells725. For example, lovastatin was shown to suppress VEGF secretion by tumor cells in vitro724. 
Similarly, atorvastatin has been shown to reduce circulating VEGF concentrations in human 
patients with coronary artery disease726. Moreover, simvastatin has been shown to decrease 
secretion of angiopoietin-2 (Ang-2) by colorectal carcinoma cell lines727. Ang-2 has been 
previously shown to promote angiogenesis in tumors, in part through binding to cellular 
integrins728–730. Finally, simvastatin and atorvastatin can reduce matrix metalloproteinase-9 
(MMP-9) expression in endothelial cells, which reduces their invasive capability731. Moreover, 
MMP-9 has been shown to be important for releasing the VEGF that is sequestered in breast cancer 
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ECM732. Thus, a reduction in MMP-9 both impacts the stimulation for and competency of 
endothelial cells to initiate angiogenesis. 
In summary, statins exert concentration-dependent effects on endothelial cells and 
angiogenesis. At low concentrations, statins exert pro-angiogenic effects through stimulation of 
PI3K/Akt and eNOS. At high concentrations, statins exert anti-angiogenic effects through 
suppression of RhoA activity, which mediates several critical signaling pathways, such as VEGFR, 
FAK, and Akt. Moreover, high statin concentrations can induce apoptosis of endothelial cells, 
reduce secretion of pro-angiogenic proteins such as VEGF, and reduce availability of matrix-
bound VEGF through reducing MMP-9 activity. Moreover, interactions between the tumor cells 
and tumor endothelium play an important role in the effects statins exert on tumor angiogenesis. 
Namely, statins directly decrease cancer cell secretion of pro-angiogenic factors, such as VEGF 
and Ang-2, which result in decreased tumor angiogenesis. Importantly, the concentration of statins 
that demonstrate anti-tumor effects coincide with those that exert anti-angiogenic effects. 
Consequently, the doses of statins that reduce cancer cell growth would negatively impact tumor 
angiogenesis. 
2.6.2.4 Statin Suppression of Cancer Cell Invasion and Metastasis 
Many in vitro studies have suggested statins reduce the invasiveness and metastatic potential of 
cancer cells through multiple different mechanisms. First, statin treatment destabilizes the 
cytoskeletal structure of tumor cells in a RhoA/RhoC dependent manner. Upon statin treatment, 
Rho delocalizes from the membrane, which causes breakdown of the actin cytoskeleton, loss of 
actin stress fibers and focal adhesion sites, and cell rounding733–736. Moreover, statin treatment is 
sufficient to block EGF-mediated RhoA membrane localization and formation of actin stress 
fiberswithout impacting EGF-mediated tyrosine phosphorylation of EGFR or HER2736,737. Second, 
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statins block adhesion of cancer cells to both ECM proteins by reducing integrin binding 
activity738. Similarly, statins downregulate E-selectin on tumor endothelial cells, which reduces 
tumor cell adhesion and invasion through an endothelial barrier739,740. Third, statins reduce 
expression and activity of the pro-migratory proteases MMP-2, MMP-9, and urokinase by 
inhibiting Ras and Rho activity733,741,742. Fourth, statin treatment can downregulate the cancer stem 
cell marker CD44 in breast cancer cells, which reduces cell migration and invasion743. Finally, 
statins can reduce expression of the transferrin receptor in breast cancer cells, which causes iron 
starvation and a reduction in tumor invasiveness691,744. 
Statins also impact tumor invasion and metastasis in ex vivo and in vivo models. Statins 
were shown to reduce prostate cancer migration towards human bone marrow stroma without 
impacting ECM adhesion745. Also, lovastatin, atorvastatin, and simvastatin have been shown to 
reduce metastatic seeding of melanoma and breast cancer cells in the lung and bone734,735,743. 
Importantly, these and most other studies that investigate the influence of statins on cancer 
metastasis inoculate tumor cells into the heart or tail vein of mice. Direct intravascular introduction 
of tumor cells precludes formation of a primary tumor, which is required to examine the metastatic 
potential of cells. As a measure of true metastatic potential, Mehta et al and Juneja et al were able 
to demonstrate that lovastatin could decrease metastasis of colon cancer cells that were inoculated 
into the spleens of mice739,746. Moreover, in breast cancer patients receiving 40mg simvastatin per 
day for 4-6 weeks before mastectomy, statin treatment was able to decrease post-explant tumor 
migration747. Moreover, simvastatin treatment reduced the activity of Rho associated protein 
kinase (ROCK) and expression of RhoC, chemokine receptor type 4 (CXCR4), and CD44747.  
In summary, statins can reduce the invasiveness and may reduce the metastasis of cancer 
cells. While the effects of the influence of statins on tumor cell migration and adhesion are well 
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studied, their effects on tumor metastasis remain unclear. Statins reduce tumor cell invasiveness 
mainly through suppression of RhoA and RhoC activity, which disorganizes the actin cytoskeleton 
and reduces migratory ability. Similarly, statins reduce the adhesion of tumor cells to ECM 
proteins and endothelial cells, in part through a reduction of integrin binding activity. Moreover, 
statins reduce activity of proteases involved with migration, such as MMP-2 and MMP-9.  
Most existing data measure the influence of statins on tumor metastasis in mice by injecting 
tumor cells into the tail vein and examining lung tumor burden. Since direct intravascular 
inoculation of tumor cells does not allow for formation of a primary tumor, critical steps of the 
metastatic cascade, such as invasion and intravasation, are ignored. In studies that employ 
experimental models that establish a primary tumor prior to gauging metastasis, scant data suggest 
statins may reduce metastasis. However, the specific effects of statin treatment on tumor metastasis 
are not very well studied, especially in the context of breast cancer. 
2.6.2.5 Conclusions 
In conclusion, many basic research studies have shown that statins can reduce tumor cell growth 
and proliferation by inducing a cell cycle arrest. Additionally, some, but not all studies, suggest 
that statins can induce apoptosis in cancer cells. In addition to affecting tumor cell growth and 
apoptosis, statins can negatively impact the tumor vasculature through suppression of 
angiogenesis. While statins exhibit a biphasic effect on angiogenesis, their anti-angiogenic effects 
are observed at similar doses to those used in studies that demonstrate anti-tumor effects. While 
statins have been shown to reduce cancer cell migration and invasion in vitro, few studies have 
demonstrated a reduction in metastasis with statin treatment in vivo. These previous studies 
motivate the investigation of statins in the context of breast cancer metastasis, in particular 
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dormancy and emergence, which is the main cause of morbidity and mortality in this patient 
population. 
Proper investigation of breast cancer metastatic emergence requires an appropriate model 
system. The liver is one of the most common metastatic sites for breast cancer and metabolizes 
commonly used breast cancer treatments as well as many of the statin drugs. Previous work has 
shown that breast cancer co-culture with primary hepatocytes is sufficient to induce MErT in the 
cancer cells, mimicking the clinical scenario of metastatic seeding45,748. Moreover, sophisticated 
ex vivo perfusion culture systems have shown these epithelial, dormant tumor cells can be coerced 
to outgrow as mesenchymal metastases when exposed to an inflammatory stimulus47,749–751. To 
illustrate the suitability of the liver as a model organ for breast cancer metastasis, the physiology 
and pathology of liver metastasis will be discussed in the next section. Moreover, technical 
considerations for cell sourcing and in vitro and ex vivo culture methods will be presented. 
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3.0  THE LIVER AS A MODEL ORGAN FOR METASTASIS AND DRUG THERAPY 
3.1 PREFACE 
The majority of this chapter is previously published as Beckwitt et al1. The purpose of this chapter 
is to introduce the reader to the physiology and culture systems available for replicating human 
liver ex vivo. This holds particular importance for this thesis, since most pertinent findings discuss 
breast cancer metastasis to the liver. 
3.2 INTRODUCTION 
The liver plays critical roles in both homeostasis and pathology. It is the major site of drug 
metabolism in the body and, as such, a common target for drug-induced toxicity and is susceptible 
to a wide range of diseases. In contrast to other solid organs, the liver possesses the unique ability 
to regenerate. Additionally, and critical for this project, the liver is the most common site for 
metastasis. The physiological importance and plasticity of this organ make it a crucial system of 
study to better understand human physiology, disease, and response to exogenous compounds. 
The purpose of this chapter is to inform the reader of the significance and available methods 
for replicating human liver physiology and pathology ex vivo, in particular modeling breast cancer 
metastasis to the liver. First, the physiologic roles of the liver and its cellular constituents will be 
discussed. Second, we will discuss the need for developing an ex vivo liver system. Third, the 
advantages and disadvantages of different cell sources used to populate the system will be 
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mentioned. Fourth, the benefits of currently employed ex vivo liver culture systems (both 
commercially available and used in research laboratories) will be discussed. Finally, future 
directions to advance these systems, including complexing liver culture systems with other organ-
based culture systems (“organ chips”), will be proposed.  
3.3 PHYSIOLOGY 
The liver is a complex organ that is integral to a multitude of whole body functions and is 
extensively reviewed in standard medical textbooks. For the purposes of this review, a few salient 
aspects are emphasized. The liver is organized into lobules, functional units of the liver, which are 
subsequently organized into larger lobes. Lobules consist of multiple hepatic sinusoids, whose 
structure is illustrated in Figure 7. The liver consists of both parenchymal and non-parenchymal 
cells, both of which will be discussed herein. 
The parenchymal cells, mainly hepatocytes, comprise 60% of the cell population and are 
responsible for the liver’s metabolic activity (including the cytochrome P450 (CYP450) isoforms), 
the production and release of acute phase proteins, production of plasma proteins (such as albumin 
and clotting factors), and the integration of various components of glucose, lipid, nitrogen, and 
oxidative metabolism752,753. These hepatocytes mature postnatally, causing different CYP450 
isoforms and assemblies thereof to be expressed in fetal, neonatal and adult hepatocytes754. For 
example, CYP3A7 is very highly expressed in fetal hepatocytes, whereas this isoform is replaced 
by CYP3A4 expression in adult hepatocytes. Moreover, pediatric hepatocytes typically exhibit 
increased clearance of CYP450-metabolized drugs as compared to adult hepatocytes755, despite no 
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differences in intrinsic CYP450 expression between the two cell sources756. Thus, hepatocyte 
functioning is key to any ex vivo system that replicates the in vivo liver.  
 
 
 
Figure 9. The architecture of the hepatic sinusoid 
Blood enters the periportal region of the liver through a hepatic arteriole and portal venule and traverses the hepatic 
sinusoid to the central vein, whereby it is drained into the larger hepatic veins. The sinusoidal endothelial cells 
mediate blood flow and are fenestrated to allow diffusion of nutrients, signaling factors, and drug compounds. The 
hepatocytes compose the parenchyma of the liver and sit deep to the endothelium. The hepatic stellate cells reside in 
the Space of Disse, a zone between the endothelium and hepatocytes. Finally, the Kupffer cells line the inside of the 
sinusoid and mediate antigen sensing and intercellular communication. 
 
 
Oxygen tension plays an important role in regulating liver zonation and functionality, with 
the liver uniquely receiving both arterial (hepatic artery, ~25%) and venous (portal circulation, 
~75%) blood. The partial pressure of oxygen drops as one progresses across the liver sinusoid, the 
functional unit of the liver, from periportal to perivenous hepatocytes757. This oxygen differential 
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regulates the response of the liver to metabolic and toxic stimuli by facilitating differential 
metabolism, termed “liver zonation.” For example, the relatively hypoxic perivenous hepatocytes 
are responsible for the majority of substrate metabolism through the CYP450 system whereas the 
relatively oxygen-rich periportal hepatocytes boast mainly oxidative metabolic functions757. Liver 
zonation is also observed in in vitro cultures758,759. Thus, the organization of the parenchyma 
motivates careful engineering to replicate hepatic function and toxicity and capture the full panoply 
seen in vivo. 
Blood flow carried by the fenestrated endothelium of the sinusoids is imperative for liver 
functions. Hepatic blood flow dictates the metabolic zonation of the liver757 and alterations in flow 
can reduce liver function and drug clearance760. Blood flow carries oxygen, nutrients, and 
chemicals that are distributed to the liver tissue. In the absence of adequate blood flow, these 
factors are consumed by the proximate cells and do not reach more distant populations. 
Reciprocally, juxtavascular cells can contribute factors to the circulation. Locally, the potency of 
hepatocyte-secreted factors is a function of the blood-to-cell volume ratio, which is approximately 
20.5 mL blood per mL tissue for healthy adult livers761. Assuming a hepatocyte volume of 3.4 
pL762, this corresponds to 14 million hepatocytes being supplied by 1 mL of blood. This 
consideration is particularly important for in vitro and ex vivo culture systems, as media flow is 
used by some to model in vivo blood flow (see “Engineered Culture Systems”). 
The non-parenchymal cells (NPC) compose the remaining 40% of the cell population and 
play a significant role in tissue architecture and in mediating responses of the tissue to metabolic 
and toxic stimuli, as well as supporting the hepatocyte function753,763. These cell types include liver 
sinusoidal endothelial cells (LSECs), Kupffer cells (KCs), hepatic stellate cells (HSCs), and pit 
cells (natural killer cells, NKs). Inclusion of NPCs in hepatocyte culture systems has shown 
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beneficial effects. For example, 3-dimensional (3D) liver tissue models show increased hepatocyte 
functions when NPCs are incorporated764. Additionally, KCs play a significant role in the response 
of the liver to injury through the production of cytokines and reactive oxygen species765. Moreover, 
HSCs respond to injury both by adopting a myofibroblast phenotype that remodels the liver 
extracellular matrix766 and increasing the CYP450 activity of hepatocytes767. Finally, LSEC 
proliferation in response to injury has been suggested to aid the liver’s potent regenerative 
capacity768. Thus, the NPCs complement the synthetic and metabolic functions of hepatocytes by 
contributing pro-regenerative, pro-inflammatory, and pro-fibrotic stimuli. 
3.4 THE LIVER AND CANCER METASTASIS 
The liver is host to many pathologies and is a common site for drug toxicity (see below). For the 
purpose of this dissertation, a brief but sufficient introduction to the liver as a common site of 
metastasis will be provided. Other disease pathologies in the liver will be covered only in the 
context of culture systems that have been designed. For a more comprehensive review of liver 
diseases, the reader is directed to more comprehensive sources769. 
The most common malignant liver lesion is a metastasis. Indeed, their prevalence is 18-40 
times higher than primary tumors770. Moreover, 25-50% of patients with solid organ tumors will 
present with liver metastases at diagnosis771. The most commonly observed metastases in the liver 
are derived from colon cancers, due in a large part to their easy accessibility to the portal 
circulation772. However, almost every cancer type has the ability to metastasize to and colonize the 
liver, with the most common cancer types being carcinomas derived from colon, lung, pancreas, 
and breast. Data from a large autopsy study of 23,000 patients are shown below in Figure 8773.  
  117 
 
Figure 10. Liver metastases histology and site of origin 
(A) Histologic classification and (B) site of origin of metastases found in livers of 23,154 patients. Graphs made 
from data in the supplement of de Ridder et al 2016773. 
 
 
The high prevalence and morbidity of liver metastases makes this organ the ideal system 
for studying metastatic colonization, outgrowth, and response to therapeutic compounds. The next 
sections will detail the important design parameters for generating a suitable culture system that 
robustly mimics the physiology of the normal liver. 
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3.5 MODELING THE LIVER MICROENVIRONMENT 
Current preclinical models for hepatotoxicity involve human cell culture and animal models. 
Recently, efforts to develop ex vivo hepatic culture systems, “liver-on-a-chip,” have been 
undertaken by many research groups and biotech companies due to the liver’s capacity for drug 
metabolism, excretion, vulnerability to drug-induced damage, and as a primary organ in many 
diseases.  Drug-induced liver injury remains a major reason for drugs being withdrawn from the 
market, and causes both morbidity and mortality for patients. Importantly, humans metabolize and 
respond to agents differently from other mammals; to the point, most all species present unique 
xenobiotic handling774. In fact, one-third of toxicities observed in humans are not predicted in any 
of the species commonly employed for drug safety testing775, possibly due to their failure to model 
reactive metabolites generated through human-specific metabolic pathways776. Moreover, 
individual animal models have a success rate of as low as 40% in predicting hepatotoxic 
compounds777, resulting in 26% of clinical trial failures being due to hepatotoxicity778.  
Current liver tissue culture systems exist on a spectrum of complexity. Historic hepatocyte 
culture systems involved collagen-sandwich culture or 2D Micro-Patterned Co-culture (MPCC) 
systems using primary rat hepatocytes and 3T3-J2 fibroblasts. Systems have progressed to include 
3D static spheroid models and perfusion culture devices, which introduce nutrient and oxygen 
gradients and shear stress that are important for hepatocyte functions779. The systems discussed 
below offer distinct advantages and disadvantages for investigating the response of hepatic micro-
tissues to different drugs and other stimuli. 
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3.6 CELL SOURCING 
The complex physiology of the liver and need for its accurate representation in engineered systems 
requires careful selection of cell type(s) and their origin. Hepatic tissue is composed of hepatocytes 
(60% of liver cells) and a complex complement of NPCs (40% of liver cells). Integration of both 
cell fractions is often needed to adequately reflect pharmacokinetics, pharmacodynamics, toxicity 
of drugs, and liver disease progression, given the intercommunication between the different liver 
cell types. Four sources of hepatocytes will be discussed: primary human cells, primary animal 
cells, immortalized human cell lines, and pluripotent stem cells. Each of these cell sources has its 
advantages and disadvantages, and each will be discussed below. A qualitative summary of cell 
selection parameters can be seen in Table 11. 
3.6.1 Primary Human Hepatocytes 
Functional primary human hepatocytes (PHH) obtained through collagenase perfusion and 
dissociation have been the gold standard in drug discovery for 25 years due to their ability to most 
accurately reflect in vivo metabolism and toxicity780–782. Primary human hepatocytes have been 
isolated from livers with benign (processes not affecting the hepatocytes) and hepatocyte-specific 
pathologies. Some examples include end stage primary biliary cirrhosis (PBC), primary sclerosing 
cholangitis (PSC), alcoholic liver disease (ALD), and resections for colorectal metastases or 
benign growths783. Several groups have found patient-specific factors to play a role in the yield of 
hepatocytes during isolation or in their functionality. While patient gender and type of disease had 
no effect on hepatocyte yield or functionality784,785, cholestasis (signified by elevated gamma 
glutamyl transferase level – GGT)784,786, severe steatosis784,787, and older age784,785,788,789 negatively 
  120 
influenced isolation outcomes. Although some patients have been exposed to chemotherapy, 
hepatocyte function and viability are not altered790. While an ideal source, limited availability of 
cells and reliance on patient surgeries are major reasons why primary hepatocytes are not more 
commonly used. Moreover, many donors are pediatric patients, whose hepatocytes may have 
metabolic dysfunction or exhibit differential clearance when compared to adult human hepatocytes 
(see “Physiology”). 
 
 
Table 15. Hepatocyte sources 
Hepatocyte 
Source Animal HepG2 HepaRG 
Primary 
Human 
Cryopreserved 
Human 
iPSC-
derived 
Viability Medium to High* High High 
Medium 
to High* Medium High 
Attachment to 
ECM High High High High Medium High 
CYP450 
Activity Medium Low Medium High High 
Low to 
Medium 
Longevity in 
Culture Medium High High Medium Low to Medium Low 
1OATP/NTCP High Low Medium High Medium Low to Medium 
Cost Medium Low Low High High High 
Availability Medium High High Low Medium Medium 
References 791–794 795–797 796–801 779–781 790,802–804 805–807 
A summary of properties from different hepatocyte sources: animal, human cell line, primary human, and iPSC-
derived. *Dependent on efficiency and time of isolation procedure. 1OATP (organic anion transporting polypeptide), 
NTCP (sodium taurocholate co-transporting polypeptide). 
 
 
Advances in cryopreservation have allowed for easier distribution and commercialization 
of primary human hepatocytes. Previous work has demonstrated cryopreserved primary human 
hepatocytes to still exhibit 94% of the clearance of model drugs (e.g. diclofenac) after 1 year in 
liquid nitrogen, as compared to freshly isolated human hepatocytes802. With proper 
cryopreservation, viabilities >90% can be achieved808. Additionally, minimal changes in metabolic 
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functions have been demonstrated even after 14 years in liquid nitrogen809. While cryopreserved 
primary human hepatocytes exhibit high viability and comparable CYP450 activity to fresh cells, 
they exhibit suboptimal attachment to extracellular matrix molecules, due to downregulation and 
degradation of the adhesion molecules β1-integrin and E-cadherin respectively during 
cryopreservation803. Additionally, decreased expression of uptake transporters such as OATP 
(organic anion-transporting polypeptide) and NTCP (sodium-taurocholate co-transporting 
polypeptide) family members results in under-prediction of drug clearance rates810. Finally, high 
viability methods often involve centrifugation to remove dead and damaged hepatocytes, which 
also reduces the cell yield. 
Cryopreserved primary human hepatocytes have been used in numerous studies to 
investigate CYP450 induction804, drug clearance811, and hepatobiliary transport812. In contrast to 
human hepatic cell lines or animal primary cells, cryopreserved primary human hepatocytes can 
probe the influence of genetic background on hepatocyte metabolism or drug clearance. For 
example, a collection of cryopreserved hepatocytes from 64 donors has been used to investigate 
gender-specific activities of CYP450 isoforms in vitro, which corroborated with in vivo findings, 
namely a higher expression of CYP3A4, the most dominant human isoform, in females813. Thus, 
while human cell lines and animal hepatocytes are more accessible, primary human hepatocytes 
will likely continue to play an important role in drug development due to their ability to most 
effectively reflect in vivo metabolism, clearance, and response to toxins by patients. 
3.6.2 Animal-Derived Hepatocytes 
Animal-based testing has formed the foundation for translating in vitro studies to clinical trials. 
Before moving to humans, the Federal Drug Administration (FDA) requires pharmacokinetic, 
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toxicity, and efficacy studies in at least one rodent (mouse, rat) and one non-rodent (dog, rabbit) 
species. Such studies are designed to examine integrated organ responses and are able to suggest, 
at least initially, the influence of genetic diversity on drug responses791. Additionally, these species 
are readily commercially available, thus serving as sources of fresh primary cells. However, animal 
studies frequently do not elicit the pharmacokinetic behavior seen in humans due to species 
differences in drug metabolism and clearance, in particular differential CYP450 metabolic 
activity792,793. Differences in CYP450 induction by model drugs between human and animal (rat, 
dog) are well established814. Improvements in predicting human-specific metabolism and clearance 
from animal studies have been made through retrospective analyses794. Yet, sourcing cells from 
animals may be cost prohibitive, ethically controversial, and futile if interspecies differences 
prevent human-relevant data from being collected815. Moreover, since animal hepatocytes express 
different CYP450 isoforms than humans, extrapolating of gender-specific differences in drug 
metabolism is challenging816. 
3.6.3 Human Hepatic Cell Lines 
Human hepatic cell lines, either cancer-derived or immortalized hepatocytes, can be effectively 
propagated in culture over multiple passages. Some of the most commonly used hepatic cell lines 
include HepG2, Huh7, Hep3B, and SK-Hep-1, all derived from hepatocellular carcinoma (HCC), 
and HepaRG, an HCC cell line that constitutes a mix of both hepatocytes and biliary-like 
cells795,796.  
One issue with using human hepatic cell lines is that they exhibit lower and variable 
CYP450 expression than primary human hepatocytes796. For example, CYP3A4 is not expressed 
in HepG2 or Hep3B cells whereas CYP2D6 is expressed at less than 5% the level of primary 
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human hepatocytes. Studies in HepG2 cells demonstrated that CYP450 expression may also vary 
according to culture duration and passage number, some isoforms varying up to 200-fold across 
the first 10 passages817. Some cell lines hold more promising results. For example, induction of 
CYP450 enzymes and the drug transporter MDR1 was seen in a novel hepatic cell line, Fa2N-4, 
in response to rifampin treatment797. 
Another issue with human hepatic cell lines is that they exhibit reduced expression of both 
sinusoidal and canalicular transporters798. These transporters function to shuttle drug compounds 
from the blood to the bile canaliculi.  While hydrophobic compounds can diffuse across the 
hepatocyte plasma membrane, hydrophilic compounds require active transport. Reduced transport 
activity and decreased CYP450-catalyzed metabolism may result in inaccurate pharmacokinetic 
and toxicity predictions. 
The HepaRG cell line is a promising substitute for primary human hepatocytes. When 
seeded at a low density, HepaRG cells are capable of proliferating and differentiating to confluency 
to form colonies of hepatocytes surrounded by biliary epithelial cells that exhibit CYP450 
expression levels comparable to primary human hepatocytes818. HepaRG cells have also been 
found to functionally express both sinusoidal and canalicular transporters799,800. Additionally, 
HepaRG cells can identify drugs likely to induce liver injury, albeit using doses up to 100-fold 
higher than would be seen clinically801. Moreover, HepaRG cells exhibit a more robust response 
to inflammatory stimuli (e.g. IL-6, TNFα) on liver drug metabolism and elimination than primary 
human hepatocytes, potentially due to genetic variation in the latter819.  
While hepatocyte cell lines are effective in predicting the metabolism and elimination of 
some drugs, their overall sensitivity to detect toxic compounds is lower than primary human 
hepatocytes (13% for HepaRG compared to 44% for PHHs)795. Further, being derived from a 
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single female donor, these cells do not account for genetic variation in drug responses that often 
uncover limiting toxicities in a subset of persons. This limitation is also seen with primary 
hepatocytes, as testing is often performed on a limited number of donors. Importantly, since human 
hepatic cell lines are derived from primary hepatic tumors, they may not accurately represent 
normal cellular responses. These weakness ultimately require the use of complementary 
approaches (i.e. normal primary cells)779. 
3.6.4 Induced and Embryonic Pluripotent Stem Cells (iPSC and ESC) 
Stem cells are defined as cells capable of self-renewal and differentiation into mature cells of a 
particular tissue type820. Stem cells encompass both those derived from blastocysts (ESC) and also 
those derived from mature cells through reprogramming (iPSC) using viral vectors, Cre-lox 
expression cassettes, or mRNA/miRNA transfection821. While iPSC generation and differentiation 
is time consuming, it allows for an easily sharable cell population with theoretically limitless 
growth potential that can mimic preliminary clinical trials in vitro, hopefully improving the success 
in subsequent human studies. 
Many protocols demonstrate differentiation of iPSC822,823 or ESC824–826 into hepatocyte-
like cells. Protocols that try to replicate liver embryogenesis can achieve hepatocyte-like cell yields 
of up to 80%826. Additionally, the expression of microRNAs (mir), specifically mir-122, during 
the differentiation process can further improve hepatocyte fidelity805. However, many 
differentiation protocols result in hepatocytes that express immature markers (e.g. alpha-feto 
protein; AFP), secrete less albumin, and exhibit dramatically reduced CYP450 activity than 
primary human hepatocytes806,807,827. Indeed, hepatocyte-like cells differentiated from iPSC using 
multiple sources and two different protocols demonstrated a phenotype akin to fetal hepatocytes828. 
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An advantage of iPSCs is the potential to study a broad spectrum of hepatocyte lines with 
different genetic, epigenetic backgrounds807,828 and disease backgrounds. Additionally, iPSCs 
exhibit sensitivity comparable to primary human hepatocytes for detecting drugs that cause drug 
induced liver injury (65% vs 70%)829. While a promising technology, current iPSC technical 
limitations include epigenetic memory, genomic instability, state of maturation to adult cells and 
variability among cell lines. Strategies to address these weaknesses include using small molecule 
treatment, avoiding targeting p53 during reprograming, and use of multiple iPSCs from different 
genetic backgrounds, respectively830. Namely, platforms aimed to analyze the influence of small 
molecules on hepatocyte expansion and differentiation of iPSCs to mature hepatocytes have shown 
promising results831. However, a steady supply of hepatocyte-like cells derived from iPSC is often 
not available to many researchers, which limits consistent use to labs with experience in their 
differentiation. Encouragingly, some companies are starting to commercialize iPSC-derived 
hepatocytes. 
3.6.5 Non-Parenchymal Cells (NPCs) 
The NPC component of the liver is critical to recreating physiologic liver functioning and response 
to injurious stimuli. As such, inclusion of NPCs is desirable to replicate metabolism and signaling 
pathways observed in vivo. Addition of NPCs in hepatic culture systems has shown to alter 
signaling networks present in the microenvironment, enhance hepatocyte synthetic functions, 
prevent hepatocyte de-differentiation in culture, and enhance hepatocyte metabolic response to 
drug treatment752,832,833. Both primary and immortalized cell types are available and will be 
discussed below. 
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Primary NPCs are isolated in a similar manner to primary hepatocytes, by liver enzymatic 
perfusion. These cells can either be harvested alone or simultaneously with primary hepatocytes. 
When harvested alone, the NPCs of the liver can be enriched, at the expense of hepatocyte 
recovery, by using a pronase-collagenase perfusion method834,835. For isolating both cell 
components, collagenase perfusion followed by density centrifugation are used to collect and 
separate the hepatocytes from the NPCs, respectively. Several methods have been used to purify 
the NPCs, which include iodixanol or percol density gradients and magnetic activated cell 
sorting836–838. Importantly, the disease state of the human donor tissue can greatly influence the 
quality and quantity of cells obtained837,839. To avoid the need for donor tissue, others have 
demonstrated generation of NPCs from human iPSCs840. 
While primary NPCs are the most effective at reproducing the microenvironment seen 
physiologically, their main disadvantages are non-specific activation and availability. Using 
primary NPCs requires having surgical specimens. Cryopreserved NPCs can be purchased 
commercially either as a collective or for specific NPC types. Due to the high cost of primary cells, 
various cell lines or alternative cell types have been employed in co-cultures with hepatocytes to 
provide similar trophic signals as primary NPCs. The next several sections will illustrate 
approaches to incorporate each NPC type into hepatic culture systems. 
3.6.5.1 Endothelial Cells 
Liver sinusoidal endothelial cells (LSECs) are a unique endothelial cell type displaying abundant 
fenestrations, high endocytotic ability, and ability to provide ideal trophic support to hepatocytes. 
These cells are often unstable in vitro841–844 and are difficult to cryopreserve845. As such, some 
groups have instead used human umbilical vein endothelial cells (HUVECs) that, in co-culture 
with hepatocytes, improve hepatocyte specific function, such as CYP450 activity and albumin 
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synthesis842,846,847. However, as HUVECs are a unique cell type that lack appreciable levels of key 
cell surface receptors CXCR3848 and EGFR849, other primary human endothelial cells have been 
employed with variable results842,850.  
Immortalized endothelial cell lines have also been used in hepatocyte co-culture. HMEC-
1 (human foreskin endothelium) cells have been shown to enhance hepatocyte albumin secretion851 
and can provide inflammatory cues that affect both the hepatocytes as well as metastatic cancer 
cells852. TMNK-1 cells are an immortalized LSEC cell line that has been used in hepatocyte co-
culture to investigate paracrine signaling (Kawasaki et al. 2010), influence on cancer cell 
phenotype763, and promote hepatocyte-specific functions in ESC-derived hepatocytes853. 
However, immortalized LSECs phenotypically resemble activated endothelial cells implicated in 
pathologic vessel formation in chronic liver disease854, and may not emulate normal physiology, 
in particular due to their lack of fenestrations. 
3.6.5.2 Kupffer Cells 
KCs are implicated in host defense and are important producers of cytokines in inflammatory 
responses and liver diseases. Immortalized KCs have been generated in mouse and rat855, but not 
human. THP-1 monocytes have been differentiated into macrophages and used in co-culture 
applications with both primary hepatocytes and human hepatic cell lines. Inflammatory responses 
were noticed in hepatocytes as a result of macrophage-secreted products856 and direct co-culture857. 
To demonstrate the importance of KC inclusion in hepatocyte cultures, LPS stimulation of a 
primary hepatocyte and KC perfusion co-culture system demonstrated no effect on hydrocortisone 
metabolism, similar to that seen clinically858. However, immortalized KCs or activated 
macrophage cell lines do not replicate physiologic KC behavior. KCs are typically quiescent and 
tolerogenic due to high basal expression of TGFβ and PD1 and expression of IL-10 upon LPS 
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stimulation859. As such, alternatives to primary KCs may promote more inflammatory-related 
changes than seen in vivo. Of benefit to labs without access to fresh primary cells, cryopreserved 
KC are commercially available for use. 
3.6.5.3 Stellate Cells 
Hepatic stellate cells (HSCs) are important cells for the storage of retinoids and other lipids and 
are implicated in hepatocyte proliferation after partial hepatectomy, hepatic fibrosis, and portal 
hypertension. Freshly isolated primary HSCs quickly activate when cultured on plastic860 and their 
gene expression in vitro does not fully reproduce that observed in vivo861. HSC quiescence can be 
preserved by culturing on laminin-rich gels or in suspension on a non-adherent surface862. Several 
immortalized HSC lines exist for study, including hTERT-HSC, GREF-X, LI90, TWNT-1 and 
more recently, LX-1 and LX-2. However, only the LX-2 cell line can be maintained in serum-free 
media and transfected with relatively high efficiency (30%)863. Importantly, while immortalized 
cell lines express many of the same markers as primary HSCs, their response to stimuli and basal 
level of activation differ from that seen observed in vivo862. Co-culture of HSCs with hepatocytes 
has been used to maintain hepatocyte differentiation in vitro by cell contact mediated signals and 
transfer of lipids864. 
3.6.5.4 NPC Considerations 
It is clear that including NPCs in culture systems influences hepatocyte functions and the tissue 
microenvironment. ECs can enhance albumin synthesis and CYP450 activity in co-culture with 
hepatocytes. KCs can elicit inflammatory changes in response to stimuli that resemble those seen 
in vivo. Finally, HSCs are important for storing lipids that can be utilized by the hepatocytes and 
preserving hepatocyte differentiation. While primary non-parenchymal cells are the gold standard, 
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they are difficult to obtain in sufficient numbers. NPC isolation yield is low when isolated 
concurrently with hepatocytes and subsequent purification steps can alter NPC function. Several 
immortalized cell lines can serve comparable (though not equivalent) roles for each NPC type, and 
also offer the benefits of being easily distributable and homogeneous. 
3.7 ENGINEERED CULTURE SYSTEMS 
The overarching goal of all liver culture systems is to provide either a high throughput, low cost, 
easy to operate, and reliable system that recapitulates a reasonable fraction of human physiology, 
or a medium to low throughput system that reliably recapitulates a maximum of liver structure and 
function (liver biomimetic). This depends on the ability of the system to generate an environment 
that reflects the in vivo phenotype of the hepatocytes and NPCs, which is highly dependent on both 
chemical and mechanical cues. A critical issue with routine 2D primary human hepatocyte culture 
systems is that hepatocyte functionality rapidly declines rapidly within days865. To overcome this, 
hepatocytes have been cultured using the collagen-sandwich method. This involves seeding a 
monolayer of hepatocytes on a gelled layer of rat tail collagen and overlaying another gelled 
collagen layer on top. This culture method allows hepatocytes to maintain synthetic function (as 
determined by albumin mRNA) for at least six weeks866. However, collagen sandwich cultures do 
not replicate the complex multi-cellular nature of the liver and do not incorporate fluid flow, which 
is important for preserving in vivo hepatocyte functions867. Several of the most recent engineering 
advances to improve hepatocyte functions and viability in culture will be discussed in this review. 
These systems are demarcated into the following categories: 2D Micro-Patterned Systems, 3D 
Spheroid Culture Systems, and Perfusion Culture Systems. For a comprehensive review of all 
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advancements made in the realm of hepatocyte culture, the reader is referred to other 
references781,868,869. 
3.7.1 Non-Perfusion Systems 
Both static and perfusion systems exist for hepatocyte culture. Static culture systems include 2D 
micro-patterned systems and 3D spheroid culture systems. A summary of the properties of these 
systems can be found in Table 12. 
3.7.1.1 2D Micro-Patterned Systems 
The use of 2D micro-patterned culture systems are an improvement upon standard sandwich 
culture as they fine-tune tissue architecture by controlling the size, geometry, and functionality of 
culture chambers. One commercialized system, HepatoPacTM by Hepregen, Corp. consists of 
micro-patterned 2D plates seeded with either rat or human hepatocytes and 3T3-J2 stromal cells. 
Cultures maintain hepatocyte specific functions for 4-6 weeks870,877,878, notably albumin and urea 
secretion, phase I/II metabolism, and formation of canalicular networks. Publications have also 
reported sensitivities of 66% and 100% for corroborating hepatotoxins when tested with one or at 
least two cell donors, respectively877. The extended hepatocyte functionality may allow for 
accurate predictions of in vivo drug transporter activity879. Additionally, this system can be used 
to model CYP450 enzyme induction878,880. However, this system’s low throughput make it less 
suitable than traditional monolayer culture for toxicity screening studies880. 
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Table 16. Non-perfusion hepatocyte culture systems 
System Type Cell Type(s) CT (d) CYP450 Urea Albumin Throughput 
HepatocPacTM by 
Hepregen, Corp.870 2D 
PHH or PRH 
+ 3T3  28-42 Stable Stable Stable Low 
PDMS Stencil871 2D PRH + 3T3 7 N.D. Stable Stable Low 
Micropatterned 96-
well Plate779 2D 
PHH or iHep 
+ 3T3 28 Stable Stable Stable High 
Spheroid 
Microarray Chip872 
3D 
Spheroid PRH + 3T3 14 N.D. Stable Stable High 
Micropatterned 
Fibrous Mat847 
3D 
Spheroid 
PRH + 3T3 + 
HUVEC 15 Stable ↓ Stable Low 
PEG-encapsulated 
Spheroid873 
3D 
Spheroid PRH + 3T3 50 Stable N.D. Stable High 
Human 
Microspheroids874 
3D 
Spheroid 
PHH + 
HNPC 35 Stable N.D. Stable High 
RegeneToxTM by 
Regenemed, Inc.875 
3D 
Spheroid 
PHH or PRH 
+ HNPC or 
RNPC 
90 Stable Stable Stable Medium 
GravityTRAPTM by 
InSphero AG876 
3D 
Spheroid HepaRG 21 Stable ↑ Stable High 
A summary of properties of different non-perfusion hepatocyte culture systems. CT (d) = Culture Time in days; 
PHH = Primary Human Hepatocyte; PRH = Primary Rat Hepatocyte; 3T3 = 3T3 Fibroblasts; iHep = iPSC-derived 
human hepatocytes; HUVEC = Human Umbilical Vein Endothelial Cells; HNPC = Human Non-Parenchymal Cells; 
RNPC = Rat Non-Parenchymal Cells; N.D = Not determined. 
 
 
Similar systems have used micro-patterned hepatocyte islands to enhance hepatocyte 
functioning in 2D culture. For example, Cho and colleagues used polydimethylsiloxane (PDMS) 
stencils to co-culture rat hepatocytes and 3T3 fibroblasts and demonstrated enhanced hepatocyte 
functions when co-cultured in a layered format (hepatocytes seeded on an island of fibroblasts) as 
compared to a co-planar format871. Ware and colleagues used micro-patterned hepatocyte-murine 
fibroblast co-cultures to predict hepatotoxicity using both primary human hepatocytes and iPSC-
derived hepatocyte-like cells829. However, these systems do not take advantage of the positive 
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influence of LSECs on hepatocyte functions, as previously shown with hepatocyte co-culture with 
HUVECs881. 
Since these systems involve a monolayer of cells, they are amenable to high content image 
analysis without confocal optics. However, these systems have not been fully characterized for co-
culture with liver-specific NPCs and are patterned using rat tail collagen I rather than liver specific 
matrix proteins779. Previous studies have shown that culturing hepatocytes on liver-specific ECM 
leads to higher attachment efficiency and lower expression of the dedifferentiation markers 
vimentin and cytokeratin 18882. Moreover, supplementation of liver-specific ECM digests in 
hepatocyte cultures showed improved albumin synthesis and CYP450 activity883,884. Enhanced 
albumin secretion and cellular connectivity is also observed with less stiff culture substrates, such 
as heparin gels, with the least physiological morphology observed on collagen coated glass885. 
These findings suggest culture materials that mimic physiologic liver extracellular matrix promote 
maintenance of in vivo hepatocyte functions.  
3.7.1.2 3D Spheroid Culture Systems 
Three dimensional culture systems add an additional layer of complexity by more accurately 
representing the tissue architecture of a whole liver. Micro-patterning and functionalizing surfaces 
can facilitate the formation of 3D hepatocyte spheroids. For example, Fukuda and colleagues 
micro-patterned cylindrical culture wells with collagen and polyethyleneglycol, which facilitated 
rat hepatocyte spheroid formation. These spheroids demonstrated enhanced albumin secretion and 
ammonia detoxification compared to monolayer culture for up to 14 days in culture872. They also 
used a photo-crosslinkable chitosan hydrogel to incorporate 3T3 fibroblasts into their spheroids886. 
Liu et al micro-patterned electrospun fibrous mats for the co-culture of rat hepatocytes, 
HUVECs, and 3T3 fibroblasts lasting up to 15 days847. They observed the formation of hepatocyte 
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spheroids and noted co-culture with both fibroblasts and endothelial cells enhanced albumin 
secretion, urea synthesis, and CYP450 expression as compared to monoculture or co-culture with 
either fibroblasts or endothelial cells alone. While this system incorporates all three cell types on 
the same culture surface, each cell type is seeded in a specific area, limiting direct contact but 
allowing paracrine communication847.  
Alternatively, primary rat hepatocytes and 3T3 fibroblasts can initially be co-cultured on 
2D micro-patterned surfaces and the resulting cell aggregates detached and encapsulated in PEG 
to form 3D spheroids873. These spheroids show dose-dependent acetaminophen toxicity responses, 
as well as CYP450 induction by model compounds, such as rifampin and phenobarbital. 
Additionally, the small size of these spheroids (~100µm) prevents the formation of a necrotic core. 
However, this system has not been characterized with human hepatocytes.  
Bell and colleagues have generated spheroids from primary human cryopreserved 
hepatocytes and NPCs that demonstrate preserved metabolic function and viability up to five 
weeks in culture874. Beneficially, this system uses all human cells, is highly scalable (made in 96 
well plates), and demonstrates long term response to hepatotoxins. However, the cell-to-media 
ratio is quite low, which may reduce the impact of paracrine factors secreted by the spheroids. 
There are two 3D spheroid systems commercially available. First, RegeneToxTM marketed 
by Regenemed Inc. allows for the co-culture of NPCs and hepatocytes through use of a transwell 
insert. NPCs are seeded above two interconnected nylon scaffolds and cultured for a week prior to 
hepatocyte isolation and seeding. The media are changed three times a week and the co-cultures 
can last more than three months in the system, as demonstrated by albumin, urea, transferrin, and 
fibrinogen secretion, and stable CYP1A1, 3A4, and 2C9 activity. Moreover, the liver tissue was 
responsive to inflammatory stimuli by releasing mediators such as TNFα and IL-8875. However, 
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this system is relatively low throughput (24-well plate equivalent) and utilizes a culture surface 
orders of magnitude stiffer than native liver tissue.  
GravityTRAPTM marketed by InSphero AG uses a hanging drop platform to seed cells in a 
concentrated suspension to grow liver tissue in 3D. These tissues can be transferred into a 
specialized 96-well plate for culture and analysis, remaining viable for at least 4 weeks. Spheroids 
demonstrate robust CYP3A4 expression and albumin production compared to 2D cultures. 
Spheroid size is highly reproducible but may be time consuming without automation. Additionally, 
spheroid size is limited, as spheroids larger than 200µm develop central necrosis due to hypoxia876.  
While the dimensionality of these systems allow for more complex intercellular 
communication than 2D culture systems, they do not incorporate flow, which is known to be 
important for maintaining liver-cell specific functions. 
3.7.2 Perfusion Culture Systems 
Perfusion culture systems allow for the incorporation of physiological “blood” flow (media), 
which is an important factor for hepatocyte detoxification of drugs887 and establishment of the 
physiological oxygen and chemical gradients. Such systems will be grouped by their size (both 
volume and cell number), designated as either macroscale or microscale. A summary of the 
properties of the discussed systems can be found in Table 13. 
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Table 17. Perfusion hepatocyte culture systems 
System Type Cell Type(s) CT (d) Flow Rate 
(μL/min) 
Volume 
(mL) CYP450 Urea Albumin Throughput 
Spinning Bioreactor 
Spheroids888 
Macr
o Perf PHH 21-28 41.6 300 Stable ↓ ↑ High 
Radial Flow 
Bioreactor889 
Macr
o Perf PRH + 3T3 5-11 830 54 N.D. ↓ ↓ Medium 
Multichamber 
Modular 
Bioreactor890 
Macr
o Perf PHH 7-21 250-500 5 
Stable or 
↓ Stable Stable Low 
LiverChipTM by CN 
Bio Innovations 
Ltd.832 
Micro 
Perf PHH + HNPC 15-29 60 1.6 Stable Stable Stable High 
Metabolomics on a 
Chip891 
Micro 
Perf HepG2/C3A 2 10 3 Stable N.D. Stable Low 
Hollow Fiber 
Perfusion 
Bioreactor892 
Micro 
Perf PHH + HNPC 10 3000 0.5 ↓ ↓ N.D. Low 
Artificial Liver 
Sinusoid893,894 
Micro 
Perf 
PHH or PRH or 
HepG2/C3A 7-8 0.01 – 0.02 0.075 N.D. N.D. Stable Low 
HµREL® biochips 
by  HµREL 
Corp.867,895 
Micro 
Perf cPHH + HNPC 6 4.5 0.1 
Stable or 
↓ N.D. N.D. Medium 
Human Liver  
Sinusoid896,897 
Micro 
Perf 
PHH & cPHH + 
EA.hy926 + 
U937 + LX-2 
28 0.08 to 0.25  0.1  Stable Stable  Stable Medium 
A summary of properties of different perfusion hepatocyte culture systems. Macro = Macroscale; Micro = Microscale; Perf = Perfusion; CT (d) = Culture Time 
in days; PHH = Primary Human Hepatocyte; cPHH = cryopreserved Primary Human Hepatocyte; PRH = Primary Rat Hepatocyte; 3T3 = 3T3 Fibroblasts; HNPC 
= Human Non-Parenchymal Cells; N.D = Not determined; EA.hy926 = human endothelial cell line; U937 = human monocyte cell line; LX-2 = human hepatic 
stellate cell line
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3.7.2.1 Macroscale 
A few groups have applied large scale perfusion bioreactor devices to the culture of hepatocyte 
spheroids for drug discovery applications. For example, Tostoes and colleagues demonstrated the 
culture of primary human hepatocyte spheroids in a spinning perfusion bioreactor for up to 3-4 
weeks888. The working volume was 300mL and 20% of this was replaced daily through medium 
perfusion. They demonstrated CYP450 induction and the metabolism of a model substrate, 7-
methoxycoumarin. While albumin synthesis increased and stabilized over the culture period, urea 
synthesis significantly decreased with culture, likely due to spheroid hypoxia. Additionally, this 
culture system has only been tested for hepatocyte monoculture. 
Another system uses a radial flow bioreactor (RFB), where the bed of matrix housing cells 
separates the media inlet and outlet, which facilitates nutrient and oxygen diffusion across the 
tissue. Park and colleagues co-cultured rat hepatocytes and 3T3-J2 fibroblasts on a series of 
stacked glass substrates, with microfabricated grooves and a collagen coating, to improve oxygen 
delivery to the tissue889. However, while RFBs culture large number of hepatocytes (2-5x107), the 
high flow rates used cause loss of hepatic-specific functions after a few days due to 
unphysiological shear stresses889. 
Vinci and colleagues cultured primary human hepatocytes on coverslips for 7 days then 
transferred the coverslips into either their multichamber bioreactor or a new dish for continued 
static culture. They found that the expression of metabolic (CYP450) and transport (OATP, 
MDR1) genes were much higher under perfusion conditions and that higher flow rates further 
enhanced expression890. The use of primary human hepatocytes makes this system amenable to 
investigating human-specific drug interactions. However, the working volume (5mL) is quite large 
compared to the cell seeding number (200k), which reduces the influence of secreted factors.  
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While macroscale perfusion culture systems allow for the influences of shear stress and 
nutrient supply on drug detoxification to be extrapolated, they carry several weaknesses. First, the 
number of cells required is substantially higher than smaller-scale culture systems, which may 
prove challenging given the limited availability of hepatocytes. Second, the media volume to cell 
volume ratio is much higher than is seen in vivo. Third, many of these systems replace the 
circulating media with fresh media on a continuous basis. As such, these systems may demonstrate 
reduced signaling from soluble factors released by the hepatic tissue. 
3.7.2.2 Microscale 
In contrast to macroscale (5-300mL) perfusion culture systems, the use of microscale (0.1-3mL) 
systems allows for higher cell-to-media volume ratios, which approach those seen in vivo. The 
LiverChip by CNBio Innovations (originally Zyoxel) models the liver tissue with a perfusion 
system on a larger volume scale than most micro-perfusion systems (1.6mL)751,753,832,898. Earlier 
generations of this system utilized alternative well geometry899,900. Hepatocytes and a full 
complement of donor matched NPCs are seeded on polystyrene (mechanically stiff) scaffolds at a 
1:1 ratio. Fluid flow is driven by pneumatic pumps at a rate of 60 µL/min through the scaffolds, 
providing direct, but physiologically representative shear stresses on the resident tissue cells 
(Figure 9). Tissues are established and remain functional up to one month, as measured by blood 
urea nitrogen levels, fibrinogen, alpha-1 antitrypsin (A1AT), and CYP450 activity. The culture 
chamber allows for a 3D hepatic tissue to form, which provides an advantage over 2D culture 
systems by facilitating cell junction formation. This culture system has been used to study 
metastasis of cancer cells in the context of the liver microenvironment751,753,832,898 and probe the 
influence of LPS on hydrocortisone metabolism858. This system offers a unique opportunity to 
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study cancer drug efficacy and hepatotoxic effects in a single system. However, there is currently 
no effective way to physically monitor tissue formation during the culture period.  
 
 
 
Figure 11. A schematic of the LiverChip by CN Bio Innovations Ltd. 
Three dimensional liver tissues are subject to fluid flow in micro-scale pores of a scaffold, which facilitates shear 
stresses and establishment of a physiological oxygen gradient. 
 
 
Choucha-Snouber and colleagues designed a liver biochip to investigate metabolic 
responses to the anticancer drug flutamide901. Their chip is fabricated from PDMS and contains 
fibronectin-coated microstructures for cell seeding. HepG2/C3a cells are seeded in the system and 
kept in culture for a total of 48 hours, 24 hours of which is for perfusion and drug treatment. In 
comparison to the LiverChip, this system uses a lower flow rate of 10µL/min. The low volume of 
the biochip (40µL) is desirable to achieve a physiologic ratio of media supply to cell volume. 
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However, this system has not tested co-culture with NPCs. Additionally, using PDMS as the 
fabrication substrate allows for gasses to readily equilibrate between the external environment and 
the cell culture chamber, which may limit modeling of a physiologically hypoxic liver 
microenvironment. Additionally, small hydrophobic compounds adsorb to PDMS, which limits 
the drugs this system can accurately assess without extensive calibration and testing. This design 
was extended to investigate kidney-liver co-culture systems891. 
Hoffmann and colleagues designed a hollow-fiber based microscale perfusion culture 
system, with a volume of 0.5mL892. A unique feature of this system is the incorporation of three 
different supply channels to the cultured tissue – two media circuits and one gas circuit. The 
authors demonstrate robust tissue formation, which includes NPCs. Moreover, NPCs were noted 
to form vascular-like structures. While the culture volume is low, the flow rate and fresh media 
replenishment rate are quite high in comparison (3mL/min and 0.5mL/hour respectively). This 
may prove a limiting factor for analyzing long-term effects of secreted factors. Additionally, the 
expression and activity of several CYP450 (3A4 and 2B6) isoforms decreases dramatically 
between days 3 and 10 of culture892. Since 50% of currently tested drugs are metabolized by 
CYP3A4902, the decrease in its activity over the culture period may make this system not suitable 
for long term toxicity or metabolic assays. 
CellAsic designed a hepatic sinusoid cord-like culture system, in which a central cord of 
cells is enveloped by a fluid transport channel. Communication between the cells and fluid channel 
was accomplished by small (1µm by 2µm) canals, limiting transport to diffusion. The system is 
primed with fluid and cells are subsequently seeded. After cell seeding, the chip is placed in the 
incubator on an incline to facilitate gravity-driven continuous flow, at rates of 10-20nL/min, to 
supply the tissue. The system can maintain hepatocytes for over 1 week, as determined by albumin 
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secretion, and exhibit dose-dependent hepatotoxicity of diclofenac as seen in vivo893,894. Thirty two 
independent culture systems can be run simultaneously on a device the size of a 96-well plate. 
While this system generates 3D tissue, an improvement over 2D culture systems, it has not been 
investigated for culture periods longer than 7 days. 
HµREL® biochips by Hurel Corp. allow up to 8 microfluidic circuits to operate in 
parallel895. These chips contain two cell culture compartments connected in series, one of which 
was designed to house liver tissue. Cells are seeded onto the polystyrene biochip either in 
monoculture or co-culture, using human hepatocytes and NPCs. Flow was generated by use of a 
peristaltic pump with a flow rate of 4.5µL/min/chip. Hepatocyte co-cultures in the system 
subjected to flow demonstrated increased metabolic activity when compared to static monocultures 
or co-cultures and remained viable for up to 6 days867. One advantage of this system is that the 
HµREL tubing exhibits limited adsorption of hydrophobic drug molecules. Additionally, the 
polystyrene housing reduces gas permeability of the device, facilitating formation of a hypoxic 
microenvironment. However, the tissues formed in this system are not 3D and the maximum 
culture period is limited compared to other systems. Moreover, CYP450 isoforms exhibit varying 
activities in the system – while CYP3A4 activity increases over the 6 day culture duration, 
CYP2D6 activity decreases after 2 days of culture867. 
Finally, the liver acinus microphysiology system (LAMPS) is a microfluidic platform to 
investigate hepatic physiology, drug safety, and disease models759 that evolved from the first 
generation liver MPS (SQL-SAL)896. The LAMPS incorporates either fresh or cryopreserved 
human hepatocytes, as well as a full complement of non-parenchymal cells: human endothelial 
(primary or TMNK-1), immune (THP-1 or U937), and stellate (LX-2) cells in a Nortis, Inc 
microfluidic device. A porcine liver extracellular matrix (LECM), ca. 10µm thick, is layered 
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between the endothelial cells and the hepatocytes. Approximately 20% of the hepatocytes and 
stellate cells contain fluorescent biosensors that measure apoptosis and reactive oxygen species for 
real-time fluorescence readouts903, along with analysis of the secretome and metabolic activity. 
Distinct zone 1 and zone 3 microenvironments are created that allow the direct determination of 
zone-specific physiological and disease functions904. This system is viable for at least 28 days 
under continuous perfusion flow and exhibits concentration- and time-dependent toxicity profiles 
to drugs (e.g. troglitazone) in a similar manner to that seen clinically905. Structurally, the 
endothelial cells are separated from the hepatocytes by a biomimetic of the Space of Disse forming 
a three-dimensional layer of cells and LECM. The immune cells permit the system to be LPS 
responsive, releasing TNFα upon stimulation and in combination with some drugs causes immune-
mediated hepatotoxicity. Moreover, the LX-2 cells can be activated in response to methotrexate 
treatment, resulting in the expression of smooth muscle actin (SMA) and the production of 
collagen 1A2, reflecting a fibrosis phenotype. Most importantly, this system is amenable to real-
time transmitted light and fluorescence imaging, allowing for investigating toxicity kinetics and 
disease progression.  
The platform is continually being evolved to replace the NPCs with either primary human 
cells or iPSC-derived cells, since the use of immortalized NPCs may not reflect full physiological 
capabilities. This platform contains PDMS which requires the presence of carrier proteins for 
hydrophobic drugs and pre-measurement of the loss of drugs to the device before making any 
interpretations897. While the media in this system is not recirculated in the current format, the small 
volumes and low flow rates allow the detection of paracrine signaling mediators secreted by the 
cells. Although, there are other advantages to having the media recirculated (see above). 
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3.7.3 Conclusions and Future Directions 
Advanced liver culture systems hold the potential to transform drug discovery and development, 
through more accurate modeling of human in vivo pharmacokinetics and pharmacodynamics, as 
well as understanding mechanisms of disease progression and toxicity. Several factors affect the 
accuracy of these model systems in predicting pharmaceutical toxicity. The cells used in the culture 
system and the culture surface (e.g. plastic, hydrogel) allow for modeling cell-cell and cell-ECM 
interactions respectively. Systems that include media flow (“blood flow”) provide mechanical 
stimuli that benefit tissue function. Inclusion of cells derived from human tissues allows for 
human-specific pathways to be modeled. Special attention should be paid to the use of primary 
versus immortalized cells, as the latter may elicit signals not seen in physiologic conditions. The 
use of animal cells instead of human cells may encounter similar intractable weaknesses. 
Importantly, the expression levels of CYP450 isoforms and drug transporters over the culture 
period may influence toxicity predictions.  
Future directions for improving these systems include incorporating lentiviral-induced 
fluorescent biosensors for an automated readout of various cellular functions903 and finer 
architectural control of liver microstructure. Importantly, the ability to image the devices in real 
time is highly advantageous. Fabrication of devices using materials other than PDMS – which 
adsorbs hydrophobic molecules and biologics – will improve the utility of these devices as 
pharmacokinetic models for drug discovery. Moreover, procurement of a universal, readily 
available cell source (potentially iPSC-derived hepatocytes) will improve the ease with which 
these systems are used for drug characterization studies. Networking of additional organ chips, 
such as gut and kidney, will contribute additional signals to the liver tissue, allow for modeling of 
drug absorption, and disposition after hepatic metabolism. Finally, further development and usage 
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of quantitative systems pharmacology as a new paradigm in drug discovery and development 
involving the integration and iteration of experimental and computational models, in parallel with 
advanced culture systems will facilitate complex data analysis and may allow for predictive models 
to be generated906,907.  
It is hoped that the development of validated human experimental model systems can be 
used in place of animal models to improve preclinical drug selection. By implementing more 
accurate human experimental model systems, it is expected that there will be increased efficacy 
and safety in clinical trials leading to improved therapeutics at a lower cost. 
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4.0  RATIONALE AND HYPOTHESES 
Developing or repurposing novel therapies to serve as long term adjuvants for women with a 
history of breast cancer is necessary in order to prevent recurrence. Statins have been shown in 
both epidemiological and experimental studies to have anti-tumor effects, yet the mechanisms and 
factors that make tumor cells more or less susceptible to statin therapy remain unclear. While 
statins have a benefit on both breast cancer recurrence and breast cancer specific mortality, no 
difference in incidence of primary cancer is noted with statin usage.  
Previous work has suggested the anti-tumor effects of statins result from a decreased 
abundance of prenylating intermediates, which reduce activity of signaling g-proteins that 
normally promote growth and survival in neoplastic cells. An example protein negatively impacted 
by lack of prenylation is Ras, whose membrane localization is critical to its signaling function. Our 
lab and others have shown that tumor dormancy is marked by a state of cellular quiescence, in 
which cells are arrested in G0/G1. One of the contributing factors to this quiescence is the growth 
suppressive effect of E-cadherin, which is re-expressed upon metastatic seeding and entry into 
dormancy. The microenvironment is abundant with growth factors and other mitotic stimuli, which 
can provoke dormant tumor cells to undergo a secondary EMT and outgrow.  
As tumor cells emerging from dormancy experience enhanced flux through pro-mitotic and 
pro-migratory signaling pathways, such as PI3K-Akt and MAPK, it is likely they are more 
susceptible to the anti-tumor effects of statins. These findings lead us to the central hypothesis of 
this work: statins act by selectively targeting dormant micrometastases that are primed to 
outgrow, keeping them suppressed in a state of quiescence and reducing breast cancer 
recurrence and mortality (Figure 12).  
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Figure 12. Proposed influence of statins on cancer mortality 
Statins block tumor cell emergence from dormancy by decreasing the proliferation of micrometastases at the 
metastatic site. This results in a decrease in cancer recurrence and mortality. EMT = epithelial-to-mesenchymal 
transition; MErT = mesenchymal-to-epithelial reverting transition. This diagram was created using images from 
Servier Medical Art46. 
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5.0  STATIN-INDUCED MEVALONATE PATHWAY INHIBITION ATTENUATES 
THE GROWTH OF MESENCHYMAL-LIKE CANCER CELLS THAT LACK 
FUNCTIONAL E-CADHERIN MEDIATED CELL COHESION 
5.1 PROLOGUE 
The first piece of work contributing to this thesis was published in Scientific Reports at the end of 
20142, which resulted mainly from work I conducted on the manuscript during my summer rotation 
in collaboration with two Japanese students working with Dr. Oltvai, the senior author on the 
study. The majority of this chapter is previously published in that manuscript, and the 
corresponding reference can be found both at the beginning of this document and in the references 
section. Of note, the “Primary Data” section refers to a discussion of the data published in the body 
of the manuscript, the “Supplemental Data” refers to data published in the supplement of the 
manuscript, and the “Supporting Data” refers to unpublished data that support the conclusions of 
this study. 
In this work, we investigated the growth suppressive effects of atorvastatin, a model 
lipophilic statin, on a panel of cancer cell lines. We confirmed that atorvastatin sensitivity was 
marked by a decrease in total intracellular cholesterol levels and that sensitive cell lines could be 
rescued from these effects upon addition of mevalonate, the product of the inhibited HMGCR 
enzyme. We demonstrate that susceptibility to atorvastatin-mediated growth suppression is not 
due to differing protein levels of the target enzyme, as all cell lines tested expressed comparable 
levels. Moreover, we find that all statin resistant cell lines strongly express E-cadherin on the 
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membrane and that expression of E-cadherin on the membrane in cells with normally no 
expression is sufficient to induce resistance to atorvastatin. 
These data are a significant foundation to this body of work for several reasons. First, this 
manuscript demonstrates direct growth suppression of tumor cells by atorvastatin by looking at 
growth kinetics. Most studies in the literature demonstrate growth suppression or cellular death by 
investigating one specific experimental time point with cytotoxicity assays. Second, this study 
demonstrates that statins act to suppress cancer cell growth by the same mechanism as they act to 
reduce cholesterol, namely by suppressing HMGCR. Finally, this study uncovers E-cadherin as 
both a biomarker and mechanism of resistance to statin therapy. Given the overarching hypothesis 
of this thesis involves the ability of statins to target metastatic-emergent breast cancer to reduce 
recurrence and mortality, these data support this theory by suggesting statins are the most effective 
against the cells that have undergone a secondary EMT to emerge from dormancy. 
5.2 MATERIALS AND METHODS 
Cell cultures. Fourteen cell lines from the NCI-60 cancer cell panel—colon cancer (HCT-116 and 
KM-12), ovarian cancer (IGROV1 and OVCAR3), breast cancer (HS-578T and T47D), lung 
cancer (HOP-92 and NCI-H322M), prostate cancer (PC-3 and DU-145), melanoma (SK-MEL-5 
and MDA-MB-435), and brain cancer (SF-295 and SF-539)—were cultured in RPMI 1640 
medium (Life Technologies, Grand Island, NY), supplemented with 10% heat-inactivated fetal 
bovine serum (HI-FBS, Life Technologies) and 1% penicillin/streptomycin (Life Technologies) at 
37°C with 5% CO2. 
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Atorvastatin treatment and cell proliferation assay. Atorvastatin (Sigma-Aldrich, St. 
Louis, MO) at a final concentration of 10 µM was dissolved in dimethyl sulfoxide (DMSO, Sigma-
Aldrich; final concentration of 0.1% in RPMI 1640 medium). The cells were seeded in 6-well 
plates at a density of 1×105 cells/ml and incubated overnight prior to treating with 10 µM 
atorvastatin or 0.1% DMSO, which served as a control. Cell proliferation was quantified at 2, 4, 
and 6 days by direct cell counting with ScepterTM Handheld Automated Cell Counter (EMD 
Millipore, Billerica, MA) using ScepterTM Tips‒60 µm sensor (EMD Millipore), or by crystal 
violet staining. Preliminary studies demonstrated that the two methods yielded congruent results. 
Mevalonic acid treatment in atorvastatin sensitive cells. To determine whether 
mevalonic acid treatment reverted the atorvastatin-sensitive phenotype, the cell lines whose 
proliferation was inhibited by atorvastatin were seeded in 6-well plates at a density of 1×105 
cells/ml, incubated overnight, and then treated with 10 µM atorvastatin and various concentrations 
(25 µM, 50 µM, 100 µM, and 200 µM) of R-mevalonic acid (Sigma-Aldrich) for 24 hours. These 
cells were also photographed with a phase-contrast microscope to capture any morphological 
changes. 
Cholesterol staining. Subconfluent (40–60% confluency) cells grown on coverslips in a 
24-well plate were incubated with RPMI 1640 medium supplemented with 10% HI-FBS, 10 µM 
atorvastatin, and a cholesterol intercellular trafficking inhibitor, 1.25 µM U18666A (Cayman 
Chemical, Ann Arbor, MI). Some of the atorvastatin sensitive cells (HOP-92 and PC-3) were also 
treated with 100 µM R-mevalonic acid (Sigma-Aldrich). Cells treated with 0.1% DMSO and 1.25 
µM U18666A served as control. After 24-hours incubation, the cells were stained using the choles-
terol cell-based detection assay kit (Cayman Chemical) according to the manufacturer’s instruc-
tions. Briefly, the cells were fixed with 4% formaldehyde in Tris-buffered saline (TBS) for 10 min 
  149 
and then washed in TBS with 0.1% Tween 20 (TBS-T). The cells were incubated with 50 μg/ml 
Filipin III in TBS, a probe used for the fluorescent detection of sterols (excitation/ emission, 340–
380/385–470 nm). After 1 hour incubation with Filipin III in the dark at room temperature (RT), 
the cells were washed in TBS-T, followed by detachment and mounting of the coverslips in the 
aqueous-based mounting medium (ClearmountTM, Invitrogen, Carlsbad, CA). Images were taken 
under an Olympus Provis fluorescence microscope (Olympus Optical, Tokyo, Japan) equipped 
with a 40X oil objective lens. Quantification of the cholesterol levels was accomplished using the 
Granularity algorithm in the MetaXpress image analysis software (Molecular Devices Corp., 
Sunnyvale CA).  The total integrated granule intensity was measured for each image and the 
percent cholesterol remaining after atorvastatin treatment was calculated as the ratio of granule 
intensity in the atorvastatin cells to that of the DMSO treated cells. 
Western blotting. After removing spent media and washing cells with cold phosphate 
buffered saline (PBS), the cells were incubated with cold Pierce RIPA lysis buffer (Thermo 
Scientific, Hudson, NH) containing HaltTM Protease Inhibitor Single-Use Cocktail, HaltTM 
Phosphatase Inhibitor Single-Use Cocktail (Thermo Scientific) and 1 mM dithiothreitol (DTT) for 
15 min with occasional swirling. Then, the cells were scraped, homogenized with a 26-gauge 
needle and vortexed at the highest setting for 1 min; the lysates were cleared by centrifuging at 
16,000g at 4 ºC for 15 min. Protein concentration was determined with the bicinchoninic acid 
(BCA) method (BCA Protein Assay - Reducing Agent Compatible; Thermo Scientific). Proteins 
were separated on NuPAGE 4‒12% Bis Tris gel electrophoresis (Life Technologies), and 
transferred to a nitrocellulose membrane (iBlot Gel Transfer Stacks Nitrocellulose; Life 
Technologies) using iBlot Gel Transfer Device (Life Technologies). The membrane was probed 
with monoclonal rabbit antibodies, anti-HMGCR (1:500, Abcam Inc., Cambridge, MA), anti-
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vimentin (1:1000, Abcam), and anti-E-cadherin (1:1000, Cell Signaling Technology, Beverly, 
MA). A monoclonal mouse antibody to β-actin (1:500, Abcam) was used as a loading control. 
Immunodetection was performed using the iBlot Western Detection chromogenic kit (Life 
Technologies). 
Immunofluorescence microscopy. Cultured cells grown on coverslips in a 24-well plate 
were fixed with 2% paraformaldehyde (Sigma-Aldrich) for 30 min, washed in PBS, and then 
permeabilized with 0.1% Triton-X-100 (Fisher Scientific, Pittsburgh, PA) made in PBS for 15 
min. Following a PBS wash, non-specific proteins were blocked in 2% BSA for 15 min at RT. The 
cells were incubated with a mixture of two primary antibodies: monoclonal rabbit antibody to 
vimentin (1:100, Abcam) and monoclonal mouse antibody to E-cadherin (1:50, Abcam) in a 
humidified atmosphere for 1 hour at 37°C. Coverslips were then probed with Alexa Fluor 488 goat 
anti-mouse IgG and Alexa Fluor 555 goat anti-rabbit IgG (both; 1:200, Abcam) in the dark for 15 
min at RT. Following a PBS wash, nuclei were stained with Hoechst 33342 (50 μg/ml) for 5 min 
at RT, washed and mounted in an aqueous-based mounting medium ClearmountTM (Invitrogen). 
Images were captured with the 40X oil objective lens on the Olympus Provis fluorescence 
microscope (Olympus Optical).  
IC50 determination. MDA-MB-231 (breast cancer) and PC-3 (prostate cancer) cell lines 
were seeded in 12-well plates at a concentration of 1×105 cells/ml. The next day, cells were treated 
with 0.1 µM, 0.3 µM, 1 µM, 3 µM, 10 µM, or 30 µM atorvastatin. Cells treated with 0.3% DMSO 
(the concentration of DMSO in the 30 µM atorvastatin treatment condition) served as a control 
group. Three days after treatment, the cells were washed with PBS and fixed in 4% formaldehyde 
(F79-1, Fisher Scientific) for 15 minutes. The cells were washed with milli-Q water and stained 
with 0.5% w/v crystal violet (Sigma-Aldrich) for 10 minutes, and excess dye was washed 
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extensively with tap water. The absorbed dye was released with 2% SDS. The supernatants were 
mixed thoroughly before transferring to a 96-well plate to be read at 560 nm using a Tecan 
SpectraFluor microplate reader (Tecan US, Durham, NC). IC50 values were determined by fitting 
a standard, four-parameter sigmoid curve to the data. All treatments were carried out in triplicate 
samples. 
5.3 PRIMARY DATA 
5.3.1 Variable Growth Inhibition of Cancer Cell Lines with Atorvastatin Treatment 
Previous experiments have demonstrated that statins, including atorvastatin (Lipitor), inhibit the 
growth of a subset of the NCI-60 cancer cell lines, and if one statin inhibited the proliferation of a 
given cell line, then the other statins also showed similar half maximal inhibitory concentration 
(IC50) values908. To confirm these results, we cultured two cell lines from each of seven organ 
types obtained from the NCI-60 collection in standard growth medium with 10µM atorvastatin. 
We found that atorvastatin affected the proliferation rates of these cancer cell lines differentially: 
the proliferation of some cell lines were fully or partially inhibited by atorvastatin while others 
were insensitive to it (Figure 13). Some cell lines derived from the same organ type showed 
differential susceptibility to atorvastatin. For example, HOP-92 and NCI-H322M are both lung 
carcinoma derived cell lines yet the former is sensitive to atorvastatin whereas the latter is resistant 
to atorvastatin (Figure 13G, H). Similarly, PC-3 and DU-145 cells are both derived from metastatic 
prostate tumors of bone and brain respectively909, yet the former is sensitive to atorvastatin whereas 
the latter is resistant (Figure 13I, J). In contrast, some cell line pairs from the same organ type 
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exhibit similar responses to atorvastatin. For example, both SF-295 and SF-539, glioblastoma and 
gliosarcoma cell lines respectively, exhibit profound atorvastatin sensitivity, even demonstrating 
possible cytotoxic effects that can be seen starting at 4 days post-atorvastatin treatment (Figure 
13M, N). These data demonstrate that atorvastatin can directly suppress tumor cell growth and that 
the degree of suppression cannot be determined solely from the tumor site of origin. 
 
 
 
Continued on the next page 
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Figure 13. Growth rate of atorvastatin treated NCI-60 cancer cell lines 
Colon cancer (A. HCT-116 and B. KM-12), ovarian cancer (C. IGROV1 and D. OVCAR3), breast cancer (E. HS-
578T and F. T47D), lung cancer (G. HOP-92 and H. NCI-H322M), prostate cancer (I. PC-3 and J. DU-145), 
melanoma (K. SK-MEL-5 and L. MDA-MB-435), and brain cancer (M. SF-295 and N. SF-539) cell lines from the 
NCI-60 cancer cell line collection were treated with 10 µM atorvastatin (purple line) or DMSO vehicle control (blue 
line), and cell proliferation was quantified at 2, 4, and 6 days by direct cell counting.  
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5.3.2 Atorvastatin sensitivity correlates with decreased cholesterol levels in atorvastatin-
treated cells 
Atorvastatin inhibits the enzymatic activity of HMGCR, thus blocking the synthesis of mevalonate 
and its downstream products that include cholesterol (Figure 11). To directly test the relationship 
between atorvastatin sensitivity and cholesterol levels, we measured the cholesterol content of the 
cell lines in the presence or absence of atorvastatin using Filipin III, a polyene macrolide routinely 
used to assess intracellular cholesterol levels910. Representative results are shown in Figure 14. 
Atorvastatin treatment for 24 hours reduced the levels of intracellular cholesterol in atorvastatin 
sensitive HOP-92 cells when compared to that of the control DMSO treatment by more than 75% 
(Figure 14G-I). In contrast, addition of the drug did not affect the levels of intracellular cholesterol 
in atorvastatin resistant DU-145 (Figure 14A-C). The partially sensitive T47D cell lines showed 
an intermediate effect on cholesterol after atorvastatin treatment, with a reduction in intracellular 
cholesterol of almost 20% (Figure 14D-F). Interestingly, while the cholesterol localization does 
not appear to change with atorvastatin treatment in resistant or partially sensitive cell lines (Figure 
14A-F), atorvastatin sensitive HOP-92 see a dramatic reduction in perinuclear cholesterol 
accumulation.  
It is possible the decreased density of cholesterol near the nucleus is due to a dramatic 
reduction in total cholesterol, yet the cholesterol appears more diffusely distributed after 
atorvastatin treatment. The complete data set for all fourteen cell lines is shown and discussed in 
the supplemental information section of this chapter (Figure 21). Thus, the sensitivity of cell lines 
to atorvastatin-induced growth inhibition inversely correlated with the intracellular cholesterol 
levels following atorvastatin treatment. These data suggest that sensitivity to statin-mediated 
growth suppression is directly proportional to the degree of shut down of the mevalonate pathway, 
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as the cells most greatly affected by growth suppression also demonstrate that most profound 
reductions in the end product of that pathway (cholesterol). 
 
 
 
Figure 14. Cholesterol content of atorvastatin treated NCI-60 cancer cell lines 
Cell lines were treated with 10µM atorvastatin or 0.1% DMSO for 24 hours. Intracellular cholesterol levels were 
determined by Filipin III staining. Results for (A-C) atorvastatin resistant (DU-145), (D-F) partially sensitive 
(T47D), and (G-I) sensitive cell lines (HOP-92) are shown. (A, C, F) DMSO control; (B, D, F) 10μM atorvastatin 
treated cells; (C, F, I) histogram of cholesterol levels normalized to the DMSO controls. 
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5.3.3 Total vimentin and E-cadherin expression are not suitable markers for statin 
sensitivity 
The differential sensitivity of tumor cell lines to atorvastatin could be utilized for adjuvant cancer 
therapy if highly sensitive biomarkers were identified. Our previous analysis of the NCI-60 cancer 
cell lines indicated that cells with larger diameters in culture are more sensitive to statin treatment. 
Furthermore, increased cell size in culture correlated with higher vimentin protein expression, a 
standard marker of mesenchymal cell lineage, while the epithelial marker E-cadherin negatively 
correlated with increased cell size911. As these two markers are routinely used in standard 
immunohistochemistry of tumor biopsy specimens, we probed their utility as biomarkers of 
atorvastatin sensitivity.  
First, we performed Western blot analyses to determine the average vimentin and E-
cadherin expression in the fourteen cell lines. We found that several cell lines express vimentin 
with absent or minimal E-cadherin expression while cell lines deficient in vimentin expressed a 
medium to high level of E-cadherin (Figure 15). Of note, some cell lines expressed both vimentin 
and E-cadherin (Figure 15); however, they also exhibited highly variable atorvastatin sensitivity. 
For example, the PC-3 and DU-145 prostate cancer cell lines express both proteins at comparable 
levels (Figure 15), yet their responses to atorvastatin are completely opposite (Figure 13). These 
data indicate that the correlation between the total expression levels of the mesenchymal marker 
vimentin and epithelial marker E-cadherin expression cannot be used as dependable biomarkers 
for predicting or identifying atorvastatin sensitive cancer cells. These data are significant as often 
changes in cancer cell phenotype that accompany EMT are determined by analysis of total levels 
of E-cadherin45, which suggest alternative analyses or markers are needed to determine 
susceptibility to statin therapy. 
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Figure 15. E-cadherin and vimentin expression of NCI-60 cancer cell lines 
The expression levels of E-cadherin and vimentin in the indicated fourteen NCI-60 cell lines were determined by 
western blotting. Colon cancer (HCT-116 and KM-12), ovarian cancer (IGROV1 and OVCAR3), breast cancer (HS-
578T and T47D), lung cancer (HOP-92 and NCI-H322M), prostate cancer (PC-3 and DU-145), melanoma (SK-
MEL-5 and MDA-MB-435), and brain cancer (SF-295 and SF-539). β-actin expression was used as the loading 
control. 
 
 
5.3.4 Membrane E-cadherin expression is a potential biomarker for atorvastatin 
sensitivity 
While vimentin is a cytoplasmic protein, E-cadherin can be found in different subcellular 
localizations within tumor cells912,913. E-cadherin homodimerization at the cell membrane provides 
survival signals whereas destabilized E-cadherin molecules are internalized and fail to signal748. 
To uncover the potential differences in E-cadherin localization in the fourteen cell lines, we 
performed double immunostaining for vimentin and E-cadherin expression, and imaged using 
immunofluorescence microscopy.  
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Based on the collected data, the fourteen cell lines were segregated into one of three groups, 
each with different patterns of vimentin and E-cadherin expression (Figure 16). First, six cell lines 
without cell surface E-cadherin expression but uniformly expressed cytoplasmic vimentin were 
atorvastatin-sensitive (Figure 16A-F). In contrast, cell lines that displayed any cell membrane E-
cadherin expression were either fully or partially atorvastatin-resistant (Figure 16H-N), 
irrespective of their cytoplasmic vimentin expression. The degree of vimentin and E-cadherin 
expression varied among the individual cell lines. For example, DU-145 cells display both 
cytoplasmic vimentin and heterogeneous cell membrane E-cadherin expression (Figure 16K), 
whereas OVCAR3 cells are vimentin negative but exhibit both cell membrane and intracellular E-
cadherin localization (Figure 16M). Despite this difference, both cell lines are fully resistant to 
atorvastatin (Figure 13).  
A similar variation exists among partially resistant cell lines. T47D and HCT-116 cells are 
positive for cell membrane and cytoplasmic E-cadherin but are vimentin negative (Figure 16H, I), 
whereas IGROV1 cell line is comprised of at least two different cell types. A subset of IGROV1 
cells are vimentin negative and positive for cell membrane E-cadherin while another subset of cells 
is positive for cytoplasmic vimentin, and exhibit cell membrane and cytoplasmic E-cadherin 
(Figure 16J). The only exception is the HS-578T breast cancer cell line that is only partially 
atorvastatin sensitive (Figure 13), even though it has similar vimentin and E-cadherin expression 
pattern as that observed in atorvastatin-sensitive cell lines (Figure 16G). These results suggest that 
cell membrane E-cadherin expression is a marker of full or partial atorvastatin resistance, whereas 
uniform vimentin expression without any cell membrane E-cadherin expression largely correlates 
with atorvastatin sensitivity. 
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Figure 16. Vimentin and E-cadherin expression and subcellular localization 
Merged images of the NCI-60 cell lines immunostained for vimentin (red, cytoplasmic), E-cadherin (green, 
membrane, cytoplasmic or nuclear), and Hoechst 33342 (blue, nucleus). A: PC-3, B: HOP-92, C: SK-MEL-5, D: 
MDA-MB-435, E: SF-295, F: SF-539, G: HS-578T, H: T47D, I: HCT-116, J: IGROV1, K: DU-145, L: NCI-
H322M, M: OVCAR3, and N: KM-12 cell lines. Cell lines are labeled as atorvastatin-sensitive (A-F), -partially 
sensitive (G-J) or -resistant (K-N) based on the results of cell proliferation studies shown in Figure 2. 
 
 
Taken together with Figure 15, the data in Figure 16 suggest that localization but not total 
expression levels of E-cadherin are significant biomarkers for resistance to atorvastatin. The 
reduction in cellular cohesion that accompanies EMT depends on decreased E-cadherin 
functionality, which can occur both transcriptionally and post translationally, the latter specifically 
relating to protein internalization and subsequent degradation914. As such, determination of E-
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cadherin localization provides more information regarding functionality (epithelial versus 
mesenchymal phenotype) than total expression levels. 
5.3.5 Forced expression of cell surface E-cadherin converts atorvastatin-sensitive cells to 
a more atorvastatin resistant state 
Given the observed correlation between atorvastatin-resistance and cell membrane E-cadherin 
expression, we aimed to determine whether exogenously expressed membrane E-cadherin would 
induce a resistant state in a statin-sensitive cell line. To this end, we used derivatives of a highly 
statin-sensitive MDA-MB-231 cell line, which express either dsRED (RFP) or dsRED and cell 
surface E-cadherin (Ecad)45. The RFP and Ecad cell lines were treated with log-dilutions of 
atorvastatin and their cell numbers were determined 3 days after treatment by crystal violet 
staining. We found that the half maximal inhibitory concentration of atorvastatin (IC50) in MDA-
MB-231 cells shifted from 1.16μM to 4.3μM when cell surface E-cadherin was expressed (Figure 
17A). A representative image of RFP and Ecad cells treated with 3µM atorvastatin illustrates this 
shift by showing a relatively higher cell density in the latter (Figure 17B,C). Additionally, the more 
statin sensitive MDA-MB-231 RFP cells appear more rounded or spindle-like after treatment with 
3µM atorvastatin (Figure 17B) whereas the MDA-MB-231 Ecad cells demonstrate a more 
cohesive and epithelial phenotype, with a lower proportion of cells exhibiting cytoskeletal 
alterations (Figure 17C).  These data suggest that forced cell surface E-cadherin expression can 
confer partial statin resistance to formerly statin-sensitive cancer cells.  
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Figure 17. Forced cell surface E-cadherin expression increases cellular resistance to atorvastatin 
(A) MDA-MB-231 RFP (●) or MDA-MB-231 RFP E-cadherin (▲) cells were treated with 0.1µM, 0.3µM, 1µM, 
3µM, 10µM, or 30µM atorvastatin. Cell viability was assessed by crystal violet staining 3 days after atorvastatin 
treatment and normalized to the 0.3% DMSO control. Error bars represent the standard deviation (n=3). The data 
were fit with a sigmoid function to extrapolate the IC50 value (lines). (B) MDA-MB-231 RFP and (C) MDA-MB-
231 RFP E-cadherin cells were treated with 3µM atorvastatin. Imaging was done with 40X oil objective lens 3 days 
after the treatment.  
 
 
That the localization of E-cadherin to the membrane is critical to induction of resistance to 
statin therapy may be related to several factors. Previous studies have demonstrated that E-
cadherin homotypic complexes result in survival signaling through the Akt-PBK and MAPK 
pathways914–916. These signals that result from cellular cohesion may decrease the potency of the 
growth suppressive effects of atorvastatin. Our lab has previously demonstrated re-expression of 
E-cadherin upon metastatic seeding of breast and prostate tumor cells45,748,917. These data that 
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demonstrate exogenously expressed E-cadherin on the membrane increases the resistance of cells 
to atorvastatin suggest that epithelioid micrometastases present at the metastatic site following 
MErT would be less susceptible to atorvastatin therapy. In contrast, cells that undergo a secondary 
EMT to emerge as dedifferentiated macrometastases would regain sensitivity to statin therapy. 
 
5.4 SUPPLEMENTAL DATA 
In order to further investigate the mechanism of atorvastatin-mediated growth suppression of 
tumor cells, we investigated whether supplementation with mevalonic acid - the product of the 
HMGCR-catalyzed reaction (Figure 11) – would reverse these effects. We found that mevalonate 
reversed the atorvastatin-induced growth inhibition of the ten cancer cell lines that displayed full 
or partial sensitivity to atorvastatin (Figure 13, Figure 18).  
The data in Figure 18 demonstrate that mevalonic acid supplementation is able to reverse 
the phenotypic changes induced by atorvastatin in both fully and partially sensitive statin cell lines. 
This suggests that the mechanism of action of statins in inhibiting tumor cell growth is by direct 
inhibition of HMGCR. Furthermore, we demonstrate that the rescue of these statin-mediated 
effects is dose dependent (Figure 19). These data indicate that the growth suppressive effects of 
atorvastatin are due to the depletion of mevalonate in tumor cells by the suppression of its synthesis 
by HMGCR. 
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Figure 18. Exogenous mevalonate prevents atorvastatin-induced growth inhibition 
Fully- and partially statin sensitive cancer cell lines were treated with 0.1% DMSO (top rows), with 10μM 
atorvastatin (middle rows) or with 10μM atorvastatin and 100μM mevalonic acid for 24 hours. The 
microphotographs of the cell cultures are shown demonstrating that mevalonic acid abrogates the atorvastatin-
induced growth inhibition. 
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Figure 19. Mevalonate bypasses atorvastatin inhibition in a dose-dependent fashion 
The statin sensitive cancer cell line, MDA-MB-435, was treated with 10μM atorvastatin and increasing 
concentrations of mevalonic acid for 72 hours. (A) Control (DMSO), (B) 10μM atorvastatin, (C) 10μM atorvastatin 
and 25μM mevalonic acid, (D) 10μM atorvastatin and 50μM mevalonic acid, (E) 10μM atorvastatin and 100μM 
mevalonic acid, (F) 10μM atorvastatin and 200μM mevalonic acid. The microphotographs of the cell cultures are 
shown demonstrating that mevalonic acid abrogates atorvastatin-induced growth inhibition in a concentration 
dependent manner. 
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Figure 20. HMGCR expression of NCI-60 cancer cell lines 
The expression levels of HMGCR in the indicated fourteen NCI-60 cell lines are shown on western blot together 
with control β-actin expression. 
 
 
In order to determine whether atorvastatin sensitivity was dependent on the abundance of 
the target enzyme HMGCR, we probed the total protein levels by western blot. We found that all 
fourteen cell lines express HMGCR at comparable levels (Figure 20), demonstrating that statin 
sensitivity is not due to differential enzyme expression. 
To further support our conclusions in Figure 14 that suggest the degree of sensitivity to 
statin therapy is denoted by post-atorvastatin treatment levels of cholesterol, we conducted Fillipin 
staining in the remaining 11 cell lines not shown in Figure 14 and present representative images 
for all 14 cell lines (Figure 21). These cell lines show identical behavior to those presented in 
Figure 14, namely that the atorvastatin sensitive cell lines exhibit the largest reduction in 
intracellular cholesterol, the partially sensitive cell lines show a partial reduction, and the resistant 
cell lines show no reduction. 
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Figure 21. Cholesterol content of atorvastatin treated NCI-60 cancer cell lines 
(A) atorvastatin-sensitive cell lines, (B) partially sensitive cell lines, and (C) atorvastatin-resistant cell lines. The 
cells were treated with 10μM atorvastatin and 1.25µM U18666A for 24 hours. The cells treated with 0.1% DMSO 
served as a control. Cholesterol was visualized by Filipin III staining. 
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To further confirm that atorvastatin reduces the cells’ cholesterol level through HMGCR 
inhibition, we measured the cholesterol content in the two most atorvastatin-sensitive cell lines 
(HOP-92 and PC-3) 24 hours after the atorvastatin treatment in the presence or absence of 
mevalonate supplementation. As expected, we found that the addition of mevalonate to the growth 
medium prevented the atorvastatin-induced depletion of cholesterol typically seen in atorvastatin 
sensitive cell lines (Figure 22). These data suggest that supplemented mevalonic acid is able to 
integrate into the mevalonate pathway (Figure 14) and overcome the lack of endogenous 
mevalonic acid that occurs with statin treatment. 
 
 
 
Figure 22. Cholesterol levels of atorvastatin treated cell lines in the presence of mevalonic acid 
HOP-92 (top row) and PC-3 cell lines (bottom row) were treated with 10µM atorvastatin in the presence or absence 
of 100µM mevalonic acid for 24 hours. U18666A was used for a cholesterol intercellular trafficking inhibitor. The 
cells treated with 0.1% DMSO served as a control. Cholesterol was visualized by Filipin III staining. 
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Figure 23. Cytoplasmic expressing E-cadherin PC-3 cells are atorvastatin sensitive 
(A, B) PC-3 low E-cadherin and (C, D) PC-3 high E-cadherin cells were stained for E-cadherin (green) and vimentin 
(red) expression, and counterstained with Hoechst 33342 (blue, nuclear). (E) Total E-cadherin and β-actin 
determination by western blot. (F) Atorvastatin IC50 curves for the PC-3 low and high E-cadherin cell lines. 
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To further characterize the role of E-cadherin in mediating statin resistance, we sought to 
determine whether higher E-cadherin expression that was not membrane localized would induce 
statin resistance. We found that membrane E-cadherin expression in MDA-MB-231 cells was 
sufficient to induce resistance to statins (Figure 17). To determine if non-membrane localized E-
cadherin could also cause atorvastatin resistance, we employed a PC-3 cell line variant that has 
higher levels of cytoplasmic E-cadherin expression (PC-3 High Ecad, Figure 23A-E). In contrast 
to the MDA-MB-231 Ecad cells, PC-3 High Ecad cells did not demonstrate an increased resistance 
to atorvastatin (Figure 23F).  
5.5 SUPPORTING DATA 
The following data are unpublished data that were collected in order to further confirm the findings 
of the previously discussed data that are published. While atorvastatin resistant cell lines have 
similar protein levels of HMGCR as atorvastatin sensitive cell lines (Figure 20), it is unknown 
whether atorvastatin treatment influences HMGCR protein levels. To determine whether resistant 
cell lines can compensate for statin treatment by upregulating HMGCR, statin resistant DU-145 
cells were treated with increasing doses of atorvastatin for 24 or 48 hours. We found that statin 
treatment at both of these time points did not change the protein levels of HMGCR, suggesting 
that upregulation of this enzyme is not a mechanism of resistance (Figure 24). 
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Figure 24. HMGCR expression does not change upon atorvastatin treatment 
HMGCR expression in DU-145 after (A) 24 hours or (B) 48 hours of atorvastatin treatment at the indicated 
concentrations. Total HMGCR protein was detected by western blot. (C) HMGCR bands were quantified using 
densitometry and normalized to GADPH and vehicle at both time points. 
 
 
We demonstrated that mevalonic acid supplementation was able to rescue atorvastatin-
mediated growth suppression in tumor cells and restore pre-treatment levels of intracellular 
cholesterol. To determine whether cholesterol supplementation would have the same rescue effect, 
statin sensitive PC-3 cells were treated with increasing doses of atorvastatin and supplemented 
with 1µM, 5µM, or 10µM cholesterol. In contrast to mevalonic acid, cholesterol supplementation 
was not able to rescue atorvastatin-mediated growth inhibition of PC-3 cells (Figure 25). If this 
were the case, a right-dose shift would be expected as was seen with E-cadherin membrane 
expression in MDA-MB-231 (Figure 17). 
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Figure 25. Cholesterol supplementation does not rescue atorvastatin efficacy 
PC-3 cells were treated with atorvastatin for 72 hours and supplemented with 1µM, 5µM, or 10µM cholesterol. Cell 
number was determined by crystal violet staining. 
 
 
To determine whether the inability of cholesterol to rescue atorvastatin treatment is due to 
its inability to be used by the cells, the cholesterol uptake was determined by using a green 
fluorescent cholesterol and quantifying fluorescent signal per cell. In all cell lines tested, 
atorvastatin decreased cholesterol uptake, except PC-3 which had very low basal levels of 
cholesterol uptake compared to the other cell lines (Figure 26). A cholesterol trafficking inhibitor 
U-18666A was able to increase cholesterol uptake in atorvastatin treated cells. Interestingly, these 
data are the opposite of what is observed in hepatocytes, namely that statin inhibition of HMGCR 
enhances cholesterol uptake due to upregulation of LDL-R571. However, as free cholesterol was 
used for this assay, it is possible that differential handling of LDL (receptor mediated) and free 
cholesterol (endocytic) can account for this discrepancy.  
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Figure 26. Cholesterol uptake in atorvastatin treated cells 
Cells were treated with vehicle (0.02% DMSO) or 10μM atorvastatin, supplemented with 20μg/mL NBD cholesterol 
for 24 hours. A cholesterol trafficking inhibitor, U-18666A, was used with vehicle at a concentration of 2.5μM as a 
positive control and vehicle without cholesterol was used as a negative control. Scale bar = 100μm.  
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The data shown in Figure 25 and Figure 26 suggest that depletion of products of the 
mevalonate pathway aside from cholesterol may be responsible for atorvastatin’s anti-tumor 
effects. For example, a mevalonate pathway-produced metabolite, geranylgeranyl pyrophosphate 
inhibits Rho GTPases, which activate transcription factors YAP and TAZ of the Hippo 
pathway694,918,919 (Figure 11). Moreover, farnesyl pyrophosphate is known to prenylate Ras, a key 
regulator of multiple downstream cascades such as PI3K-Akt-PKB and the MAPK pathway920. 
Therefore, statin inhibition of HMGCR may arrest cancer cell proliferation by inactivating 
downstream signaling proteins and transcription factors. 
5.6 CONCLUSIONS 
This study demonstrates the potential for statins to be used as anti-tumor agents due to their growth 
suppressive effects. Importantly, not all tumor cells are sensitive to statin treatment. The cells that 
exhibit sensitivity to statins show a reduction in intracellular cholesterol levels upon treatment, 
confirming that statin-mediated shutdown of the mevalonate pathway is critical to the observed 
effects. This was further confirmed by rescue studies that demonstrate the ability of mevalonate, 
but not cholesterol, to rescue statin-mediated growth suppression in sensitive cell lines. To 
demarcate statin sensitive from statin resistant cells, we found that membrane-localized E-cadherin 
was both a marker and mechanism for statin resistance, confirmed by the inability of increased 
cytoplasmic E-cadherin to contribute to statin response. In contrast, expression of the target 
enzyme and total E-cadherin levels were not found to be predictive of statin sensitivity. 
The most relevant component of this study to the overarching hypothesis of this project is 
the influence of E-cadherin on statin susceptibility. Upon metastatic seeding, cells undergo MErT 
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and re-express E-cadherin on the membrane45,748,914. Upon stimulation by the microenvironment, 
these cells can undergo a secondary EMT to outgrow as mesenchymal de-differentiated masses. 
As such, statin therapy should be the most effective against the metastatic cells primed to outgrow, 
as the epithelial micrometastases would be relatively more statin resistant. A selectivity for 
suppression of emergent cells may explain the clinical reduction in cancer-specific mortality seen 
in breast cancer patients taking statins. 
The next components of this thesis will focus on attempts to better characterize the growth 
suppressive effects of statins from a mechanistic perspective and identify alternative biomarkers 
that demarcate statin sensitive and resistant cells. Moreover, statins will be tested in sophisticated 
ex vivo and in vivo models of breast cancer metastasis to determine whether statins are indeed able 
to reduce the proliferation and outgrowth of these eventually mortal micrometastases. 
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6.0  LIPOPHILIC STATINS LIMIT CANCER CELL GROWTH AND SURVIVAL, 
VIA INVOLVEMENT OF AKT SIGNALING 
6.1 PROLOGUE 
The second piece of work contributing to this thesis was published in PloS One in May, 20184 . It 
is one of the two submitted first author publications that have resulted from my thesis work. The 
majority of this chapter is taken directly from that manuscript, and the corresponding reference 
can be found both at the beginning of this document and in the references section. Of note, the 
“Primary Data” section refers to a discussion of the data published in the body of the manuscript, 
and the “Supplemental Data” section refers to data published in the supplement of the manuscript. 
In this work, we investigated the growth suppressive effects of multiple statin drugs on a 
panel of cancer cell lines. We found that high affinity, lipophilic statins (atorvastatin and 
simvastatin) suppressed cancer growth with higher efficacy than the hydrophilic statins 
(rosuvastatin and pravastatin). When comparing atorvastatin to rosuvastatin, we find that the 
former is more effective at suppressing breast cancer proliferation and can even induce cell death 
in vitro. To examine the cellular response of breast cancer cells to atorvastatin, we determined the 
prenylation status of Ras, a critical signaling node for both the MAP kinase and PI3K-Akt 
pathways. We found that statin sensitive breast cancer cells showed a time-dependent decrease in 
Ras prenylation, which was not seen in statin resistant cells. Downstream of Ras, we found that 
the PI3K-Akt pathway was the primary pathway suppressed by atorvastatin. Moreover, combined 
use of a PI3K inhibitor with atorvastatin was able to potentiate atorvastatin efficacy. 
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These data are a significant foundation to this body of work for several reasons. First, this 
manuscript demonstrates the role of statin pharmacologic properties in guiding anti-tumor 
efficacy. Namely, the most effective statins have high binding affinity for the target enzyme, 
HMGCR, and are lipophilic. Second, we found that atorvastatin-mediated growth suppression is a 
result of both suppressing proliferation and reducing survival of cancer cells. Finally, these data 
show that statins suppress signaling through Ras and Akt, which contributes to their anti-tumor 
effects. As discussed in Chapter 1 above, these proteins play critical roles in breast cancer 
progression, metastasis, and emergence from dormancy. Since the overarching hypothesis of this 
thesis involves the ability of statins to target metastatic-emergent breast cancer to reduce 
recurrence and mortality, these data support this theory by suggesting statins can suppress 
emergence from dormancy by reducing signaling through Ras and Akt. 
6.2 MATERIALS AND METHODS 
Cell Sourcing and Cell Culture: All cell lines were sourced directly from the ATCC. Cell lines 
derived from the following tumor primary sites were employed: breast (MCF-7 and MDA-MB-
231), prostate (DU-145), brain (SF-295), and melanoma. DU-L and DU-H describe DU-145 cells, 
both directly sourced from the ATCC, with low and high levels of E-cadherin respectively, and 
are described more comprehensively in the following reference921. MCF-7 RFP, MDA-MB-231 
RFP, MDA-MB-231 RFP/Ecad, and DU-145 RFP were previously developed in our lab by stable 
transfection of RFP45. All cells were maintained in RPMI 1640, GlutaMax Supplement (Gibco, 
ThermoFisher Scientific) supplemented with 10% HI-FBS (Gemini Bioproducts) and 0.5% 
penicillin-streptomycin (Gibco, ThermoFisher Scientific), henceforth referred to as RPMI. Stably 
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transfected RFP or RFP/Ecad cells were maintained with additional supplementation of puromycin 
(Gibco, ThermoFisher Scientific) or G418 (Teknova) at the following concentrations: 1μg/mL 
puromycin (MCF-7 RFP), 5μg/mL puromycin (MDA-MB-231 RFP), 900μg/mL G418 (MDA-
MB-231 RFP/Ecad and DU-145 RFP). Antibiotic selection media was removed prior to beginning 
experiments. Primary human hepatocytes were obtained as isolates from excess pathology 
specimens at UPMC as part of an NIDDK-funded Liver Tissue and Cell Distribution System run 
by Dr. David Gellar and funded by NIH contract #HHSN276201200017C. Hepatocytes were 
isolated by collagenase perfusion for subsequent distribution to investigators. 
Chemicals: Atorvastatin (PHR-1422), rosuvastatin (SML-1264), pravastatin (P4498), and 
simvastatin (S6196) were all obtained from Sigma Aldrich, USA. Atorvastatin and rosuvastatin 
were dissolved in DMSO at a concentration of 50mM. DMSO was used for both statins to maintain 
carrier consistency between the two primary statins used for this work. Pravastatin was dissolved 
in sterile milli-Q water at a concentration of 50mM. Simvastatin lactone was dissolved in 200-
proof EtOH at a concentration of 50mM. Activated simvastatin was prepared by dissolving 
simvastatin lactone at a concentration of 50mg/mL in 200-proof EtOH. 1N NaOH was added to a 
final concentration of 450mN, and the solution was heated in a 50oC water bath for 2 hours. After 
heating, the solution was stored in aliquots and frozen. Prior to treatment, the pH was lowered to 
7.4 by adding 1N HCl. Human EGF (E9644, Sigma, USA) was reconstituted in 1% BSA in normal 
saline at a concentration of 1mM. PD98059 (S1177, SelleckChem, USA) was reconstituted in 
DMSO at a concentration of 20mM. LY294002 (S1105 ,SelleckChem, USA) was reconstituted in 
DMSO at a concentration of 10mM.  
Statin IC50 Determination: Cells were seeded in 24-well plates at a concentration of 5x104 
cells/mL in a volume of 500μL. The next morning, cells were treated with atorvastatin, 
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rosuvastatin, pravastatin, or simvastatin in half log doses between 100nM and 100μM. The vehicle 
control treatment used for each statin was 0.2% DMSO for atorvastatin and rosuvastatin, 0.2% 
EtOH for simvastatin, or complete media for pravastatin. For co-treatment with PD98059 or 
LY294002, statin solutions were prepared in solutions of the desired PD98059 or LY294002 
concentration. After 72 hours of treatment, treatment solutions were aspirated, and cells were fixed 
with 3.7% formaldehyde (F79-1, ThermoFisher Scientific) for 15 minutes. After fixation, cells 
were incubated with 0.5% w/v crystal violet for 10 minutes, and excess dye was removed by 
copious washing with tap water. The absorbed dye was released with 2% SDS, mixed thoroughly 
before transferring to a 96 well microplate, and read at 560nm using a Tecan SpectraFluor 
microplate reader (Tecan US, Durham, NC). IC50 values were determined by fitting a standard, 
four-parameter sigmoid curve to the data. All treatments were carried out in triplicate samples, and 
all data are representative of at least three independent experiments. 
Transfection: MDA-MB-231 RFP cells were seeded in 6-well plates at a concentration of 
1.5x105 cells/mL in a volume of 2mL. The next morning, cells were transfected in 2mL Optimem 
(Gibco, ThermoFisher Scientific) with 10μL/well of Lipofectamine RNAi-Max (ThermoFisher 
Scientific) and either 20nM non-coding (NC) siRNA (Silencer Select Negative Control No. 1 
siRNA, Cat # = 4390843, ThermoFisher Scientific) or 20nM HMGCR siRNA (Silencer Select 
siRNA, siRNA ID = 141, Cat# = 4392420, ThermoFisher Scientific). Four hours after transfection, 
media was changed to complete media for two hours to allow cells to recover. Cells were then 
seeded in 24-well plates, as per the “Statin IC50 Determination” protocol above, to determine the 
IC50 of the cells to atorvastatin, pravastatin, and doxorubicin (APP Pharmaceuticals LLC). 
Statin Proliferation Assay: MCF-7 RFP, MDA-MB-231 RFP, or MDA-MB-231 
RFP/Ecad cells were seeded in 12-well plates on heat-sterilized glass coverslips (Cat# 12-545-80, 
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ThermoFisher Scientific) at a concentration of 1.5x105 cells/mL in a volume of 1mL. The next 
morning, cells were treated with atorvastatin or rosuvastatin at doses of 1μM, 5μM, 20μM, or 
60μM for 48 hours. Cells treated with 0.12% DMSO served as the vehicle control. After 24 hours 
of treatment, concentrated EdU (ThermoFisher Scientific) was added to each well to a final 
concentration of 10μM. After 24 hours of EdU treatment (48 hours of statin treatment), treatment 
solutions were aspirated, and cells were fixed with 3.7% formaldehyde (F79-1, ThermoFisher 
Scientific) for 15 minutes and stained for EdU as described below. 
EdU Staining: Cells fixed on coverslips were permeabilized with 0.1% Triton-X-100 
(ThermoFisher Scientific) for 20 minutes and then washed once with 3% Bovine Serum Albumin 
(Sigma). Cells were stained for EdU using the Click-iT EdU Alexa Fluor 488 Imaging Kit 
(ThermoFisher Scientific), per the manufacturer’s instructions. After EdU staining, the cells were 
counter-stained with 2.5μg/mL DAPI for 15 minutes, washed three times in normal saline, and 
mounted using a glycerol and PVA based mounting medium, courtesy of the Center for Biological 
Imaging at the University of Pittsburgh. Coverslips were allowed to harden overnight prior to 
imaging. 
Statin Survival Assay: MCF-7 or MDA-MB-231 cells were seeded in 12-well plates at a 
concentration of 1.5x105 cells/mL in a volume of 1mL. The next morning, cells were treated with 
1μg/mL propidium iodide and either complete media (control), 1μM doxorubicin, or 5μM 
atorvastatin for 72 hours. Cells were imaged on an inverted microscope (Olympus, Model IX70) 
using a 10x objective to capture both phase contrast and red fluorescence images (561nm) 0, 24, 
48, and 72 hours after treatment. 
Cytoplasmic and Membrane Protein Extraction: Cells were harvested using 0.25% 
Trypsin (ThermoFisher Scientific) and quenching with RPMI. Cells were spun at 1000 RPM for 4 
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minutes and washed once with 1.5mL ice cold PBS with Calcium and Magnesium (Corning). Cells 
were respun at 1000 RPM for 4 minutes, and the supernatant was carefully aspirated. The cell 
pellet was resuspended in 50μL 0.2% w/v Saponin (Sigma) supplemented with 1:100 protease 
inhibitor cocktail V (CalBioChem) and incubated for 15 minutes on ice. After incubation, the 
membrane was pelleted by centrifuging at 13000g for 15 minutes at 4oC using a refrigerated 
microcentrifuge (Savant, SFR13K). The supernatant was carefully separated from the membrane 
pellet and labeled as the cytoplasmic protein fraction. The membrane pellet was washed twice with 
1.5mL of 0.2% saponin and the pellet was centrifuged after each wash by spinning at 13000g for 
15 minutes at 4oC. Extra washing steps of the membrane were performed to further purify the 
membrane tethered protein that remained after the initial saponin extraction of the cytoplasm. After 
the second wash, the membrane protein was eluted by adding ice cold 50μL RIPA buffer (50mM 
Tris-HCl, 150mM NaCl, 1mM EDTA, 0.1% SDS, 0.5% deoxycholate, 1% NP-40, pH 8.0) 
supplemented with 1:100 protease inhibitor cocktail V and incubating for 15 minutes on ice. After 
incubation, the samples were sonicated for 2 seconds (BioLogics Inc., Model 150 V/T) and 
centrifuged at 13000g for 10 minutes at 4oC. The supernatant was carefully separated from the 
pellet and labeled as the membrane protein fraction. 
Phospho-Protein Extraction: Cells were lysed using RIPA buffer supplemented with 
1:100 protease inhibitor cocktail V (CalBioChem, USA) and 1mM Na3VO4 and collected into 
Eppendorf tubes using a cell scraper. The samples were sonicated for 2 seconds and centrifuged at 
13000g for 10 minutes at 4oC. The supernatant was carefully separated from the pellet into a new 
tube for sample preparation. 
Active Ras Analysis: The Ras Activation Assay Kit (Cat# 17-218, Millipore Sigma, USA) 
was used to pull down Ras-GTP with agarose beads GST-tagged with the Raf-1 Ras binding 
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domain (Raf-1 RBD), per the manufacturer’s instructions. MDA-MB-231 RFP cells were treated 
with or without 1μM atorvastatin for 48 hours, and then cells were stimulated with 5nM EGF for 
5 minutes. Cells were lysed using the kit-provided lysis buffer, supplemented with 1:100 protease 
inhibitor cocktail V (CalBioChem, USA); the lysates were collected into Eppendorf tubes using a 
cell scraper. The samples were sonicated for 2 seconds and centrifuged at 13000g for 10 minutes 
at 4oC. The supernatant was carefully separated from the pellet into a new tube for sample 
preparation. The supernatants were incubated with Raf-1 RBD agarose beads for 45 minutes at 
4oC with continuous gentle mixing. After incubation, beads were pelleted at 14000g for 10 seconds 
and washed three times with lysis buffer. After the third washing step, beads were resuspended in 
loading buffer, boiled for 5 minutes, and processed per the “Western Blotting” protocol below, 
taking care to centrifuge agarose beads prior to sample loading. The ‘active’ form runs at a mobility 
slightly faster than the inactive form, which is also pulled down, though less efficiently. 
Western Blotting: Protein concentration was determined by the BCA Protein Assay Kit 
(Pierce, ThermoFisher Scientific). Samples were prepared and boiled for 5 minutes prior to 
loading. Proteins were separated on 9% or 15% Tris Bis-acrylamide gels prepared the same day at 
96V (E-C Apparatus Corp., EC-105) until adequate separation was achieved. Samples were 
transferred onto nitrocellulose membrane at room temperature at 300mA for 1.5 hours (E-C 
Apparatus Corp., EC135-90). After transferring, membranes were blocked in 5% w/v non-fat dry 
milk in tris buffered saline with 0.5% Tween-20 (TBS-T). Membranes were probed with primary 
antibodies in 5% w/v non-fat dry milk overnight at 4oC on a rotator. The primary antibodies used 
were anti-Pan Ras (1:1000, MA1-012X, ThermoFisher Scientific), anti-MHC-I (1:500, sc-55582, 
Santa Cruz Biotech), anti-GAPDH (1:20000, G9545, Sigma), anti-E-cadherin (1:1000, 3195S, 
Cell Signaling), anti-HMGCR (1:1000, ab174830, Abcam), anti-Pan Akt (1:1000, 4691S, Cell 
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Signaling), anti-Erk1/2 (1:2000, 4695S, Cell Signaling), anti-Phospho-Akt (1:1000, 4060S, Cell 
Signaling), and anti-phospho-Erk1/2 (1:2000, 4370S, Cell Signaling). After primary incubation, 
membranes were washed 3 times for 10 minutes each in TBS-T. Species-specific horseradish-
peroxidase conjugated secondary antibodies were applied at room temperature in 5% w/v non-fat 
dry milk for 1 hour. The two secondary antibodies used were anti-rabbit IgG (1:5000, Sigma, 
A9169) and anti-mouse IgG (1:5000, Sigma, A4416). After secondary incubation, membranes 
were washed 3 times for 10 minutes each in TBS-T. Membranes were incubated with ECL western 
blotting substrate (Pierce, ThermoFisher Scientific) and photo developed. Western blots were 
scanned at a resolution of 300 DPI and grayscale bit depth of 16. Bands were quantified using 
Image J software. 
Immunofluorescence Microscopy: Single field fluorescent images were taken using an 
Olympus BX40 upright microscope with a 10x objective and fluorescence excitation wavelengths 
of 405 (DAPI), 488 (Click-iT EdU), and 561 (RFP). Exposures were kept identical across 
coverslips for each individual experiment for consistency. Image analysis was performed in NIS 
Elements version 4.5. Nuclei (DAPI), and proliferating nuclei (EdU) channels were labeled using 
spot detection for bright, clustered spots. The same parameters were used for all images. Once 
individual channel masks were created, combined channel masks were generated by using the 
“having” command, which creates a new mask that illustrates all pixels of the first mask that 
contain at least one pixel of the second. This strategy was used to create a mask for DAPI + EdU 
(proliferating cell number). After generating all masks, data were measured and extracted for 
organization and presentation. 
Statistics: Statistics were conducted using GraphPad Prism 7 (Graphpad, USA). In all 
figures, the data are presented as the mean of three independent experiments conducted in triplicate 
  183 
with the error bars representing the standard error of the mean. Comparisons of individual columns 
in Figure 28, Figure 34, and Figure 36 were determined by use of a student’s two-tailed unequal 
variance t-test. Significance levels are reported in the figure legends and are kept consistent across 
all figures with symbols denoting * P < 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. 
6.3 PRIMARY DATA 
6.3.1 Statins suppress cancer cell growth differentially 
We previously demonstrated that atorvastatin could suppress the growth of many cancer cell lines2. 
We were curious whether other statins would show similar growth suppressive effects or whether 
growth suppression would be governed by the pharmacological properties of the specific statin. 
To compare to the lipophilic atorvastatin, we also tested rosuvastatin and pravastatin, both 
hydrophilic statins. While rosuvastatin shares a similar affinity for HMGCR as atorvastatin, 
pravastatin has approximately a 10-fold lower affinity for the enzyme (Figure 27H).  
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Figure 27. Lipophilic statins are more effective than hydrophilic statins 
Lipophilic atorvastatin is more effective at suppressing cancer cell growth than hydrophilic rosuvastatin or 
pravastatin. Dose response curves for (A) MCF-7 RFP, (B) MDA-MB-231 RFP, (C) MDA-MB-231 RFP/Ecad, (D) 
DU-145 RFP, (E) SF-295, and (F) MDA-MB-435 cancer cells when cultured with atorvastatin (red), rosuvastatin 
(green), or pravastatin (blue) for 72 hours. Cell number was determined by crystal violet staining. (G) Sigmoidal 
curves were fit to the dose response data, and IC50 values of atorvastatin and rosuvastatin in each cell line were 
extrapolated. (H) Pharmacologic parameters of atorvastatin, rosuvastatin, and pravastatin as found in the 
literature562,922. All data are representative of at least three independent experiments.  
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We found that atorvastatin was the most effective and pravastatin was the least effective at 
suppressing the growth of cancer cell lines, including breast (MCF-7 RFP, MDA-MB-231 RFP, 
and MDA-MB-231 RFP/Ecad, Figure 27A-C), prostate (DU-145, Figure 27D), brain (SF-295, 
Figure 27E), and melanoma (MDA-MB-435, Figure 27F). Rosuvastatin was 2.3- to 3.9-fold less 
potent than atorvastatin, even though the former has higher affinity for HMGCR (5.4nM vs. 
8.2nM)562. Additionally, pravastatin demonstrated no growth suppressive efficacy up to 
concentrations of 100μM, even in sensitive cell lines. These results suggest that lipophilic, high 
potency statins are the most effective at suppressing tumor cell growth.  
The inefficacy of pravastatin has been previously reported923 and is likely due to a 
combination of low affinity for HMGCR and hydrophilicity. Whereas lipophilic statins easily 
diffuse across the membrane, hydrophilic statins rely more on active transport. The four major 
statin transporters in the liver are SLCO1B1, 1B3, 1A2, 2B1592. While statin transport is handled 
by all of these carriers, the major part of atorvastatin handling is accomplished by SLCO1B1, 
which is why we focused on this transporter. Additionally, mutations in the SLCO1B1 gene are 
known to predispose to statin-induced myopathy924. Indeed, exogenous expression of SLCO1B1 
has been found to increase pravastatin uptake798. Unfortunately, we were unable to stably express 
SLCO1B1 transporters in our cells to demonstrate this causality. In sum, our data suggest that the 
low efficacy of both hydrophilic and low affinity statins is due to decreased HMGCR inhibition. 
This underscores the importance of the mevalonate pathway for cancer cell growth. 
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6.3.2 Atorvastatin more potently suppresses proliferation of breast cancer cells in vitro 
than rosuvastatin 
Since we observed atorvastatin was more effective at suppressing cell growth than rosuvastatin, 
we wanted to determine if this growth suppression was due to a decrease in cellular proliferation. 
Focusing on the breast cancer cell lines, we treated MCF-7 RFP, MDA-MB-231 RFP, or MDA-
MB-231 RFP/Ecad with atorvastatin for 48 hours, incorporating EdU (a DNA analog) in the last 
24 hours of treatment to quantify proliferation (Figure 28A). We observed a dose dependent 
decrease in the percentage of proliferating cells exposed to both atorvastatin and rosuvastatin in 
MCF-7 RFP (Figure 28B), MDA-MB-231 RFP (Figure 28C), and MDA-MB-231 RFP/Ecad 
(Figure  28D). Concurrent with our growth curve data, we found that atorvastatin was more 
effective at suppressing cell proliferation than rosuvastatin at the same treatment dosage.  
We previously and herein demonstrate a higher resistance of membrane E-cadherin 
expressing MDA-MB-231 cancer cells to atorvastatin than their E-cadherin negative counterpart. 
When we examined the percentage of cells that had proliferated after 24 hours in the absence of 
statin treatment, we observed that the E-cadherin expressing MDA-MB-231 cells were roughly 
50% less proliferative than the cells lacking E-cadherin (Figure 28, Figure 29). Moreover, similarly 
to the growth inhibition data, E-cadherin expressing MDA-MB-231 cells demonstrate less of a 
reduction in proliferating cells with statin treatment (Figure 29). 
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Figure 28. Atorvastatin decreases breast cancer cell proliferation more potently than rosuvastatin 
(A) Experimental schematic for assessing the proliferation of breast cancer cells under treatment with atorvastatin or 
rosuvastatin for 48 hours (B) MCF-7 RFP, (C) MDA-MB-231 RFP, and (D) MDA-MB-231 RFP/Ecad were 
cultured with atorvastatin or rosuvastatin for 48 hours; during the final 24 hours the media included 10uM EdU. 
Cells were fixed, EdU was detected, and cells were counterstained with DAPI to label all nuclei. Cellular 
proliferation was quantified by determining the percentage of EdU positive cells (green, all nuclei are blue - DAPI). 
All data are representative of at least three independent experiments.  * P < 0.05, ** P < 0.01, *** P < 0.001 
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Figure 29. E-cadherin increases resistance to atorvastatin-mediated proliferation suppression 
(A-D) MDA-MB-231 RFP and (E-H) MDA-MB-231 RFP/Ecad cells treated with (A,E) 0μM, (B,F) 1μM, (C,G) 
5μM, or (D,H) 20μM atorvastatin demonstrate both E-cadherin mediated growth suppression and atorvastatin 
resistance. Green = EdU, Blue = DAPI. Scale bar = 200µm. 
 
 
These findings demonstrate that statins exert direct effects on cancer cell proliferation. 
Other authors have reported direct induction of apoptosis and cell death in tumor cells after statin 
treatment, in cancer cell lines derived from breast925, lung926, and prostate927 as well as decreases 
in cell number or viability537. In contrast,  there are only a few reports of statins reducing 
proliferation of cancer cells by directly quantifying cycling cells928. The majority of studies in the 
literature use methods that do not distinguish between cell viability and growth, such as MTT and 
ATP based assays. We show a decrease in proliferating percentage of adherent breast cancer cells 
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(those that have survived the anti-survival effects of statin therapy), which demonstrates direct 
effects on cell proliferation (Figure 28). 
6.3.3 Atorvastatin treatment induces cellular death in statin sensitive MDA-MB-231 cells 
but not statin resistant MCF-7 cells 
Given the anti-proliferative effects we observed of atorvastatin on breast cancer cells, we next 
wanted to determine whether atorvastatin also impacts individual cell survival. We treated statin 
sensitive MDA-MB-231 cells and statin resistant MCF-7 cells with 5μM atorvastatin for 72 hours 
and assayed cell death by including propidium iodide in the culture medium. We took phase 
contrast and fluorescent images every 24 hours to assess for cellular uptake of propidium iodide.  
We found that atorvastatin reduced the survival of MDA-MB-231 cells, starting 24 hours 
after treatment (Figure 29A-H). In contrast, the survival of MCF-7 cells was unaffected by 
atorvastatin, even at 72 hours of treatment (Figure 29M-T). The survival of both cell lines was 
decreased with 1μM of doxorubicin (Figure 29I-L, U-X).  
These data suggest that cell viability is reduced with atorvastatin treatment in cell lines that 
are susceptible to its growth inhibitory (Figure 27) and anti-proliferative (Figure 28) effects. 
Importantly, these data are an independent finding from the proliferative data shown in Figure 28, 
as the latter were normalized to the total adherent cell number, which omits dead cells. As such, 
statins likely suppress tumor cell growth by two main mechanisms: 1) they decrease tumor cell 
proliferation (Figure 28), and 2) they decrease tumor cell survival (Figure 30).  
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Figure 30. Atorvastatin decreases survival of sensitive but not resistant breast cancer cells 
(A-L) MDA-MB-231 or (M-X) MCF-7 breast cancer cells were treated with (A-D and M-P) 0.01% DMSO (untx), 
(E-H and Q-T) 5μM atorvastatin (5uM Atorv), or (I-L and U-X) 1μM Doxorubicin (1uM Doxo) for (left) 0 hours, 
(middle-left) 24 hours, (middle-right) 48 hours, or (right) 72 hours in the presence of 1μg/mL propidium iodide. 
Cells were imaged using an inverted microscope to detect propidium iodide (red) and to look at cell morphology and 
density using phase contrast microscopy. Scale bar = 200μm. All data are representative of at least three independent 
experiments. 
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6.3.4 Atorvastatin treatment decreases the proportion of membrane-tethered Ras in 
statin sensitive cells 
To ascertain the mechanism by which atorvastatin treatment decreases both proliferation and 
survival, we queried whether a product of HMG-CoA reductase, which can be rescued by 
mevalonate bypassing the blockade of HMG-CoA reductase, was involved. These products are 
involved with protein lipidation to redirect otherwise soluble proteins to the cellular membranes. 
Thus, we investigated effects on the canonical intermediary pathways that contribute to both 
proliferation and survival in cancer cells, those thru MEK-Erk and PI3-kinase-Akt. Both of these 
can be activated downstream of Ras signaling, and Ras activation requires juxtamembrane 
positioning accomplished by protein prenylation.  
As such, we investigated Ras prenylation in statin sensitive MDA-MB-231 RFP, and statin 
resistant MCF-7 RFP cells when treated with 1μM atorvastatin to determine if there is altered Ras 
signaling or downstream elements. We observe that statin sensitive MDA-MB-231 RFP cells show 
a 50-fold increase in cytoplasmic Ras and a 50% decrease in membrane-bound Ras over 48 hours 
of treatment (Figure 31A-C). This is consistent with most of Ras being membrane-associated and 
statins not completely eliminating the production of geranyl-geranylphosphate. In contrast, Ras 
localization is unchanged with atorvastatin treatment in statin resistant MCF-7 RFP cells (Figure 
32A-C). These data suggest that atorvastatin treatment in statin sensitive cells decreases the 
proportion of signaling competent Ras. 
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Figure 31. Atorvastatin decreases membrane-bound Ras in statin sensitive MDA-MB-231 
MDA-MB-231 RFP cells were treated with atorvastatin for 0, 1, 2, 4, 8, 24, or 48 hours, and protein was collected in 
cytoplasmic and membrane fractions. (A,B) Cytoplasmic Ras increased in statin treated MDA-MB-231 RFP cells 
over the course of 48 hours whereas (A,C) membrane Ras decreased. All data are representative of at least three 
independent experiments. 
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Figure 32. Atorvastatin does not affect membrane-bound Ras in statin resistant MCF-7 
MCF-7 RFP cells were treated with atorvastatin for 0, 1, 2, 4, 8, 24, or 48 hours, and protein was collected in 
cytoplasmic and membrane fractions. (A,B) Cytoplasmic and (A,C) membrane Ras were unchanged by atorvastatin 
treatment in MCF-7 RFP cells. All data are representative of at least three independent experiments. 
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It has been postulated that part of the anti-tumor effect of statins is caused by reduction in 
the prenylation, and thus localization, of signaling proteins such as Ras and the Rho family of 
proteins560. Decreases in membrane anchoring of H-Ras have been shown in breast cancer cells 
treated with statins741. Above, we demonstrate that the localization of Ras is dependent on the 
statin sensitivity of the cells undergoing treatment. While the statin sensitive MDA-MB-231 RFP 
cells demonstrate a shift from membrane to cytoplasmic Ras localization over the course of 48 
hours of statin treatment, the same increases are not seen in statin resistant MCF-7 RFP cells 
(Figure 31, Figure 32). Thus, the influence of statins on the prenylation status of Ras, which affects 
its subcellular localization, correlates with the sensitivity of the cells to statin-mediated growth 
suppression. 
6.3.5 Atorvastatin treatment blunts EGF-stimulated phosphorylation of Erk and Akt in a 
sensitivity-dependent manner 
EGF is a growth factor that signals proliferation and migration in breast cancer and is present as 
an autocrine stimulatory factor in most all aggressive mammary carcinomas. Our lab has 
previously shown that EGF stimulation of dormant breast cancer cells can drive outgrowth from 
dormancy in an ex vivo microphysiological system model for breast cancer metastasis to the liver 
751,832,898. Given the importance of EGF in promoting breast cancer growth and metastasis, we 
wanted to determine whether atorvastatin pre-treatment could influence the phosphorylation of 
Akt and Erk in breast cancer cells. We pre-treated MCF-7 RFP, MDA-MB-231 RFP, or MDA-
MB-231 RFP/Ecad with 5μM atorvastatin for 24 hours. We then stimulated cells with 5nM EGF 
for either 5 or 30 minutes. We found that atorvastatin pre-treatment was able to blunt EGF-
mediated increases in Akt phosphorylation in all three cell lines and Erk-mediated phosphorylation 
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in MDA-MB-231 RFP/Ecad and MCF-7 RFP cell lines (Fig. 5 A-C). MDA-MB-231 RFP has high 
levels of tonic Erk phosphorylation due to autocrine EGF signaling45.  
Next, we quantified the blunted EGF response by comparing the vehicle pre-treatment to 
atorvastatin pre-treatment at each time point for EGF stimulation. With no EGF stimulation, we 
found that atorvastatin decreased the basal phosphorylation of Akt in statin sensitive MDA-MB-
231 RFP cells but not in the more resistant MDA-MB-231 RFP/Ecad or MCF-7 RFP cells. With 
5 or 30 minutes of EGF stimulation, we observed that the degree to which atorvastatin pre-
treatment decreased EGF-stimulated Akt phosphorylation directly correlated with the sensitivity 
of these cell lines to atorvastatin-mediated growth inhibition (Figure 27, Figure 33D). These data 
suggest that the susceptibility to statin-mediated growth inhibition involves inhibition of Akt 
signaling and are consistent with the decrement in Ras localization to the membrane. 
As stated previously, micrometastases often remain in a state of dormancy for years or 
decades before emerging as clinically evident metastases. Our lab has previously demonstrated 
that dormant micrometastases can be stimulated to outgrowth in an ex vivo microphysiological 
system model for breast cancer metastasis to the liver by using a combined stimulus of EGF and 
LPS832. To determine whether atorvastatin would influence the EGF responsiveness of our breast 
cancer cell lines, we treated MCF-7 RFP, MDA-MB-231 RFP, and MDA-MB-231 RFP/Ecad with 
atorvastatin for 24 hours and then stimulated with 5nM EGF for 5 or 30 minutes. We found that 
all three cell lines demonstrated increases in Akt and Erk phosphorylation with EGF stimulation 
and that atorvastatin pretreatment could block these increases in a manner that correlated with their 
sensitivity to atorvastatin-mediated growth inhibition (Figure 33). The decrease in Akt 
phosphorylation seen after 30 minutes of EGF treatment is most likely secondary to receptor 
internalization and degradation due to the high abundance of soluble ligands929,930.  
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Figure 33. Atorvastatin sensitivity correlates with blunted Akt phosphorylation in response to EGF 
(A) MDA-MB-231 RFP, (B) MDA-MB-231 RFP/Ecad, and (C) MCF-7 RFP cells were treated with 5μM 
atorvastatin for 24 hours and then stimulated with 5nM EGF for 5 or 30 minutes. (D) Akt phosphorylation fold 
change, defined as the density of pAkt under atorvastatin pretreatment divided by the density of pAkt under vehicle 
treatment, was quantified for 0, 5, or 30 minutes of 5nM EGF stimulation. All data are representative of at least 
three independent experiments.  
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These data suggest that atorvastatin may decrease growth-factor stimulated growth of 
breast cancer cells. Moreover, the E-cadherin mediated resistance to atorvastatin suppression of 
Akt stimulation by EGF suggests that epithelial micrometastases that undergo a secondary EMT 
and outgrow will be more selectively suppressed by statin treatment than those that remain in 
dormancy. As atorvastatin effects are most noted when E-cadherin is absent from the plasma 
membrane2, the cells that are epithelial and dormant as micrometastases would likely be relatively 
unaffected. However, when these cancer cells undergo a secondary EMT that limits E-cadherin 
presentation during metastatic outgrowth, they would then be susceptible to statin suppression. 
6.3.6 Inhibition of Akt but not Erk signaling is synergistic with atorvastatin-mediated 
growth suppression 
To explore what may potentiate the anti-proliferative effects of atorvastatin, we investigated the 
two effected pathways: the PI3K-Akt and MAP kinase signaling networks, as both are downstream 
from Ras signaling and at least partially inhibited by statins. It has previously been shown that 
both pathways play important roles in breast cancer cell growth and migration200,237. To probe 
these signaling pathways, we employed a pan-PI3K inhibitor (LY294002) and a Mek1/2 inhibitor 
(PD98059), which inhibit their phosphorylation of Akt and Erk1/2 respectively. As crosstalk 
between these two pathways has been previously reported, we first determined the effect of each 
inhibitor on the opposing pathway.  
To probe the effects of these two inhibitors on influencing the susceptibility of breast 
cancer cells to atorvastatin, we co-treated MCF-7 RFP, MDA-MB-231 RFP, or MDA-MB-231 
RFP/Ecad with atorvastatin and either PD98059 or LY294002 for 72 hours. With PD98059 and 
atorvastatin co-treatment, we observed no change in the atorvastatin IC50 to cell growth inhibition 
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(Figure 34A-D). Additionally, we observed an increase in Erk phosphorylation with 5μM 
atorvastatin treatment in statin sensitive MDA-MB-231 RFP cells at each dose of PD98059 used 
(Figure 34E,F). In contrast, we observed a dose-dependent potentiation of atorvastatin with 
LY294002 co-treatment (Figure 34G-J). When probing Akt phosphorylation after atorvastatin 
treatment, we found that 5μM atorvastatin significantly decreased basal Akt phosphorylation in 
statin sensitive MDA-MB-231 RFP cells, which was further decreased with LY294002 treatment 
(Figure 34K,L).  
When inhibiting two of the main downstream pathways of Ras, we found that reduction of 
Akt signaling through PI3K inhibition significantly potentiated the growth suppression of 
atorvastatin, whereas reduction of Erk signaling through Mek1/2 inhibition did not affect 
atorvastatin efficacy (Figure 34). Western blotting demonstrated a significant reduction of Akt 
phosphorylation in atorvastatin treated MDA-MB-231 RFP cells, whereas Erk phosphorylation 
was increased with atorvastatin treatment (Figure 34). Previous studies have demonstrated 
crosstalk between the PI3K-Akt and MAPK signaling pathways at the level of Akt and Raf931. 
These findings suggest that the reduction in Akt phosphorylation observed with statin treatment 
may be the source of the increase in Erk phosphorylation. Others have demonstrated decreases in 
Akt phosphorylation with statin treatment in prostate689 and breast541 cancer cell lines. 
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Figure 34. Inhibition of Akt but not Erk signaling is synergistic with atorvastatin 
(A,G) MCF-7 RFP, (B,H) MDA-MB-231 RFP, and (C,I) MDA-MB-231 RFP/Ecad cells were cultured with 
atorvastatin and either (A-C) 0μM, 3μM, or 10μM PD98059 or (G-I) 0μM, 3μM, or 10μM LY294002 for 72 hours. 
(D,J) IC50 values for atorvastatin susceptibility were extrapolated from sigmoid curve fits of the dose response data. 
MDA-MB-231 RFP cells were treated with (E,F) 0μM, 3μM, or 10μM PD98059 or (K,L) 0μM, 3μM, or 10μM 
LY294002 with or without 5μM atorvastatin for 24 hours and (E,K) probed by western blot and (F,L) quantified by 
densitometry. * P < 0.05, *** P < 0.001, and **** P < 0.0001. All data are representative of at least three 
independent experiments. 
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6.4 SUPPLEMENTAL DATA 
In order to test another lipophilic statin, we examined the ability of simvastatin to suppress growth 
of breast cancer cells. The lipophilicity and affinity of simvastatin and atorvastatin are comparable 
(Table 14, Table 15). We found that simvastatin demonstrated comparable efficacy to atorvastatin 
in MCF-7 RFP and MDA-MB-231 RFP cells (Figure 35A,B). Activation of simvastatin by 
conversion from its lactone form into its acid form did not alter its growth suppressive efficacy 
(Figure 35C,D), which suggests simvastatin lactone can be hydrolyzed in culture media. These 
data further emphasize the importance of lipophilicity in determining statin efficacy. 
To confirm the growth suppressive effects of statins are due to its known mechanism of 
action (inhibition of HMGCR), we reduced HMGCR levels using siRNA transfection (Figure 36). 
We found that a knockdown of 50% at the protein level (Figure 36H,I) in MDA-MB-231 breast 
cancer cells was sufficient to suppress cell growth (Figure 36A-C) and also potentiated the efficacy 
of both atorvastatin and pravastatin by over an order of magnitude (Figure 36D,F,G). In contrast, 
sensitivity to doxorubicin, a chemotherapeutic used in the clinical management of breast cancer, 
was unchanged with HMGCR knockdown (Figure 36E,G).  
 The HMGCR siRNA data presented in Figure 36 are significant for three reasons. First, 
knockdown of HMGCR alone was sufficient to reduce cell growth by approximately 20%. Since 
the IC50 of atorvastatin in MDA-MB-231 RFP cells is approximately 2µM, the atorvastatin 
equivalent dose for a growth reduction of 20% would be approximately 800nM. Second, 
pravastatin, which previously demonstrated no efficacy up to concentrations of 100µM, was 
dramatically potentiated by knockdown of HMGCR (Figure 27, Figure 36). Finally, knockdown 
of HMGCR did not potentiate pravastatin by intrinsically reducing cell viability, as the potency of 
doxorubicin was unaffected by transfection. 
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Figure 35. Simvastatin exhibits similar growth suppressive potency as atorvastatin 
(A) MCF-7 RFP and (B) MDA-MB-231 RFP cells were cultured with atorvastatin or simvastatin for 72 hours, and 
cell number was determined by crystal violet staining. (C) MCF-7 RFP and (D) MDA-MB-231 RFP cells were 
cultured with simvastatin lactone (un-activated) or simvastatin acid (activated) for 72 hours, and cell number was 
determined by crystal violet staining. All data are representative of at least three independent experiments. 
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Figure 36. HMGCR knockdown decreases cell growth and potentiates statin therapy 
HMGCR was knocked down by siRNA treatment in MDA-MB-231 cells, and cells were subsequently treated with 
(A,D) atorvastatin, (B,E) doxorubicin, or (C,F) pravastatin for 72 hours. Data were normalized to the (A-C) non-
coding RNA control and then further normalized to the (D-F) lowest dose of drug used. (G) IC50 values for 
atorvastatin (Atorv), doxorubicin (Dox), and pravastatin (Prav) were calculated based on sigmoid curve fits to the 
dose response data. (H) HMGCR immunoblotting 24, 48, and 72 hours after siRNA knockdown with (I) 
quantification by densitometry. * P < 0.05. All data are representative of at least three independent experiments. 
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Figure 37. Ras localization in atorvastatin treated MDA-MB-231 RFP cells 
MDA-MB-231 RFP cells were treated with 1μM atorvastatin for 0, 24, 48, or 72 hours, and protein was collected in 
cytoplasmic and membrane fractions and (A) probed by western blot. (B) Cytoplasmic Ras and (C) membrane Ras 
were quantified by densitometry. All data are representative of at least three independent experiments. 
 
 
 In order to determine the localization of Ras after atorvastatin treatment at a time point 
later than 48 hours, we carried out statin treatment to 72 hours. After prolonged statin treatment, 
we see degradation of cytoplasmic Ras (Figure 37A,B), as has been previously reported in the 
literature932. Moreover, we observe a continued reduction of membrane-bound Ras between the 48 
and 72 hour time points (Figure 37A,C). These data suggest that prolonged treatment with 
atorvastatin results in the release of Ras from the membrane into the cytoplasm, where it is 
gradually degraded. 
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Figure 38. Atorvastatin pre-treatment reduces EGF-stimulated Ras activation 
MDA-MB-231 RFP cells were treated with or without 1μM atorvastatin for 48 hours, and then cells were stimulated 
with 5nM EGF for 5 minutes. Activated Ras (Ras-GTP) was isolated from cell lysates, (A,B) probed by western 
blot, and (C) quantified by densitometry of the faster mobility fraction, indicated by the arrow. Atorv = Atorvastatin, 
NT = No treatment, A = 1uM Atorvastatin for 48 hours, EGF = 5nM EGF for 5 minutes. Error bars represent the 
SEM. * P < 0.05. All data are representative of at least three independent experiments. 
 
 
 While membrane localization of Ras has been previously shown to be correlated with 
activity195, we assessed Ras activity after atorvastatin treatment directly by determining its binding 
affinity to its downstream partner Raf-1. After 48 hours of atorvastatin treatment, the ability of 
EGF to activate Ras was reduced by approximately 80% (Figure 38). In comparison, after 48 hours 
of atorvastatin treatment, the membrane fraction of Ras is reduced by approximately 50% (Figure 
37). These data suggest that the membrane localization of Ras is directly linked to its activity. 
Moreover, atorvastatin can directly reduce EGF-mediated activation of Ras. 
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Finally, to further investigate crosstalk between the MAP Kinase and PI3K-Akt pathways, 
we determined the phosphorylation of Erk and Akt after treatment with the PI3K inhibitor 
LY294002 or the Mek1/2 inhibitor PD98059, respectively. While the PI3K inhibitor increased Erk 
phosphorylation in a dose-dependent manner, we saw no effect of the Mek1/2 inhibitor on Akt 
phosphorylation (Figure 39). 
 
 
 
Figure 39. PI3K inhibition enhances Erk phosphorylation  
MDA-MB-231 RFP cells were treated with or without 5μM atorvastatin supplemented with (A) 0μM, 3μM, or 
10μM LY294002, an inhibitor of PI3 kinase or (B) 0μM, 3μM, or 10μM PD98059, an inhibitor of MEK for 24 
hours. (A) pErk and total Erk or (B) pAkt and total Akt were probed by western blot. Importantly, the distinction 
being made is with increasing doses of either LY294002 or PD98059 (comparing lanes 1, 3, and 5). The effect of 
atorvastatin treatment (comparing lanes 1 & 2, 3 & 4, and 5 & 6) on Akt and Erk phosphorylation is the same as 
shown in Figure 6. All data are representative of at least three independent experiments. 
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6.5 CONCLUSIONS 
This study adds to the previous study by examining the pharmacologic properties of statins that 
guide efficacy and the signaling pathways and cellular responses that result in the growth 
suppressive efficacy of statins. Importantly, not all statins are equally effective, with high affinity 
and lipophilic statins demonstrating the highest anti-tumor efficacy. Statins suppress cancer 
growth bi-directionally: by decreasing proliferation and by reducing cell survival. In part, statin 
efficacy is due to a reduction in prenylation and hence membrane localization of Ras, a critical 
node for signaling through downstream pathways to affect cell proliferation and survival. 
Specifically, statin treatment reduces signaling through the PI3K – Akt pathway, and further 
inhibition of this signaling pathway can potentiate statin efficacy. In contrast, we found that Erk 
activity was increased with atorvastatin treatment, suggesting crosstalk between these two 
signaling pathways. 
The most relevant components of this study to the overarching hypothesis of this project 
are twofold. First, the differing potencies of statin drugs have important clinical implications. Our 
data suggest lipophilic statins may be more effective at suppressing micrometastatic outgrowth 
because they have increased uptake into cancer cells. For cancer patients already receiving statins 
for other conditions, such as hypercholesterolemia, changing to a more potent anti-cancer statin, 
such as atorvastatin, may provide a mortality benefit without adversely affecting their primary 
indication for statin therapy. Second, this study demonstrates that atorvastatin can reduce signaling 
through the Ras – PI3K – Akt signaling pathway. Previous studies in breast cancer have shown 
that Akt can regulate E-cadherin expression and induce EMT228,933. Since statins can reduce Akt 
activity, this finding suggests statins may reduce Akt-mediated EMT of breast cancer cells. 
Moreover, since E-cadherin directly provides survival signaling through the PI3K-Akt 
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pathway914,934, statin therapy, while itself less effective in E-cadherin expressing cells2, may 
partially reduce these survival signals and sensitize cells to other anti-tumor therapies. 
The next section of this thesis will focus on attempts to identify alternative biomarkers that 
demarcate statin sensitive and resistant cells. The final experimental section of this thesis will test 
atorvastatin in sophisticated ex vivo and in vivo models of breast cancer metastasis to determine 
whether statins are indeed able to reduce the proliferation and outgrowth of these eventually mortal 
micrometastases. 
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7.0  BIOMARKER IDENTIFICATION FOR STATIN SENSITIVITY OF CANCER 
CELL LINES 
7.1 PROLOGUE 
This piece of work contributing to this thesis was published in Biomedical and Biophysical 
Research Communications at the start of 20183, which resulted from work I did with a graduate 
student in Dr. Benos’s lab at the University of Pittsburgh. The majority of this chapter is previously 
published in that manuscript, and the corresponding reference can be found both at the beginning 
of this document and in the references section. Of note, the “Primary Data” section refers to a 
discussion of the data published in the body of the manuscript and the “Supplemental Data” refers 
to data published in the supplement of the manuscript. 
In our previous work, we demonstrated that not all cancer cell lines are susceptible to statin-
mediated growth suppression2. As such, a genetic signature of statin sensitivity would enable 
researchers and clinicians to focus on predicted sensitive and resistant cell lines, tissues, and 
patients for further mechanistic and clinical studies. Moreover, those predictions would identify 
candidate biomarkers and genes that play a role in tumor susceptibility or resistance to statins. 
Finally, this model may suggest a role for statins in anticancer therapy for patients with predicted 
statin-sensitive tumors.  
In this work, we utilized transcriptome data from fourteen NCI-60 cancer cell lines and 
their sensitivity data to two statin drugs to produce a genetic signature identifying statin sensitive 
cells. We enriched these data with publicly available gene expression data from the National 
Cancer Institute (NCI-60) and the Cancer Cell Line Encyclopedia (CCLE), and with biomarker 
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discovery algorithms that can distinguish direct from indirect interactions in large datasets. We 
experimentally confirmed the validity of the identified biomarker signature in an independent set 
of cell lines, showed that a subset of TCGA tumors are predicted to display statin sensitivity, and 
demonstrated the biological viability of the predicted signature.  
These data contribute significantly to this body of work for a couple reasons. First, this 
study demonstrates that statin susceptibility data can be converted into a biomarker signature 
which can successfully predict the sensitivity of novel cell lines. This is clinically relevant as 
biomarker signature data could be matched to that of the primary tumor to determine whether a 
patient may benefit from adjuvant statin therapy after primary resection. Finally, the combined 
bioinformatics-experimental approach described here can be used to generate biomarker 
sensitivity signatures for anticancer therapies and generate hypotheses of mechanism of action of 
drug sensitivity and resistance. In summary, this work takes the first steps towards identifying 
tumors that may benefit the most from statin therapy. 
7.2 MATERIALS AND METHODS 
Cell culture, statin treatment and cell proliferation assay. We selected seven pairs of cell lines 
from the NCI-60 cancer cell panel. These cell lines represent seven different major solid tumor 
types. For each site, we selected one cell line with low and one with high protein synthesis rate, as 
previously reported2. The selected cell lines - colon cancer (HCT-116, KM-12), ovarian cancer 
(IGROV1, OVCAR3), breast cancer (HS-578T, T47D), lung cancer (HOP-92, NCI-H322M), 
prostate cancer (PC-3, DU-145), melanoma (SK-MEL-5, MDA-MB-435), and brain cancer (SF-
295, SF-539) - were cultured in RPMI 1640 medium (Life Technologies, Grand Island, NY), 
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supplemented with 10% heat-inactivated fetal bovine serum (HI-FBS, Life Technologies) and 
0.5% penicillin/streptomycin (Life Technologies) at 37°C with 5% CO2. Atorvastatin (Sigma-
Aldrich, St. Louis, MO) and Rosuvastatin (Santa Cruz Biotechnology, Santa Cruz, CA) were 
dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich; final concentration of 0.1% in RPMI 
1640 medium) at a final concentration of 10 µM. The cells were seeded in 6-well plates at a density 
of 1×105 cells/ml and incubated overnight prior to treatment with 10 µM Atorvastatin, 10 µM 
Rosuvastatin, or 0.1% DMSO (DMSO served as solvent control). Three independent experiments 
were performed. Cell proliferation was quantified at 2, 4, and 6 days by direct cell counting with 
ScepterTM Handheld Automated Cell Counter (EMD Millipore, Billerica, MA) using ScepterTM 
Tips‒60 µm sensor (EMD Millipore).  
IC50 determination. Predicted statin-resistant (BT-474 and NCI-H2170) and sensitive 
(SK-MES-1 and SK-MEL-24) cell lines were cultured as above, and seeded in 24-well plates at a 
concentration of 0.5×105 cells/mL (500µL per well). The next day, cells were treated with 0.1 µM, 
0.3 µM, 1 µM, 3 µM, 10 µM, 30 µM, and 100 µM atorvastatin (Sigma). Cells treated with 0.2% 
DMSO (the concentration of DMSO in the 100 µM atorvastatin treatment condition) served as the 
control. Three days after treatment, the cells were washed with PBS and fixed in 3.7% 
formaldehyde (F79-1, ThermoFisher Scientific) for 15 minutes. Next, the cells were stained with 
0.5% w/v crystal violet (Sigma-Aldrich) for 10 minutes. Excess dye was washed extensively with 
tap water. The absorbed dye was released with 2% SDS. The supernatants were mixed thoroughly 
before transfer to a 96-well plate to be read at 560 nm using a Tecan SpectraFluor microplate 
reader (Tecan US, Durham, NC). IC50 values were determined by fitting a standard, four-
parameter sigmoid curve to the data. All treatments were carried out in triplicate samples and data 
are representative of three independent experiments. 
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Immunofluorescence microscopy. Cultured BT-474, NCI-H2170, SK-MES-1 and SK-
MEL-24 cells grown on coverslips in a 12-well plate were fixed with 3.7% formaldehyde (F79-1, 
ThermoFisher Scientific) for 15 min, and then permeabilized with 0.1% Triton-X-100 (Fisher 
Scientific, Pittsburgh, PA) made in PBS for 20 min. Next, non-specific proteins were blocked in 
3% BSA for 45 min at RT. The cells were incubated with a monoclonal mouse antibody to human 
E-cadherin (1:500, 13-5700, Invitrogen) in a humidified container overnight at 4°C. After 
overnight incubation, coverslips were washed three times with 0.5% BSA for 5 minutes each and 
then were probed with an Alexa Fluor 488 goat anti-mouse IgG (1:200, Fisher Scientific) in the 
dark for 1 hour at RT. Following one 5-minute wash with 0.5% BSA, nuclei were stained with 
DAPI (1 μg/ml) in PBS for 15 min at RT, washed three times with PBS, and mounted in an 
aqueous-based mounting medium (gelvatol, recipe courtesy of U-Pitt Center for Biological 
Imaging). Images were captured with the 60X oil objective lens on an Olympus BX40 fluorescence 
microscope (Olympus Optical).  
Computational Models. Mixed Graphical Models [1] (MGM) is a new method to learn 
the direct associations in a dataset con-sisting of both categorical and continuous data. MGM 
characterizes the joint distribution of the categorical and continuous variables under the 
assumptions of linear Gaussian continuous variables and multinomial categorical variables. To 
prevent overfitting a sparsity penalty, λ, is employed. In accordance with Sedgwick et al. [2], we 
utilize separate sparsity penalties for each type, and the MGM method is used without modification 
from this work. A common problem with using probabilistic graphical models for biomarker 
identification in highly structured data, like gene expression, is strong correlations between 
variables (genes). These correlations result in a lack of stability of the biomarkers as small changes 
in the data can result in changes amongst the selected biomarkers; and multiplicity of the predictive 
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signatures, since multiple signatures that each contains highly correlated features, can be equally 
predictive. To mitigate this problem, we developed the Tree-Guided Recursive Cluster Selection 
(T-ReCS) procedure [3], which performs feature selection at the cluster level, on clusters that are 
generated dynamically during the feature selection process. We refer the reader to [3] for full 
details of the T-ReCS algorithm. 
7.3 PRIMARY DATA 
7.3.1 Biomarker identification for statin sensitivity using statin growth inhibition data 
Previous experiments have demonstrated that statins, including atorvastatin (Lipitor), inhibit the 
growth of a subset of NCI-60 cancer cell lines, and that a subset of statins show similar half-
maximal inhibitory concentration (IC50) values908. To test if the chemical properties of statins 
affect their inhibition of tumor cells, we cultured fourteen cancer cell lines from the NCI-60 
collection, derived from seven organ types, in standard growth medium in the presence of a 
lipophilic (10 µM atorvastatin) or hydrophilic (10 µM rosuvastatin) statin. Importantly, in enzyme 
assays these statins have similar affinities for their enzyme target, HMG-CoA reductase 
(HMGCR), with IC50 values of 8.2nM and 5.4nM for atorvastatin and rosuvastatin, 
respectively562. We previously demonstrated that atorvastatin affected the growth of these cancer 
cell lines differentially; some cell lines displayed full or partial growth inhibition while others were 
completely insensitive to atorvastatin treatment2. In the current study, we have found that all the 
atorvastatin sensitive cell lines except HOP-92 are partially or fully resistant to rosuvastatin at the 
tested drug concentrations (Figure 40). 
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Figure 40. Growth rate of atorvastatin and rosuvastatin treated NCI-60 cancer cell lines 
Colon cancer (A. HCT-116 and B. KM-12), ovarian cancer (C. IGROV1 and D. OVCAR3), breast cancer (E. 
HS578T and F. T47D), lung cancer (G. HOP-92 and H. NCI-H322M), prostate cancer (I. PC-3 and J. DU-145), 
melanoma (K. SK-MEL-5 and L. MDA-MB-435), and brain cancer (M. SF-295 and N. SF-539) cell lines from the 
NCI-60 cancer cell line collection were treated with 10 µM atorvastatin (pink line), 10 µM rosuvastatin (blue line), 
or DMSO vehicle control (black line) and cell growth was quantified at 2, 4, and 6 days through direct cell counting. 
The results are representative of three independent experiments. Error bars represent the standard deviation (n=3). 
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We utilized gene expression data from these fourteen NCI-60 cancer cell lines908,935 and 
statin dose-response data (Figure 40) to produce a genetic signature distinguishing between 
atorvastatin and rosuvastatin sensitive and resistant cell lines. Specifically, our training set 
consisted of baseline gene expression data for the fourteen (non-treated) NCI-60 cell lines, and a 
measure of statin sensitivity as our response variable. We computed this response variable over a 
growth period of six days utilizing atorvastatin (ato), rosuvastatin (rosu), ato + rosu, or vehicle 
treatment on each cell line. From these data, dose-response curves were formed, depicting the 
number of (proliferating) cells at each time point. Using these curves, we found the ratio of the 
area under the dose response curve for the control and the area under the dose response curve for 
the treatment group, and used this number as a final response variable for each cell line. 
To determine a genetic signature of statin sensitivity, the variables that were found to be 
associated to the sensitivity score measure from our graphical modeling methods were selected as 
important features. Specifically, we used three different methods for feature selection in this 
analysis. First, we used the “Atorva MGM” approach, which simply used the mixed graphical 
model (MGM) to produce an undirected graphical network from the NCI-60 data, and used all the 
genes adjacent to the statin sensitivity variable in the network as features. Nineteen genes were 
selected by this approach (Table 18). To determine the reliability of the selected genes, we 
employed a leave-one-out cross validation method using a support vector machine (SVM) 
regression model, and we obtained a cross validation error rate of 0.0082 for this set of features.  
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Table 18. Selected biomarkers for each identification method 
Atorva-MGM Combined-MGM Atorva-TReCS 
GABRA3 GABRA3 GABRA3 
TM4SF18 TM4SF18 TM4SF18 
ATP8B1  ATP8B1 
CKAP4  CKAP4 
IL13RA2 IL13RA2  
KRT7  KRT7 
LAMA4  LAMA4 
MACC1  MACC1 
MISP  MISP 
MMP14  MMP14 
NFKBIZ  NFKBIZ 
SCNN1A  SCNN1A 
SLC16A4  SLC16A4 
SLC27A2  SLC27A2 
SLC6A8 SLC6A8  
SPINT2  SPINT2 
TNFRSF10D TNFRSF10D  
HIST1H1A ANPEP CD70 
SRPX GFPT2 CTSK 
 PTGFRN IFITM2 
 RGS4  
Overlapping genes from all three methods are shown in red, and overlapping genes from two methods are shown in 
bold. 
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Our second approach was the “Combined” approach. Here, we used the MGM selected 
features from rosuvastatin on the NCI-60 dataset with the sensitivity scores from the rosuvastatin 
experiments. We combined them with the MGM selected features from the atorvastatin cell lines, 
and applied Tree-Guided Recursive Cluster Selection (T-ReCS) on the NCI-60 dataset to produce 
clusters of genes predictive of statin sensitivity. Following this step, we searched for those genes 
from the rosuvastatin MGM selected features that were in any cluster from the atorvastatin features 
selected. These were then utilized as the genetic signature. In total, nine genes were selected using 
this approach (Table 18), but the cross validation error rate was higher (0.1967).  
Our final approach was the Atorva_TReCS approach. Here, we used the MGM features for 
the atorvastatin data as the original features for T-ReCS. Then, we ran our T-ReCS algorithm to 
produce clusters on these features. We then choose the final selected features for prediction, by 
simply taking a single gene from each cluster that had the highest correlation to the statin 
sensitivity variable. In total, seventeen genes were selected using this approach (Table 18) (as some 
genes from the original MGM selection appeared in the same cluster), with a cross validation error 
rate of 0.0285. 
For each of these approaches, we used the corresponding gene expression signature to train 
a predictive linear regression model (a support vector machine (SVM) regression model trained 
via MATLAB’s “fitrsvm” library) on the NCI-60 gene expression data. To validate the predictive 
power of this model, we obtained gene expression data from the Broad Institute’s Cancer Cell Line 
Encyclopedia (CCLE)936, and these data were used to predict an Atorvastatin sensitivity score for 
each of the cell lines in the CCLE database. We utilized the predictions from each of the three 
genetic signature selection approaches in the following manner. First, using the genes selected 
from each of the methods the top ten statin resistant cell lines were predicted using the model 
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trained on the NCI-60 database. Then, each of these cell line sets were combined and duplicates 
were removed resulting in 26 resistant cell lines. The same approach was employed on the set of 
23 predicted statin sensitive cell lines. It is evident that the predictions by the three methods yielded 
a partial overlap for both the most statin sensitive and statin resistant cell lines. For this full data 
set with all of the scores for each of the three biomarker identification methods, the reader is 
directed to the supplemental material of the published manuscript3.  
7.3.2 Experimental Validation of Biomarker Predictions 
Next, we assessed the fidelity of the predicted biomarkers by experimentally testing the statin 
sensitivity of yet untested cell lines. To reduce the number of cell lines to be experimentally tested, 
we clustered the predicted 23 statin sensitive and 26 statin resistant cell lines based on their whole 
transcriptome profiles, since cells displaying highly similar transcriptome profiles are likely to 
have similar biologic behavior. We performed principal component analysis on the full gene 
expression data for the predicted 26 statin resistant cell lines, and the cell lines were clustered 
according to their first two principal components using a k-means clustering with k = 10. The same 
approach was employed on the set of 23 predicted statin sensitive cell lines. These data are shown 
in the “supplemental information” section. 
To test the atorvastatin sensitivity of representative cell lines from the predicted sensitive 
and resistant groups, we selected the NCI-H2170 (lung cancer-derived) and BT-474 (breast cancer-
derived) predicted statin resistant; and the SK-MES-1 (lung cancer-derived) and SK-MEL-24 
(melanoma-derived) predicted statin sensitive cell lines. To determine the IC50 of atorvastatin, we 
treated the cell lines with half log doses of atorvastatin, between 100nM and 100uM. As shown in 
Figure 25, cell lines predicted to be sensitive (SK-MES-1 and SK-MEL-24) were more sensitive 
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to atorvastatin than the cell lines predicted to be resistant (NCI-H2170 and BT-474) to it (Figure 
41A, B), confirming the fidelity of the predicted statin-sensitivity gene expression signature. 
Statin resistance correlates with cell membrane E-cadherin expression in cancer cell lines2. 
To determine the expression of E-cadherin in BT-474, NCI-H2170, SK-MES-1, and SK-MEL-24 
cell lines we immunostained these cell lines for E-cadherin, as previously described2. We find that 
statin resistant cells with high mRNA for E-cad (BT-474 and NCI-H2170) have high membrane 
E-cadherin expression. In contrast, statin-sensitive cells with low mRNA for E-cad (SK-MES-1 
and SK-MEL-24) have no detectable E-cadherin staining (Figure 41C-F). The uncovered E-
cadherin expression pattern agrees with E-cadherin mRNA expression data deposited for these cell 
lines in Oncomine937 and demonstrates that membrane E-cadherin is a marker of statin-resistant 
cells as we have found in previous studies2. Moreover these data further support the paradigm that 
tumor cells with an epithelial phenotype are more resistant to statin therapy, thus suggesting cells 
primed to undergo EMT and outgrow as mesenchymal masses would be selectively targeted by 
statins. 
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Figure 41. Statin sensitivity data correlates with predictions and membrane E-cadherin expression 
(A) Dose response curves for Atorvastatin in predicted resistant (BT-474 and NCI-H2170) and predicted sensitive 
(SK-MES-1 and SK-MEL-24) cell lines. (B) Predicted resistant cell lines exhibited higher IC50 values to 
atorvastatin than predicted sensitive cell lines. Data are representative of three independent experiments. All 
experiments were carried out in triplicate (N=3). Error bars represent the standard error of the mean. Atorvastatin 
resistant cell lines (C) BT-474 and (D) NCI-H2170 display strong membrane E-cadherin (green) staining. In 
contrast, atorvastatin sensitive cell lines (E) SK-MES-1 and (F) SK-MEL-24 exhibited no E-cadherin staining. DAPI 
(blue) was used to counterstain the cell nuclei. Scale bar = 50µm. 
 
 
7.3.3 Determination of Potential Combination Statin Therapies 
To determine if there was potential for combination therapies with statins across cell lines, we 
analyzed publicly available pharmacological profiles from the Cancer Cell Line Encyclopedia and 
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the Sanger Center Genomics of Drug Sensitivity project. The CCLE data profiled 24 molecules 
across 504 cell lines936, and the Sanger Center profiled 250 molecules across 549 cell lines938. Cell 
line sensitivity measurements for each molecule on each profiled cell line was computed using the 
IC50 value and the area under the dose response curve (AUC) for the CCLE data and the Sanger 
center data, respectively. These sensitivity measurements were compared to predict statin 
sensitivity on only those cell lines appearing in both the CCLE baseline gene expression dataset 
as well as the pharmacological profiling datasets, and correlation scores were produced (Table 19). 
The main drugs with highest statistical significance are BRAF inhibitors (Dabrafenib, 
PLX-4720, SB590885), MEK inhibitors (Refametinib, Selumetinib), Bcl-2/Bcl-x/Mcl-1 inhibitors 
(TW37), NF-ĸB inhibitors (piperlongumine) and HSP-90 inhibitors (Elesclomol) (Table 19).  In 
recent studies, simvastatin was shown to have additive or synergistic effects in combination 
therapy with BRAF-inhibitor, PLX-4720939,940, which seem to depend on the mutational status of 
melanoma cells940. A MEK inhibitor was also shown to synergize with statin in a Drosophila model 
of lung cancer941. Thus, other inhibitors of the Ras-Raf-MEK-ERK pathway could also be tested 
for synergy with statins. Treatment with mitogen-activated protein kinase (MAPK) pathway 
targeted therapies (i.e., combined BRAF and MEK inhibitors) is the current standard of care for 
patients with BRAF-mutant advanced melanoma demonstrating the clinical relevance of MEK-
inhibitors. However, response to these therapies in patients typically lasts less than a year, 
suggesting that further research is necessary for the better clinical management of these patients942.  
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Table 19. Drugs predicted to synergize with statin therapy 
Drug Name Target Correlation P Value 
Dabrafenib BRAF 0.456976009 2.38E-18 
PLX-4720 BRAF 0.376159659 4.97E-13 
(5Z)-7-Oxozeaenol TAK1 0.376014976 8.61E-13 
SB590885 BRAF 0.340372121 4.32E-09 
TW 37 BCL2, BCL-XL, MCL1 0.27305505 1.89E-06 
Piperlongumine NF-ĸB 0.226445462 0.000199099 
Cisplatin DNA crosslinker 0.233847531 0.000250235 
Lestauritinib FLT3, JAK2, NTRK1, 
NTRK2, NTRK3 
0.218300548 0.000905096 
Elesclomol HSP90 0.206861021 0.002058482 
Refametinib MEK1, MEK2 0.183970201 0.004239963 
Bleomycin dsDNA break induction 0.183339449 0.004370418 
Temsirolimus MTOR 0.182232337 0.01021699 
Nutlin-3a (-) MDM2 0.176424024 0.010924768 
Selumetinib MEK1, MEK2 0.165658468 0.010924768 
AZ628 BRAF 0.296949736 0.011550955 
PD0325901 MEK1, MEK2 0.173101761 0.011550955 
Serdemetan MDM2 0.164726002 0.011550955 
Trametinib MEK1, MEK2 0.166312205 0.011550955 
Docetaxel Microtubule stabilizer 0.169092858 0.013420485 
BX796 TBK1, PDK1 (PDPK1), 
IKK, AURKB, AURKC 
0.167710541 0.013718152 
Embelin XIAP 0.157305764 0.016974867 
FH535 PPARγ, PPARΔ 0.154672573 0.02034349 
YK-4-279 RNA helicase A 0.158950401 0.026108609 
Rucaparib PARP1, PARP2 0.147699505 0.027477555 
CI-1040 MEK1, MEK2 0.152967932 0.032836113 
SN-38 TOP1 0.140036378 0.040080871 
CHIR-99021 GSK3A, GSK3B 0.135343422 0.041404418 
Pharmacological profiles from CCLE and Sanger Center drug sensitivity data were used to predict combination 
therapy with statins. Molecules with positive correlation and FDR Q-Value < .05 were included. For CCLE profiles, 
IC50 was used as a proxy for sensitivity, and for Sanger center profiles, the area under the dose-response curve 
(AUC) was used. 
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HSP-90 family members can both suppress or contribute to tumor invasiveness. Also, cell 
surface HSP-90 contributes to metastasis formation943, while the mitochondrial HSP-90, TRAP-1 
suppresses tumor cell invasiveness and plays a role mediating the switch from OxPhos to aerobic 
glycolysis944. Indeed, recent studies have also demonstrated that simvastatin synergizes with the 
HSP-90 inhibitors, 17-DMAG940 or 17-AAG939 in inhibiting melanoma cell proliferation. 
Although they have not yet been tested in combination with statins the other main identified 
mechanisms are also of potential interest for statin co-therapy. Bcl-2 and Bcl-xL can promote cell 
migration, invasion and metastasis perhaps by their promotion of mitochondrial ROS formation945; 
In contrast, pro-apoptotic Bcl-2 family members, Bax and Bak attenuate cell migration and 
metastasis formation945. The selective Bcl-2 inhibitor ABT199/ Venetoclax is FDA approved and 
used for treating relapsed/ refractory CLL with 17p deletion. Similarly, the essential role of NF-
kB in epithelial-mesenchymal transition (EMT), the main initial event in metastasis development, 
is well recognized946,947, and its inhibitors can delay breast cancer invasiveness948. These data argue 
that if they are expressed to a sufficient degree in a given cell line, the inhibition of both Bcl-2 
and/ or NF-kB may synergize with the tumor growth-inhibitory function of statins. 
7.3.4 Limitations of this Computational Approach 
While this study generated a computational framework for approaching a genetics-based approach 
for predicting statin sensitivity, our current approach is limited by the data upon which it was built. 
First, the vast majority of available large datasets (e.g., TCGA) are derived from primary tumors; 
this skews the analysis towards relatively well differentiated (epithelial, E-cadherin-positive) cells 
that are not epidemiologically linked to reduction in mortality from cancer which is more related 
to disseminated/metastatic disease (usually mesenchymal, E-cadherin low/absent). Thus, the 
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tumor selection is not enriched in the tumor cells that are postulated as the direct targets for statins. 
Second, since the gene expression data are derived from whole tumors, tumor heterogeneity is 
expected to further obscure the statin sensitivity/resistance signal. Third, gene expression data is 
inherently limited by high dimensionality (i.e., few cell lines per tumor type compared to the large 
number of genes/variables), which reduces statistical power. Moreover, predicted sensitivity genes 
were not examined at the genetic level to determine whether altered expression influences statin 
efficacy. Finally, predicted synergistic drug combinations with statins were not tested 
experimentally in these cell lines, although some have been already confirmed in the literature. 
These limitations are beyond the scope of this work and will be addressed in subsequent studies. 
7.4 SUPPLEMENTAL DATA 
In order to determine genes that would denote sensitivity to atorvastatin, rosuvastatin, or both, we 
employed the Atorva-MGM (Figure 42), Combined-MGM (Figure 43), and Atorva-TReCS 
computational algorithms (Figure 44). As stated in the main text, nineteen, nine, and seventeen 
genes were identified by each of these three approaches, respectively. There were two overlapping 
genes found using all three approaches (Table 18) which are GABRA3 and TM4SF18. GABRA3 
is GABAA receptor alpha 3, which is typically only found in adult brain but has also been found 
in cancers of lung and breast949,950. Interestingly, GABRA3 expression in lung cancer was found 
to be expressed more highly in low grade tumors950 whereas in breast cancer high expression 
correlated with worse survival949. TM4SF18 is a Transmembrane-4-L-six-family protein that is 
found mostly in adult kidney, but its paralog TM4SF1 and other family members have been shown 
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to be upregulated in many cancers951. These data suggest that the genes extracted from all three of 
these computational methods have been previously shown to be relevant in cancer aggressiveness. 
7.4.1 Selection of statin sensitive tumors from the TCGA breast cancer samples 
The experimentally confirmed gene expression signatures allow the selection of those subsets of 
primary tumors or metastases that may be sensitive to statin treatment. To this end, we have applied 
the biomarker search for transcriptome profiles obtained from breast cancer samples that are 
deposited in the Cancer Genome Atlas (TCGA)952. We find that a small subset of primary breast 
tumors is predicted to be sensitive to statins while many of them are not (Figure 45). We find no 
significant correlation with tumor stage, age, race, presence or absence of metastasis (p=0.590, 
p=.101, p=.290, p=.275, respectively) (Table 20).  
Subsequently, we have repeated the procedure for all tumor types in TCGA, finding overall 
similar trends. For the full complement of tumor type analyses, the reader is referred to the 
published manuscript’s supplemental information document3. These data suggest that statin 
sensitivity is multifactorial and thus sophisticated biomarker signatures are needed in order to 
accurately predict the statin sensitivity of a particular tumor. Furthermore, while no correlation 
between statin sensitivity and metastasis was uncovered, the transcriptome profiles in the TCGA 
are derived from the primary tumor and thus may not be reflective of the rare cells that 
metastasized in those patients952. 
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Figure 42. Potential biomarkers of atorvastatin sensitivity using Atorva-MGM 
The CCLE cell lines’ tissue of origin, mRNA expression levels (4-12) of potential biomarker genes and scores for 
atorvastatin sensitivity (1 to -1) are shown using the Atorva-MGM method. 
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Figure 43. Potential biomarkers of atorva- and rosuva-statin sensitivity using combined-MGM 
The CCLE cell lines’ tissue of origin, mRNA expression levels (4-12) of potential biomarker genes and scores for 
atorvastatin sensitivity (1 to -1) are shown using the combined-MGM method. 
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Figure 44. Potential biomarkers of atorvastatin sensitivity using Atorva-TReCS 
The CCLE cell lines’ tissue of origin, mRNA expression levels (4-12) of potential biomarker genes and scores for 
atorvastatin sensitivity (1 to -1) are shown using the Atorva-TReCS method. 
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Figure 45. Predicted statin sensitivity of breast cancers deposited in TCGA 
Transcriptome profiles of breast cancer samples deposited in TCGA were used as input into our statin sensitivity 
predictive model. Clinical covariates showed no significant relationship with statin sensitivity.  
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Table 20. Correlations of clinical covariates with predicted statin sensitivity 
Tumor Type COAD  LUAD OV PRAD 
Metastasis 1.59E-02 NA NA NA 
Gender 7.13E-01 4.60E-01 NA NA 
Age 9.51E-01 5.55E-02 6.62E-03 3.14E-01 
Tumor Stage 3.53E-01 6.61E-01 2.18E-01 NA 
Weight 7.08E-01 NA NA NA 
Race 6.51E-02 3.95E-01 5.15E-01 3.73E-01 
Tumor Type SKCM GBM KIPAN LAML 
Metastasis 2.55E-01 NA NA NA 
Gender 2.39E-01 1.33E-01 5.23E-04 8.47E-01 
Age 2.87E-01 6.41E-01 9.93E-01 1.25E-02 
Tumor Stage 6.79E-01 NA 1.30E-11 NA 
Weight 9.54E-01 NA 1.40E-02 NA 
Race 5.44E-01 5.19E-01 2.36E-01 2.14E-01 
Correlations are shown as p-values with the null hypothesis of zero correlation. Statistically significant non-zero 
correlations with p < .05 are bolded. Columns refer to different tumor types from the TCGA, and rows refer to the 
clinical covariate. COAD = Colon Adenocarcinoma; LUAD = Lung Adenocarcinoma; OV = Ovarian Carcinoma; 
PRAD = Prostate Adenocarcinoma; SKCM = Cutaneous Melanoma; GBM = Glioblastoma Multiforme; KIPAN = 
Pan-Kidney Carcinoma; LAML: Acute Myeloid Leukemia. 
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7.4.2 Gene Ontology Enrichment Analysis 
To validate the biological significance of the predictive biomarkers we performed gene ontology 
enrichment analyses using the Database for Annotation, Visualization and Integrated Discovery 
(DAVID)527. Three gene lists were submitted to the resource, representing the three major gene 
clusters (consisting of more than two genes) that we identified by the Atorva_T-ReCS approach 
(Tables 21-23). We only used the Atorva_T-ReCS approach for this analysis because unclustered 
predictive biomarkers tend to have a single representative from each pathway (since expression of 
genes in the same pathway tend to be correlated or anti-correlated), and thus ontological analysis 
would be unable to recognize important terms or important pathways. Through T-ReCS clustering, 
we mitigate this problem by finding multiple co-expressed genes in a single signature (see 
Materials and Methods).  
 
 
Table 21. Ontology of cluster one from identified biological signature 
GO Term Relevant Genes Corrected P-Value 
Axonal transport of mitochondrion UCHL1, NEFL 0.13939585 
Axon cytoplasm UCHL1, NEFL 0.250536938 
Extracellular space CXCL5, CD70, IL13RA2 0.439228308 
Extracellular region CXCL5, MMP1, IL13RA2 0.45323271 
Myelin sheath UCHL1, NEFL 0.466479946 
Rheumatoid arthritis CXCL5, MMP1 0.473252751 
Cell-cell signaling CXCL5, CD70 0.959289219 
Gene ontology terms from cluster one of genes from the Atorva-T-ReCS identified biological signature. P-Value 
correction for multiple testing was applied using the Bonferroni correction method. 
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Table 22. Ontology of cluster two from identified biological signature 
GO Term Relevant Genes Corrected P-Value 
Extracellular space CTSK, EREG, IL18, GAL, TNFAIP2 0.260167934 
Angiogenesis EREG, IL18, TNFAIP2 0.647369645 
SNARE binding VAMP8, TNFAIP2 0.66437542 
Extracellular region CTSK, EREG, IL18, GAL 0.759814148 
Inflammatory response TNFRSF10D, IL18, GAL 0.764152784 
Rheumatoid arthritis CTSK, IL18 0.801237029 
Positive regulation of smooth muscle cell 
proliferation EREG, IL18 0.814152797 
Legionellosis IL18, EEF1A2 0.861642906 
Gene ontology terms from cluster two of genes from the Atorva-T-ReCS identified biological signature. P-Value 
correction for multiple testing was applied using the Bonferroni correction method. 
 
 
Several ontological terms related to the submitted gene lists have evidence of association 
to statins in the literature. The two major ontological terms from cluster one (Table 21) refer to 
axonal transport of mitochondria and axon cytoplasm. Though there is no evidence for statins 
directly acting upon axons, their inhibition of the cholesterol synthesis pathway has been shown 
to delay axonal growth953.  From cluster two (Table 22), statins have been shown to have biphasic 
effects on angiogenesis713, and they have anti-inflammatory properties through their reduction in 
quantity of circulating C-reactive protein (CRP)954. Also, though it is not yet clear if statins have 
a direct effect on SNARE protein binding, we note that statins may affect the release of insulin, in 
which SNARE proteins also have a role955. Cluster three (Table 23) depicts two main terms: cell 
adhesion/migration and extracellular matrix organization. It has been shown that statins affect the 
adhesion related expression of selectin and VCAM-1956, and they further inhibit migration of cell 
lines, and in fact this may relate to their anti-inflammatory properties957,958. In addition, statins 
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have been shown to modulate the metabolism of the extracellular matrix to prevent fibrosis by 
inhibiting connective tissue growth factor (CTGF) production959.  
 
 
Table 23. Ontology of cluster three from identified biological signature 
GO Term Relevant Genes Corrected P-Value 
Cell adhesion LAMA4, LPXN, SRPX, TNC, POSTN, CDH2, ITGB3, THBS1, ENG, FN1, PCDH18, THY1 9.06E-08 
Focal adhesion LPXN, TNC, HSPA1A, CDH2, ITGB3, ENG, PLAU, THY1 1.81E-04 
Extracellular matrix LAMA4, SERPINE2, TNC, SERPINE1, POSTN, THBS1, FN1 2.46E-04 
Extracellular matrix 
organization 
LAMA4, TNC, SERPINE1, POSTN, ITGB3, THBS1, 
FN1 2.58E-04 
Extracellular space SERPINE2, TNC, SERPINE1, CD109, AXL, POSTN, DPYSL3, THBS1, ENG, PLTP, PLAU, FN1 2.64E-04 
Cell surface SRPX, CD109, AXL, VAMP5, ITGB3, THBS1, ENG, PLAU, HLA-DRA 2.71E-04 
Extracellular region 
INHBA, LAMA4, CHRDL1, SERPINE2, GLIPR1, 
TNC, SERPINE1, HIST1H3C, THBS1, PLTP, 
PLAU, FN1 
8.55E-04 
Regulation of cell migration LAMA4, SERPINE2, DPYSL3, ITGB3, THY1 0.00136393 
ECM-receptor interaction LAMA4, TNC, ITGB3, THBS1, FN1 0.002847294 
Negative regulation of 
plasminogen activation SERPINE2, SERPINE1, THBS1 0.003599381 
Gene ontology terms from cluster three of genes from the Atorva-T-ReCS identified biological signature. P-Value 
correction for multiple testing was applied using the Bonferroni correction method. 
 
 
Overall, this demonstrates the relevance of the genes in our predicted signature to the mechanisms 
underlying the physiological effect of statin. 
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7.5 CONCLUSIONS 
In this work, we have utilized several feature selection approaches to identify a predictive genetic 
signature of statin sensitivity from RNA-Seq data from TCGA. We applied this signature to several 
cancer cell lines from the NCI-60 database and externally validated the sensitivity predictions, 
confirming all four of our experimental predictions. We then applied our predictive signature to 
the TCGA-Breast Invasive Carcinoma project and found a subset of tumor samples predicted to 
be sensitive to statins, and we further validated our predictive signature through an ontological 
analysis for relevance of the selected genes.  
These results contribute to this overall body of work by suggesting that genetic signatures 
can be used to determine tumors that may be responsive to statin therapy. Importantly, many of 
these predictions are made using specimens derived from primary tumors, and as such may not be 
reflective of the genetics of the metastatic cells. However, this study lays a framework for 
developing more sophisticated genetic signatures of metastatic cancer susceptibility to statin 
therapy. This will be critical for patient stratification, namely selecting those patients whom will 
benefit from adjuvant statin therapy after primary tumor resection.  
In summary, we have developed a combined algorithm-experiment blueprint that is able to 
generate biomarker sensitivity signatures for anticancer therapies, as exemplified here by 
identifying an initial biomarker signature for statin sensitivity in human cancer cell lines and 
tumors. This signature was validated both in terms of biological sensibility and by experimental 
validation, and it confirms many recent physiological effects of statins as shown through our 
ontological analyses. Future studies will be aimed at validating these results in sophisticated ex 
vivo and in vivo models of cancer metastasis and testing predicted synergistic drug combinations.  
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8.0  STATINS INHIBIT OUTGROWTH OF BREAST CANCER METASTASES 
8.1 PROLOGUE 
The fourth piece of work contributing to this thesis is currently in review at British Journal of 
Cancer960. It is the second of the two submitted first author publications that have resulted from 
my thesis work. The majority of this chapter is taken directly from that manuscript, and the 
corresponding reference can be found both at the beginning of this document and in the references 
section. Of note, the “Primary Data” section refers to a discussion of the data published in the body 
of the manuscript and the “Supplemental Data” section refers to data published in the supplement 
of the manuscript. 
In this work, we investigated the growth suppressive effects statins in 2D in vitro, 3D ex 
vivo, and in vivo models of breast cancer metastasis. We found that statins exhibit similar anti-
tumor properties in breast cancer 2D co-culture with primary human hepatocytes. Moreover, 
atorvastatin is able to block LPS/EGF stimulated outgrowth of dormant tumor cells in a 3D ex vivo 
microphysiological system (MPS) model of breast cancer metastases in the liver. Finally, two 
independent mouse models of spontaneous breast cancer metastasis to the liver and lung, 
respectively, demonstrate that atorvastatin can suppress the growth of metastatic but not primary 
tumor cells.  
These data are a significant foundation to this body of work for two main reasons. First, 
this section demonstrates the ability of atorvastatin to block stimulated outgrowth of dormant 
tumor cells. This is important in the context of reducing breast cancer recurrence, as many 
clinically detectable macrometastases often begin as dormant micrometastases961. Second, and 
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most importantly, we demonstrate that atorvastatin exhibits divergent effects on primary and 
metastatic tumor cells. While atorvastatin does not affect proliferation of primary tumor cells, it 
decreases proliferation of metastatic tumor cells. The central hypothesis of this thesis proposes that 
statin suppression proliferation and emergence of dormant micrometastases is responsible for the 
clinically observable reduction in breast cancer recurrence and mortality in women with breast 
cancer. The data discussed below greatly support this hypothesis because they demonstrate that 
atorvastatin can both suppress dormant tumor cell emergence and reduce proliferation at the 
metastatic site. 
8.2 MATERIALS AND METHODS 
Human Cells: Use of human cells were adjudicated as exempted by the University of Pittsburgh 
IRB, and all animal investigations were approved by the Pittsburgh VA Health System IACUC.  
Reagents: Atorvastatin (PHR-1422) and rosuvastatin (SML-1264) were obtained from 
Sigma Aldrich, USA. Atorvastatin and rosuvastatin were dissolved in dimethyl sulfoxide (DMSO) 
at a concentration of 50mM. PD98059 (S1177, SelleckChem) was reconstituted in DMSO at a 
concentration of 20mM. LY294002 (S1105, SelleckChem) was reconstituted in DMSO at a 
concentration of 10mM. Lipopolysaccharide (LPS, Sigma) and mouse epidermal growth factor 
(EGF, Corning) were reconstituted in sterile deionized water at concentrations of 1mg/ml and 
50μg/mL respectively. 
Cell Sourcing and Cell Culture: MCF-7 red fluorescent protein (RFP), MDA-MB-231 
RFP, and MDA-MB-231 RFP/Ecad were previously transfected and stably selected45. These cell 
lines will be referred to in the results and discussion without inclusion of the RFP suffix. All cells 
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were maintained in RPMI 1640, GlutaMax Supplement (Gibco, ThermoFisher) supplemented with 
10% heat inactivated fetal bovine serum (HI-FBS, Gemini Bioproducts) and 0.5% penicillin-
streptomycin (Gibco, ThermoFisher), henceforth referred to as RPMI. Puromycin (Gibco, 
ThermoFisher) and G418 (Teknova) were used to maintain expression cassettes, at the following 
concentrations: 1μg/mL puromycin (MCF-7 RFP), 5μg/mL puromycin (MDA-MB-231 RFP), 
900μg/mL G418 (MDA-MB-231 RFP/Ecad). Antibiotic selection media was removed at least 24 
hours prior to beginning experiments. Primary human hepatocytes and non-parenchymal cells 
were obtained as isolates from excess pathology specimens at the University of Pittsburgh Medical 
Center (UPMC) as part of a National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK)-funded Liver Tissue and Cell Distribution System run by Dr. David Gellar and funded 
by NIH contract #HHSN275201700005C. Hepatocytes were isolated by collagenase perfusion for 
subsequent distribution to investigators. Non-parenchymal cells were further isolated by density 
centrifugation using a percoll gradient, as previously described844. 
Statin IC50 Curve Determination: Cancer cells were seeded in 24-well plates at a 
concentration of 5x104 cells/mL in a volume of 500μL. The next morning, cells were treated with 
atorvastatin in half log doses between 100nM and 100μM. The vehicle control treatment was 0.2% 
DMSO. After 72 hours of treatment, treatment solutions were aspirated and cells were fixed with 
3.7% formaldehyde (F79-1, ThermoFisher) for 15 minutes. After fixation, cells were incubated 
with 0.5% w/v crystal violet for 10 minutes and excess dye was removed by copious washing with 
tap water. The absorbed dye was released with 2% sodium dodecyl sulfate (SDS) and mixed 
thoroughly before transferring to a 96-well microplate and reading at 560nm using a Tecan 
SpectraFluor microplate reader (Tecan US, Durham, NC). Dose-response curves were generated 
by fitting a standard, four-parameter sigmoid curve to the data. 
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Western Blotting: Cancer cells were seeded in 12-well plates at concentrations of 7.5x104 
and 20x104 cells/mL in a volume of 1mL. Cells were lysed using RIPA buffer supplemented with 
1:100 protease inhibitor cocktail V (CalBioChem, USA) and collected into Eppendorf tubes using 
a cell scraper. The samples were sonicated for 2 seconds and centrifuged at 13000g for 10 minutes 
at 4oC. The supernatant was carefully separated from the pellet into a new tube for sample 
preparation. Protein concentration was determined by the BCA Protein Assay Kit (Pierce, 
ThermoFisher Scientific). Samples were prepared and boiled for 5 minutes prior to loading. 
Proteins were separated on a 7.5% Tris Bis-acrylamide gel prepared the same day at 96V (E-C 
Apparatus Corp., EC-105) until adequate separation was achieved. Samples were transferred onto 
a nitrocellulose membrane at room temperature at 300mA for 1.5 hours (E-C Apparatus Corp., 
EC135-90). After transferring, membranes were blocked in 5% w/v non-fat dry milk in tris 
buffered saline with 0.5% Tween-20 (TBS-T). Membranes were probed with primary antibodies 
in 5% w/v non-fat dry milk overnight at 4oC on a rotator. The primary antibodies used were rabbit 
anti-GAPDH (1:10000, G9545, Sigma), rabbit anti-E-cadherin (1:1000, 24E10, Cell Signaling), 
and rabbit anti-vimentin (1:3000, Cat# ab92547, Abcam). After primary incubation, membranes 
were washed 3 times for 10 minutes each in TBS-T. Anti-rabbit IgG (1:5000, Sigma, A9169) was 
applied at room temperature in 5% w/v non-fat dry milk for 1 hour. After secondary incubation, 
membranes were washed 3 times for 10 minutes each in TBS-T. Membranes were incubated with 
ECL western blotting substrate (Pierce, ThermoFisher Scientific) and photo developed. Western 
blots were scanned at a resolution of 300 DPI and grayscale bit depth of 16.  
Hepatocyte – Breast Cancer Co-Culture: Primary human hepatocytes (6x105) were 
seeded onto Nunc Thermanox Plastic coverslips (Cat# 174950, ThermoFisher) in 12-well plates 
on Day 0. On Day 1, 1000 MDA-MB-231 RFP or 5000 MCF-7 RFP cells were seeded in each 
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well. On Day 2, cells were treated with atorvastatin or rosuvastatin, with or without LY294002 or 
PD98059, for 72 hours. On the last 24 hours of drug treatment, EdU (Cat# E10187, ThermoFisher) 
was added to a final concentration of 10µM to detect dividing cells. After 72 hours of treatment, 
treatment solutions were aspirated and cells were fixed with 3.7% formaldehyde (F79-1, 
ThermoFisher) for 15 minutes and then changed to PBS before further processing. 
Microphysiological System (MPS) for Breast Cancer Metastasis in the Liver: The 
Liver MPS System (CNBio Innovations) was employed as previously described1,47,750,751, and is 
schematized in Figure 4A. In brief, 6x105 primary human hepatocytes and 6x105 primary human 
non-parenchymal cells were seeded on high impact polystyrene scaffolds coated with 1% rat tail 
collagen type I (BD Biosciences) on Day 0. On Day 3, 1000 MDA-MB-231 RFP cells were seeded 
on top of established hepatocyte microtissues. From Day 7-10, scaffolds were treated with 1µM 
Doxorubicin (APP Pharmaceuticals LLC). From Day 11-15, scaffolds were treated with 5µM 
atorvastatin. Finally, from Day 13-15, scaffolds were treated with 1µg/mL LPS (Sigma) and 
20ng/mL mouse EGF (Corning). Scaffolds were continuously perfused at a rate of 1µL/s over the 
entire culture duration. Media were changed every two days and the supernatant was collected for 
analysis by the University of Pittsburgh Medical Center CLIA-certified clinical labs. On Day 15, 
the scaffolds were fixed with 2% paraformaldehyde in PBS (Sigma) for 1 hour at 4oC and then 
changed to PBS before further processing. 
Mice and Drug Treatments: NOD-SCID gamma (NSG) female mice were obtained from 
Jackson Labs. Mice were 8 weeks of age upon the start of all experiments. Mice were injected 
intraperitoneally (IP) with atorvastatin at 2mg/kg or 10mg/kg, EdU at 10mg/kg, or the 2% DMSO 
vehicle at a volume of 10μL/mg body weight. Mice were euthanized by asphyxiation in a chamber 
with adequate CO2 flow as per AVMA procedures.  
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Intrasplenic Inoculation Model for Breast Cancer Metastasis to the Liver: On Day 0, 
mice were anesthetized, their spleens were exposed using a left lateral abdominal incision, and 
5x104 MDA-MB-231 RFP cells were injected into the spleen in a volume of 50μL using a 26.5 
gauge needle. The peritoneum was closed using one simple stitch with a 5-0 vicryl suture and the 
skin was closed using staples. Mice were kept on a heating blanket and monitored until they 
recovered from surgery and were subsequently housed individually. On Day 7, daily IP injections 
of atorvastatin (at 2mg/kg or 10mg/kg) or vehicle were started. On Day 26, two days before 
euthanizing the mice, a single EdU IP injection was given. On Day 28, mice were euthanized and 
the spleen, liver, and quad muscle were harvested for analysis. 
Mammary Fat Pad Inoculation Model for Breast Cancer Metastasis to the Lung: On 
Day 0, 1x106 MDA-MB-231 RFP cells were injected into the right inguinal mammary fat pad in a 
volume of 200μL using a 26.5 gauge needle and were subsequently housed in cages of two. On 
Day 10, six IP injections per week of atorvastatin (at 2mg/kg or 10mg/kg) or vehicle were started. 
On Day 30, mice were euthanized and the mammary tumor and lungs were harvested for analysis. 
Tissue Histology: Harvested mouse tissues were immediately fixed in 10% neutral 
buffered formalin and submitted to the University of Pittsburgh Health Sciences Tissue Bank, 
where the tissue was paraffin embedded and sectioned. Additionally, Ki-67 and E-cadherin 
immunohistochemistry (IHC), terminal deoxynucleodityl transferase dUTP nick end labeling 
(TUNEL), and hematoxylin and eosin (H&E) staining were performed by their well validated 
protocols921. Blank splenic tumor and liver tumor slides were obtained for in house EdU staining. 
E-cadherin and Vimentin Immunofluorescence: MCF-7 RFP, MDA-MB-231 RFP, and 
MDA-MB-231 RFP/Ecad cells were fixed and probed using mouse anti-E-cadherin (1:500, Cat# 
13-5700, Invitrogen) or rabbit anti-vimentin (1:200, Cat# ab92547, Abcam) overnight at 4oC. The 
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appropriate species secondary antibody was used - goat anti-mouse Alexa Fluor 488 (1:200, Cat# 
A-11001, ThermoFisher) or goat anti-rabbit Alexa Fluor 488 (1:200, Cat# A-11008, 
ThermoFisher) - for 1 hour at room temperature. After antibody staining, cells were counterstained 
with 2.5µg/mL DAPI for 15 minutes at room temperature and washed three times in normal saline. 
Coverslips were mounted using a glycerol and PVA based mounting medium, courtesy of the 
Center for Biological Imaging at the University of Pittsburgh, and were allowed to harden 
overnight prior to imaging. 
EdU Staining: Cells fixed on coverslips, MPS scaffolds, or mouse tissue slides were 
permeabilized with 0.1% Triton-X-100 (ThermoFisher) for 20 minutes then washed once with 3% 
Bovine Serum Albumin (Sigma). Cells were stained for EdU using the Click-iT EdU Alexa Fluor 
488 Imaging Kit (ThermoFisher) per the manufacturer’s instructions. After EdU staining, the cells 
were counter-stained with 2.5μg/mL (coverslips) or 10μg/mL (MPS scaffolds) DAPI for 15 
minutes at room temperature, and washed three times in normal saline. Coverslips were mounted 
using a glycerol and PVA based mounting medium, courtesy of the Center for Biological Imaging 
at the University of Pittsburgh, and were allowed to harden overnight prior to imaging. MPS 
scaffolds were kept in PBS until imaging. 
Imaging: E-cadherin and vimentin stained cells (Figure 46) and MPS scaffolds (Figure 49) 
were imaged on a Nikon A1 confocal microscope (Nikon) using 40x and 10x objectives 
(Olympus), respectively. For MPS scaffolds, the large image and Z-stack features of the A1 scope 
were used, to take 4x4 fields of view for each of seven Z-planes, spaced 20μm apart. The images 
shown are the maximum intensity projection of the z-stacks whereas the quantification was 
performed by summation of the individual stacks. For the hepatocyte – breast cancer co-culture 
coverslips (Figure 47, Figure 48, Figure 55), cells were imaged on a 90i widefield microscope 
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(Nikon) using a 10x objective (Olympus). The large image feature was used to take 10x14 fields 
of view (60mm2, 45% coverslip area) for each coverslip. Use of these two scopes was generously 
provided by the Center for Biological Imaging at the University of Pittsburgh, supported by NIH 
grant 1S10OD019973-01. Mouse tissue images (Figures 50-53, Figure 57, Figure 58) were taken 
using an Olympus BX40 upright microscope with a 10x and 40x objective using either brightfield 
(H&E, TUNEL, and Ki-67 IHC images) or fluorescence excitation wavelengths of 405nm (DAPI) 
and 488nm (Click-iT EdU). 
Image Analysis: Image analysis was performed in NIS Elements version 5.0. Nuclei 
(DAPI) and proliferating nuclei (EdU) channels were labeled using spot detection for bright, 
clustered spots, and using the same parameters for all images associated with that experiment. The 
thresholding function was used to label all RFP-positive area (RFP), which represents the area 
encompassed by the breast cancer cells. Once individual channel masks were created, combined 
channel masks were generated by using the “having” command, which creates a new mask that 
illustrates all pixels of the first mask that contain at least one pixel of the second. After generating 
all masks, data were measured and extracted for analysis. Specifically, the parameters reported 
are: Nuclei Number (DAPI), % Proliferating Cancer Cells ((DAPI + RFP + EdU) / (DAPI + RFP)), 
and Normalized Area (percent area of the total image encompassed by the RFP threshold, 
normalized to the vehicle control). 
Statistics: In all figures, the data are presented as the mean of three independent 
experiments, when counting the experiments were performed in triplicate, with the error bars 
representing the standard error of the mean, unless otherwise stated. Comparisons of individual 
columns in Figure 47 and Figure 49 were determined by use of a student’s two-tailed unequal 
variance t-test. Comparisons of dose curves in Figure 48 were made using a two way ANOVA 
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without sample matching, with significance reported as the probability for interaction between the 
atorvastatin and LY294002 or PD98059 treatment, to test for potentiation. Comparisons in Figures 
50-54 were performed using Kruskal Wallis one way ANOVA, with post-hoc Dunn’s multiple 
comparison test to determine significance between individual columns. Significance levels are 
reported in the figure legends and are kept consistent across all figures with symbols denoting * P 
< 0.05, ** P < 0.01, *** P < 0.001, and **** P < 0.0001. 
8.3 PRIMARY DATA 
8.3.1 Mesenchymal breast cancer cells that lack membrane E-cadherin are more sensitive 
to atorvastatin suppression 
We previously demonstrated that membrane E-cadherin was a marker and mechanism of resistance 
to atorvastatin treatment, whereas vimentin did not correlate with atorvastatin resistance2. Herein 
in breast cancer cells, we found the mesenchymal MDA-MB-231 cells were more sensitive to 
atorvastatin-mediated growth suppression than the epithelial MCF-7 cells (Figure 46A). As we 
demonstrated previously2, expression of membrane E-cadherin on MDA-MB-231 cells was 
sufficient to increase resistance to atorvastatin treatment, though not to the same level as MCF-7 
(Figure 46). To compare epithelial and mesenchymal nature of these cell lines, we determined 
expression and localization of E-cadherin and vimentin by western blot (Figure 46B) and 
immunofluorescent microscopy (Figure 46C-H). MCF-7 cells expressed E-cadherin to a greater 
level and with more membrane presentation than MDA-MB-231 Ecad while MDA-MB-231 cells 
did not express detectable E-cadherin (Figure 46B-E). In contrast, MCF-7 cells did not express 
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detectable vimentin whereas MDA-MB-231 and MDA-MB-231 Ecad cells expressed vimentin 
that stained in a filamentous cytoplasmic pattern (Figure 46B,F-H). These findings confirm our 
earlier reports2,3 of E-cadherin membrane expression correlating with relative resistance to statin 
growth suppression. 
8.3.2 Atorvastatin suppresses growth of mesenchymal breast cancer cells in co-culture 
with primary human hepatocytes 
The liver is a common site for breast cancer metastasis and is the primary site for drug metabolism 
in the body962. As such, we next wanted to determine whether hepatocytes would influence the 
efficacy of atorvastatin against breast cancer cells. To accomplish this goal, we co-cultured 
primary human hepatocytes with MCF-7 RFP or MDA-MB-231 cells for 4 days (Figure 47A). 
Importantly, less than 1% of the cells in these co-cultures were breast cancer cells, in order to 
model the relative overabundance of liver resident cells as compared to tumor cells in the context 
of micrometastases750. After allowing the breast cancer cells to integrate into the established 
hepatocyte monolayer, we treated the co-cultures with atorvastatin for 72 hours and included EdU 
in the culture media for the last 24 hours to detect any cells that transited the S phase (Figure 47A). 
After treatment, the co-cultures were fixed, imaged using widefield microscopy, and quantified by 
image analyses to assess statin toxicity (total nuclei number), influence on breast cancer 
proliferation (% EdU+ cancer cells), and tumor burden (normalized tumor area). 
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Figure 46. Atorvastatin suppresses mesenchymal breast cancer cells 
(A) MCF-7 RFP, MDA-MB-231 RFP, and MDA-MB-231 RFP/Ecad were grown in the presence of atorvastatin for 
72 hours and total cell number was determined by crystal violet staining and normalized to the control. IC50 values 
for each cell line are reported. (B) MCF-7 RFP, MDA-MB-231 RFP, and MDA-MB-231 RFP/Ecad were seeded 
either at 7.5x104 or 20x104 cells per well and probed for their total cell levels of E-cadherin and vimentin. The 
expression of (C-E) E-cadherin and (F-H) vimentin in (C,F) MCF-7 RFP, (D,G) MDA-MB-231 RFP, and (E,H) 
MDA-MB-231 RFP/Ecad was probed by immunofluorescent imaging. The data are representative of three 
independent experiments. Scalebar = 50µm. 
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Figure 47. Atorvastatin is more effective than rosuvastatin in 2D co-culture with hepatocytes 
(A) The experimental outline for hepatocyte – breast cancer co-culture using primary human hepatocytes (Heps; 
6x105) and RFP tagged breast cancer cells (BrCa; 5000 MCF-7 RFP or 1000 MDA-MB-231 RFP). (B-D) 
Atorvastatin treatment in co-cultures with MCF-7 RFP or MDA-MB-231 RFP. (B) Atorvastatin did not influence 
total nuclei number, but did reduce MDA-MB-231 RFP (C) proliferation and (D) total cancer cell area. (E-G) 
Atorvastatin and rosuvastatin treatment in hepatocyte – MDA-MB-231 RFP co-cultures. (E) Rosuvastatin 
demonstrated a reduction in nuclei number at the highest dose and a lesser potency at (F) suppressing proliferation 
and (G) total cancer cell area than atorvastatin. The data are representative of three independent experiments. Error 
bars represent the standard error of the mean (n=3).  * p < 0.05, ** p < 0.01, *** p < 0.001 compared to vehicle. # p 
< 0.05, ## p < 0.01, ### p < 0.001 compared to the same dose of atorvastatin. 
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Atorvastatin treatment did not affect the total nuclei number (Figure 47B). While 
atorvastatin treatment significantly decreased MDA-MB-231 proliferation in a dose-dependent 
manner, proliferation of MCF-7 cells was unaffected (Figure 47C). Similarly, atorvastatin 
decreased tumor burden in co-cultures with MDA-MB-231 cells but not those with MCF-7 cells 
(Figure 47D). Atorvastatin appears to be less potent at suppressing growth in this 2D co-culture 
system than in 2D monoculture of breast cancer cells (Figure 46). 
We previously demonstrated that the lipophilic atorvastatin was more potent at suppressing 
cancer cell growth than the hydrophilic rosuvastatin in cancer cell line monolayer cultures3. To 
determine whether this effect persisted in the context of the hepatic microenvironment, we co-
cultured MDA-MB-231 cells with primary human hepatocytes. In contrast to atorvastatin 
treatment, we found that rosuvastatin decreased total nuclei number by approximately 40% at the 
highest dose (Figure 47E) suggesting toxicity towards the liver cells. The hepatotoxicity of 
rosuvastatin has been reported in the literature and is thought to be due to the higher selective 
uptake of rosuvastatin by hepatocytes as compared to other statins963.  Rosuvastatin was 
significantly less potent than atorvastatin at all tested doses at suppressing the growth of the MDA-
MB-231 cells (Figure 47F). Thus, while the highest dose of atorvastatin was able to significantly 
suppress tumor burden, the same dose of rosuvastatin was ineffective (Figure 47G). 
Even though rosuvastatin has a higher in vitro affinity for its target enzyme, HMGCR, than 
atorvastatin562, it exhibit lower potency at suppressing MDA-MB-231 proliferation. While the 
lipophilic atorvastatin can diffuse across tumor cell membranes, the hydrophilic rosuvastatin relies 
more on active transport. Hepatocytes but not breast cancer cells express the OATP1B1 and 1B3 
transporters responsible for statin cellular uptake592. We have previously shown that atorvastatin 
is more effective than rosuvastatin at suppressing cancer cell growth3,4. These data additionally 
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suggest that the direct effects of statins on tumor cells play a larger role in proliferation suppression 
than indirect effects from statins influencing the neighboring hepatocytes. Moreover, we found 
atorvastatin could reduce tumor burden – defined as the normalized area of breast cancer cells - at 
the highest dose whereas rosuvastatin was ineffective (Figure 47). These data also suggest that, in 
the context of the hepatic microenvironment, statins act mainly in a cytostatic manner, as the anti-
proliferation effects occur at lower doses than a reduction in tumor burden (Figure 47). In support, 
previous studies have shown statins can induce apoptosis in breast cancer cells in vitro but not in 
human biopsy samples after neoadjuvant statin treatment in breast cancer patients699,706.  
8.3.3 PI3K inhibition potentiates atorvastatin-mediated suppression of MDA-MB-231 
proliferation in co-culture with primary human hepatocytes 
The PI3K-Akt and MAP kinase signaling pathways play significant roles in breast cancer cell 
growth and survival200,237. To determine whether these pathways played a role in breast cancer 
sensitivity to atorvastatin, we co-cultured MDA-MB-231 cells with primary human hepatocytes 
(Figure 48A). During atorvastatin treatment, cells were additionally treated with 3µM or 10µM 
LY294002 (a pan-PI3K inhibitor) or 10µM PD98059 (a Mek1/2 inhibitor). Inhibition of PI3K or 
Mek1/2 did not significantly influence hepatocyte health (Figure 48B) or tumor burden (Figure 
48C) as compared to atorvastatin treatment alone, but PI3K inhibition potentiated atorvastatin-
mediated suppression of MDA-MB-231 proliferation in a dose dependent manner (p-value = 0.01) 
(Figure 48D,E). In contrast, Mek1/2 inhibition had no effect on potentiating atorvastatin (Figure 
48D,E). These results are consistent with our finding that, in breast cancer cell lines, atorvastatin 
decreases Ras prenylation, its attachment to intracellular membranes, and thus activation4. 
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Figure 48. PI3K inhibition potentiates atorvastatin in 2D co-culture with hepatocytes 
(A) The experimental outline for hepatocyte – breast cancer co-culture using primary human hepatocytes (Heps; 
6x105) and RFP tagged breast cancer cells (BrCa; 1000 MDA-MB-231 RFP). Co-cultures were treated with 
atorvastatin for 72 hours with 3µM or 10µM LY294002 (LY; PI3K inhibitor), 10µM PD98059 (PD; Mek1/2 
inhibitor), or vehicle. (B) Nuclei number and (C) cancer cell area were unaffected by PI3K or Mek1/2 inhibition. 
PI3K inhibition but not Mek1/2 inhibition significantly inhibited MDA-MB-231 RFP (D) proliferation and (E) 
potentiated the growth suppressive effect of atorvastatin, illustrated by the p-value for interaction by two-way 
ANOVA. The data are representative of three independent experiments. Error bars represent the standard error of 
the mean (n=3). The data are representative of three independent experiments.  **** p < 0.0001. 
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8.3.4 Atorvastatin suppresses stimulated outgrowth dormant breast cancer cells 
Since we found atorvastatin could decrease the proliferation of breast cancer cells, we next wished 
to determine whether atorvastatin could suppress stimulated outgrowth of dormant breast cancer 
cells in the context of the liver microenvironment. To accomplish this goal, we employed an all-
human microphysiological system (MPS) for breast cancer metastasis in the liver. This system has 
been extensively characterized and has been shown to model metastatic dormant-emergent breast 
cancer47,750,898. In this system, a micro-hepatic tissue is established by seeding primary human liver 
cells, hepatocytes and a full complement of non-parenchymal cells, in a porous scaffold subject to 
a physiological flow. A full description of the functionality of the MPS has been published753,964. 
In brief, RFP-labeled breast cancer cells are seeded into these microtissues, perturbed by various 
drug treatments, and examined two weeks later by clinical chemistry assays and microscopy.  
The experimental outline is shown in Figure 49A. In summary, we first treated cells with 
doxorubicin for 72 hours to eliminate cycling cells so that the dormant cell fraction remained. We 
next treated with atorvastatin for 4 days and on the last two days of treatment, stimulated with an 
LPS/EGF cocktail, a physiologically relevant inflammatory stimulus designed to drive dormant 
breast cancer cells to emerge and proliferate750. After two days of stimulation, we fixed the cells 
and imaged scaffolds on a confocal microscope (Figure 49B-E). Atorvastatin significantly 
suppressed LPS/EGF stimulated outgrowth of the mesenchymal MDA-MB-231 cells (Figure 49F). 
These data suggest that atorvastatin can suppress emergence of the statin sensitive MDA-MB-231 
cells from tumor dormancy. Similar to in 2D co-culture (Figure 47), statins appear to act as 
cytostatic agents, as the normalized cancer area is similar between doxorubicin treated scaffolds 
and doxorubicin, atorvastatin, and LPS/EGF treated scaffolds (Figure 49F). 
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Figure 49. Atorvastatin suppresses stimulated outgrowth of mesenchymal breast cancer cells 
(A) The experimental outline for microphysiological system culture of primary human hepatocytes (Hep; 6x105), 
non-parenchymal cells (NPC; 6x105), and MDA-MB-231 RFP cells (1000), with media changes represented as red 
day numbers. Confocal microscopy was used to generate large Z-stack images for analysis, with representative 
images shown for each drug treatment: (B) vehicle, (C) Dox, (D) Dox + LPS/EGF, and (E) Dox + LPS/EGF + 
Atorv. Red = RFP, Green = EdU, Blue = DAPI. (F) Atorvastatin treatment was able to suppress LPS/EGF 
stimulated outgrowth of MDA-MB-231 RFP cells. Dox = 1µM doxorubicin, LPS/EGF = 1µg/mL LPS + 20ng/mL 
EGF, and Atorv = 5µM atorvastatin. The data are representative of two independent experiments each of which with 
a technical n = 2. Error bars represent the standard error of the mean (n=4). * p < 0.05. Scale bar = 500µm.  
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8.3.5 Atorvastatin suppresses proliferation of breast cancer liver metastases but not the 
primary tumor 
Since we found atorvastatin was able to suppress the stimulated outgrowth of breast cancer cells 
in the liver MPS, we wanted to examine whether systemic atorvastatin administration in a mouse 
model for spontaneous breast cancer metastasis to the liver would show the same affect. The 
experimental outline is shown in Figure 50A. In summary, we inoculated MDA-MB-231 into the 
spleens of female NSG mice. After allowing the primary tumor to establish for 1 week, we treated 
the mice with daily IP injections of 2mg/kg atorvastatin, 10mg/kg atorvastatin, or vehicle for 3 
weeks. Two days before euthanizing the mice, we also injected 10mg/kg EdU to detect cell 
proliferation. We found that all mice developed primary tumors in the spleen without having overt 
liver macrometastases. To assess statin toxicity we examined skeletal muscle; all mice exhibited 
healthy quadriceps (quad) muscle tissue (Figure 50B).  
We found the primary tumor size did not significantly change with atorvastatin treatment 
(Figure 5D). Primary tumors grew alongside the splenic parenchyma and would often invade 
through the splenic capsule as they grew (Figure 50C). Primary tumor proliferation was quantified 
by assessing the EdU positivity of the peripheral zone of the tumor. The proliferation of the 
primary tumor was not significantly affected by atorvastatin treatment (Figure 50E,F).  
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Figure 50. Atorvastatin does not suppress breast cancer primary splenic tumor growth 
(A) The experimental outline for a splenic inoculation model for spontaneous breast cancer metastasis to the liver. 
MDA-MB-231 RFP cells (5x104) were inoculated into the spleens of mice on day 0, mice were treated with daily 
intraperitoneal (IP) injections of 2mg/kg or 10mg/kg atorvastatin or vehicle (Veh, 2% DMSO in saline) starting on 
day 7, and mice were euthanized on day 28 for tissue harvesting. (B) Gross pathology was used to examine primary 
tumor size, the presence or lack of overt liver macrometastases, and myotoxicity. (C) Histology was determined by 
H&E staining and (D) primary tumor size was determined by splenic cross-sectional area. (E,F) Primary tumor 
proliferation was assessed by EdU incorporation on the two days prior to harvesting tissue, with EdU represented in 
green and DAPI counterstaining shown in blue. Error bars represent the standard error of the mean. ** p < 0.01, *** 
p < 0.001, **** p < 0.0001. White scale bar = 1cm, red and black scale bars = 100µm. 
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We found that the total size of the liver did not significantly change with atorvastatin 
treatment (Figure 51A). Breast cancer metastases ranged in size, but were at the largest several 
hundred micrometers in diameter (Figure 51B); these nodules still represented only a minor 
fraction of total liver tissue reflecting the micrometastatic nature of the tumor nodules. To assess 
proliferation of liver metastases, EdU staining was performed. Tumor nodules were easy to 
identify by the lack of green hepatocyte auto-fluorescence (Figure 51C). We found that 
atorvastatin significantly decreased proliferation density of metastatic nodules in a dose dependent 
manner (Figure 51D).  
 
 
 
Figure 51. Atorvastatin suppresses breast cancer liver metastatic proliferation 
The paired liver metastasis data with the splenic primary data shown in Figure 50. (A) The histology of liver 
metastases was determined by H&E staining and (B) gross metastatic burden was assessed by liver cross-sectional 
area. (C,D) Liver metastases proliferation was assessed by EdU incorporation on the two days prior to harvesting 
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tissue, with EdU represented in green and DAPI counterstaining shown in blue. Error bars represent the standard 
error of the mean. ** p < 0.01, *** p < 0.001, **** p < 0.0001. Red and black scale bars = 100µm. 
8.3.6 Atorvastatin suppresses proliferation of breast cancer lung metastases but not the 
primary tumor 
Since we found atorvastatin could significantly suppress the growth of micrometastases, we next 
wanted to determine if atorvastatin would reduce metastatic proliferation at a different site: the 
lung, the most common site for clinically evident breast cancer metastasis50. The experimental 
outline is shown in Figure 52A. In summary, we inoculated MDA-MB-231 breast cancer cells into 
the inguinal mammary fat pad (MFP) of female NSG mice. After allowing the primary tumor to 
establish for 10 days, we treated the mice with six IP injections per week of 2mg/kg or 10mg/kg 
atorvastatin or vehicle for 3 weeks. We found that all mice developed primary tumors and were 
void of overt lung macrometastases (Figure 52B). 
We found the primary tumor size did not significantly change with atorvastatin treatment 
(Figure 52D). Primary tumors were marked by central regions of necrosis (Figure 52C). Primary 
tumor proliferation was quantified by assessing the Ki-67 positivity of the peripheral zone of the 
tumor. The proliferation of the primary tumor was not significantly affected by atorvastatin 
treatment (Figure 52E,F). In contrast to the primary tumor, the lung metastases were much smaller 
and exhibited no necrotic regions (Figure 53A). Moreover, we found that atorvastatin reduced the 
proliferation of lung metastases in a dose dependent manner, though this trend did not reach 
statistical significance in the small number of animals challenged (Figure 53H,I).  
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Figure 52. Atorvastatin does not suppress breast cancer primary fat pad tumor growth  
(A) The experimental outline for a mammary fat pad (MFP) inoculation model for spontaneous breast cancer 
metastasis to the lung. MDA-MB-231 RFP cells (5x105) were inoculated into the right MFP of mice on day 0, mice 
were treated with six per week intraperitoneal (IP) injections of 2mg/kg or 10mg/kg atorvastatin or vehicle (Veh, 2% 
DMSO in saline) starting on day 10, and mice were euthanized on day 28 for tissue harvesting. (B) Gross pathology 
was used to examine primary tumor size and the presence or lack of overt lung macrometastases. (C) Primary tumor 
histology was determined by H&E staining and (D) size was determined by tumor cross-sectional area. (E,F) 
Primary tumor proliferation was assessed by Ki-67 immunohistochemistry, with Ki-67 represented in brown and 
counterstained by hematoxolin. Error bars represent the standard error of the mean. White scale bar = 1cm, red and 
black scale bars = 100µm. 
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Figure 53. Atorvastatin suppresses breast cancer lung metastatic proliferation 
The paired lung metastasis data with the fat pad primary data shown in Figure 52. (A) Histology of lung metastases 
was determined by H&E staining. (B,C) Lung metastases proliferation was assessed by Ki-67 
immunohistochemistry, with Ki-67 represented in brown and counterstained by hematoxolin. Examples of 
individual tumor nodules are circled in red. Significant outliers (n=1 in the vehicle and 10mg/kg atorvastatin groups) 
as detected by Grubbs’ test were removed from the analysis in I. Error bars represent the standard error of the mean. 
Red and black scale bars = 100µm. 
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8.3.7 Atorvastatin suppresses growth of metastases but not the primary tumor 
As demonstrated in the previous two subsections, we employed two independent models 
of spontaneous breast cancer metastasis: spleen-to-liver and mammary fat pad (MFP)-to-lung. 
Importantly, these models encompass the entire metastatic cascade, beginning with growth of a 
primary tumor and ending with distant metastases. This is in contrast to tail vein or intra-cardiac 
injection models, which primarily probe direct hematogenous seeding of cancer cells and bypass 
the pathophysiologic changes needed for both initial escape from the primary tumor and seeding 
as singular cells in the ectopic tissues. In our spleen-to-liver metastasis model, we found that 
atorvastatin treatment could significantly suppress proliferation of liver metastatic nodules but not 
the primary tumor (Figure 50, Figure 51). Moreover, this effect on proliferation was dose 
dependent. Atorvastatin did not induce cell death in either the primary tumor or metastatic nodules, 
confirming our in vitro evidence that statins mainly act as growth suppressive in the context of the 
tumor microenvironment (Figure 47, Figure 49). In our MFP-to-lung metastasis model, we found 
that atorvastatin did not affect primary tumor proliferation but reduced proliferation of lung 
metastases (Figure 52, Figure 53). We believe the atorvastatin-mediated suppression of lung 
metastasis proliferation did not achieve statistical significance due to a higher variability in 
spontaneous metastasis to the lung, which can be observed in vehicle treated mice.  
To assess the effect of atorvastatin on any site metastasis or primary tumor, we normalized 
proliferation rates for both the spleen-to-liver (Figure 50, Figure 51) and MFP-to-lung (Figure 52, 
Figure 53) models to their respective vehicle treatments. We found that atorvastatin did not affect 
the proliferation of the primary tumors (Figure 54A) yet significantly decreased the proliferation 
of the metastases in a dose-dependent manner (Figure 54B). These data suggest that statins act to 
reduce metastatic tumor growth (Figure 12). 
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Figure 54. Atorvastatin suppresses proliferation of metastatic but not primary tumor cells 
Proliferation of primary tumor cells and metastatic tumor cells obtained for the intrasplenic inoculation model of 
spontaneous breast cancer metastasis to liver (Figure 5) and the mammary fat pad (MFP) inoculation model of 
spontaneous breast cancer metastasis to lung (Figure 6) were normalized to their respective vehicle controls. (A) 
Primary tumor cell proliferation was assessed by combining the normalized proliferation values for the splenic and 
MFP experiments. (B) Metastatic tumor cell proliferation was assessed by combining the normalized proliferation 
values for the liver and lung metastases. Error bars represent the standard error of the mean. 
 
 
8.4 SUPPLEMENTAL DATA 
In order to best characterize the influence of atorvastatin and rosuvastatin treatment on 2D co-
cultures of breast cancer cells and primary human hepatocytes, a high content wide-field imaging 
strategy was employed. For each treatment condition, 140 images were taken and stitched into one 
large image (Figure 55A), upon which the subsequent image analysis was performed.  
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Figure 55. Breast cancer and hepatocyte co-cultures 
MDA-MB-231 RFP cells (1000) and MCF-7 RFP (5000) cells were cultured with 6x105 primary human 
hepatocytes and fixed after 96 hours of co-culture. (A) A widefield microscope was used to take and stitch 140 
congruent fields of view. Scale bar = 100µm. (B) MCF-7 RFP and (C) MDA-MB-231 RFP co-cultures were 
additionally stained for E-cadherin, to demonstrate cancer cell integration into the hepatocyte monolayer. Scale bar 
= 50µm. Blue = DAPI, Green = EdU, Red = RFP, White = E-cadherin. 
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Analysis of a large culture area was needed to accurately assess the influence of statin treatment 
due to the high variability in individual images taken (Figure 55A). Higher power imaging 
demonstrated that both MCF-7 (Figure 55B) and MDA-MB-231 (Figure 55C) cells could integrate 
into the hepatocyte monolayer. Thus, the influence of statins on the cancer cells in this system 
were either direct effects on the tumor cells or indirect effects through affecting the hepatocytes. 
 In order to determine whether atorvastatin reduced viability of hepatocytes in the liver MPS 
(Figure 49), clinical chemistry assays were done to assess AST and ALT release into the effluent. 
Similar to the results for the 2D co-culture model, in which no decrease in nuclei number was 
noted with atorvastatin treatment, we found none of the drug treatments damaged the hepatocytes 
as shown by no increase in AST and ALT release into the effluent (Figure 56). 
 
 
 
Figure 56. Atorvastatin does not affect hepatocyte health in the MPS 
Supernatant from MPS wells containing hepatocyte and non-parenchymal cells cultured with MDA-MB-231 RFP 
were tested for leakage of (A) ALT and (B) AST using assays performed in clinical chemistry laboratories at the 
University of Pittsburgh Medical Center (UPMC). The initially high markers of hepatocyte damage reflect the 
isolation protocols. NT = no treatment, Dox = 1µM doxorubicin for days 7-10, LE = 1µg/mL LPS + 20ng/mL EGF 
for days 13-15, and A = 5µM atorvastatin for days 11-15. Error bars represent the standard error of the mean (n=2). 
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To better characterize the primary tumor and metastases in the spleen-to-liver mouse model 
of spontaneous breast cancer metastasis, E-cadherin immunohistochemistry was performed. 
Similar to in vitro, the primary tumors were marked by a lack of E-cadherin expression (Figure 
57A,B). While small micrometastases exhibited membrane E-cadherin expression, larger 
metastases (>100µm) were largely E-cadherin negative (Figure 57C,D), having undergone a 
second EMT748,965. 
To assess for tumor cell death, TUNEL staining was performed. Primary splenic tumors 
exhibited minimal TUNEL staining (Figure 58A,B) that was unaffected by 10mg/kg atorvastatin 
treatment (Figure 58C). Similarly, liver metastases stained negative for TUNEL (Figure 58D,E) 
that was unaffected by 10mg/kg atorvastatin treatment (Figure 58F). These data suggest that 
cytotoxic effects of atorvastatin were minimal in this mouse model for breast cancer metastasis. 
8.5 CONCLUSIONS 
This study adds to the previous study by examining the growth suppressive effects of statins in 
models of metastatic breast cancer of increasing complexity. In breast cancer 2D co-culture with 
primary human hepatocytes, the lipophilic atorvastatin remains more effective than the hydrophilic 
rosuvastatin (Figure 47). Similarly, in this co-culture system, the synergy of inhibiting the PI3K-
Akt pathway was preserved (Figure 48). In a 3D MPS model of breast cancer metastases in the 
liver, atorvastatin could significantly suppress LPS/EGF stimulated outgrowth of breast cancer 
cells (Figure 49). Finally, in two independent models for spontaneous breast cancer metastasis to 
the liver and lung, respectively, atorvastatin was able to suppress proliferation of metastatic but 
not primary tumor cells (Figures 50-54). 
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Figure 57. MDA-MB-231 RFP cells re-express E-cadherin in small liver micrometastases 
MDA-MB-231 RFP cells in the intrasplenic inoculation model of breast cancer metastasis to liver (Figure 50, Figure 
51) were assessed for E-cadherin expression in (A,B) the splenic primary tumor and (C) large or (D) small liver 
metastases. Scale bar = 100µm 
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Figure 58. Atorvastatin is not cytotoxic to MDA-MB-231 primary tumor or metastatic cells 
MDA-MB-231 RFP cells in the intrasplenic inoculation model of breast cancer metastasis to liver (Figure 50, Figure 
51) were assessed for cell death by TUNEL staining. Cell death was assessed for (A,B,D,E) vehicle and (C,F) 
10mg/kg atorvastatin treatment in (A-C) the splenic primary tumor and (D-F) liver metastases. Scale bar = 100µm 
 
 
The in vivo data (Figures 50-54) are the most significant contribution of this study to the 
overall hypothesis of this thesis. First, the doses of atorvastatin used in both mouse models are 
similar to those used for moderate-intensity lipid lowering therapy in clinical patients607. 
Accounting for the difference in volume of distribution, the 2mg/kg and 10mg/kg doses in mice 
are approximately equivalent to 20mg and 80mg doses in human patients966. Thus, the doses of 
atorvastatin that suppress metastatic proliferation are similar to those already employed clinically 
with little systemic toxicity. Second, we found a divergent effect of atorvastatin on breast cancer 
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cells. While the primary tumor cells were unaffected by statin treatment, the metastatic cells were 
suppressed. This was found in our two mouse models and in our MPS model of breast cancer 
metastasis to the liver (Figures 49-54). These results are similar to other reports that statins can 
delay the formation of metastases in mice743,967. Breast cancer cells are known to re-express E-
cadherin and enter a period of quiescence at the metastatic site45. Since atorvastatin was able to 
suppress stimulated outgrowth of dormant MDA-MB-231 cells (Figure 49), this suggests that 
atorvastatin can suppress emergence of dormant tumor cells. 
The divergent effects of atorvastatin on the primary and metastatic tumor cells is supported 
by the clinical data suggesting a mortality but not incidence benefit of statins in breast cancer531,532. 
Other studies have reported statin suppression of primary tumor growth and induction of apoptosis 
in mouse models537,968. However, previous studies have not compared proliferation at the primary 
and metastatic sites and used doses higher than those used for cholesterol-lowering. Our data 
suggest atorvastatin can preferentially suppress metastatic breast cancer outgrowth and as such, 
may be useful as a long term adjuvant for preventing emergence of dormant breast cancer 
micrometastases that eventually progress to clinically evident disease. Since the concentrations 
needed to achieve these anti-metastasis effects are currently seen with clinical use in 
cardiovascular disease, targeted clinical trials of adjuvant statin therapy in breast cancer patients 
at risk for metastatic recurrence may improve mortality without causing significant toxicity. 
Moreover, atorvastatin efficacy should be examined in metastasis models of other cancer types, 
such as metastatic prostate cancer. 
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9.0  CLINICAL IMPLICATIONS 
There are several critical insights to draw from these research findings. First, statin drugs have 
differential effects on tumor cells depending on their potency and lipophilicity. The fact that the 
lipophilic atorvastatin and simvastatin are more potent at suppressing cancer cell growth is critical 
to investigating statins as anti-cancer agents. The results of the present work suggest that women 
with a history of breast cancer who are currently taking a hydrophilic statin for cardiovascular 
indications should be switched to a lipophilic statin. Approximately 20% of patients taking statins 
receive a hydrophilic statin, which suggests there is a significant portion of the female breast cancer 
population that would benefit from this therapeutic switch. Additionally, all future clinical trials 
that investigate statins in cancer therapy should only be conducted using lipophilic statins, as the 
present work has proven that hydrophilic statins are ineffective for cancer treatment. 
Second, statins have different effects on primary and metastatic tumor cells, because they 
suppress proliferation of metastases while having no effect on growth of the primary tumor. The 
inefficacy of statins against primary tumor cells suggests they are not useful as neoadjuvant 
therapy. In contrast, these data motivate statin use as an adjuvant therapy to prevent tumor 
recurrence. Indeed, the largest retrospective cohort studies suggest statins benefit tumor recurrence 
and mortality531,664. Most importantly, atorvastatin was shown to block stimulated outgrowth of 
dormant tumor cells, which suggests statins can directly block tumor recurrence in the context of 
the liver microenvironment.  
Third, transcriptomic analysis as used in the present work can reveal candidate genes that 
are involved with susceptibility to statin-mediated growth suppression. Moreover, drugs expected 
to synergize with statins can be predicted using these advanced computational models. While both 
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these candidate biomarkers and synergistic drugs need experimental validation, the present work 
lays a foundation for discovery and validation of factors that can be expected to potentiate statin 
efficacy in human cancer patients or identify the patients who are most likely to respond to statin 
therapy. 
Finally, this work reveals important signaling networks that contribute to statin sensitivity. 
In the breast cancer cell lines tested, a reduction in Ras signaling through PI3K-Akt was found to 
be responsible for statin-mediated growth suppression. Since PI3K and Akt inhibitors have shown 
significant clinical toxicity, combination therapy with statins may allow for a lower dose of these 
drugs to be used to achieve similar efficacy with a reduction in toxicity.  
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10.0  FUTURE DIRECTIONS 
Further investigation of statins as anti-tumor agents will encompass both basic research and 
clinical research studies. Promising avenues of research indicated by the results of the present work 
are described below.   
10.1 BASIC RESEARCH STUDIES 
The present work has discovered mechanistic and pharmacologic insight into the use of statins as 
anti-tumor agents, but additional questions remain regarding their use in breast cancer. First, the 
efficacy of statins against breast cancer cells with different molecular subtypes is not yet well 
understood. The breast cancer cell lines used for the majority of this work were either hormone 
receptor positive (MCF-7) or triple-negative (MDA-MB-231). While MDA-MB-231 cells were 
found to be more sensitive to statin therapy, it is not known whether this holds true for all triple-
negative breast cancer cell lines. The susceptibility of many breast cancer cell lines – hormone 
receptor positive, HER2 positive, and triple-negative – should be investigated in order to determine 
whether molecular subtype plays a role in statin sensitivity. Moreover, patient-derived cells should 
be tested to validate the cell line data. 
Second, the difference in efficacy of statins against primary and metastatic tumor cells 
should be further investigated. It is not yet known whether human metastasis, which often occurs 
over much longer time scales, will be reflected by the results of the mouse models described herein. 
The evolution of tumor cells between the primary and metastatic tumor may explain the selectivity 
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of statins for the latter. In order to better investigate the differential potency of statins against 
primary and metastatic tumor cells, paired biopsy samples from clinical patients should be used in 
the in vitro, ex vivo, and in vivo models described in this thesis. This may reveal the relative 
importance of intrinsic differences in statin susceptibility of the primary and metastatic cells and 
the differences in the primary and metastatic microenvironments. Moreover, there may be a 
difference in statin susceptibility with the site of metastasis. Indeed, the mouse models of 
spontaneous breast cancer metastasis used in this work demonstrated a more potent effect of statins 
against metastatic cells that migrated to liver as compared to lung. Understanding the site 
dependence of statin anti-tumor efficacy is critical in determining which patients may benefit the 
most from their use. 
Third, it is critical to understand how statins interact with currently used breast cancer 
therapies, as statin use may either enhance or diminish their efficacy. For example, since statins 
work by inducing growth arrest and decreasing proliferation, the efficacy of chemotherapeutic 
agents may be compromised since they are only effective against cycling cells. If the findings from 
the mouse models hold true for human disease, patients should stop taking their statin during 
chemotherapy cycles. In contrast, statins have been shown to induce oxidative stress in cancer 
cells, which may compromise the health of tumor cells and make them more susceptible to 
cytotoxic drugs. If these findings hold true in humans, patients who don’t normally take statins 
should supplement their chemotherapy regimen with a lipophilic statin. Finally, since most statins 
are metabolized by CYP450 isozymes, most commonly CYP3A4 and CYP2C9, they may interfere 
with the metabolism of chemotherapeutic drugs and possibly induce additional adverse events. 
Examining statins in combination with other chemotherapeutic drugs in ex vivo liver culture 
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systems and in vivo will suggest which drug combinations may result in higher clinical efficacy 
and toxicity. 
Finally, there is a need for a continued systematic search for existing drugs and novel 
compounds that can potentiate the growth inhibitory effect of lipophilic statins. The sophisticated 
tools available for this discovery process included unbiased screening, bioinformatics, network 
biology, and hypothesis-driven approaches. Chapter 7 of this dissertation has already demonstrated 
how powerful and successful these computational approaches can be. After identifying candidate 
compounds, these drugs should be tested in combination with statins in experimental systems (such 
as the ex vivo and in vivo models discussed in this dissertation) to determine the efficacy and/or 
limitations of these approaches. These studies will pave the way for clinical translation of 
promising combination therapies to reduce the morbidity and mortality of breast cancer. 
10.2 CLINICAL RESEARCH STUDIES 
Since statins have been shown to be effective primarily against metastatic tumor cells, prospective 
clinical trials should investigate their use as adjuvant therapy in breast cancer. Since the studies 
that demonstrate a cancer mortality benefit with statin use are quite large, prospective clinical trials 
would need to be conducted in a targeted patient population. For example, investigating adjuvant 
statin therapy in triple-negative or HER2-positive patients would be more feasible than a trial of 
hormone receptor positive patients since the former two groups typically relapse earlier. Moreover, 
patients with nodal metastases or locally invasive primary tumors would be prime candidates for 
these trials, as they are at the highest risk for metastatic relapse. Patients would be randomized to 
a lipophilic statin (likely atorvastatin) or placebo and followed longitudinally. These trials would 
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contain defined interim analysis periods to allow patients to crossover from placebo to statin 
should the statin recurrence or mortality benefits prove significant. 
10.3 CONCLUSIONS 
Future basic research studies and clinical trials that build upon the results of the present work have 
the potential to establish statins as effective and safe agents to delay breast cancer recurrence and 
mortality. In the short term, studies should address whether current statin users for cardiovascular 
indications with a history of breast cancer should be uniformly prescribed lipophilic statins. In 
parallel, basic studies should determine how statins interact with the efficacy and toxicity of 
clinically used breast cancer treatments. In the long term, clinical trials should address whether 
statins play a role in adjuvant management of breast cancer in women who do not otherwise require 
a statin. It is hoped that accomplishing both of these short and long term goals will improve the 
quality of life and survival rates of women with breast cancer. 
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McGowan Annual Retreat, Nemacolin, PA, (3rd Place) 
5. Statin inhibition of cancer cell growth tracks with lack of functional E-cadherin mediated cell 
cohesion and is dependent on statin pharmacologic properties. Beckwitt CH*, Warita K*, 
Warita T, Schurdak ME, Clark A, Wheeler S, Vazquez A, Wells A, Oltvai ZN. May 2016: 
CMP Program Retreat, University of Pittsburgh, Pittsburgh, PA, (3rd Place) 
6. Pheochromocytoma: A Catecholamine-secreting Neuroendocrine Tumor of the Adrenal 
Medulla. Beckwitt CH, Trejo Bittar HE, Nine J. March 2015: Autopsy Discovery Program 
Poster Session, University of Pittsburgh, Pittsburgh, PA, (3rd place) 
7. Statin inhibition of cancer cell growth tracks with mesenchymal phenotype and lack of 
functional E-cadherin mediated cell cohesion. Beckwitt CH*, Warita K*, Warita T, 
Schurdak ME, Clark A, Wheeler S, Vazquez A, Wells A, Oltvai ZN. August 2014: Pitt 
MSTP Program Retreat, University of Pittsburgh, Pittsburgh, PA 
8. Mucin multilayers assembled through sugar-lectin interactions. Beckwitt CH, Crouzier T, 
Ribbeck K. March, 2013: MIT Biological Engineering Graduate School poster session, MIT, 
Cambridge, MA 
Local Oral Presentations 
1. Atorvastatin inhibits outgrowth of breast cancer metastases. CMP Retreat, May 23, 2018 
2. Breast cancer metastatic dormancy and emergence, a role for adjuvant statin therapy. 
CATER Training Program Lunch Seminar, March 23, 2018 
3. Statins Suppress Growth of Metastatic Breast Cancer in the Context of the Liver 
Microenvironment. Pitt MSTP retreat, August 25, 2017 
4. Statin Mediated Suppression of Breast Cancer Growth. Department of Pathology Lunch 
Seminar, Dec 7, 2016 
5. Statin-Mediated Suppression of Tumor Cell Growth. CATER Training Program Lunch 
Seminar, October 14, 2016 
6. Statin-Mediated Suppression of Cancer Cell Growth. Pitt MSTP retreat, August 19, 2016. 
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